A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multicenter 
Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the
Treatment of Patients with Diarrhea-p redominant Irritable Bowel Syndrome 
(IBS-D) 
Study Registry ID: [REMOVED] 
Final Protocol, Version 3.0 (Amendment 2), dated 12-August-2019
Final Protocol, Version 2.0 (Amendment 1), dated 0 -May-2019
Final Protocol, Version 1.0, dated 25-Jan XDU\ -2019
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%263URWRFRO'DWHDQG9HUVLRQ$XJXVWY
&21),'(17,$/ 3DJHRI&/,1,&$/75,$/35272&2/ 
6WXG\7LWOH  $3KDVHD5DQGRPL]HG'RXEOHEOLQG
3ODFHERFRQWUROOHG0XOWLF HQWHU6WXG\WR(YDOXDWHWKH
(IILFDF\6DIHW\DQG7ROHUDELOLW\RI%26LQWKH7UHDWPHQWRI3DWLHQW VZLWK'LDUUKHDSUHGRPLQDQW,UULWDEOH
%RZHO6\QGURPH,%6'
6WXG\1XPEHU  %26
5HJXODWRU\
,GHQWLILFDWLRQ1XPEHUV ,1'
6WXG\3KDVH  D
,QYHVWLJDWLRQDO3URGXFW %26
,QGLFDWLRQ  'LDUUKHDSUHGRPLQDQW,UUL WDEOH%RZHO6\QGURPH
6SRQVRU  %RVWRQ3KDUPDFHXWLFDOV,QF
&DPEULGJH3DUNZD\6XLWH&DPEULGJH0DVVDFKXVHWWV86$
9HUVLRQ 'DWH
)LQDOY $XJXVW
&RQILGHQWLDOLW\6WDWHPHQW
7KHLQIRUPDWLRQLQWKLVGRFXPHQW LVFRQILGHQWLDODQGZLOOQRWE HGLVFORVHGWRRWKHUV
ZLWKRXWZULWWHQDXWKRUL]DW LRQIURPWKHVSRQVRU H[FHSWWRWKHH[WHQWQHFHVVDU\WR
REWDLQLQIRUPHGFRQVHQWIURPSHUV RQVUHFHLYLQJWKHVWXG\GUXJR UWKHLUOHJDO
JXDUGLDQVRUIRUGLVFXVVLRQVZLW K5HJXODWRU\$XWKRULWLHV,QVW LWXWLRQDO5HYLHZ%RDUGV
,QGHSHQGHQW(WKLFV&RPPLWWHHVRU SHUVRQVSDUWLFLSDWLQJLQWKH FRQGXFWRIWKHVWXG\
'RQRWFRS\RUGLVWULEXWHZLW KRXWZULWWHQSHUPLVVLRQIURPWKHV SRQVRU

&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI63216256,*1$785(3$*(
3URWRFRO7LWOH$3KDVHD5DQG RPL]HG'RXEOHEOLQG3ODFHERF RQWUROOHG0XOWLFHQWHU
6WXG\WR(YDOXDWHWKH(IILFDF\6DIHW\DQG7ROHUDELOLW\RI%26 LQWKH7UHDWPHQWRI
3DWLHQWVZLWK'LDUUKHDSUHGRPLQD QW,UULWDEOH%RZHO6\QGURPH,% 6'
3URWRFRO1XPEHU%269HUVLRQ1XPEHUDQG'DWHY$XJXVW,WKHXQGHUVLJQHGKDYHDSSURYHGWKHILQDOYHUVLRQRIWKLV&OL QLFDO7ULDO3URWRFRO

 'DWH

 'DWH


JS S
PPD
PPD
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI,19(67,*$725$*5((0(17
3URWRFRO7LWOH$3KDVHD5 DQGRPL]HG'RXEOHEOLQG3ODFHERF RQWUROOHG0XOWLFHQWHU
6WXG\WR(YDOXDWHWKH(IILFDF\6 DIHW\DQG7ROHUDELOLW\RI%26 LQWKH7UHDWPHQWRI
3DWLHQWVZLWK'LDUUKHDSUHGRPLQDQ W,UULWDEOH%RZHO6\QGURPH,% 6'
3URWRFRO1XPEHU%269HUVLRQ1XPEHUDQG'DWHY$XJXVW,WKHXQGHUVLJQHGKDYHUHDGWKH SURWRFRODQGDJUHHWRFRQGXFW WKHWULDOLQFRPSOLDQFH
ZLWKWKH,QWHUQDWLRQDO&RXQFLOIR U+DUPRQL]DWLRQ,&+JXLGHOLQ HVDQGDQ\RWKHU
DSSOLFDEOHUHJXODWRU\ UHTXLUHPHQWVDVZH OODV*RRG&OLQLFDO3U DFWLFH*&3VWDQGDUGV
&303,&+
,ZLOOSURYLGHFRSLHVRIWKHSURW RFRODQGDOOSHUWLQHQWLQIRUPD WLRQWRDOOLQGLYLGXDOVZKR
DVVLVWLQWKHFRQGXFWRIWKLVVWXG\ ,ZLOOGLVFXVVWKLVPDWHUL DOZLWKWKHPWRHQVXUHWKH\
DUHIXOO\LQIRUPHGUHJDUGLQJW KHLQYHVWLJDWLRQDOSURGXFWDQGWK HFRQGXFWRIWKHVWXG\
,ZLOOXVHRQO\WKH,QIRUPHG&RQV HQW)RUPDSSURYHGE\WKHVSRQV RURULWVUHSUHVHQWDWLYH
DQGZLOOIXOILOODOOUH VSRQVLELOLWLHVIRUVXEPLWWLQJSHUWLQHQW LQIRUPDWLRQWRWKH,QVWLWXWLRQDO
5HYLHZ%RDUG,QGHSHQGHQW(WKLFV&R PPLWWHH,5%,(&UHVSRQVLEOH IRUWKLVVWXG\
,DJUHHWKDWWKHVSRQVRURULWV UHSUHVHQWDWLYHVZLOOKDYHDFFHV VWRDQ\VRXUFH
GRFXPHQWVIURPZKLFKFDVHUHSRU WIRUPLQIRUPDWLRQPD\KDYHEHHQ JHQHUDWHG

 
,QYHVWLJDWRU
V6LJQDWXUH  'DWH
1DPHRI,QYHVWLJDWRU W\SHGRUSULQWHG 
,QVWLWXWLRQ1DPH 

&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI7$%/(2)&217(176
7$%/(2)&217(176    
/,672)7$%/(6    
/,672)),*85(6    
/,672)$33(1',&(6    
$%%5(9,$7,216    
 35272&2/6800$5<    
 6\QRSVLV    
 6WXG\6FKHPD    
 6FKHGXOHRI$FWLYLWLHV    
 ,1752'8&7,21    
 6WXG\5DWLRQDOH    
 %DFNJURXQG    
  'LVHDVH8QGHU6WXG\    
  7KHÂ³5(7Â´Â³5(DUUDQJHG'XULQJ7UDQV IHFWLRQÂ´*HQHDQGWKH(QWHU LF
1HUYRXV6\VWHP    
  ,QYHVWLJDWLRQDO3URGXFW    
  1RQFOLQLFDO6XPPDU\    
  ,Q9LWUR6WXGLHV   
  ,Q9LYR6WXGLHV   
  3KDUPDFRNLQHWLFVDQG3URGXFW0HWDEROLVPLQ$QLPDOV   
  7R[LFRORJ\DQG1RQFOLQLFDO$VVHVVPHQWRI6DIHW\   
  &OLQLFDO([SHULHQFH    
 5LVN%HQHILW$VVHVVPHQW    
  5LVN$VVHVVPHQW    
  %HQHILW$VVHVVPHQW    
  2YHUDOO5LVN%HQHILW&RQFOXVLRQ    
 2%-(&7,9(6$1'(1'32,176    
 678'<'(6,*1    
 2YHUDOO'HVLJQ    
  6WXG\'XUDWLRQIRU3DWLHQWV    
  1XPEHURI3DWLHQWV    
  5HSODFHPHQWRI3DWLHQWV    
  1XPEHURI6LWHV    
 5DWLRQDOHIRU6WXG\'HVLJQ    
 -XVWLILFDWLRQIRU'RVH    
 (QGRI6WXG\'HILQLWLRQ    
 678'<3238/$7,21    
 ,QFOXVLRQ&ULWHULD    
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI ([FOXVLRQ&ULWHULD    
 /LIHVW\OH&RQVLGHUDWLRQV    
 6FUHHQ)DLOXUHV    
 ,19(67,*$7,21$/352'8&7    
 ,QYHVWLJDWLRQDO3URGXFWV    
  ,QYHVWLJDWLRQDO3URGXFW'HVFULSWLRQ    
 3UHSDUDWLRQ+DQGOLQJ 6WRUDJH$FFRXQWDELOLW\   
  $FTXLVLWLRQDQGDFFRXQWDELOLW\    
  3URGXFW6WRUDJHDQG6WDELOLW\    
 0HDVXUHVWR0LQLPL]H%LDV    
 'RVLQJDQG$GPLQLVWUDWLRQ    
 'RVHPRGLILFDWLRQ    
 ,QYHVWLJDWLRQDO3URGXFW&RPSOLDQFH    
 &RQFRPLWDQW7KHUDS\    
  5HVFXH0HGLFLQH    
 ,QWHUYHQWLRQ$IWHUWKH(QGRIWKH6WXG\    
 ',6&217,18$7,21:,7+'5$:$/    
 'LVFRQWLQXDWLRQRI,QYHVWLJDWLRQDO3URGXFW    
 'LVFRQWLQXDWLRQ:LW KGUDZDOIURPWKH6WXG\   
 /RVWWR)ROORZXS    
 678'<$66(660(176 $1'352&('85(6   
 6WXG\3HULRGV    
 6FUHHQLQJ$VVHVVPHQWV    
 (IILFDF\$VVHVVPHQWV    
  :RUVW$EGRPLQDO3DLQ    
  %ULVWRO6WRRO)RUP6FDOH    
  ,%6'*OREDO6\PSWRP6FRUH    
  ,%66HYHULW\6FRUH6\VWHP    
 6DIHW\DQG2WKHU$VVHVVPHQWV    
  $GYHUVH(YHQWVDQG6HULRXV$GYHUVH(YHQWV   
  3K\VLFDO([DPLQDWLRQV    
  9LWDO6LJQV    
  (OHFWURFDUGLRJUDPV    
  &OLQLFDO6DIHW\/DERU DWRU\$VVHVVPHQWV   
 $GYHUVH(YHQWVDQG6HULRXV$GYHUVH(YHQWV   
  'HILQLWLRQRI$GYHUVH(YHQWV    
  (YHQWVRI6SHFLDO,QWHUHVW    
  'HILQLWLRQRI6HULRXV$GYHUVH(YHQWV    
  &ODVVLILFDWLRQRIDQ$GYHUVH(YHQW    
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI  $VVHVVPHQWRI6HYHULW\    
  $VVHVVPHQWRI&DXVDOLW\    
  ([SHFWHGQHVV    
  7LPH3HULRGDQG)UHTXHQF\IRU(Y HQW$VVHVVPHQWDQG)ROORZXS   
  $GYHUVH(YHQW5HSRUWLQJ    
  5HSRUWLQJRI3UHJQDQF\    
 7UHDWPHQWRI2YHUGRVH    
 3KDUPDFRNLQHWLFV    
 %LRPDUNHUV3KDUPDFRG\QDPLFV    
 67$7,67,&$/&216,'(5$7,216    
 7LPLQJRI$QDO\VHV    
 6DPSOH6L]H'HWHUPLQDWLRQ    
 3RSXODWLRQVIRU$QDO\VHV    
 6WDWLVWLFDO$QDO\VHV    
  (IILFDF\$QDO\VHV    
  3ULPDU\(QGSRLQW    
  6HFRQGDU\(QGSRLQW    
  2WKHU(IILFDF\(QGSRLQWV    
  0LVVLQJ'DWD    
  6DIHW\$QDO\VHV    
  $GYHUVH(YHQWV    
  &OLQLFDO/DERUDW RU\(YDOXDWLRQV    
  7ZHOYHOHDG(OHFWURFDUGLRJUDP V9LWDO6LJQVDQG3K\VLFDO
([DPLQDWLRQV    
  2WKHU$QDO\VHV    
  3KDUPDFRNLQHWLF$QDO\VLV    
  %DVHOLQH'HVFULSWLYH6WDWLVWLFV    
  6XEJURXS$QDO\VHV    
 3ODQQHG,QWHULP$QDO\VHV    
 6833257,1*'2&80(17$ 7,21$1'23(5$7,21$/
&216,'(5$7,216    
  5HJXODWRU\(WKLFDODQG6W XG\2YHUVLJKW&RQVLGHUDWLRQV   
  5HJXODWRU\DQGHWKL FDOFRQVLGHUDWLRQV    
  ,QIRUPHG&RQVHQW$VVHQW3URFHVV    
  &RQILGHQWLDOLW\DQG3ULYDF\    
  4XDOLW\$VVXUDQFH DQG4XDOLW\&RQWURO    
  'DWD+DQGOLQJDQG5HFRUG.HHSLQJ    
  'DWD&ROOHFWLRQDQG0 DQDJHPHQW5HVSRQVLELOLWLHV   
  6WXG\5HFRUGV5HWHQWLRQ    
  6WXG\DQG6LWH'LVFRQW LQXDWLRQDQG&ORVXUH   
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI  'LVVHPLQDWLRQRI&OLQLFDO6WXG\'DWD    
  3XEOLFDWLRQ3ROLF\    
 5()(5(1&(6    
 $33(1',&(6    

/,672)7$%/(6
7DEOH  6FKHGXOHRI$FW LYLWLHV   
7DEOH  3URWRFROUHTXLUHG6DIHW\ /DERUDWRU\$VVHVVPHQWV   
7DEOH  +LJKO\(IIHFWLYH&RQW UDFHSWLYH0HWKRGV   

/,672)),*85(6
)LJXUH  6WXG\6FKHP DWLF   

/,672)$33(1',&(6
$SSHQGL[  &OLQLFDO/DERUDW RU\7HVWV   
$SSHQGL[  &RQWUDFHSWLYH*XLGDQFHDQG&ROO HFWLRQRI3UHJQDQF\,QIRUPDWLRQ   
$SSHQGL[  7KH%ULVWRO6WRRO )RUP6FDOH   
$SSHQGL[  &RQFRPLWDQW0HGLFDWLRQV    
$SSHQGL[  3URWRFRO$PHQGP HQW+LVWRU\   
$SSHQGL[  3URWRFRO6XPPD U\RI&KDQJ HV   

&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI$%%5(9,$7,216 
$( DGYHUVHHYHQW
$.7 SURWHLQNLQDVH% 
$/7 DODQLQHDPLQRWUDQVIHUDVH 
$67 DVSDUWDWHDPLQRWUDQVIHUDVH 
$8& DUHDXQGHUWKHFRQFHQWUDWLRQYHUVXVWLPHFXUYH 
$8& DUHDXQGHUWKHFRQFHQWUDWLRQYHUV XVWLPHFXUYHIURPWLPH]HUR WR
KRXUVSRVWGRVH 
$8& DUHDXQGHUWKHFRQFHQWUDWLRQYHUV XVWLPHFXUYHIURPWLPH]HUR WR
KRXUVSRVWGRVH
$8&W DUHDXQGHUWKHFRQFHQWUDWLRQYHUV XVWLPHFXUYHIURPWLPH]HUR WR
WKHODVWPHDVXUDEOHFRQFHQWUDWLRQ 
%6)6 %ULVWRO6WRRO)RUP6FDOH 
%0, ERG\PDVVLQGH[ 
&)5 &RGHRI)HGHUDO5HJXODWLRQV 
&PD[ PD[LPXPSODVPDFRQFHQWUDWLRQ 
&PLQ PLQLPXPSODVPDFRQFHQWUDWLRQ 
&16 FHQWUDOQHUYRXVV\VWHP 
&216257 &RQVROLGDWHG6W DQGDUGVRI5HSRUWLQJ7ULDOV
&5) FDVHUHSRUWIRUP 
&65 FOLQLFDOVWXG\UHSRUW 
&<3 F\WRFKURPH3 
(&* HOHFWURFDUGLRJUDP 
('& HOHFWURQLFGDWDFDSWXUH 
(16 HQWHULFQHUYRXVV\VWHP 
(5. H[WUDFHOOXODU VLJQDOUHJXODWHGNLQDVH 
)'$ )RRGDQG'UXJ$GPLQLVWUDWLRQ 
)'5 ILUVWGHJUHHUHODWLYH*&3 *RRG&OLQLFDO3UDFWLFH 
*'1) JOLDOFHOOOLQHGHU LYHGQHXURWURSKLFIDFWRU 
*)5Ä® JOLDOFHOOOLQHGHULYHGQ HXURWURSKLFIDFWRUIDPLO\UHFHSW RUDOSKD
*, JDVWURLQWHVWLQDO 
*/3 JOXFDJRQOLNHSHSWLGH 
+%9 KHSDWLWLV%YLUXV 
+&9 KHSDWLWLV&YLUXV 
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI+'3( KLJKGHQVLW\SRO\HWK\OHQH
K(5* KXPDQHWKHUjJ RJRUHODWHGJHQH 
+57 KRUPRQHUHSODFHPHQWWKHUDS\
,% ,QYHVWLJDWRUÂ¶V%URFKXUH 
,%6 LUULWDEOHERZHOV\QGURPH 
,%6& LUULWDEOHERZHO V\QGURPHFRQVWLSDWLRQ 
,%6*6 ,UULWDEOH%RZHO6\QGURPH*OREDO6FDOH 
,%6' LUULWDEOHERZH OV\QGURPHGLDUUKHD 
,%60 LUULWDEOHERZHOV\QGURPHPL[HG 
,%666 ,UULWDEOH%RZHO6\QGURPH6HYHULW\6FRUH 
,%68 LUULWDEOHERZHO V\QGURPHXQFODVVLILHG
,& KDOIPD[LPDOLQKLELWRU\FRQFHQWUDWLRQ 
,&) ,QIRUPHG&RQVHQW)RUP 
,&+ ,QWHUQDWLRQDO&RXQFLOIRU+DUPRQLVDWLRQ 
,(& ,QGHSHQGHQW(WKLFV&RPPLWWHH,/& JURXSLQQDWHO\PSKRLGFHOOV 
,5% ,QVWLWXWLRQDO5HYLHZ%RDUG 
,77 LQWHQWLRQWRWUHDW 
,9 LQWUDYHQRXV 
,:56 LQWHUDFWLYHZHEUHVSRQVHV\VWHP 
-$. -DQXVNLQDVH 
0HG'5$ 0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV 
12$(/ QRREVHUYHGDGYHUVHHIIHFWOHYHO 
156 QXPHULFUDWLQJVFDOH17($( QRQWUHDWPHQWHPHUJHQWDGYHUVHHYHQW 
3%2 SODFHER 
3' SKDUPDFRG\QDPLFV
3( SK\VLFDOH[DPLQDWLRQ 
3JS 3JO\FRSURWHLQ 
3,. SKRVSKRLQRV LWLGHNLQDVH 
3. SKDUPDFRNLQHWLFV 
352 SDWLHQWUHSRUWHGRXWFRPH 
3<< SDQFUHDWLFSHSWLGH<< 
4& TXDOLW\FRQWURO 
47F% 47LQWHUYDOFRUUHFW HGE\%D]HWWÂ¶VIRUPXOD
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI47F) 47LQWHUYDOFRUUHFWHGE\)ULGHULFLDÂ¶VIRUPXOD 
5$6 UDWVDUFRPD 
5%& UHGEORRGFHOO 
5(7 5(DUUDQJHGGXULQJ7UDQVIHFWLRQ 
5,%$ 5HFRPELQDQW,PPXQREORW$VVD\
6$( VHULRXVDGYHUVHHYHQW 
6$3 6WDWLVWLFDO$QDO\VLV3ODQ 
6& VXEFXWDQHRXV 
6.1$6 DKXPDQQHXUREO DVWRPDFHOOOLQH 
67$7 VLJQDOWUDQVGXFHUDQGDFWL YDWRURIWUDQVFULSWLRQSURWHLQV 
686$5 VXVSHFWHGXQH[SHFWH GVHULRXVDGYHUVHUHDFWLRQ 
7($( WUHDWPHQWHPHUJHQWDGYHUVHHYHQW 
7PD[ WLPHWRPD[LPXPFRQFHQWUDWLRQ 
77 DKXPDQWK\URLGPHGXOODU\FDUFLQRPDFHOOOLQH 
8/1 XSSHUOLPLWRIQRUPDO 
:$3 ZRUVWDEGRPLQDOSDLQ 
:2&%3 ZRPDQRIFKLOGEHDULQJSRWHQWLDO 

&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI 35272&2/6800$5<
 6\QRSVLV
6SRQVRU %RVWRQ3KDUPDFHXWLFDOV,QF
7LWOH $3KDVHD5DQGRPL]HG'RXEOHE OLQG3ODFHERFRQWUROOHG
0XOWLFHQWHU6WXG\WR(YDOXDWHWKH(IILFDF\6DIHW\DQG7ROHUDELOLW\RI%26LQW KH7UHDWPHQWRI3DWLHQWVZLWK
'LDUUKHDSUHGRPLQDQW,UULWDEO H%RZHO6\QGURPH,%6'
3URWRFRO1XPEHU %26
3KDVH D
2EMHFWLYHVDQG
(QGSRLQWV2%-(&7,9(6 (1'32,176
3ULPDU\
x 7RHYDOXDWHLQSDWLHQWV
ZLWK,%6'WKHDEGRPLQDO
SDLQUHVSRQVHWR%26DIWHUZHHNVRIWUHDWPHQWUHODWLYHWRSODFHER3%2x KRXUZRUVWDEGRPLQDO
SDLQVFRUHV:$3DW
'D\FRPSDUHGWREDVHOLQHDYHUDJHGRYHUWKHZHHNSULRUWRHDFKUHVSHFWLYHWLPHSRLQW
x 7RHYDOXDWHWKHRYHUDOO
VDIHW\DQGWROHUDELOLW\RI%26LQWKHWUHDWPHQWRI,%6'GXULQJZHHNV
RIWUHDWPHQWUHODWLYHWR
3%2x ,QFLGHQFHRIDGYHUVH
HYHQWV$(VVHULRXVDGYHUVHHYHQWV6$(VGLVFRQWLQXDWLRQVEHFDXVH
RI$(VDQGDQ\
WUHDWPHQWUHODWHGVHYHUH$(V
6HFRQGDU\
x 7RHYDOXDWHWKHWUHDWPHQW
HIIHFWRI%26RQGHIHFDWLRQDIWHUZHHNVUHODWLYHWR3%2x &KDQJHLQVWRRO
FRQVLVWHQF\PHDVXUHGE\WKHGDLO\%ULVWRO6WRRO)RUP6FRUH%6)6DW
'D\FRPSDUHGWR
EDVHOLQHDYHUDJHGRYHUWKHZHHNSULRUWRHDFKUHVSHFWLYHWLPHSRLQW
x&KDQJHLQVWRRO
IUHTXHQF\PHDVXUHGE\
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRIWKHWRWDOQXPEHURI 
 VSRQWDQHRXVERZHO
PRYHPHQWVLQKRXUVDW'D\FRPSDUHGWREDVHOLQHDYHUDJHGRYHUWKHZHHNSULRUWRHDFKUHVSHFWLYHWLPHSRLQW
x 7RHYDOXDWHWKHWUHDWPHQW
HIIHFWRI%26RQ
,%6UHODWHGVLJQVDQGV\PSWRPVx &KDQJHLQWKH,%6
6HYHULW\6FRUH,%666
DW'D\FRPSDUHGWREDVHOLQH
x &KDQJHLQWKH,%6*OREDO
6FDOH,%6*6DW'D\
FRPSDUHGWREDVHOLQHDYHUDJHGRYHUWKHZHHNSULRUWRHDFKUHVSHFWLYHWLPHSRLQW
x 7RHYDOXDWHWKH
VWHDG\VWDWH
SKDUPDFRNLQHWLFV3.RI%26 x 0D[LPXPREVHUYHG
SODVPDFRQFHQWUDWLRQ
&
PD[WLPHWR& PD[7PD[
PLQLPXPSODVPDFRQFHQWUDWLRQ&
PLQDUHD
XQGHUWKHFRQFHQWUDWLRQYHUVXVWLPHFXUYH$8&IURPWLPH]HURWRKRXUVSRVWGRVH$8&
$8&
IURPWLPH]HURWRWKHODVWTXDQWLILDEOHFRQFHQWUDWLRQ$8&
W
6WXG\'HVLJQ  $SKDVHDUDQGRPL]HGGRXEOH EOLQG3%2FRQWUROOHG
PXOWLFHQWHUWULDOWRSURYLGHSU RRIRISULQFLSOHHIILFDF\RI
%26LQ,%6'SDWL HQWVDQGWRLQIRUPGRVHVHOHFWLRQIRU
VXEVHTXHQWGHYHORSPHQW
7KHVWXG\ZLOOFRPSULVHSKDVHV$3UHWUHDWPHQW3KDVH RIXSWRZHHNVLQZKLFKDOO
SDWLHQWVZLOOEHDVVHVVHGWRGHW HUPLQHHOLJLELOLW\7KLVSKDVH
ZLOOFRQVLVWRILQLWLDOVFUHHQLQJDVVHVVPHQWVDIWHUZKLFKHOLJLEOHSDWLHQWV ZLOOHQWHUD5XQLQ 3HULRGRIXSWRZHHNV
'XULQJWKH5XQLQSHULRGW KHSDWLHQWVZLOOFRPSOHWHDQ
HOHFWURQLFGLDU\WRFROOHFWGD LO\LQIRUPDWLRQUHODWHGWRWKHLU
,%6'V\PSWRPVERZHOIXQFWLRQ DQGUHVFXHPHGLFDWLRQXVH
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRIWRFRQILUPGLVHDVHDFWLYLW\DQGGLDU\FRPSOLDQFH
8SRQFRPSOHWLRQRIWKH5XQLQ3HU LRGSDWLHQWVZLOOUHWXUQWR
WKHVWXG\VLWHWRFRQILUPHOLJLE LOLW\IRUUDQGRPL]DWLRQLQWRWK H
GRXEOHEOLQGHG7UHDW PHQW3KDVH
$7UHDWPHQW3KDVH LQZKLFKHOLJLEOHSDWLHQWVZLOOEH
UDQGRPL]HGWRUHFHLYH %26RU3%2WZLFHGDLO\
ELGIRUDWRWDORIZHHNV% 26ZLOOEHDGPLQLVWHUHGDW
RIGRVHOHYHOV3DWL HQWVZLOOEHUDQGRPL]HGWRWKH
IROORZLQJFRKRUWV
x &RKRUW+LJK'RVHPJ%26ELGRUDOO\
x &RKRUW/RZ'RVH PJ%26ELGRUDOO\
x &RKRUW3%2PDWFKLQJ 3%2RUDOWDEOHWVELG
'XULQJWKHWUHDWPHQWSKDVH SDWLHQWVZLOOFRQWLQXHWR
FRPSOHWHWKHHOHFWURQLFGLDU\ WRFROOHFWGDLO\LQIRUPDWLRQ
UHODWHGWRWKHLU,%6'V\PSWRP VERZHOIXQFWLRQDQGUHVFXH
PHGLFLQH
$3RVWWUHDWPHQW3KDVH LQZKLFKDOOSDWLHQWVZKRFRPSOHWH
ZHHNVRIWUHDWPHQWZLOOUHWXUQ WRWKHFOLQLFDOIRUDZHHN
IROORZXSYLVLW
3DWLHQWVZKRGLVFRQWLQXHWUHDW PHQWHDUO\ZLOOEHDVNHGWR
UHWXUQWRWKHFOLQLFIRUVDIHW\DVVHVVPHQWV
6WXG\3RSXODWLRQ 0DOHDQGIHPDOHSDWLHQWVWR \HDUVRIDJHLQFOXVLYH
ZLWKDGLDJQRVLVRI,%6'
1XPEHURI3DWLHQWV3ODQQHG$SSUR[LPDWHO\SDW LHQWVZLOOEHVFUHHQHG ZLWKWKHLQWHQWRI
UDQGRPL]LQJSDWLHQW VIRUWKHVWXG\
'XUDWLRQRI3DWLHQW
3DUWLFLSDWLRQDQG6WXG\7KHGXUDWLRQRISDWL HQWSDUWLFLSDWLRQLV DQWLFLSDWHGWREHXSW R
ZHHNV
7KHGXUDWLRQRIWKH VWXG\LVDQWLFLSDWHG WREHDSSUR[LPDWHO\
PRQWKV
6WXG\6LWHV  8SWRVLWHVLQWKH8QLWHG6WDWHV
,QYHVWLJDWLRQDO
3URGXFW%26RUDOGRVHVELG
5HIHUHQFH 0DWFKLQJ3%2RUDOGRVHVELG
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI7UHDWPHQW 
&RQFRPLWDQW
3URGXFW1RWDSSOLFDEOH
6WDWLVWLFDO0HWKRGV (IILFDF\
7KLVLVDSKDVHDSURRIRISU LQFLSOHVWXG\'HVFULSWLYHDQG
LQIHUHQWLDOVWDWLVWLFDOPHW KRGVZLOOEHHPSOR\HG$VWDQGDORQH
6WDWLVWLFDO$QDO\VLV3ODQZLOO EHGHYHORSHGDQGDSSURYHGSULRU
WRGDWDEDVHORFN
$KLHUDUFKLFDOK\SRWKHVLV WHVWZLOOEHHPSOR\HGIRUWKH
SULPDU\HIILFDF\HQGSRLQWGHIL QHGDVDFKDQJHIURPEDVHOLQH
WR'D\LQWKHSDWLHQWUHSRU WHGRXWFRPHIRU:$3PHDVXUHG
GDLO\RQDQSRLQWQXPHULF UDWLQJVFDOH0HDQFKDQJHIURP
EDVHOLQHZLOOEHPHDVXUHGDV DFRQWLQXRXVYDULDEOHDQG
FRPSDUHGEHWZHHQWUHDWPHQWJU RXSVLQWKHIROORZLQJWHVWLQJ
RUGHUXVLQJDWWHVWRIHTXDOYDU LDQFHVZLWKDWZRWDLOHGDOSKD 
RI
+\SRWKHVLV
$FWLYH7UHDWPHQW*URXS &RKRUW&RKRUWYHUVXV
3%2&RKRUW
,IVWDWLVWLFDOO\VLJQLILFDQWDW 3WKHQSURFHHGWR
+\SRWKHVLV
+\SRWKHVLV
&RKRUW+LJK'RVHYHUVXV&RKRUW3%2,IVWDWLVWLFDOO\VLJQLILFDQWDW 3WKHQSURFHHGWR
+\SRWKHVLV
+\SRWKHVLV
&RKRUW/RZ'RVHYHUVXV&RKRUW3%2,IVWDWLVWLFDOO\VLJQLILFDQWDW 3WKHQSURFHHGWR
+\SRWKHVLV
+\SRWKHVLV
&RKRUW+LJK'RVHYHUVXV&RKRUW/RZ'RVH
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI6DIHW\
$GYHUVHHYHQWVZLOOEHUHFRUGHG IURPWKHWLPHRIFRQVHQWXQWLO
WKH'D\(QGRI6WXG\)RO ORZXSYLVLW7KHQXPEHUDQG
SHUFHQWDJHRISDWLHQW VZLWK$(VZLOOEHGL VSOD\HGE\V\VWHP
RUJDQFODVVDQGSUHIHUUHGWHUP XVLQJ0HGLFDO'LFWLRQDU\IRU
5HJXODWRU\$FWLYLWLHV9HUVL RQRUKLJKHUE\VWXG\
WUHDWPHQW6XPPDULHVLQWHUPVRI VHYHULW\DQGUHODWLRQVKLSWR
LQYHVWLJDWLRQDOSURGXFWZLOODOVR EHSURYLGHG$OOVHULRXV$(V
ZLOOEHVXPPDUL]HGLQDVLPLODU PDQQHU3DWLHQWOLVWLQJVRIDOO 
$(VFDXVLQJGLVFRQWLQXDWLRQRIL QYHVWLJDWLRQDOSURGXFWDQGDOO
6$(VZLOOEHSURGXFHG
$OO$(VZLOOEHOLVWHGIRULQGL YLGXDOSDWLHQWVVKRZLQJERWK
YHUEDWLPDQGSUHIHUUHGWH UPV6HSDUDWHVXPPDULHVRI
WUHDWPHQWHPHUJHQW6$(VDQG WUHDWPHQWHPHUJHQW$(V
UHODWHGWRLQYHVWLJDWLRQDOS URGXFWZLOOEHJHQHUDWHG
&RPSRXQG%26  %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%263URWRFRO'DWHDQG9HUVLRQ$XJXVWY
&RQILGHQWLDO   3DJHRI 6WXG\6FKHPD
)LJXUH 6WXG\6FKHPDWLF




&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO   3DJHRI 6FKHGXOHRI$FWLYLWLHV
7DEOH 6FKHGXOHRI$FWLYLWLHV

6FUHHQLQJ
'D\VWR
6WXG\9LVLW
5XQLQ3HULRGD
'D\VWR
6WXG\9LVLW
%DVHOLQH
'D\
6WXG\9LVLW
'D\Â“GD\
6WXG\9LVLW

'D\ Â“GD\
6WXG\9LVLW

'D\ Â“GD\
6WXG\9LVLW

'D\ Â“GD\
(QGRI7UHDWPHQW
(DUO\7HUPLQDWLRQE
6WXG\9LVLW
'D\ Â“GD\V
(QGRI6WXG\
6WXG\9LVLW 

3URFHGXUHV 3UHWUHDWPHQW 7UHDWPHQW )ROORZXS
,QIRUPHGFRQVHQW ;       
'HPRJUDSKLFV ;       
0HGLFDODQGVXUJLFDOKLVWRU\ ;       
5RPH,9DVVHVVPHQW ;       
&RQFRPLWDQWPHGLFDWLRQUHYLHZ ; ; ; ; ; ; ; ;
$GYHUVHHYHQWUHYLHZDQGHYDOXDWLRQ  ;  FRQWLQXRX V ;
3K\VLFDOH[DPLQDWLRQF ;  ;    ; 
+HLJKWZHLJKWDQGERG\PDVVLQGH[ ;G  ;  ;  ; ;
9LWDOVLJQV ;  ; ; ; ; ; ;
OHDGHOHFWURFDUGLRJUDP ;      ; 
&OLQLFDOVDIHW\ODERUDWRU\WHVWVH ; ; ; ;  ; 
+,9+&9+%9WHVWLQJ ;       
8ULQHSUHJQDQF\WHVW;   ;     ;  ; 
&UHDFWLYHSURWHLQDQGHU\WKURF\WH
VHGLPHQWDWLRQUDWHWHVWV;  ;  ;  ; ;
%LRPDUNHUVDPSOHFROOHFWLRQ   ;  ;  ; ;
3KDUPDFRNLQHWLFVDPSOHFROOHFWLRQI  ;  ;  ;  ;   
:RUVWDEGRPLQDOSDLQ ; ;J ;  K  ; ;K
%ULVWRO6WRRO)RUP6FDOH ; ;J;  K  ; ;K
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO   3DJHRI
6FUHHQLQJ
'D\VWR
6WXG\9LVLW
5XQLQ3HULRGD
'D\VWR
6WXG\9LVLW
%DVHOLQH
'D\
6WXG\9LVLW
'D\Â“GD\
6WXG\9LVLW

'D\ Â“GD\
6WXG\9LVLW

'D\ Â“GD\
6WXG\9LVLW

'D\ Â“GD\
(QGRI7UHDWPHQW
(DUO\7HUPLQDWLRQE
6WXG\9LVLW
'D\ Â“GD\V
(QGRI6WXG\
6WXG\9LVLW 

3URFHGXUHV 3UHWUHDWPHQW 7UHDWPHQW )ROORZXS
6SRQWDQHRXVERZHOPRYHPHQWVWRWDO
QXPEHURIVWRROV;J ;  K  ; ;K
,%6*6  ;J ;  K  ; ;K
5HVFXHPHGLFDWLRQV  ;J ;  K  ; ;K
,%666   ;    ; ;
(OLJLELOLW\UHYLHZ ;  ;     
5DQGRPL]DWLRQ   ;     
$GPLQLVWUDWLRQRILQYHVWLJDWLRQDOSURGXFW   'D\   'D\  
+%9 KHSDWLWLV%YLUXV+&9  KHSDWLWLV&YLUXV+,9 KXPDQL PPXQRGHILFLHQF\YLUXV,%6*6 ,UULWDEOH%RZHO6\QGURPH*OREDO 6FDOH
,%666 ,UULWDEOH%RZHO6\ QGURPH6HYHULW\6FRUH
D5XQLQPD\EHH[WHQGHGE\XSWR RQHZHHNLQDFFRUGDQFHZLWKWKH LQYHVWLJDWRUVMXGJHPHQW7KHIXOO ZHHN'D\VWRPD\ EHXVHGWR
UDQGRPL]HHOLJLEOHSDWLHQWV+ RZHYHUHIIRUWVVKRXOGEHPDGHWR UDQGRPL]HHOLJLEOHSDWLHQWVZLWK LQWRGD\VDIWHUFRPSOHWLQ JUXQLQSHULRG
E3URFHGXUHVSHUIRUPHGDW9LVLW (QGRI7UHDWPHQWRUXSRQ(DUO\ 7HUPLQDWLRQ(DUO\7HUPLQDWLRQSU RFHGXUHVDUHWREHSHUIRUPHGL QFORVH
SUR[LPLW\WRGLVFRQWLQXDWLRQRI GRVLQJIRUSDWLHQWVZKRDUHZLW KGUDZQIURPWKHVWXG\2WKHUSURFHGXUHVPD\EHSHUIRUPHGDW,QY HVWLJDWRURU
6SRQVRUGLVFUHWLRQ
F)XOOSK\VLFDOH[DPWR EHFRQGXFWHGDW6FUHHQLQJ6\PSWRPGLUHFW HGSK\VLFDOH[DPLQDWLRQVVKRXOGEH FRQGXFWHGDWVXEVHTXHQWYLVL WV
G+HLJKWDQGERG\PDVVLQGH[WREH FROOHFWHGDW6FUHHQLQJ9LVLWR QO\
H+HPDWRORJLFFRPSOHWHVHUXPFKHPLVWU\XULQDO\VLVSDQHOVDQGIH FDOFDOSURWHFWLQWREHFRPSOHWHGDVQRWHGLQ $SSHQGL[ 3DWLHQWVVKRXOG
UHIUDLQIURPIRRGRUGULQNVRWKHUWKDQZDWHUIRUDWOHDVWK RXUVSULRUWRREWDLQLQJDIDVWLQJJOXFRVHOHYHO
I3KDUPDFRNLQHWLF3.VHULDOEORRGVDPSOHVDUHWREHFROOHFWHGR Q'D\DQG'D\DWSUHGRVHDQG DWDQGKRXUVSRV WGRVH,I3.
VHULDOEORRGVDPSOHVFDQQRWEHFROOHFWHGRQ'D\3.VHULDOE ORRGVDPSOHVVKRXOGEHFROOHFWHG RQ'D\$SUHGRVHVDPSOHZL OOEH
REWDLQHGRQDOORWKHU7UHDWPHQW6W XG\9LVLWV$OORZDEOHVDPSOLQ JZLQGRZVIRU3.EORRGGUDZVZLOO EHPLQXWHVSULRUWRGRVLQJ IRUWKHSUHGRVH
VDPSOHWKHQÂ“PLQXWHVIRU DQGKRXUSRVWGRVHDQGÂ“ PLQXWHVIRUDQGKRXUVSRVWGRVH
J'DWDZLOOEHFROOHFWHGGDLO\IRUHQWLUH5XQLQ3HULRG
K'DWDZLOOEHFROOHFWHGGDLO\XQW LO(DUO\7HUPLQDWLRQRUXQWLO( QGRI6WXG\9LVLWZKLFKHYHULVODWHU

&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI ,1752'8&7,21
 6WXG\5DWLRQDOH
,UULWDEOHERZHOV\QGURPH,%6L VDJDVWURLQWHVWLQDO*,LOOQH VVZLWKDSUHYDOHQFHRI
DSSUR[LPDWHO\WRJOREDOO\ DQGFKDUDFWHUL]HGE\DFRQVWHO ODWLRQRIFOLQLFDO
V\PSWRPV(VWDEOLVKLQJDGLDJQR VLVDQGDVVHVVLQJUHVSRQVHWRWU HDWPHQWUHPDLQV
FKDOOHQJLQJEHFDXVHW KHUHDUHQRELRPDUNHUV WKDWUHOLDEO\FRUUH ODWHZLWKGLVHDVHVWDWH
%26LVDQRUDODJHQ WZLWKOLPLWHGV\VWHPLF DEVRUSWLRQWKDW LQKLELWV5(7
5(DUUDQJHGGXULQJ7UDQVIHFWLRQ DUHFHSWRUW\URVLQHNLQDVHWK DWLVK\SRWKHVL]HGWR
SOD\DNH\UROHLQWKHPDLQWHQDQ FHRIDKHDOWK\HQWHULFQHUYRXV V\VWHP(16,QKLELWLRQ
RI5(7PD\UHSUHVHQWDQRYHOW KHUDSHXWLFVWUDWHJ\IRUWKHWUHDW PHQWRI,%6E\
DWWHQXDWLQJYLVFHUDOK\SHUVHQVLW LYLW\DQGRUFRORQLFPRWLOLW\
%26KDVEHHQHYDOXDWHGLQKHDOWK \KXPDQVXEMHFWVDWGRVHVX SWRPJWZLFH
GDLO\ELGIRUZHHNV&RQVLVW HQWZLWKLWVORZRUDOELRDYDLOD ELOLW\%26ZDVVDIH
DQGZHOOWROHUDWHGZLWKQRVLJQLIL FDQWVDIHW\VLJQDOVLGHQWLILH G7KHSXUSRVHRIWKLVVWXG\
LVWRHYDOXDWHWKHHIILFDF\VDI HW\DQGWROHUDELOLW\RI%26 LQWKHWUHDWPHQWRI
SDWLHQWVZLWKGLDUUKHDS UHGRPLQDQW,%6,%6'
 %DFNJURXQG
 'LVHDVH8QGHU6WXG\
,UULWDEOHERZHOV\QGURPHLVDU HODWLYHO\FRPPRQ*,LOOQHVVFKDU DFWHUL]HGE\DQXPEHURI
FOLQLFDOV\PSWRPVLQFOXGLQJDE GRPLQDOSDLQDQGGLVFRPIRUWDEQ RUPDOERZHOKDELWV
DQGEORDWLQJ 6XEW\SHVRI,%6EDVHGRQWKHSUHGRPLQDQWERZHOKDELWVUHSRUW HGE\,%6SDWLHQWVLQFOXGHGL DUUKHD,%6'
FRQVWLSDWLRQ,%6&PL[HG, %60RUXQFODVVLILHG,%68& XUUHQWO\DSSURYHG
PHGLFDWLRQVIRU,%6DGGUHVVWKHUH VWRUDWLRQRISDWLHQWVÂ¶ERZHO KDELWVDQGDUHPLQLPDOO\
HIIHFWLYHLQDGGUHVVLQJDEGRPL QDOSDLQDQGGLVFRPIRUW%HFDXVH WKHHWLRORJ\RIWKH
GLVHDVHKDVQRWEHHQFOHDUO\HVW DEOLVKHGGLDJQRVLVLVGLIILFXO WDQGUHOLHVSULPDULO\RQWKH
SUHVHQFHRIDVSHFLILFV\PSWRPF RPSOH[RFFXUULQJLQWKHDEVHQFH RIDQDOWHUQDWLYH
H[SODQDWLRQ7KHGHYHORSPHQWRIFU LWHULDE\H[SHUWSDQHOVZLWK UHFHQWLWHUDWLRQVDV
UHFHQWO\DVKDVLPSURYHGWKHGLDJQRVLVDQGPDQDJHPHQWRI ,%6SDWLHQWV
   
,WLVJHQHUDOO\EHOLHYHGWKDWWKH VHQVRU\LQSXWVRXWSXWVLQWKH (16DQGFHQWUDOQHUYRXV
V\VWHP&16DUHDOWHUHGLQSDW LHQWVZLWK,%6DQGWKLVFRQWULEX WHVWRWKHVLJQVDQG
V\PSWRPVWKH\H[SHULHQFH)RUH [DPSOHSDWLHQWVZLWK,%6KDYHD KHLJKWHQHGDQG
GLVSURSRUWLRQDWHVHQVRU \H[SHULHQFHYLVFHUD OK\SHUVHQVLWLYLW\ IRUDJLYHQVWLPXOXV
 9LVFHUDOK\SHUVHQVLWLYLW\ DQGDEQRUPDOERZHOKDELWVPD\UHV XOW
IURPYLVFHUDODIIHUHQWQHXURQV RULQFUHDVHGQHUYHILEHUGHQVLW\ DQGVSURXWLQJWKDWKDYH
EHHQREVHUYHGLQWKHLQWHVWLQDOPXF RVDOWLVVXHVRI,%6SDWLHQWV  
7KHVHQVLWL]LQJHYHQWFDXVLQJYLVFHUDOCCI
CCI
CCI
CCI
CCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRIK\SHUVHQVLWLYLW\PD\EHWUDQVLHQW RUFKURQLFKRZHYHULWVLPSD FWRQWKH&16DQG(16
PD\EHORQJODVWLQJ 6XSHUQDW DQWVIURPWKHVHLQWHVWLQDO
WLVVXHVFDQVWLPXODWHQHUYHRXW JURZWKDQGLQFUHDVHQHXURQDOVLJ QDOLQJLQYLWUR
VXJJHVWLQJWKDWQHXURWURSKLFIDFW RUVDQGRULQIODPPDWRU\F\WRNL QHVPLJKWEHPHGLDWRUV
RIQHXURQDOSODVWLFLW\LQ,%6 
*LYHQWKHFHQWUDOUROHWKH(16 PD\SOD\LQPHGL DWLQJVLJQDOV 
EHWZHHQWKH&16DQGWKH LQWHVWLQH(16PRGXODWLRQPD\SURYLGHW KHUDSHXWLFEHQHILWWR
,%6SDWLHQWVE\LPSDFWLQJYLVFHUD OK\SHUVHQVLWLYLW\DQGLQWHVWL QDOPRWLOLW\ 
7KHRQO\GUXJVFXUUHQWO\DSSURYHG E\WKH)RRGDQG'UXJ$GPLQLVW UDWLRQ)'$IRUWKH
WUHDWPHQWRI,%6DUHDORVHWURQI RUZRPHQRQO\ULID[LPLQDQG HOX[DGROLQHIRUUHIUDFWRU\
,%6'DQGSOHFDQDWLGH OLQDFORWLGHDQGOXELSURVWRQHIRU,%6& 7KHPDMRULW\RIWKHVH
GUXJVDQGWKRVHXVHGRIIODEHOWRWU HDW,%6WDUJHWSDWLHQWVÂ¶ V\PSWRPVE\DOWHULQJ*,
PRWLOLW\DQGDUHPLQLPDOO\HIIH FWLYHLQDGGUHVVLQJDEGRPLQDOSD LQDQGGLVFRPIRUW2IWKH
)'$DSSURYHGDJHQWVRQO\DORVHWU RQLVK\SRWKHVL]HGWRPRGXODWH WKH&16DQG(16
 7KHUHIRUHDQDJHQWVXFKDV%26ZKLFKPD\DPHOLRUDWHYLVFHUDO K\SHUVHQVLWLYLW\DQGSRWHQWLDOO\ LPSDFWLQWHVWLQDOPRWLOLW\
ZRXOGDGGUHVVDVLJQLILFDQWXQP HWPHGLFDOQHHGIRU,%6DVVRFLDW HGSDLQ
 7KHÂ³5(7Â´Â³5(DUUDQJHG'XUL QJ7UDQVIHFWLRQÂ´*HQHDQGWKH (QWHULF
1HUYRXV6\VWHP
7KH5(7JHQHORFDOL]HGRQKXPDQFK URPRVRPHTHQFRGHVD UHFHSWRUW\SH
W\URVLQHNLQDVHZLWKDQH[WUDFH OOXODUGRPDLQDWUDQVPHPEUDQHG RPDLQDQGDQ
LQWUDFHOOXODUW\URVLQHNLQDVH GRPDLQ 7KHOLJDQGVIRU5(7KD YH
EHHQLGHQWLILHGDVQHXURWURSKLFID FWRUVRIWKHJ OLDOFHOOOLQH GHULYHGQHXURWURSKLFIDFWRU
*'1)IDPLO\LQFOXGLQJ*'1) QHXUWXULQDUWHPLQDQGSHUVHSKL Q/LJDQGELQGLQJWRLWV
FRUUHVSRQGLQJ*'1)IDPLO\UHFHSWRU
DOSKD*)5Ä®FR UHFHSWRUWULJJHUV5(7
GLPHUL]DWLRQDQGVXEVHTXHQWWUDQVSKRVSKRU\ODWLRQRILQWUDFHOOXO DUW\URVLQHV
 DQGOHDGVWRWKHDFWLYDWLRQRIG LIIHUHQWLQWUDFHOOXODUVLJQD OLQJ
FDVFDGHVLQFOXGLQJWKH-DQXVNLQ DVHVLJQDOWUDQVGXFHUDQGDFWL YDWRURIWUDQVFULSWLRQ
SURWHLQV-$.67$7 SKRVSKRLQRVLWLGH NLQDVHSURWHLQNLQDVH %3,.$.7DQGUDW
VDUFRPDH[WUDFHOOXODUVLJQDO UHJXODWHGNLQDVH5$6 (5.SDWKZD\V
0LFHGHILFLHQWLQWKH*'1)OLJD QGLWVFRUHFHSWRU*)5Ä®RUWKH 5(7SURWHLQLWVHOI
H[KLELWVHYHUHGHIHFWVLQNLGQH\D QG(16GHYHORSPHQW7KLVLPSO LFDWHV5(7VLJQDOLQJ
DVFULWLFDOWRWKHGHYHORSPHQWR IQRUPDONLGQH\VDQGWKH(16  7KH
UROHRI5(7LQWKHGHYHORSPHQWR IWKH(16LVDOVRDSSDUHQWLQS DWLHQWVZLWK
+LUVFKVSUXQJÂ¶VGLVHDVHZKRIUHTXHQWO\VXIIHUIURPFRORQLFREVW UXFWLRQEHFDXVHRID
ODFNRIQRUPDOFRORQLFLQQHUYD WLRQ,Q+LUVFKSUXQJÂ¶VGLVHDVHG LIIHUHQWORVVRIIXQFWLRQ
PXWDWLRQVWKDWRFFXULQWKH 5(7JHQHDFFRXQWIRUWKHKLJKHVWS URSRUWLRQRIERWKIDPLOLDO
DQGVSRUDGLFFDVHVRIWKHGLVHDVH 
:KLOHLWVUROHGXULQJWKHGHYHORSPHQ WRIWKH(16KDVEHHQZHOOHVWDEO LVKHGUHFHQW
UHSRUWVDOVRLPSOLFDWHDVLJQLIL FDQWUROHIRU5(7LQWKHPDLQWH QDQFHDQGSODVWLFLW\RIWKH
DGXOW(161HXURQVZLWKLQWKHVXEP XFRVDODQGP\HQWHULFSOH[XVR IWKHDGXOWKXPDQCCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRIFRORQKDYHEHHQVKRZQWRH[SUHVV 5(7DQGLWVFRUHFHSWRUV*)5Ä® DQG*)5Ä®ZKLOH
WKH*'1)OLJDQGLVH[SUHVVHGLQW KHPXVFXODULVPXFRVDDQGLQFL UFXODUDQGORQJLWXGLQDO
PXVFOHWLVVXH 6\VWHPLFDGP LQLVWUDWLRQRI*'1)LQDGXOW
URGHQWVUHVXOWVLQVLJQLILFDQWLQF UHDVHVLQVXEPXFRVDOQHXURQG HQVLW\LQERWKWKHVPDOO
LQWHVWLQHDQGFRORQDQ GDOWHUHGIXQFWLRQ  )XUWKHUPRUHDFRQGLWLRQDO
NQRFNRXWRIWKH5(7FRUHFHSWRU*)5Ä®UHVXOWVLQGHFUHDVHGFR ORQLFK\SHUVHQVLWLYLW\
LPSOLFDWLQJDUROHIRU5(7VLJQ DOLQJLQYLVFHUDOQRFLFHSWLRQ  
7KHUHIRUHE\UHGXFLQJ5(7VLJQD OLQJLQKLELWLRQRI5(7PD\PRG XODWH(16DFWLYLW\
 ,QYHVWLJDWLRQDO3URGXFW
%26IRUPHUO\*6.LV DSRWHQWDQGVHOHFWLYHLQKLELW RURI5(7WKDWKDV
EHHQVKRZQWRUHGXFHYLVFHUDOK\SHU VHQVLWLYLW\LQDQDQLPDOPRG HORI,%6DQGLQKLELW
FKROLQHUJLFLQGXFHGLQFUHDVHVLQ FRORQLFPRWLOLW\GHWDLOVDUH SURYLGHGLQWKH%26
,QYHVWLJDWRUÂ¶V%URFKXUH>,%@7 KHUHVXOWVIURPWKHVHSUHFOLQLF DOVWXGLHVVXJJHVWWKDW
LQKLELWLRQRI5(7ZLW KDSRWHQWVHOHFWLYHDQGJXWUHVWULFWHG VPDOOPROHFXOHPD\
UHSUHVHQWDQRYHOWKHUDSHXWLFVWU DWHJ\IRUWKHWUHDWPHQWRIDEG RPLQDOSDLQDQG
GHIHFDWLRQDEQRUPDOLWLHVLHG LDUUKHDLQSDWLHQWVZLWK,%6 WKURXJKWKHDWWHQXDWLRQRI
YLVFHUDOK\SHUVHQVLWLYLW\DQGRUF KROLQHUJLFDOO\ PHGLDWHGLRQW UDQVSRUWDQGFRORQLF
PRWLOLW\7KHSDWLHQWSRSXODWLRQ OLNHO\WRGHULYHWKHJUHDWHVW EHQHILWZRXOGFRPSULVH
LQGLYLGXDOVZLWK,%6'ZLW KLQFUHDVHG*,PRWLOLW\
 1RQFOLQLFDO6XPPDU\
$UDQJHRI LQYLWURDQGLQYLYRVWXGLHVKDYHEHHQFRQGXFWHGWR LQYHVWLJDWHWKHSULPDU\
VHFRQGDU\DQGVDIHW\SKDUPDFRORJ\ RI%26'HWDLOVDUHSURY LGHGLQWKH%26
,%
 ,Q9LWUR6WXGLHV









CCI
CCI
CCICCI
CCI
CCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI



 ,Q9LYR6WXGLHV










 3KDUPDFRNLQHWLFVDQG 3URGXFW0HWDEROLVPLQ$QLPDOV
















CCI
CCI
CCI
CCI
CCI
CCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI


 7R[LFRORJ\DQG1RQF OLQLFDO$VVHVVPHQWRI6DIHW\

























CCI
CCI
CCI
CCI
CCI
CCI
CCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI


























CCI
CCI
CCI
CCI
CCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI &OLQLFDO([SHULHQFH
6WXG\ HYDOXDWHGWKHVDIHW\WROH UDELOLW\SKDUPDFRNLQHWLFV3. DQG
H[SORUDWRU\SKDUPDFRG\QDPLFV3 'RIHVFDODWLQJVLQJOHDQGPXOW LSOHRUDOGRVHVRI
%26UDQJLQJIURPWRPJL QWKHIDVWHGVW DWHDQGPJ LQWKHIHGVWDWH$OO
GRVHVLQWKHVLQJOHDVFHQGLQJG RVHSRUWLRQRIWKHVWXG\ZHUHJH QHUDOO\VDIHDQGZHOO
WROHUDWHGZLWKDVDIHW\SURILOH VLPLODUWRWKDWRISODFHER3% 26LPLODUO\UHSHDWGRVH
DGPLQLVWUDWLRQRI%26IRU GD\VDWGRVHVUDQJLQJIURPW RPJELGLQWKHIHG
VWDWHZDVJHQHUDOO\VDIHDQGZHOO WROHUDWHG7KHUHZHUHQRGUXJ UHODWHGFOLQLFDOO\
VLJQLILFDQWFKDQJHVLQVDIHW\ODERU DWRU\WHVWVYLWDOVLJQV(& *VRUVWRROSDWWHUQVDV
DVVHVVHGE\WKH%ULVWRO6WRRO)R UP6FDOH%6)6LQWKLVVWXG\ 7KHUHZHUHQRVHULRXV
DGYHUVHHYHQWV6$(VFRQVLGHUHG UHODWHGWRWKHDGPLQLVWUDWLRQ RI%26$UHYLHZRI
DOO*,DGYHUVHHYHQWV$(VGHP RQVWUDWHGWKDWWKHRFFXUUHQFHRI *,$(VZDVVLPLODULQ
WKH3%2DQG%26W UHDWPHQWJURXSV7KHUHZDVQRSDWWHUQRU WUHQGZLWKGRVH
HVFDODWLRQVXJJHVWLYHRIDWUHDWPHQWHIIHFW
7KH3.SURILOHRI%26GHPRQVW UDWHGOLPLWHGRUDOELRDYDLODEL OLW\DQGV\VWHPLF
H[SRVXUHZLWKSODVPDFRQFHQWUDWL RQVJHQHUDOO\OHVVWKDQQJP /ZKHQPHDVXUHG
XWLOL]LQJDVHQVLWLYH DQDO\WLFDOPHWKRGWRGHWHFWFRQFHQWUDWLRQ VDVORZDVSJP/
([SRVXUHVZHUHGRVHGHSHQGHQW DQGOHVVWKDQGRVHSURSRUWLRQDO DOWKRXJKER[SORWVRI
GRVHQRUPDOL]HGSDUDPHWHUVVXJ JHVWHGGRVHSURSRUWLRQDOLW\EHWZH HQPJDQG
PJ'RVLQJZDVHVFDODWHGWR WKHKLJKHVWSRVVLEOHGRVHEHFDX VHSUHGLFWHGPHDQ
V\VWHPLFH[SRVXUHVGLGQRWH[FH HGWKHGHILQHGSODVPDWR[LFRNLQH WLFOLPLWV$8& WDQG
&PD[RIQJ
KP/DQGQJP/ UHVSHFWLYHO\DQGWKHUHZDVQR HYLGHQFHRI
GRVHOLPLWLQJWR[LFLWLHV7KHUH ZDVDFFXPXODWLRQRI%26ZLW KUHSHDWGRVLQJEXW
V\VWHPLFH[SRVXUHVUHPDLQHGYHU\ ORZDIWHUGD\VRIGRVLQJZ LWKUHVSHFWLYH
JHRPHWULFPHDQ&9$8& WDQG& PD[YDOXHVRIK
QJP/DQG
QJP/IRUWKHKLJKHV WGRVHRIPJELG%26Z DVOLNHO\DWVWHDG\
VWDWHEHIRUHWKDWWLPH$FFXPXOD WLRQZDVORZHUIRUGRVHVEHORZ PJELGWR
IROGDQGKLJKHVWIRUWKHKLJKHV WGRVHRIPJELGW RIROG
7KHVWXG\LQFOXGHGDSLORWIRRGH IIHFWJURXSWRHYDOXDWHWKHPD JQLWXGHRIDIRRG
FKDOOHQJHRQWKHELRDYDLODELOLW\ RIVLQJOHGRVH%26)ROORZ LQJDGPLQLVWUDWLRQRID
VLQJOHGRVHRI%26PJLQW KHIHGVWDWHW KHUHZDVDVPDO OGHFUHDVHLQH[SRVXUH
ZLWKIRRGZLWKGHFUHDVHVLQPHDQ& PD[DQG$8& YDOXHVLQWKHUDQJHRIWR
7KHWLPHWR& PD[7PD[UHPDLQHGWKHVDPHZLWKRUZ LWKRXWIRRG7KHVHIRRGHIIHFW
UHVXOWVZHUHGHHPHGQRWFOLQLFDO O\LPSRUWDQWGRVLQJ%26ZL WKRUZLWKRXWIRRGLVQRW
DQWLFLSDWHGWRDIIHFWIXWXUHHYDO XDWLRQRIVDIHW\RUHIILFDF\
%HFDXVH5(7LVH[SUHVVHGLQ HQWHURHQGRFULQHFHOOV OLQLQJWKHLQ WHVWLQDOPXFRVDDQ
H[SORUDWRU\REMHFWLYHRIWKHVWXG\ ZDVWRH[SORUHWKHHIIHFWRI %26RQJOXFDJRQOLNH
SHSWLGH*/3DQGSDQFUHDWLF SHSWLGH<<3<<H[FXUVLRQVLQ SODVPDKRZHYHUQR
FOHDUUHODWLRQVKLSRULPSDFWR Q%26DGPLQLV WUDWLRQDQGSHSW LGHVHFUHWLRQZDV
LGHQWLILHGCCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI 5LVN%HQHILW$VVHVVPHQW
6XPPDULHVRIILQGLQJVIURPQRQFOLQ LFDODQGFOLQLFDOVWXGLHVFRQ GXFWHGZLWK%26
FDQEHIRXQGLQWKH,%UHIHUWR WKH,%IRUDGGLWLRQDOGHWDLOV 7KHIROORZLQJVHFWLRQ
RXWOLQHVWKHULVNDVVHVVPHQWDQGPL WLJDWLRQVWUDWHJ\IRUWKLVS URWRFRO
7KHFXUUHQWVWXG\%26 UHSUHVHQWVWKHILUVWDGPLQLVWUD WLRQRI%26WR
SDWLHQWVZLWK,%6'& RQVLGHUDWLRQVIRUVDIHW\PRQLWRULQJDUHG HULYHGSULPDULO\IURPWKH
OLWHUDWXUHUHJDUGLQJ5( 7H[SUHVVLRQLQWKH LQWHVWLQHQRQFOLQLF DOGDWDDQGFOLQLFDO
H[SHULHQFHGRVLQJ%26WRQRU PDOKHDOWK\YROXQWHHUV6WXG\  LQ
ZKLFKQRFOLQLFDOO\UHOHYDQWUL VNVZHUHLGHQWLILHGWKDWZRXOGS UHFOXGHGRVLQJD5(7
LQKLELWRUIRUXSWRZHHNV LQSDWLHQWVZLWK,%6'
 5LVN$VVHVVPHQW











CCI
CCI
CCI
CCI
CCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI %HQHILW$VVHVVPHQW
3DWLHQWVUDQGRPL]HGWRWKHDFWLYH WUHDWPHQWDUPVPD\SRWHQWLDOO \H[SHULHQFH
LPSURYHPHQWLQWKHLU,%6'GXULQ JWKHFRXUVHRIWKHVWXG\7KRV HUDQGRPL]HGWRWKH
3%2DUPDUHQRWH[SHFWHGWRREWDL QDQ\EHQHILWEH\RQGWKDWRIW KHLUEDFNJURXQG
WUHDWPHQW
 2YHUDOO5LVN%HQHILW&RQFOXVLRQ
2QWKHEDVLVRIQRQFOLQLFDODQGF OLQLFDOVWXG\UHVXOWVWRGDWH OLPLWHGHIIHFWLYHDOWHUQDWLYH
WUHDWPHQWVDQGWKHVWUHQJWKR IWKHVFLHQWLILFK\SRWKHVLVXQGHU HYDOXDWLRQ%26LV
FRQVLGHUHGWRKDYH DIDYRUDEOHEHQHILW ULVNSURILOHIRUSDWL HQWVZLWK,%6'
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI 2%-(&7,9(6$1'(1'32,176
2%-(&7,9(6 (1'32,176
3ULPDU\
x 7RHYDOXDWHLQSDW LHQWVZLWK,%6'
WKHDEGRPLQDOSDLQUHVSRQVHWR
%26DIWHUZHH NVRIWUHDWPHQW
UHODWLYHWRSODFHER3%2x KRXUZRUVWDEGRPLQDOSDLQVFRUHV
:$3DW'D\FRPSDUHGWREDVHOLQH
DYHUDJHGRYHUWKHZHHNSULRUWRHDFKUHVSHFWLYHWLPHSRLQW
x 7RHYDOXDWHWKHRYHUDOOVDIHW\DQG
WROHUDELOLW\RI%26LQWKH
WUHDWPHQWRI,%6'GXULQJZHHNVRIWUHDWPHQWUHODWLYHWR3%2x ,QFLGHQFHRIDGYHUVHHYHQWV$(V
VHULRXVDGYHUVHHYHQWV6$(V
GLVFRQWLQXDWLRQVEHFDXVHRI$(VDQGDQ\WUHDWPHQWUHODWHGVHYHUH$(V
6HFRQGDU\ 
x 7RHYDOXDWHWKHWUHDWPHQWHIIHFWRI
%26RQGHIHFDWLRQDIWHU
ZHHNVUHODWLYHWR3%2
x &KDQJHLQVWRROFRQVLVWHQF\PHDVXUHG
E\WKHGDLO\%ULVWRO6WRRO)RUP6FRUH
%6)6DW'D\FRPSDUHGWREDVHOLQHDYHUDJHGRYHUWKHZHHNSULRUWRHDFKUHVSHFWLYHWLPHSRLQW
x&KDQJHLQVWRROIUHTXHQF\PHDVXUHG
E\WKHWRWDOQXPEHURIVSRQWDQHRXVERZHOPRYHPHQWVLQKRXUVDW'D\FRPSDUHGWREDVHOL QHDYHUDJHGRYHU
WKHZHHNSULRUWRHDFKUHVSHFWLYHWLPHSRLQW

x 7RHYDOXDWHWKHWUHDWPHQWHIIHFWRI
%26RQ,%6UHODWHGVLJQVDQG
V\PSWRPV
x &KDQJHLQWKH,%66HYHULW\6FRUH
,%666DW'D\FRPSDUHGWR
EDVHOLQH
x &KDQJHLQWKH,%6*OREDO6FDOH
,%6*6DW'D\FRPSDUHGWREDVHOLQHDYHUDJHGRYHUWKHZHHNSULRUWRHDFKUHVSHFWLYHWLPHSRLQW
x7RHYDOXDWHWKHVWHDG\VWDWH
SKDUPDFRNLQHWLFVRI%26 x0D[LPXPREVHUYHGSODVPD
FRQFHQWUDWLRQ& PD[WLPHWR& PD[7PD[
PLQLPXPSODVPDFRQFHQWUDWLRQ& PLQ
DUHDXQGHUWKHFRQFHQWUDWLRQYHUVXVWLPHFXUYH$8&IURPWLPH]HURWRKRXUVSRVWGRVH$8&
$8&IURP
WLPH]HURWRWKHODVWTXDQWLILDEOHFRQFHQWUDWLRQ$8&
W
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI 678'<'(6,*1
 2YHUDOO'HVLJQ
7KLVVWXG\LVDSKDVHDUDQGRPL] HGGRXEOHEOLQG3%2FRQWURO OHGPXOWLFHQWHUWULDO
GHVLJQHGWRSURYLGHWKHILUVWSUR RIRISULQFLSOHHIILFDF\RI%2 6LQ,%6'SDWLHQWV
DQGWRLQIRUPGRVHVHOHFWLRQIRU VXEVHTXHQWGHYHORSPHQW7KHVW XG\ZLOOFRQVLVWRID
SUHWUHDWPHQWSKDVHDZHHN GRXEOHEOLQGWUHDWPHQWSKDVHDQG DZHHN
SRVWWUHDWPHQWIROORZXSSHULRG
3UH7UHDWPHQW3KDVH 'XULQJWKHSUHWUHDWPHQWSKDVH SDWLHQWVZLOOEHHYDOXDWHGIRU
XSWRZHHNVWRDVVHVVHOLJLELO LW\7KHSUHWUHDWPHQWSKDVHZL OOFRQVLVWRILQLWLDO
VFUHHQLQJDVVHVVPHQWVDQG D5XQLQSHULRG
$IWHUWKHLQLWLDOVFUHHQLQJDVVH VVPHQWVKDYHEHHQSHUIRUPHGHO LJLEOHSDWLHQWVZLOOHQWHU
D5XQLQSHULRGRIXSWRZHHNV 'XULQJWKH5XQLQSHULRGWKH SDWLHQWVZLOOFRPSOHWH
DQHOHFWURQLFGLDU\WRFROOHFW GDLO\LQIRUPDWLRQUHODWHGWRWKH LU,%6'V\PSWRPVERZHO
IXQFWLRQDQGUHVFXHPHGLFLQHXVH WRFRQILUPGLVHDVHDFWLYLW\ DQGGLDU\FRPSOLDQFH
3DWLHQWVZLOODOVREHUHTXHVWHGWR GLVFRQWLQXHDQ\SURKLELWHGP HGLFDWLRQVGXULQJWKLV
SKDVHRIWKHVWXG\
8SRQFRPSOHWLRQRIWKH5XQLQS HULRGSDWLHQWVZLOOUHWXUQWRW KHVWXG\VLWHWRFRQILUP
HOLJLELOLW\IRUUDQGRP L]DWLRQLQWRDZHHNGRXEOHEOLQGHG7UHD WPHQW3KDVH
7UHDWPHQW3KDVH (OLJLEOHSDWLHQWVZLOOEHUDQGRPL]HGLQWRWKHIROORZL QJFRKRUWV
x &RKRUW+LJK'RVHPJ%26ELGRUDOO\
x &RKRUW/RZ'RVH PJ%26ELGRUDOO\
x &RKRUW3%2PDWFKLQJ3%2R UDOWDEOHWVELGRUDOO\
'XULQJWKHZHHNVRIGRXEOHEOLQ GWUHDWPHQWSDWLHQWVZLOOFRQ WLQXHWRUHFRUGWKHLUGDLO\
,%6'V\PSWRPVERZHOIXQFWLRQ DQGUHVFXHPHGLFLQHXVHLQWKH HOHFWURQLFGLDU\DV
GHVFULEHGLQ 6HFWLRQ 
3RVWWUHDWPHQW3KDVH $ZHHNSRVWWUHDWPHQWIROORZ XSYLVLWZLOORFFXUIRUSDWLHQ WV
ZKRFRPSOHWHWKH7UHDWPHQW3KDVH 'XULQJWKHZHHNVRIIROORZ XSSDWLHQWVVKRXOG
FRQWLQXHWRUHFRUGWKHLUGDLO\,% 6'V\PSWRPVERZHOIXQFWLRQ DQGUHVFXHPHGLFLQHXVH
LQWKHHOHFWURQLFGLDU\
3DWLHQWVZKRSUHPDWXUHO\GLVF RQWLQXHWUHDWPHQWVKRXOGUHWXUQWR WKHVWXG\FHQWHUWR
FRPSOHWHWKHHDUO\WHUPLQDWLRQ DVVHVVPHQWVDVVRRQDVSRVVLEOH DIWHUVWRSSLQJWKH
WUHDWPHQW
'DWDDQDO\VHVZLOORFFXUDIWHU DOOSDWLHQWVLQWKHWULDOKDYHF RPSOHWHG WKHODVWYLVLWRU
SURFHGXUHVKRZQLQWKH6F KHGXOHRI$FWLYLWLHV 6HFWLRQ 
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI3RVWVWXG\$FFHVVWR7KHUDS\ 1RSRVWWUHDWPHQWDFFHVVWRWKHUDS\ZLOOEHSURYLGHG
WRSDWLHQWVUDQGRPL]HGLQWKHVWXG\
 6WXG\'XUDWLRQIRU3DWLHQWV
8QOHVVVKRUWHQHGE\LQWROHUDEOH$(V RUUDSLGGLVHDVHSURJUHVVLR QHDFKSDWLHQWÂ¶V
SDUWLFLSDWLRQLQWKLVVWXG\LVDQW LFLSDWHGWRODVWXSWRZHH NV
7KHWRWDOGXUDWLRQRIWKLVVWXG\ LVDQWLFLSDWHGWREHDSSUR[LPD WHO\PRQWKVLQFOXGLQJ
SDWLHQWHQUROOPHQWWUHDWPHQWDQGIROORZXS
 1XPEHURI3DWLHQWV
$SSUR[LPDWHO\SDWLHQWV ZLOOEHVFUHHQHGWRUDQGRPL]HDSSUR[ LPDWHO\SDWLHQWV
ZLWK,%6'SDWLHQWVSHUFRKRUW
 5HSODFHPHQWRI3DWLHQWV
3DWLHQWVZKRVLJQWKH,&)DQGDU HUDQGRPL]HGEXWGRQRWUHFHLYH WKHLQYHVWLJDWLRQDO
SURGXFWPD\EHUHSODFHG2QFHU DQGRPL]HGSDWLHQWVZKRKDYHUHF HLYHGDWOHDVWGRVH
RILQYHVWLJDWLRQDOSURGXFWDQG DUHZLWKGUDZQIU RPWKHUDS\EHIRU HFRPSOHWLQJGD\VRI
GRVLQJRUDUHGLVFRQWLQXHGIURP WKHVWXG\IRUDQ\UHDVRQZLOOQ RWEHUHSODFHG
 1XPEHURI6LWHV
8SWRVLWHVLQWKH8QLWHG6WDW HVPD\SDUWLFLSDWHLQWKLVVWX G\
 5DWLRQDOHIRU6WXG\'HVLJQ
.H\DVSHFWVRIWKHVWXG\HJ HOLJLELOLW\FRKRUWVL]HVWRSS LQJFULWHULDVDIHW\GDWD
FROOHFWLRQHIILFDF\DVVHVVPHQWV XVHRI3%2DVFRQWURODQGXV HRISDWLHQWUHSRUWHG
RXWFRPH>352@WRROVDUHEDVHG XSRQJHQHUDOO\DFFHSWHGFOLQLFDO WULDOPHWKRGRORJLHVIRU
SKDVHDHIILFDF\VWXGLHVDQGSULR UVWXGLHVFRQGXFWHGLQSDWLHQ WVZLWK,%6
7KH5RPH,9 GLDJQRVWLFFULWHU LDIRU,%6LVWKHEHVWDFFHSWHG WRROIRU
VWDQGDUGL]HG,%6GLDJQRVLV
$5XQLQ3KDVHLVGHVLJQHGWRD FFRXQWIRUIOXFWXDWLRQVLQV\PSW RPVDQGWKHSRWHQWLDOIRU
ZLGHYDULDWLRQVLQERZHOKDELWV SDWLHQWGLDULHVWKDWUHFRUGIU HTXHQF\DQGVHYHULW\RI
GDLO\V\PSWRPVZLOOEHXVHGWRHQV XUHWKDWV\PSWRPVHYHULW\IOX FWXDWLRQVDUHLGHQWLILHG
DQGWDNHQLQWRDFFRXQWIRUVXEMHF WHOLJLELOLW\3DWLHQWVZLOOD OVREHDVVHVVHGRQWKHLU
DELOLW\WRUHFRUGWKHLUGLVHDVH UHODWHGLQIRUPDWLRQLQWKHUHTX LUHGPDQQHU
7KHXVHRI3%2DVDFRQWUROFRP SDUDWRULQ,%6FOLQLFDOWULDOVL VDFFHSWDEOHJLYHQWKH
ODFNRIFRQVLVWHQWO\HIIHFWLYHWU HDWPHQWV3ODFHERLVDQLPSRUW DQWFRPSRQHQWRI,%6
FOLQLFDOWULDOVJLYHQWKHKLJK 3%2HIIHFWLQWKLVSRSXODWLRQCCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI7KHNH\SULPDU\DQGVHFRQGDU\H QGSRLQWVLQWKLVVWXG\DUHEDVHG RQ352
DVVHVVPHQWV7KHVHDVVHVVPHQWVHY DOXDWHSDLQGHIHFDWLRQDQG, %6VLJQVDQG
V\PSWRPV$EGRPLQDOSDLQLQWHQVLW \LVPHDVXUHGXVLQJDQSRLQ WLHWR
QXPHULFUDWLQJVFDOH156WKDWD VNVSDWLHQWVGDLO\WRUDWHWKH LUZRUVWDEGRPLQDOSDLQ
:$3RYHUWKHSDVWKRXUV DVUHFRPPHQGHGE\WKH)'$JXLGDQFHRQ,%6 )'$
0D\ 7KHXVHRIWKH156IRUSDLQ KDVEHHQYDOLGDWHG LQ,%6FOLQLF DOVWXGLHV
 7KH,%66HYHULW\6FRUH,%666 DQG,%6*OREDO6FDOH,%6*6 DUHY DOLGDWHGDQGVWDQGDUGPHWKRGVRI
DVVHVVLQJ,%6V\PSWRPVLQFOLQLFDOWULDOV
$OWKRXJKWUHDWPHQWGXUDWLRQVO RQJHUWKDQZHH NVZLOOEHUHTXLU HGIRUWUXHDVVHVVPHQW
RIHIILFDF\LQ,%6SDWLHQWVLQ WKLVLQLWLDOSKDVHDVWXG\ ZHHNVVKRXOGEHVXIILFLHQWWR
LGHQWLI\DQ\HIILFDF\VLJQDOWKD WZDUUDQWVIXUWKHUFOLQLFDOLQY HQWLRQ
7KHXVHRIPXOWLSOHHQ UROOLQJVLWHVLVDLPHGDWPD[LPL]LQJH[WH UQDOYDOLGLW\DQGWR
PLQLPL]LQJWKHSRWHQWLDOLQIOXH QFHRIUHJLRQDOYDULDWLRQVLQGL HWH[HUFLVHKDELWVDQG
HWKQLFLW\
 -XVWLILFDWLRQIRU'RVH



















CCI
CCI
CCI
CCICCI CCI
CCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI
 (QGRI6WXG\'HILQLWLRQ
7KHHQGRIWKHVWXG\LVGHILQHGDV FRPSOHWLRQRIWKHODVWYLVLW RUSURFHGXUHVKRZQLQWKH
6FKHGXOHRI$FWLYLWLHVLQWKHWU LDOJOREDOO\$ SDWLHQWZLOOEH FRQVLGHUHGWRKDYHFRPSOHWHG
WKHVWXG\LIKHRUVKHKDVFRP SOHWHGDOOSKDVHVRIWKHVWXG\L QFOXGLQJWKHODVWYLVLWRU
WKHODVWVFKHGXOHGSURFHGXUHVK RZQLQWKH6FKHGXOHRI$FWLYLWLH V6HFWLRQ CCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI 678'<3238/$7,21
%HIRUHDQ\VWXG\VSHFLILFDFW LYLWLHVSURFHGXUHVWKHDSSURSULDW HZULWWHQLQIRUPHG
FRQVHQWPXVWEHREWDLQHG3URVSHF WLYHDSSURYDORISURWRFROGHYL DWLRQVWRUHFUXLWPHQW
DQGHQUROOPHQWFULWHULDDOVRNQRZ QDVSURWRFROZDLYHUVRUH[HP SWLRQVLVQRWSHUPLWWHG
 ,QFOXVLRQ&ULWHULD
,QRUGHUWREHHOLJLEOHWRSDUWL FLSDWHLQWKLVVWXG\DQLQGLYL GXDOPXVWPHHWDOORIWKH
IROORZLQJFULWHULD
$JH
 0DOHDQGIHPDOHSDWLHQWVPXVW EHWR\HDUVRIDJHLQFO XVLYHDWWKHWLPHRI
VLJQLQJLQIRUPHGFRQVHQW
5XQLQH'LDU\&RPSOLDQFH
 3DWLHQWKDVFRPSOHWHGWKHGD LO\HOHFWURQLFGLDU\RQDWOHDVW RIWKHGD\VGXULQJWKH
ZHHNSULRUWRUDQGRPL]DWLRQ$1' DWOHDVWRIWKHGD\VGXUL QJWKHZHHNVSULRU
WRUDQGRPL]DWLRQ3DWLHQWVKDYH XSWRZHHNVWRPHHWWKHVHFUL WHULD
7\SHRI3DWLHQWDQG'LVHDVH&KDUDFWHULVWLFV
 3DWLHQWPHHWVWKHGLDJQRVLVR I,%6EDVHGRQWKH5RPH,9GLDJ QRVWLFFULWHULD
  
 
x 5HFXUUHQWDEGRPLQDOSDLQRFFX UULQJRQDYHUDJHDWOHDVWGD\ SHUZHHNDQG
DVVRFLDWHGZLWKRUP RUHRIWKHIROORZLQJ
R 5HODWHGWRGHIHFDWLRQ
R $VVRFLDWHGZLWKDFKDQJHLQIU HTXHQF\RIERZHOPRYHPHQWV
R $VVRFLDWHGZLWKDFKDQJHLQ IRUPDSSHDUDQFHRIVWRRO

7KHVHFULWHULDPXVWEHIXOILOO HGIRUWKHODVWPRQWKVSULRU WRUDQGRPL]DWLRQDQG
RQVHWPXVWKDYHRFFXUUHGDWOHDV WPRQWKVSULRUWRUDQGRPL]DWL RQ
 3DWLHQWPHHWVWKHGLDJQRVLVR I,%6'VXEW\SHEDVHGRQ5RPH, 9GLDJQRVWLFFULWHULD
 2QGD\VZKHQWKHSDWLHQ WH[SHULHQFHV,%6V\PSWRPV
x $WOHDVWRIVWRROVDUH ORRVHRUZDWHU\$1'
x )HZHUWKDQRIV WRROVDUHKDUGCCI
CCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI 2YHUWKHILQDOGD\VRIWKH UXQLQSHULRGWKHSDWLHQWKDV DQDYHUDJHRI:$3VFRUHV
LQWKHSULRUKRXUVRIWR RQDWRQXPHULFDOUDW LQJVFDOHZKHUH
LQGLFDWHVQRSDLQDQGLQGLFD WHVZRUVWSDLQLPDJLQDEOH
 2YHUWKHILQDOGD\VRIWKH UXQLQSHULRGWKHSDWLHQWKDV DQDYHUDJHGDLO\%6)6
VFRUHÂ•RQDWRVFDOHZ KHUH KDUGOXPS\VWRROVD QG ZDWHU\OLTXLG
VWRROVDQGWKHUHPXVWEHDWOHDV WGD\VZLWKVWRROFRQVLVWHQ F\RI7\SHÂ•
 3DWLHQWLVQRWSODQQLQJWRF KDQJHKLVRUKHUXVXDOGLHWDQG OLIHVW\OHGXULQJWKHFRXUVH
RIWKHVWXG\
'LDJQRVWLF$VVHVVPHQWV
 3DWLHQWPXVWXQGHUJRRUSUH YLRXVO\KDYHXQGHUJRQHDDQDSS URSULDWHHYDOXDWLRQIRU
WKHLU,%6V\PSWRPVLQFOXGLQJDQ HYDOXDWLRQIRURUJDQLFVWUXFWX UDOHWLRORJLHVLILQWKH
SUHVHQFHRIDODUPV\PSWRPVD QGEDJHDSSURSULDWHVFUHHQLQJ IRUFRORUHFWDO
FDQFHULIDSSOLFDEOH
D ,IDWOHDVWRQHRIWKHIROORZLQJ DODUPIHDWXUHVDUHSUHVHQW WKHQWKHSDWLHQWPXVW
KDYHKDGDFRORQRVFRS\WKDWVKRXO GLQFOXGHELRSV\VLQFHWKHRQV HWRIV\PSWRPV
RUZLWKLQWKHSDVW\HDUV ZKLFKHYHULVOHVV
x 'RFXPHQWHGDQGXQH[SOD LQHGZHLJKWORVVRIÂ• ZLWKLQWKHSDV W
PRQWKV
x 1RFWXUQDOGLDUUKHD
x %ORRGPL[HGZLWKVWRROH[FHS WKHPRUUKRLGDOEOHHGLQJGHILQHG DV
RFFDVLRQDOEORRGIRXQGRQWKH WRLOHWSDSHURQO\ RUOLPLWHGGULS SLQJRIEORRG
LQWRWKHWRLOHWERZODIWHUGHIHFDWLRQ
x 8QH[SODLQHGLURQGHILFLHQF\DQHPLD
E ,IQRDODUPIHDWXUHVDUHSUH VHQWWKHQWKHSDWLHQWPXVWKDYH KDGDFRORQRVFRS\
RURWKHUDSSURSULDWHH[DPEDVHG RQFULWHULDDV RXWOLQHGEHORZ &RORUHFWDOFDQFHU
VFUHHQLQJWHVWVRWKHUWKDQFRORQRVF RS\DUHFRQVLGHUHGVHFRQGWL HUDQGFDQEH
GLVFXVVHGZLWKWKHVSRQVRU> @
x $JHÂ•Â•LI$IULFDQ$PHUL FDQ&RORQRVFRS\ZLWKLQWKHSD VW\HDUV
x )LUVWGHJUHHUHODWLYH)'5GLD JQRVHGZLWKFRORUHFWDOFDQFHUX QGHUDJH
25)'5VGLDJQRVHGZLWKFRORUHFWDOFDQFHUDWDQ\DJH&RORQRVF RS\
ZLWKLQSDVW\HDUV EHJLQQLQJ\HDUVEHIRUHDJHRI\RXQJHVW)'5DW
WLPHRIGLDJQRVLV
x $JHÂ•$1')'5GLDJQRVHGZLWKFR ORUHFWDOFDQFHUDWDQ\DJH 
&RORQRVFRS\ZLWKLQ SDVW\HDUVCCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI 3DWLHQWLVQHJDWLYHIRUVHUXP WLVVXHWUDQVJOXWDPLQDVH,J$DQ WLERG\W7*,J$SOXV
KDVHYLGHQFHRIGHWHFWDEOHVHUXP ,J$ZLWKLQWKHQRUPDOUHIHUHQF HUDQJH
:HLJKW
%RG\PDVVLQGH[%0,ZL WKLQWKHUDQJHWRNJPLQFOXVLYH
*HQGHU
0DOHDQGIHPDOHSDWL HQWVDUHHOLJLEOHLI
D 0DOHSDWLHQWV
$PDOHSDWLHQWPXVWDJUHHWRXVH FRQWUDFHSWLRQDVGHWDLOHGLQ $SSHQGL[ RI
WKLVSURWRFROGXULQJWKHWUHDWP HQWSHULRGDQGIRUDWOHDVWZ HHNVDIWHUWKH
ODVWGRVHRILQYHVWLJDWLRQDOSU RGXFW3DWLHQWVPXVWDOVRDJUHH WRUHIUDLQIURP
GRQDWLQJVSHUPGXULQJWKLVSHULRG
E )HPDOHSDWLHQWV
$IHPDOHSDWLHQWLVHOLJLEOHWR SDUWLFLSDWHLIVKHLVQRWSUHJQ DQWVHH
$SSHQGL[ QRWEUHDVWIHHGLQJDQGDWOHDVW RIWKHIROORZLQJFRQGLWLRQ V
DSSOLHV
L 1RWDZRPDQRIFKLOGEHDULQJ SRWHQWLDO:2&%3DVGHILQHGLQ
$SSHQGL[ 25
LL $:2&%3ZKRDJUHHVWRIROORZ WKHFRQWUDFHSWLYHJXLGDQFHLQ
$SSHQGL[ GXULQJWKHWUHDWPHQWSHULRG DQGIRUDWOHDVWZHHNVDIWHU
WKHODVWGRVHRILQY HVWLJDWLRQDOSURGXFW
,QIRUPHG&RQVHQW
&DSDEOHRIJLYLQJVLJQHGLQIR UPHGFRQVHQWZKLFKLQFOXGHVF RPSOLDQFHZLWKWKH
UHTXLUHPHQWVDQGUHVWULFWLRQVOLV WHGLQWKH,QIRUPHG&RQVHQW)R UP,&)DQGLQWKLV
SURWRFRO
3DWLHQWLVZLOOLQJWREHFR PSOLDQWZLWKVWXG\SURFHGXUHVL QFOXGLQJFRPSOHWLQJWKH
GDLO\HOHFWURQLFGLDU\GXULQJ WKH5XQLQ3HULRGDQGWKURXJKRXW WKHVWXG\
 ([FOXVLRQ&ULWHULD
$QLQGLYLGXDOIRUZKRPDQ\RIWK HIROORZLQJFULWHULDDSSO\ZLOO EHH[FOXGHGIURP
SDUWLFLSDWLRQLQWKLVVWXG\
*DVWURLQWHVWLQDOUHODWHG0HGLFDO&RQGLWLRQV
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI $WWKHWLPHRIVFUHHQLQJSDWL HQWKDVDGLDJQRVLVRIDQ,%6 VXEW\SHRWKHUWKDQ,%6'
EDVHGRQ5RPH,9FULWHULD %DV HGRQVWRROSDWWHUQVRQGD\VW KDW
WKHSDWLHQWH[SHULHQFHVV\PSWRPV RWKHU,%6VXEW\SHVDUHGHILQH GDVIROORZV
D ,%6&KDUGRUOXPS\VWRROV Â•RIERZHOPRYHPHQWVDQGORR VHRUZDWHU\
VWRROVÂ”RIERZHOPRYHPHQWV
E ,%60KDUGRUOXPS\VWRROV Â•RIERZHOPRYHPHQWVDQGORR VHRUZDWHU\
VWRROVÂ•RIERZHOPRYHPHQWV
F ,%68KDUGRUOXPS\VWRROV Â”RIERZHOPRYHPHQWVDQGORR VHRUZDWHU\
VWRROVÂ”RIERZHOPRYHPHQWV
 3DWLHQWKDVDKLVWRU\RILQI ODPPDWRU\RULPPXQHPHGLDWHG*, GLVRUGHUVLQFOXGLQJ
EXWQRWOLPLWHGWRLQIODPPDWR U\ERZHOGLVHDVHLH&URKQ
V GLVHDVHXOFHUDWLYH
FROLWLVPLFURVFRSLFFROLWLVDQGFHOLDFGLVHDVH
 3DWLHQWKDVKDGDQHSLVRGHRIG LYHUWLFXOLWLVZLWKLQPRQWKV SULRUWR6FUHHQLQJ
 3DWLHQWKDVDKLVWRU\RILQW HVWLQDOREVWUXFWLRQVWULFWXUH WR[LFPHJDFRORQ*,
SHUIRUDWLRQIHFDOLPSDFWLRQJDV WULFEDQGLQJEDULDWULFVXUJHU \DGKHVLRQVLVFKHPLF
FROLWLVRULPSDLUHGLQWHVWLQDOF LUFXODWLRQHJDRUWRLOLDFR FFOXVLYHGLVHDVH
 3DWLHQWKDVDQ\RIWKHIROORZLQJVXUJLFDOKLVWRU\
D &KROHF\VWHFWRP\ZLWK$1<KLVW RU\RISRVWFKROHF\VWHFWRP\ELO LDU\WUDFWSDLQ
$VXFFHVVIXOFKROHF\VWHFWRP\ZLW KQRSRVWRSHUDWLYHELOLDU\WUDF WSDLQLVQRW
H[FOXVLRQDU\
E $Q\DEGRPLQDOVXUJHU\ZLWKLQW KHPRQWKVSULRUWR6FUHHQLQJ 
F 0DMRUJDVWULFHVRSKDJHDOKHSDW LFSDQFUHDWLFRULQWHVWLQD OVXUJHU\
DSSHQGHFWRP\KHPRUUKRLGHFWRP\RU SRO\SHFWRP\JUHDWHUWKDQ PRQWKVSRVW
VXUJHU\DUHDOORZHG
 3DWLHQWKDVDKLVWRU\RUFX UUHQWHYLGHQFHRIOD[DWLYHDEXVH  
2WKHU0HGLFDO&RQGLWLRQV
 3DWLHQWKDVDKLVWRU\RIDF DUGLRYDVFXODUHYHQWLQFOXGLQJV WURNHP\RFDUGLDO
LQIDUFWLRQFRQJHVWLYHKHDUWIDLOXUH RUWUDQVLHQWLVFKHPLFDWW DFNZLWKLQPRQWKVSULRU
WR6FUHHQLQJ
 3DWLHQWKDVDKLVWRU\RIPD OLJQDQF\ZLWKLQ\ HDUVSULRUWR 6FUHHQLQJH[FHSW
VTXDPRXVDQGEDVDOFHOOFDUFLQRPDV RIWKHVNLQDQGFHUYLFDOFDU FLQRPDLQVLWX
 3DWLHQWKDVDKLVWRU\RIDOF RKRODEXVHRUELQJHGULQNLQJCCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI3DWLHQWKDVXQFRQW UROOHGK\SHUWHQVLRQ GHILQHGDVV\VWROLF EORRGSUHVVXUH
!PP+JRUDGLDVWROLFEORRG SUHVVXUH!PP+JDWWKHWLPH RI6FUHHQLQJ
3DWLHQWKDVDKLVWRU\RIVLJQL ILFDQWK\SHUVHQVLWLYLW\LQWR OHUDQFHRUDOOHUJ\WRDQ\GUXJ
FRPSRXQGIRRGRURWKHUVXEVWDQF HXQOHVVDSSURYHGE\WKH,QYH VWLJDWRU
/DERUDWRU\$VVHVVPHQWV  
)HFDOFDOSURWHFWLQ!ÈJJ 
+HPRJORELQ$FOHYHOÂ• RUDFRQILUPHGIDVWLQJSODVPDJ OXFRVHOHYHO
Â•PJG/
&RQILUPHGDODQLQH DPLQRWUDQVIHUDVH$/ 7![XSSHUOLPLWR IQRUPDO8/1
&RQILUPHGWRWDOELOLUXELQ!8 /1XQOHVVWKHSDWLHQWKDVDG RFXPHQWHGKLVWRU\RI
*LOEHUWÂ¶VV\QGURPH
&RQILUPHG47LQWHUYDOFRUUHF WHGE\)ULGHULFLDÂ¶VIRUPXOD47 F)RU47LQWHUYDO
FRUUHFWHGE\%D]HWWÂ¶VIRUP XOD47F%!PVHF
(YLGHQFHRIDFWLYHKHSDWLWLV% YLUXV+%9LQIHFWLRQEDVHG RQDSRVLWLYHKHSDWLWLV%
VXUIDFHDQWLJHQ+%V$JVFUHHQ
(YLGHQFHRIKHSDWLWLV&YLUXV +&9LQIHFWLRQEDVHGRQDSR VLWLYH+&9DQWLERG\
VFUHHQ3DWLHQWVZLWKDSRVLWLY H+&9DQWLERG\DWVFUHHQLQJPD\ EHHOLJLEOHLI
FRQILUPDWRU\WHVWLQJLH5 HFRPELQDQW,PPXQREORW$VVD\>5,%$@ RU+&951$YLUDO
ORDGSURYLGHGE\WKHVWXG\VLWH LVQHJDWLYH3DWLHQWVZKRKDYH EHHQ
VXFFHVVIXOO\WUHDWHGIRU+&9DUH HOLJLEOHLIDQXQGHWHFWDEOH+& 9YLUDOORDGDWOHDVW
PRQWKVDIWHUFRPSOHWLRQRIWU HDWPHQWFDQEHGHPRQVWUDWHG
+XPDQLPPXQRGHILFLHQF\YLUXV +,9RU+,9DQWLERG\SRVL WLYH
3ULRU&RQFRPLWDQW7KHUDS\
:LWKLQGD\VRIUDQGRPL]DWL RQSDWLHQWKDVXVHGHLWKHURI WKHIROORZLQJ
x K\GUR[\WULSWDPLQH+7 RU+7 UHFHSWRUDQWDJRQLVWVHJDORVHWURQ
RQGDQVHWURQRUUDPRVHWURQ
x (OX[DGROLQH
x $Q\RIWKHVWURQJLQKLELWRUV RI3JO\FRSURWHLQOLVWHGLQ $SSHQGL[ 
:LWKLQGD\VRIUDQGRPL]DW LRQSDWLHQWKDVXVHGDQ\RIWK HIROORZLQJCCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRIx /RSHUDPLGH1RWHORSHUDPLGHF DQEHXVHGGXULQJWKHVWXG\DV UHVFXH
PHGLFDWLRQEDVHGRQSURWRF ROVSHFLILHGJXLGHOLQHV>VHH 6HFWLRQ @
x %LOHDFLGVHTXHVWUDQWVVXFKDVF KROHVW\UDPLQHFROHVWLSRORU FROHVHYHODP

x $VSLULQRUDVSLULQFRQWDLQLQJ PHGLFDWLRQV!PJRIDVSLULQ SHUGD\RU
QRQVWHURLGDODQWLLQIODPPDWRU\G UXJVZKHQWDNHQVSHFLILFDOO\I RUWKH
V\PSWRPVRI,%6
x 1DUFRWLFRURSLRLG FRQWDLQLQJDJHQWV
x &DQQDELVFRQWDLQLQJSURGXFWV
x 'RFXVDWH
x (QHPDV
x *,SUHSDUDWLRQVLQFOXGLQJDQWDFLG VFRQWDLQLQJDOXPLQXPRUPDJ QHVLXP
DQWLGLDUUKHDODJHQWVDQWLVSDV PRGLFDJHQWVELVPXWKSHSSHUPLQW RLO
,%JDUG)'JDUGRUSURNLQHWLFDJHQWV
:LWKLQGD\VRIUDQGRPL]DWL RQUHFHLSWRIDQ\SUHVFULEHG RURYHUWKHFRXQWHU
V\VWHPLFKHUEDOLQFOXGLQJ6W- RKQÂ¶VZRUWRUWRSLFDOPHGLFD WLRQRUDQ\H[SHFWDWLRQ
RIUHTXLULQJXVHRIVXFKPHGLFDWL RQZKLOHSDUWLFLSDWLQJLQWKH VWXG\WKDWLQWKH
RSLQLRQRIWKH,QYHVWLJDWRUZRXOG LQWHUIHUHZLWKVWXG\SURFHGX UHVFRPSURPLVH
VDIHW\RUWKHVFLHQWLILF LQWHJULW\RIWKHGDWD
3DWLHQWKDVXVHGRULVH[ SHFWHGWRXVHWKHIROORZLQJDQWL ELRWLFV
x 5LID[LPLQZLWKLQGD\V SULRUWRUDQGRPL]DWLRQ
x 2WKHURUDODQWLELRWLFVZLWKLQ GD\VRIUDQGRPL]DWLRQZLWKW KHH[FHSWLRQ
RIWRSLFDODQWLELRWLFVRUD GD\FRXUVHZLWKDQDQWLELRWLF
+RZHYHUDSDWLHQWZLOOEHDOOR ZHGWRUHPDLQLQWKHVWXG\VKRXO GXQSODQQHGXVHRI
DQWLELRWLFVRWKHUWKDQULID[LPLQRF FXUDIWHUWKHSDWLHQWKDVEH HQUDQGRPO\DVVLJQHGWR
VWXG\GUXJ
:LWKLQPRQWKVSULRUWRU DQGRPL]DWLRQSDWLHQWKDVKDGVLJ QLILFDQWFKDQJHVWRKLVRU
KHUDQWLGHSUHVVDQWUHJLPHQLH DGGLWLRQRIDQHZDJHQWGLVF RQWLQXDWLRQRIDSULRU
DJHQWVLJQLILFDQWPRGLILFDWLRQVWR WKHGRVHRIDFXUUHQWPHGLF DWLRQ3DWLHQWVRQ



3DWLHQWVZLWKGLDJQRVLVRIRUV XVSHFWHGWRKDYHELOHDFLGPDOD EVRUSWLRQDUHQRWVSHFLILFDOO\H[FOXGHG
JLYHQWKHFKDOOHQJHRIGLDJQRVL QJWKHVHSDWLHQWVKRZHYHUXVH RIELOHDFLGVHTXHVWUDQWVDUHSURKLELWHG
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRIFKURQLFVWDEOHGRVHVRIDQWLGHSU HVVDQWVZLOOEHDOORZHGWRSDUW LFLSDWHLQWKHVWXG\
$VQHHGHGXVHRIEXVSLURQHDQGEHQ] RGLD]HSLQHVIRUDQ[LHW\LVS HUPLWWHGGXULQJWKH
VWXG\
:LWKLQGD\VSULRUWRUDQGRP L]DWLRQRUKDOIOLYHVLI NQRZQWKHSDWLHQWKDV
UHFHLYHGDQLQYHVWLJDWLRQDOGUXJ RULVFXUUHQWO\HQUROOHGLQD QLQYHVWLJDWLRQDOVWXG\
2WKHU([FOXVLRQV  
3DWLHQWLVXQDEOHWRVZDOORZ VROLGRUDOGRVDJHIRUPVZKROH ZLWKWKHDLGRIOLTXLG
SDWLHQWVPD\QRWFKHZGLYLGHG LVVROYHRUFUXVKWKHVWXG\GU XJ
3DWLHQWKDVDQHOHFWLYHV XUJHU\SODQQHGRUH[SHFWVWRQHHG HOHFWLYHVXUJHU\DWDQ\
WLPHGXULQJWKHVWXG\
3DWLHQWLVSUHJQDQWRUEUHDVWIHHGLQJ3DWLHQWKDVDQ\PHGLFDORUS V\FKRORJLFDOGLVRUGHURUFRQGLW LRQWKDWLQWKHRSLQLRQRI
WKH,QYHVWLJDWRUZRXOGFRPSUR PLVHWKHZHOOEHLQJRIWKHSDWLHQW RUWKHVWXG\RU
SUHYHQWWKHSDWLHQWIURPPHHWLQJRU SHUIRUPLQJVWXG\UHTXLUHPHQ WV
3DWLHQWKDVSRRUSHU LSKHUDOYHQRXVDFFHVV
3DWLHQWLVDQHPSOR\HHRIWKH ,QYHVWLJDWRURUVWXG\FHQWHU ZLWKGLUHFWLQYROYHPHQWLQ
WKHSURSRVHGVWXG\RURWKHUVWXGL HVXQGHUWKHGLUHFWLRQRIWKDW ,QYHVWLJDWRURUVWXG\
FHQWHUDVZHOODVIDPLO\PHPEHU VRIWKHHPSOR\HHVRUWKH,QYHV WLJDWRU
 /LIHVW\OH&RQVLGHUDWLRQV
'XULQJWKLVVWXG\SDWLHQWVZLOO EHDVNHGWRDEVWDLQIURPVWUHQ XRXVH[HUFLVHIRUKRXUV
EHIRUHHDFKEORRGFROOHFWLRQIRU FOLQLFDOODERUDWRU\WHVWV
2QO\RQGD\VZKHQSRVW GRVH3.EORRGVDPSOHVDUHWREHWDNHQVH HIRRWQRWHILQWKH
6FKHGXOHRI$FWLYLWLHV 6HFWLRQ SDWLHQWVZLOOEHDVNHGWR UHIUDLQIURPFRQVXPSWLRQ
RIIRRGDQGZDWHUIRUKRXUSUL RUWRDQGIRUKRXUVDIWHUDGP LQLVWUDWLRQRI
LQYHVWLJDWLRQDOSURGXFW) RRGDQGZDWHUPD\EHFRQVXPHG DGOLELWXPDWDOORWKHUWLPHV
GXULQJWKHVWXG\,QYHVWLJDWLRQD OSURGXFWVKRXOGEHWDNHQZLWK DSSUR[LPDWHO\P/
ZDWHU
 6FUHHQ)DLOXUHV
6FUHHQIDLOXUHVDUHGHILQHGDV SDWLHQWVZKRFRQVHQWWRSDUWLFLS DWHLQWKHFOLQLFDOWULDOEXW
DUHQRWVXEVHTXHQWO\UDQGRPL]HG$P LQLPDOVHWRIVFUHHQIDLOXU HLQIRUPDWLRQLVUHTXLUHG
WRHQVXUHWUDQVSDUHQWUHSRUWLQJR IVFUHHQIDLOXUHSDWLHQWVWR PHHWWKH&RQVROLGDWHG
6WDQGDUGVRI5HSRUWLQJ7ULDOV&216 257SXEOLVKLQJUHTXLUHPHQWV DQGWRUHVSRQGWR
TXHULHVIURPUHJXODWRU\ DXWKRULWLHV0LQLPDOLQIRUPDWLRQLQFOXG HVGHPRJUDSK\VFUHHQ
IDLOXUHGHWDLOVHOLJLELOLW\FULWHULDDQGDQ\6$(
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI,QGLYLGXDOVZKRGRQRWPHHWWKHFU LWHULDIRUSDUWLFLSDWLRQLQW KLVWULDOVFUHHQIDLOXUHPD\
EHUHVFUHHQHGZLWK0HGLFD O0RQLWRUDSSURYDO

&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI ,19(67,*$7,21$/352'8&7
 ,QYHVWLJDWLRQDO3URGXFWV
 ,QYHVWLJDWLRQDO3URGXFW'HVFULSWLRQ
,QYHVWLJDWLRQDO
3URGXFW1DPH %26 3ODFHER
'RVDJH)RUPXODWLRQ  7DEOHW 7DEOHW
8QLW'RVH
6WUHQJWKV'RVDJH
/HYHOVPJ[PJWDEOHWVDQG
PJ[PJWDEOHWV9LVXDOO\PDWFKLQJSODFHERWDEOHWV
DFURVVERWK%26GRVHOHYHOV
5RXWH
RI$GPLQLVWUDWLRQ 2UDO 2UDO
'RVLQJ,QVWUXFWLRQV 6ZDOORZZKROHZLWKDJODVVRI
ZDWHUGRQRWFKHZGLYLGH
GLVVROYHRUFUXVK6ZDOORZZKROHZLWKDJODVVRI
ZDWHUGRQRWFKHZGLYLGH
GLVVROYHRUFUXVK
3DFNDJLQJ
DQG/DEHOLQJ ,QYHVWLJDWLRQDOSURGXFWZLOOEH
SURYLGHGLQZKLWHRSDTXH
KLJKGHQVLW\SRO\HWK\OHQH+'3(
ERWWOHVZLWKDFKLOGUHVLVWDQW
FORVXUH(DFKERWWOHZLOOEHODEHOHG
DVSHUFRXQWU\UHTXLUHPHQW,QYHVWLJDWLRQDOSURGXFWZLOOEH
SURYLGHGLQZKLWHRSDTXH+'3(
ERWWOHVZLWKDFKLOGUHVLVWDQW
FORVXUH(DFKERWWOHZLOOEHODEHOHG
DVSHUFRXQWU\UHTXLUHPHQW
0DQXIDFWXUHU  :X;L67$6KDQJKDL&KLQD :X;L67$6KDQJKDL&KLQD
 3UHSDUDWLRQ+DQGOL QJ6WRUDJH$ FFRXQWDELOLW\
 $FTXLVLWLRQ DQGDFFRXQWDELOLW\
7KH,QYHVWLJDWRURUGHVLJQHHP XVWFRQILUPDSSURSULDWHWHPSHUDWX UHFRQGLWLRQVKDYH
EHHQPDLQWDLQHGGXULQJWUDQVLWIRU DOOLQYHVWLJDWLRQDOSURGXFW UHFHLYHGDQGDQ\
GLVFUHSDQFLHVDUHUHSRUWHGDQGUHVR OYHGEHIRUHXVHRIWKHLQYHV WLJDWLRQDOSURGXFW
7KH,QYHVWLJDWRULQVWLWXWLRQR UWKHKHDGRIWKHPHGLFDOLQVWL WXWLRQZKHUHDSSOLFDEOHLV
UHVSRQVLEOHIRULQYHVWLJDWLRQDO SURGXFWDFFRXQWDELOLW\UHFRQFL OLDWLRQDQGUHFRUG
PDLQWHQDQFHLHUHFHLSWUHF RQFLOLDWLRQDQGILQDOGLVSRVLWL RQUHFRUGV
 3URGXFW6WRUDJHDQG6WDELOLW\
$OOLQYHVWLJDWLRQDOSURGXFWPXVW EHVWRUHGLQDVHFXUHHQYLURQ PHQWDOO\FRQWUROOHGDQG
PRQLWRUHGPDQXDORUDXWRPDWHGD UHDLQDFFRUGDQFHZLWKWKHODE HOHGVWRUDJH
FRQGLWLRQVZLWKDFFHVVOLPLWHG WRWKH,QYHVWLJDWRUDQGDXWKRUL] HGVLWHVWDII
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI)XUWKHUJXLGDQFHDQGLQIRUPDWLRQIR UWKHILQDOGLVSRVLWLRQRIX QXVHGLQYHVWLJDWLRQDO
SURGXFWVDUHSURYLGHGLQWKH3KDUPDF\0DQXDO
 0HDVXUHVWR0LQLPL]H%LDV
7KLVLVDUDQGRPL]HGGRXEOHE OLQGHG3%2FRQWUROOHGVWXG\3DW LHQWVVKRXOGEH
UDQGRPL]HGDVFORVHDVSRVVLEOH WRWKHWLPHRI WKHSODQQHGILUV WGRVHRIVWXG\WUHDWPHQW
5DQGRPL]DWLRQZLOOEHF RQGXFWHGYLDDQLQWHUDFWLYHZHEUHVSRQVH V\VWHP,:56LQD
UDWLRIRUSDWLHQWVWRUHF HLYH%26PJ%26 PJRU3%23DWLHQWV
ZLOOEHDVVLJQHGWRWKHWUHDWPHQWD UPVXVLQJDSHUPXWHGEORFNU DQGRPL]DWLRQVWUDWLILHG
E\VLWHSDWLHQWVSHUJURXS 7KHUDQGRPL]DWLRQVFKHGXOHZLO OEHJHQHUDWHGE\WKH
6WXG\%LRVWDWLVWLFLDQDQGZLOO EHWUDQVIHUUHGWRWKH,:56WHDP IRUORDGLQJLQWRWKH
V\VWHP7KHUDQGRPL]DWLRQILOHZ LOOEHKHOGE\W KH6WXG\%LRVWD WLVWLFLDQXQWLOWKHHQGRI
WKHWULDODQGZKHQWKH GDWDEDVHKDVEHHQORFNHG
7KHVSRQVRUVLWHVWDIIDQGSDW LHQWVZLOOEHEOLQGHGWRWKHWU HDWPHQWDVVLJQPHQW
%26DQG3%2ZLOOEHVLPLODU LQDSSHDUDQFHDQGSURYLGHGLQ ZKLWHRSDTXH
KLJKGHQVLW\SRO\HWK\OHQH+'3( ERWWOHVHDFKZLWKDFKLOGUHV LVWDQWFORVXUH(DFK
ERWWOHZLOOEHODEHOHGDV SHUFRXQWU\UHTXLUHPHQW
2QO\LQDPHGLFDOHPHUJHQF\ZLO ODSDWLHQWÂ¶VWUHDWPHQWDVVLJQPH QWEHXQEOLQGHGDQG
WKLVSURFHVVZLOOEHSHUIRUPHGDQ GGRFXPHQWHGLQWKH,:56(YHU \HIIRUWVKRXOGEH
PDGHWRFRQWDFWWKH0HGLFDO0RQL WRUWRGLVFXVVXQEOLQGLQJSULRU WREUHDNLQJWKHEOLQG
 'RVLQJDQG$GPLQLVWUDWLRQ
2QO\SDWLHQWVHQUROOHGLQWKHVW XG\PD\UHFHLYHLQYHVWLJDWLRQDO SURGXFWDQGRQO\
DXWKRUL]HGVLWHVWDIIPD\VXSSO\RU DGPLQLVWHULQYHVWLJDWLRQDO SURGXFW
(OLJLEOHSDWLHQWVZLOO EHUDQGRPL]HGWRUHFHLYHIRUDW RWDORIZHHNV%26DW
RIGRVHOHYHOVRU3%2ELG 3DWLHQWVZLOOEHUDQGRPL]HGWRW KHIROORZLQJFRKRUWV
x &RKRUW+LJK'RVH[PJ WDEOHWVIRUWKHPJ%26 ELGRUDOO\
x &RKRUW/RZ'RVH[PJW DEOHWVIRUWKHPJ%26E LGRUDOO\
x &RKRUW3%2[YLVXDOO\PDW FKHG3%2WDEOHWVELGRUDOO\
)RUHDFKGRVHOHYHODQGDWHDFK GRVLQJWLPHSRLQWWKHWDEOHWV DUHWREHVZDOORZHGZLWK
DSSUR[LPDWHO\P/URRPWHPSHUDWX UHZDWHUDQGDUHWREHVZDOO RZHGZKROHLHQRW
GLYLGHGFUXVKHGGLVVROYHGR UFKHZHG2QGD\VZKHQSRVWGRVH 3.EORRGVDPSOHVDUH
WREHWDNHQVHHIRRWQRWHIL QWKH6FKHGXOHRI$FWLYLWLHV 6HFWLRQ SDWLHQWVZLOOEH
DVNHGWRUHIUDLQIURPFRQVXPSWLR QRIIRRGDQGZDWHUIRUKRXU SULRUWRDQGIRUKRXUV
DIWHUDGPLQLVWUDWLRQRILQYHV WLJDWLRQDOSURGXFW)RRGDQGZDWHU PD\EHFRQVXPHG DG
OLELWXPDWDOORWKHUWLPHVGXULQJWKHVWXG\
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI3DWLHQWVZLOOEHLQVWUXFWHGWRWD NHWKHLQYHVWLJDWLRQDOSURGXFW DSSUR[LPDWHO\HYHU\
KRXUVDWDSSUR[LPDWHO\WKHVD PHWLPHHDFKGD\,IDSDWLHQW PLVVHVDGRVHDWDJLYHQ
WLPHSRLQWDQGWKHWLPHLVZLWKLQ KRXUVRIWKHUHJXODUO\VFKH GXOHGGRVLQJWLPHWKH
SDWLHQWVKRXOGEHLQVWUXFWHGWRWD NHWKHLQYHVWLJDWLRQDOSURGXF W,ILWKDVEHHQORQJHUWKDQ
KRXUVWKHSDWLHQWVKRXOGVNLS WKHPLVVHGGRVHDWWKDWWLPHSR LQWDQGUHVXPHWKH
UHJXODUO\VFKHGXOHGGR VLQJVFKHGXOHDWWKHQH[WVFKHGXOHGWLPHS RLQW
,QWKHHYHQWRIYRPLWLQJIROORZL QJDGPLQLVWUDWLRQ%26VKRX OGQRWEHWDNHQXQWLOWKH
QH[WVFKHGXOHGGRVH
 'RVHPRGLILFDWLRQ
6WXG\WUHDWPHQWVKRXOGEHLQWHUU XSWHGLIWKHSDWLHQWUHSRUWVDQ \WUHDWPHQWUHODWHGVHYHUH
$(7KHUDS\VKRXOGRQO\ EHUHVWDUWHGDIWHU DSSURYDOE\WKH0HGL FDO0RQLWRU
,IWKHUDS\LVUHVWDUWHGWKHVDPH GRVHVKRXOGEH DGPLQLVWHUHGD VWKDWSULRUWR
RFFXUUHQFHRIWKH$(,IWKHSDW LHQWLVVWLOOKDYLQJWROHUDELOL W\LVVXHVDQGDQ$(UHRFFXUV
WKHGRVHPD\EHUHGXFHGIURPW DEOHWVRIVWXG\WUHDWPHQWELGW RWDEOHWRIVWXG\
WUHDWPHQWELGZLWKRXWEU HDNLQJWKHVWXG\EOLQG
,IDQRWKHU$(RFFXUVDIWHUWKHVW XG\WUHDWPHQWGRVHUHGXFWLRQ VWXG\WUHDWPHQWZLOOEH
SHUPDQHQWO\GLVFRQWLQXHGDQGWKH VXEMHFWIROORZ HGXQWLOWKHHQG RIWKHVWXG\
 ,QYHVWLJDWLRQDO3 URGXFW&RPSOLDQFH
$OOSDWLHQWVLQWKLVVWXG\ZLOOFR PPHQFHWKHUDS\RQVLWHRQ6WX G\'D\RUDO
LQYHVWLJDWLRQDOSURGXFWZLOOEH DGPLQLVWHUHGXQGHUFOLQLFVWDII VXSHUYLVLRQ$IWHUSDWLHQWV
DUHGLVFKDUJHGWRFRQWLQXHWKHUDS \DWKRPHFRPSOLDQFHZLOOEH DVVHVVHGRQ
VXEVHTXHQWYLVLWVE\UHWXUQHGWDEO HWFRXQW$GPLQLVWUDWLRQRIL QYHVWLJDWLRQDOSURGXFWDQG
DQ\GHYLDWLRQVIURPWKHSUH VFULEHGGRVDJHUHJLPHQVKRXOGEHU HFRUGHGLQWKHFDVH
UHSRUWIRUP&5)DQG'UXJ$FFRXQWDELOLW\5HFRUG
 &RQFRPLWDQW7KHUDS\
5HIHUWR$SSHQGL[ IRUPRUHGHWDLOVRQZKLFKF RQFRPLWDQWPHGLFDWLRQVDUH
SHUPLWWHGDQGZKLFKDUHH[FOXGHG ZKLOHSDWLHQWVDUHRQVWXG\
$Q\SULRURUFRQFRPLWDQWWKHUDS\ LQFOXGLQJRYHUWKHFRXQWHURU SUHVFULSWLRQPHGLFLQHV
YLWDPLQVDQGRUVXSSOHPHQWVWDN HQGD\VSULRUWRWKHILUVWG RVHRILQYHVWLJDWLRQDO
SURGXFWWKURXJKWKH(QGRI6WXG\9LVLWPXVWEHUHFRUGHGDORQJ ZLWK
x 5HDVRQIRUXVH
x 'DWHVRIDGPLQLVWUDWLRQLQ FOXGLQJVWDUWDQGHQGGDWHV
x 'RVDJHLQIRUPDWLRQLQFOXGLQJGRVHDQGIUHTXHQF\ 
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI7KH0HGLFDO0RQLWRUVKRXOGEHF RQWDFWHGLIWKHU HDUHDQ\TXHVWL RQVUHJDUGLQJ
FRQFRPLWDQWRUSULRUWKHUDS\
)RUWKLVSURWRFRODS UHVFULSWLRQPHGLFDWL RQLVGHILQHGDVDPH GLFDWLRQWKDWFDQEH
SUHVFULEHGRQO\E\DSURSHUO\DXW KRUL]HGOLFHQVHGFOLQLFLDQ0H GLFDWLRQVWREHUHSRUWHG
LQWKH&5)DUHFRQFRPLWDQWSUHVF ULSWLRQPHGLFDWLRQVRYHUWKHF RXQWHUPHGLFDWLRQV
YDFFLQHVYLWDPLQVDQGVXSSOHPHQWV
 5HVFXH0HGLFLQH
'XULQJWKHGRXEOHEOLQG7UHDWPHQ W3KDVHRIWKHVWXG\SDWLHQWV ZLOOEHDOORZHGWRWDNH
ORSHUDPLGHUHVFXHPHGLFDWLRQIRU WKHDFXWHWUHDWPHQWRIXQFRQWU ROOHGGLDUUKHD,WLV
UHFRPPHQGHGWKDWSDWLHQWVUHIUDL QIURPORSHUDPLGHXQOHVVDPLQL PXPRIRUPRUH
XQFRQWUROOHGGLDUUKHDHYHQWVWKDW FDXVHVLJQLILFDQWGLVFRPIRUW DQGSUHYHQWQRUPDO
HYHU\GD\DFWLYLWLHVDUHH[SHULH QFHGLQDJLYHQKRXUSHULRG
,IORSHUDPLGHPXVWEHXVHGSDWL HQWVPXVWQRWH[FHHGWKHPJ XQLWGRVHZKLFKPD\
EHWDNHQRQFHDSSUR[LPDWHO\HYHU \KRXUVDQGPXVWQRWH[FHHGW KHIROORZLQJGRVLQJ
UHTXLUHPHQWV
x 1RPRUHWKDQXQLWGRVHVRYHU DFRQWLQXRXVKRXUWLPHSHULR GPJGD\
x 1RPRUHWKDQXQLWGRVHVRYHU DFRQWLQXRXVKRXUWLPHSHULR GPJRYHU
GD\V
x 1RPRUHWKDQXQLWGRVHVRYH UDFRQWLQXRXVGD\WLPHSHULRG 
7KHXVHRIORSHUDPLGHUHVFXHPH GLFDWLRQVKRXOGEHUHFRUGHGHOHF WURQLFDOO\
 ,QWHUYHQWLRQ$IWHU WKH(QGRIWKH6WXG\
%26ZLOOQRWEHSURYLGHGWRV WXG\SDWLHQWV DIWHUWKHHQGRI WKHVWXG\
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI ',6&217,18$7,21:,7+'5$:$/
 'LVFRQWLQXDWLRQRI,Q YHVWLJDWLRQDO3URGXFW
$SDWLHQWPD\GLVFRQWLQXHIURPV WXG\WUHDWPHQWDWDQ\WLPHDWK LVRUKHURZQUHTXHVWRU
PD\EHZLWKGUDZQDWDQ\WLPHDW WKHGLVFUHWLRQRIWKH,QYHVWLJD WRUIRUVDIHW\EHKDYLRUDO
RUDGPLQLVWUDWLYHUHDVRQV'LVFR QWLQXDWLRQIURPWKHLQYHVWLJDWL RQDOSURGXFWGRHVQRW
PHDQGLVFRQWLQXDWLRQIURPWKHVWXG \DQGUHPDLQLQJVWXG\SURFHG XUHVVKRXOGEH
FRPSOHWHGDVLQGLFDWHGE\WKHVW XG\SURWRFRO,IDFOLQLFDOO\V LJQLILFDQWILQGLQJ LVLGHQWLILHG
LQFOXGLQJEXWQRWOLPLWHGWR FKDQJHVIURPEDVHOLQHDIWHUHQ UROOPHQWWKH,QYHVWLJDWRURU
TXDOLILHGGHVLJQHHZLOOGHWHUPL QHLIDQ\FKDQJHLQSDWLHQWPDQD JHPHQWLVQHHGHG$Q\
QHZFOLQLFDOO\UHOHYDQWILQGL QJZLOOEHUHSRUW HGDVDQ$(
8SRQLQYHVWLJDWLRQDOSURGXFWGLVF RQWLQXDWLRQSDWLHQWVVKRXOGF RPSOHWHDOOSURFHGXUHV
FROOHFWHGLQWKH'D\(QGRI7UH DWPHQWYLVLWDVDSSOLFDEOHSH UWKH6FKHGXOHRI
$FWLYLWLHV 6HFWLRQ 
 'LVFRQWLQXDWLRQ:LWKGUDZDOIURPWKH6WXG\
$SDWLHQWPD\ZLWKGUDZ IURPWKHVWXG\DWDQ\WLPHDWKLVRUKHU RZQUHTXHVWRUPD\EH
ZLWKGUDZQDWDQ\WLPHDWWKHGLVFU HWLRQRIWKH,QYHVWLJDWRUIRU WKHIROORZLQJUHDVRQV
x ,IDQ\FOLQLFDO$(ODERUDWRU\ DEQRUPDOLW\RURWKHUPHGLFDOF RQGLWLRQRUVLWXDWLRQ
RFFXUVVXFKWKDWFRQWLQXHGSDUWL FLSDWLRQLQWKHVWXG\ZRXOGQRW EHLQWKHEHVW
LQWHUHVWRIWKHSDWLHQW
x 'LVHDVHSURJUHVVLRQWKDWUHTXLUH VGLVFRQWLQXDWLRQRIWKHLQYHV WLJDWLRQDOSURGXFW
x 3UHJQDQF\
x ,IWKHSDWLHQWPHHWVDQH[FOXVL RQFULWHULRQHLWKHUQHZO\GHYH ORSHGRUQRW
SUHYLRXVO\UHFRJQL]HGWKDWSUHFO XGHVIXUWKHUVWXG\SDUWLFLSDWL RQDIWHUFRQVXOWDWLRQ
ZLWKWKH0HGLFDO0RQLWRU
x 6LJQLILFDQWLQYHVWLJDWLR QDOSURGXFWQRQFRPSOLDQFH
x 7HUPLQDWLRQRIWKHVWXG\E\WKHVSRQVRU
,IWKHSDWLHQWZLWKGUDZVFRQVHQWI RUGLVFORVXUHRIIXWXUHLQIRU PDWLRQWKHVSRQVRUPD\
UHWDLQDQGFRQWLQXHWRXVHDQ\ GDWDFROOHFWHGEHIRUHVXFKDZLW KGUDZDORIFRQVHQW
,IDSDWLHQWZLWKGUDZVIURPWKHVW XG\KHRUVKHPD\UHTXHVWGH VWUXFWLRQRIDQ\VDPSOHV
WDNHQDQGQRWWHVWHGDQGWKH,QYH VWLJDWRUPXVWGRFXPHQWWKLVL QWKHVLWHVWXG\UHFRUGV
6HH6FKHGXOHRI$FWLYLWLHV 6HFWLRQ IRUGDWDWREHFROOHFWHGDWWKHWLPHRIVWXG\
GLVFRQWLQXDWLRQDQGIR OORZXSDQGIRUDQ\IXUWKHUHYDOXDWLRQVW KDWQHHGWREHFRPSOHWHG
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI7KHUHDVRQIRUSDWLHQWGLVFRQWLQ XDWLRQRUZLWKGUDZDOIURPWKHV WXG\ZLOOEHUHFRUGHGRQ
WKH&5)
3DWLHQWVZKRVLJQWKH,&)DQGDU HUDQGRPL]HGEXWGRQRWUHFHLYH WKHLQYHVWLJDWLRQDO
SURGXFWPD\EHUHSODFHG2QFHU DQGRPL]HGSDWLHQW VZKRDUHZLWK GUDZQIURPWKHUDS\
EHIRUHFRPSOHWLQJGD\VRIGRV LQJRUDUHGLVFRQWLQXHGIURPWK HVWXG\IRUDQ\UHDVRQ
ZLOOQRWEHUHSODFHG
&OLQLFDODQGRUODERUDWRU\FULWHU LDWKDWPD\ZDUUDQWVWXG\GUXJ GLVFRQWLQXDWLRQ 
,IDSDWLHQWH[SHULHQFHVDQ\RIWKHIROORZLQJFOLQLFDORUODERU DWRU\HYHQWVVWXG\
WUHDWPHQWVKRXOGEHLPP HGLDWHO\VXVSHQGHG
x $Q\6$(FRQVLGHUHGVWXG\GUXJUHODWHG
x 1RERZHOPRYHPHQWIRUGD\V
x $Q\FOLQLFDOHYLGHQFHVXJJHVWLYH VHYHUHFRQVWLSDWLRQREVWLSDW LRQRULQWHVWLQDO
REVWUXFWLRQJDVWURLQWHVWLQDOKHP RUUKDJHVLJQLILFDQWJDVWURLQW HVWLQDOLQIHFWLRQ
x $EQRUPDOOLYHUIXQFWLRQVFRQFHU QLQJIRUGUXJLQGXFHGDVIROORZ V
R &RQILUPHG$/7![8/1
R &RQILUPHG$/7![8/1DQGDQ\ RIWKHIROORZLQJVLJQVRUV\PSW RPV
IDWLJXHQDXVHDYRPLWLQJUL JKWXSSHUTXDGUDQWSDLQIHYHUU DVKRU
HRVLQRSKLOLD
R &RQILUPHG$/7![8/1DQGWRWDO ELOLUXELQ![8/1RU,15! VKRXOG
EHUHSHDWHGLQKRXUV 
6KRXOGDQ\RIWKHVHHYHQWVRFFXU DIXOOHYDOXDWLR QRIRWKHUFD XVHVRIOLYHUHQ]\PH
HOHYDWLRQVKRXOGEHXQGHUWDNHQ DQGSDWLHQWVZRXOGEHIROORZHGD WUHJXODULQWHUYDOVXQWLO
ODEVUHWXUQWRQRUPDOVWDELOL]H RUDQDOWHUQDWHGLDJQRVLVLVF RQILUPHG
,ISDWLHQWVGHYHORSDV\PSWRPDWLF HOHYDWLRQVRIWKH$/7RI![ 8/1DQGLIWKHUHDUH
SHUVLVWHQWHOHYDWLRQVXSRQUHSHDWWH VWLQJFORVHREVHUYDWLRQVK RXOGEHLPSOHPHQWHG
DQGGLVFRQWLQXDWLRQ RIWKHGUXJVKRXOG EHFRQVLGHUHG
'HSHQGLQJRQWKHQDWXUHVHYHULW \DQGRXWFRPHWKH6SRQVRUZLO OGHFLGHWRDQG
GRFXPHQWZLWKVXSSRUWLQJUDWLRQDOH HLWKHUGLVFRQWLQXHVWXG \GUXJUHTXHVW
DGGLWLRQDOVDIHW\GDWDRUFRQW LQXHGRVLQJDWFXUUHQWGRVHR UUHGXFHGGRVHVHH
6HFWLRQ 
,IRUPRUHSDWLHQWVH[SHULHQFH DQ\RIWKHDERYHFULWHULDQRW HVWXG\GUXJUHODWHG6$(V
PXVWEHLQWKHVDPHV\VWHPRUJDQ FODVVWKHVWXG\HQUROOPHQWZL OOEHKDOWHG7KH
6SRQVRUDQLQGHSHQGHQW*,SK\VLFL DQQRWLQYROYHGZLWKWKHVWXG \DQGWKHOHDG
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRILQYHVWLJDWRUZLOOUHYLHZDYDLODEO HGDWDWRGHWHUPLQHZKHWKHULQ GLYLGXDOSDWLHQWXQEOLQGLQJ
LVZDUUDQWHGDPHQGPHQWVDUHUHTXL UHGIRUWKHSURWRFRODQGZKH WKHUSDWLHQWVFXUUHQWO\
RQWUHDWPHQWVKRXOGDOVRGLVFRQWL QXHVWXG\GUXJ$GHFLVLRQWR FRQWLQXHZLWKRUZLWKRXW
PRGLILFDWLRQVRUGLVFRQWLQXH WKHVWXG\ZLOOEHPDGH$OOVXSSR UWLQJUDWLRQDOHZLOOEH
GRFXPHQWHG 
 /RVWWR)ROORZXS
$SDWLHQWZLOOEHFRQVL GHUHGORVWWRIROORZXSLIKHRUVKHUHS HDWHGO\IDLOVWRUHWXUQIRU
VFKHGXOHGYLVLWVDQGLVXQDEOHWR EHFRQWDFWHGE\WKHVWXG\VLW HVWDII
7KHIROORZLQJDFWLRQVPXVWEHWDNHQLIDSDWLHQWIDLOVWRUHWXU QWRWKHFOLQLFIRUDUHTXLUHG
VWXG\YLVLW
x 7KHVLWHZLOODWWHPSWWRFRQWDF WWKHSDWLHQWDQGUHVFKHGXOHWK HPLVVHGYLVLWDVVRRQ
DVSRVVLEOHFRXQVHOWKHSDWLHQW RQWKHLPSRUWDQFHRIPDLQWDLQL QJWKHDVVLJQHGYLVLW
VFKHGXOHDQGDVFHUWDLQLIWKH SDWLHQWZLVKHVWRDQGRUVKRXOG FRQWLQXHLQWKHVWXG\
x %HIRUHDSDWLHQWLVGHHPHGORV WWRIROORZXSWKH,QYHVWLJDWRU RUGHVLJQHHZLOOPDNH
HYHU\HIIRUWWRUHJDLQFRQWDFWZLW KWKHSDWLHQWZKHUHSRVVLEOH WHOHSKRQHFDOOVDQG
LIQHFHVVDU\DFHUWLILHGOHWWH UWRWKHSDWLHQWÂ¶VODVWNQRZQPD LOLQJDGGUHVVRUORFDO
HTXLYDOHQWPHWKRGV7KHVHFRQWDF WDWWHPSWVVKRXOGEHGRFXPHQWHG LQWKHSDWLHQWÂ¶V
PHGLFDOUHFRUGRUVWXG\ILOH
x 6KRXOGWKHSDWLHQWFRQWLQXHWR EHXQUHDFKDEOHKHRUVKHZLOO EHFRQVLGHUHGWRKDYH
ZLWKGUDZQIURPWKHVWXG\ZLWKD SULPDU\UHDVRQRIORVWWRIROOR ZXS

&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI 678'<$66(660(176 $1'352&('85(6
3ODQQHGWLPHSRLQWVIRUDOODVVH VVPHQWVDUHSURYLGHGLQWKH6FKH GXOHRI$FWLYLWLHV
6HFWLRQ 
 6WXG\3HULRGV
7KHVWXG\ZLOOFRPSULVHSKDVHV
3UH7UHDWPHQW3KDVH XSWRZHHNVLQZKLFKDOO SDWLHQWVZLOOEHDVVHVVHGIRU
HOLJLELOLW\7KHSUHWUHDWPHQW SKDVHZLOOFRQVLVWRILQLWLDOVF UHHQLQJDVVHVVPHQWV
9LVLWDQGD5XQLQSHULR G9LVLWWKURXJK9LVLW
 $7UHDWPHQW3KDVH ZHHNVLQZKLFKDOOSDWLHQW VZLOOUHWXUQWRWKHFOLQLFDOI RU
UDQGRPL]DWLRQDQGVWDUWRIWUHDWP HQW9LVLWÂ±'D\IROORZHG E\ZHHNO\YLVLWV
9LVLWÂ±'D\> Â“GD\@9LVLWÂ±'D\> Â“GD\@9LVLWÂ±'D\> Â“GD\@XQWLO
9LVLWÂ±'D\ Â“GD\DQG
 $)ROORZXS3KDVH ZHHNVLQZKLFKSDWLHQWVZ KRFRPSOHWH9LVLWZLOOEHDVN HG
WRUHWXUQIRUDQ(QGRI6WXG\) ROORZXSYLVLW9LVLWÂ±'D\ >Â“GD\V@IRU
DVVHVVPHQWRIWUHDWPHQ WRXWFRPHHJVDIHW\GXUDELOLW\RIHI IHFW
 6FUHHQLQJ$VVHVVPHQWV
$IWHUVLJQLQJWKH,&)VWKH SDWLHQWZLOOXQGHUJRWKHLQLWLDO VFUHHQLQJDVVHVVPHQWVDQG
SURFHGXUHVDVGHVFULEHGLQW KH6FKHGXOHRI$FWLYLWLHV 6HFWLRQ WRGHWHUPLQH
HOLJLELOLW\
(OLJLEOHSDWL HQWVZLOOHQWHUWKH5XQLQ SHULRG$WWKHEHJLQQLQ JRIWKH5XQLQSHULRG
SDWLHQWVZLOOUHFHLYHLQVWUXFWL RQVIRUFRPSOHWLQJDQHOHFWURQLF GLDU\WRFROOHFWGDLO\
LQIRUPDWLRQUHODWHGWRWKHLU, %6'V\PSWRPVWKHLUERZHOIXQFWL RQDQGUHVFXH
PHGLFDWLRQXVH
3DWLHQWVZKRPHHWWKHIROORZL QJUHTXLUHPHQWVZLOOEHHOLJLEOHI RUSDUWLFLSDWLRQDQG
LPPHGLDWHUDQGRPL]DWLRQLQWRW KHGRXEOHEOLQGWUHDWPHQWSKDVH LHDOOGLDU\FRQGLWLRQV
OLVWHGPXVWEHPHWWRTXDOLI \IRUUDQGRPL]DWLRQ
x KDYHFRPSOHWHGWKHGDLO\HOHFW URQLFGLDU\RQDWOHDVWRIWKH GD\VGXULQJWKH
ZHHNSULRUWRUDQGRPL]DWLRQ$1'D WOHDVWRIWKHGD\VGXUL QJWKHZHHNV
SULRUWRUDQGRPL]DWLRQ
x RYHUWKHILQDOGD\VRIWKHUX QLQSHULRGWKHSDWLHQWKDVDQ DYHUDJHRI:$3
VFRUHVLQWKHSULRUKRXUVRI WRRQDWRQXPHUL FDOUDWLQJVFDOH
ZKHUHLQGLFDWHVQRSDLQDQG LQGLFDWHVZRUVWSDLQLPDJLQDEO H
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRIx RYHUWKHILQDOGD\VRIWKHUX QLQSHULRGWKHSDWLHQWKDVDQ DYHUDJHGDLO\%6)6
VFRUHÂ•RQDWRVFDOHZ KHUH KDUGOXPS\VWRROVD QG ZDWHU\
OLTXLGVWRROVDQGWKHUHPXVW EHDWOHDVWGD\VZLWKVWRROFR QVLVWHQF\RI7\SHÂ•
DQG
x KDYHQRWXVHGDQ\ORSHUDPLGHUH VFXHPHGLFDWLRQLQWKHZHHNV SULRUWR
UDQGRPL]DWLRQ
(OLJLEOHSDWLHQWVZLOOEHLQVWUXF WHGWRUHWXUQWRWKHVWXG\VLW HIRUWKH%DVHOLQHYLVLWRQ
'D\
,ISDWLHQWVGRQRWPHHWDOORIW KHGLDU\FRQGLWLRQVUHTXLUHG IRUHQWU\GXULQJWKHZHHN
UXQLQSHULRGWKHUXQLQPD\ EHH[WHQGHGIRUDQDGGLWLRQDOZHH NLQDFFRUGDQFHZLWK
LQYHVWLJDWRUMXGJPHQWIRUDWRWD OUXQLQSHULRGRIXSWRZHH NV(OLJLELOLW\ZLOOWKHQEH
EDVHGRQWKHPRVWUHFHQWGD \VRIWKHH[WHQGHG UXQLQSHULRG 
 (IILFDF\$VVHVVPHQWV
7KHHIILFDF\REMHFWLYHVRIWKHVW XG\DUHWRHYDOXDWHWKHHIIHFW RI%26UHODWLYHWR
3%2DIWHUZHHNVRIWKHUDS\RQ SDLQGHIHFDWLRQDQGNH\,%6 'UHODWHGVLJQVDQG
V\PSWRPV
'XULQJWKHZHHNVRIWKHGRXEOH EOLQGWUHDWPHQWSKDVHSDWLHQW VZLOOEHUHTXLUHGWR
DFFHVVWKHLUHOHFWURQLFGLDU\HY HU\GD\SUHIHUDEO\DWWKHVDPH WLPHHDFKGD\WRUHFRUG
,%6'V\PSWRPGDWDDQG LQIRUPDWLRQUHODWHGWRWKHLUERZHOIXQFW LRQDQGUHVFXH
PHGLFDWLRQXVH
 :RUVW$EGRPLQDO3DLQ
7KURXJKRXWWKHZHHNVRIWKHGRXEO HEOLQGWUHDWPHQWSKDVHSDW LHQWVZLOOEHDVNHGWR
UDWHWKHLU:$3LQWKHSDVWKRXU V7KHSDWLHQWUHSRUWHG:$3L QWKHSDVWKRXUVZLOO
EHUHFRUGHGRQDWRVFDOH ZKHUHFRUUHVSRQGVWRQRSDLQ DQGFRUUHVSRQGVWR
ZRUVWLPDJLQDEOHSDLQ
 %ULVWRO6WRRO)RUP6FDOH
3DWLHQWVZLOOEHDVNHGWRUHFRUG GDLO\VWRROFRQVLVWHQF\DFFRUG LQJWRWKH%6)6PRVW
UHSUHVHQWDWLYHRIWKHSDVW KRXUVDQGZRUVWVWRROFRQVLVWHQF\ GHILQHGDVWKHORRVHVW
VWRROZLWKWKHKLJKHVW%6)6VFR UHLQWKHSDVWKRXUV7KHSD WLHQWUHSRUWHG%6)6
FRQVLVWHQF\VFRUHLVEDVHGRQD WRVFDOHZKHUHFRUUHVSRQG VWRDKDUGVWRRODQG
FRUUHVSRQGVWRZDWHU\GLD UUKHD 3OHDVHUHIHUWR $SSHQGL[ 
 ,%6'*OREDO6\PSWRP6FRUH
3DWLHQWVZLOOEHDVNHGWRUHFRU GGDLO\WKHLURYHUDOO,%6'JORE DOV\PSWRPVLQWKHSULRU
KRXUV7KHSDWLHQWUHSRUWHGGDL O\,%6*6LVEDVHGRQDWR VFDOHZKHUHCCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRIx FRUUHVSRQGVWRQRV\PSWRPV
x FRUUHVSRQGVWRPLOGV\PSWRPV
x FRUUHVSRQGVWRPRGHUDWHV\PSWRPV
x FRUUHVSRQGVWRVHYHUHV\PSWRPVDQG
x FRUUHVSRQGVWRYHU\VHYHUHV\PSWRPV
 ,%66HYHULW\6FRUH6\VWHP
3DWLHQWVZLOOEHDVNHGWRFRPSO HWHTXHVWLRQVUHJDUGLQJWKHVH YHULW\RIWKHLU,%6(DFK
RIWKHTXHVWLRQVJHQHUDWHD PD[LPXPVFRUHRIOHDGLQJWR DWRWDOSRVVLEOHVFRUH
RI
 6DIHW\DQG2WKHU$VVHVVPHQWV
 $GYHUVH(YHQWVDQG 6HULRXV$GYHUVH(YHQWV
6HH6HFWLRQ 
 3K\VLFDO([DPLQDWLRQV
$FRPSOHWHSK\VLFDOH[DPLQDWL RQ3(ZLOOEHSHU IRUPHGDW6FUHH QLQJ$WDPLQLPXPD
WDUJHWHG3(ZLOOEHSH UIRUPHGDWWKHWLPHSRL QWVVSHFLILHGLQWK H6FKHGXOHRI$FWLYLWLHV
6HFWLRQ ZLWKDGGLWLRQDOV\PSWRP GLUHFWHGH[DPLQDWL RQSHUIRUPHGDVFOL QLFDOO\
LQGLFDWHG$Q\FOLQLFDOO\VLJQL ILFDQW3(ILQGLQJQRWHGDW6FUHH QLQJZLOOEHUHFRUGHGDV
PHGLFDOKLVWRU\LQWKHVRXUFHGRF XPHQW$Q\FOLQLFDOO\VLJQLILF DQW3(ILQGLQJQRWHGDW
DIWHUHQUROOPHQWZLOOEHUHYLHZ HGIRUUHSRUWLQJDVDQ$(VHH 6HFWLRQ 
$FRPSOHWH3(ZLOOLQFOXGHDWD PLQLPXPDVVHVVPHQWRIWKHFDU GLRYDVFXODU
UHVSLUDWRU\*,DQGQHXURORJLFDO V\VWHPV$WDUJHWHG3(ZLOOL QFOXGHDWDPLQLPXP
DVVHVVPHQWVRIWKHOXQJVFDUG LRYDVFXODUV\VWHPDQGDEGRPHQO LYHUDQGVSOHHQ
+HLJKWDQGZHLJKWZLOODOVREHP HDVXUHGDQG%0,ZLOOEHFDOFXOD WHGDQGWKHGDWD
UHFRUGHGDWWKHWLPHSRLQWVVSHF LILHGLQWKH6F KHGXOHRI$FWLYLW LHV6HFWLRQ 
,QYHVWLJDWRUVVKRXOGSD\VSHFLDO DWWHQWLRQWRFOLQLFDOVLJQVUH ODWHGWRSUHYLRXVVHULRXV
LOOQHVVHV
 9LWDO6LJQV
$WWKHWLPHSRLQWVVSHFLILHGLQ WKH6FKHGXOHRI$FWLYLWLHV 6HFWLRQ DQGEHIRUHDQ\
EORRGVDPSOHFROOHFWLRQYLWDOV LJQVZLOOEHPHDVXUHGLQDVXSL QHSRVLWLRQDIWHUPLQXWHV
UHVWDQGZLOOLQFOXGHRUDOWHPSHU DWXUHV\VWROLFDQGGLDVWROLF EORRGSUHVVXUHSXOVHDQG
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRIUHVSLUDWRU\UDWH$Q\FOLQLFDOO\ VLJQLILFDQWDEQRUPDOYLWDOVLJ QYDOXHZLOOEHUHFRUGHGDV
DQ$(VHH 6HFWLRQ 
 (OHFWURFDUGLRJUDPV
6LQJOHOHDG(&*VZLOOEHSHUIR UPHGDWWKHWLPHSRLQWVVSHFLIL HGLQWKH6FKHGXOHRI
$FWLYLWLHV 6HFWLRQ DQGEHIRUHDQ\EORRGVDPSOHFR OOHFWLRQ(OHFWURFDUGLRJUDP
LQWHUYDOPHDVXUHPHQWVDQGLQWHUS UHWDWLRQQRUPDODEQRUPDOQRW FOLQLFDOO\VLJQLILFDQW
DEQRUPDOFOLQLFDOO\VLJQLILFDQW ZLOOEHUHFRUGHGLQWKHVRXUFH GRFXPHQW$Q\FOLQLFDOO\
VLJQLILFDQWFKDQJHLQ(&*LQWHUSU HWDWLRQZLOOEHUHFRUGHGDVDQ $(VHH6HFWLRQ 
 &OLQLFDO6DIHW\/DERUDWRU\$VVHVVPHQWV
6HH$SSHQGL[ IRUWKHOLVWRIFOLQLFDOODERUDW RU\WHVWVWREHSHUIRUPHGDQGW RWKH
6FKHGXOHRI$FWLYLWLHV 6HFWLRQ IRUWKHWLPLQJDQGIUHTXHQF\
7KH,QYHVWLJDWRUPXVWUHYLHZW KHODERUDWRU\U HSRUWGRFXPHQWWK LVUHYLHZDQGUHFRUGLQ
WKH$(VHFWLRQRIWKH&5)DQ\F OLQLFDOO\UHOHYDQWFKDQJHVRFFXU ULQJGXULQJWKHVWXG\
7KHODERUDWRU\UHSRUWVPXVWEHI LOHGZLWKWKHVRXUFHGRFXPHQWV &OLQLFDOO\VLJQLILFDQW
DEQRUPDOODERUDWRU\ILQGLQJVDUHW KRVHWKDWDUHQRWDVVRFLDWHG ZLWKWKHXQGHUO\LQJ
GLVHDVHXQOHVVMXGJHGE\WKH,Q YHVWLJDWRUWREHPRUHVHYHUHWK DQH[SHFWHGIRUWKH
SDWLHQWÂ¶VFRQGLWLRQ
$OOODERUDWRU\WHVWV ZLWKYDOXHVFRQVLGHUHGFOLQLFDOO\VLJQLILF DQWO\DEQRUPDOGXULQJ
SDUWLFLSDWLRQLQWKH VWXG\VKRXOGEHUHSHDW HGXQWLOWKHYDOXHV UHWXUQWRQRUPDORU
EDVHOLQHRUDUHQRORQJHUFRQVLGHU HGFOLQLFDOO\VLJQLILFDQWE\ WKH,QYHVWLJDWRURU0HGLFDO
0RQLWRU,IVXFKYDOXHVGRQRWU HWXUQWRQRUPDOEDVHOLQHZLWKLQ DSHULRGRIWLPHMXGJHG
UHDVRQDEOHE\WKH,QYHVWLJDWRUW KHHWLRORJ\VKRXOGEHLGHQWLIL HGDQGWKHVSRQVRU
QRWLILHG
$OOSURWRFROUHTXLU HGODERUDWRU\DVVHVVP HQWVDVGHILQHGLQ $SSHQGL[ PXVWEH
FRQGXFWHGLQDFFRUGDQFHZLWKW KHODERUDWRU\PDQXDODQGWKH6FKH GXOHRI$FWLYLWLHV
,IODERUDWRU\YDOXHVIURPQRQSURWR FROVSHFLILHGODERUDWRU\DVV HVVPHQWVSHUIRUPHGDW
WKHLQVWLWXWLRQÂ¶VOR FDOODERUDWRU\UHTXLUH DFKDQJHLQSDWLHQW PDQDJHPHQWRU
DUHFRQVLGHUHGFOLQLFDOO\VLJQLIL FDQWE\WKH,QYHVWLJDWRUHJ 6$(RU$(RUGRVH
PRGLILFDWLRQWKHQWKHUHVXOWV PXVWEHUHFRUGHGLQWKH&5)
 $GYHUVH(YHQWVDQG 6HULRXV$GYHUVH(YHQWV
$GYHUVHHYHQWVZLOOEHUHSRUWHG E\WKHSDWLHQWRUZKHQDSSURS ULDWHE\DFDUHJLYHU
VXUURJDWHRUWKHSDWLHQW
VOHJDO O\DXWKRUL]HGUHSUHVHQWDWLYH 
7KH,QYHVWLJDWRUDQGDQ\TXDOLI LHGGHVLJQHHVDUHUHVSRQVLEOHIR UGHWHFWLQJDQG
GRFXPHQWLQJHYHQWVWKDWPHHWWKH GHILQLWLRQRIDQ$(RU6$(DQG DUHUHVSRQVLEOHIRU
IROORZLQJDOO$(V
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI 'HILQLWLRQRI$GYHUVH(YHQWV
$Q$(LVDQ\XQWRZDUG PHGLFDORFFXUUHQFHLQDSDWLHQWRUFOLQLF DOVWXG\SDUWLFLSDQW
WHPSRUDOO\DVVRFLDWHGZLWKWKH XVHRILQYHVWLJDWLRQDOSURGXFW ZKHWKHURUQRWFRQVLGHUHG
UHODWHGWRWKHLQYHVWLJDWLRQDOS URGXFW$Q$(F DQWKHUHIRUHEH DQ\XQIDYRUDEOHDQG
XQLQWHQGHGVLJQLQFOXGLQJDQDE QRUPDOODERUDWRU\ILQGLQJV\P SWRPRUGLVHDVHQHZ
RUH[DFHUEDWHGWHPSRUDOO\DVVRFL DWHGZLWKWKHXVHRILQYHVWLJD WLRQDOSURGXFW
 (YHQWVRI6SHFLDO,QWHUHVW
1RWDSSOLFDEOH
 'HILQLWLRQRI6HU LRXV$GYHUVH(YHQWV
,IDQHYHQWLVQRWDQ$(SHUGHI LQLWLRQDERYHWKHQLWFDQQRWE HDQ6$(HYHQLIVHULRXV
FRQGLWLRQVDUHPHWHJKRVSLWD OL]DWLRQIRUVLJQVV\PSWRPVRI WKHGLVHDVHXQGHUVWXG\
GHDWKEHFDXVHRISURJUHVVLRQRIGLVHDVH
$6$(LVGHILQHGDVDQ\ XQWRZDUGPHGLFDOR FFXUUHQFHWKDWDWDQ \GRVH
x 5HVXOWVLQGHDWK
x ,VOLIHWKUHDWHQLQJ
7KHWHUP
OLIHWKUHDWHQLQJ
LQW KHGHILQLWLRQRI
VHULRXV
UHIH UVWRDQHYHQWLQZKLFK
WKHSDWLHQWZDVDWULVNRIGHDW KDWWKHWLPHRIWKHHYHQW,WG RHVQRWUHIHUWRDQ
HYHQWZKLFKK\SRWKHWLFDOO\PLJKWKDYHFDXVHGGHDWKLILWZHUH PRUHVHYHUH
x 5HTXLUHVLQSDWLHQWKRVSLWDOL]DW LRQRUSURORQJDWLRQRIH[LVWLQJ KRVSLWDOL]DWLRQ
,QJHQHUDOKRVSLWDOL]DWLRQVLJQLI LHVWKDWWKHVXEMHFWRUSDWLH QWKDVEHHQGHWDLQHG
XVXDOO\LQYROYLQJDWOHDVWDQRY HUQLJKWVWD\DWWKHKRVSLWDO RUHPHUJHQF\ZDUG
IRUREVHUYDWLRQDQGRUWUHDWPHQW WKDWZRXOGQRWKDYHEHHQDSSUR SULDWHLQWKH
SK\VLFLDQÂ¶VRIILFHRURXWSDWLHQ WVHWWLQJ&RPSOLFDWLRQVWKDWRF FXUGXULQJ
KRVSLWDOL]DWLRQDUH$(V,IDFRP SOLFDWLRQSURORQJVKRVSLWDOL]D WLRQRUIXOILOOVDQ\
RWKHUVHULRXVFULWHULDWKHHY HQWLVVHULRXV:KHQLQGRXEWDV WRZKHWKHU
Â³KRVSLWDOL]DWLRQÂ´RFFXUUHGRUZ DVQHFHVVDU\WKH$(VKRXOGEHF RQVLGHUHG
VHULRXV
+RVSLWDOL]DWLRQIRUHOHFWLYHWU HDWPHQWRIDSUHH[LVWLQJFRQGLW LRQWKDWGLGQRW
ZRUVHQIURPEDVHOLQHLVQRWFRQVLGHUHGDQ$(
x 5HVXOWVLQSHUVLVWHQWGLVDELOLW\LQFDSDFLW\
7KHWHUPGLVDELOLW\PHDQVDVXEVW DQWLDOGLVUXSWLRQRIDSHUVRQÂ¶ VDELOLW\WRFRQGXFW
QRUPDOOLIHIXQFWLRQV7KLVGHI LQLWLRQLVQRWLQWHQGHGWRLQFOX GHH[SHULHQFHVRI
UHODWLYHO\PLQRUPHGLFDOVLJQLI LFDQFHVXFKDVXQFRPSOLFDWHGKHD GDFKHQDXVHD
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRIYRPLWLQJGLDUUKHDLQIOXHQ]D DQGDFFLGHQWDOWUDXPDHJVSU DLQHGDQNOHWKDW
PD\LQWHUIHUHZLWKRUSUHYHQWH YHU\GD\OLIHIXQFWLRQVEXWGRQR WFRQVWLWXWHD
VXEVWDQWLDOGLVUXSWLRQ
x ,VDFRQJHQLWDODQRPDO\ELUWKGHIHFW
0HGLFDORUVFLHQWLILFMXGJPHQWV KRXOGEHH[HUFLV HGZKHQGHFLGLQ JLI6$(UHSRUWLQJLV
DSSURSULDWHLQRWKHUVLWXDWLRQVV XFKDVLPSRUWDQWPHGLFDOHYHQW VWKDWPD\QRWEH
LPPHGLDWHO\OLIHWKUHDWHQLQJRU UHVXOWLQGHDWKRUKRVSLWDOL]DW LRQEXWPD\MHRSDUGL]HWKH
SDWLHQWRUPD\UHTXLUHPHGLFDORU VXUJLFDOLQWHUYHQWLRQWRSUHY HQWDQ\RIWKHRWKHU
RXWFRPHVOLVWHGLQWKHDERYHGHILQ LWLRQ7KHVHHYHQWVVKRXOGXV XDOO\EHFRQVLGHUHG
VHULRXV([DPSOHVRIVXFKHYHQWV LQFOXGHLQYDVLYHRUPDOLJQDQW FDQFHUVLQWHQVLYH
WUHDWPHQWLQDQHPHUJHQF\URRPRU DWKRPHIRUDOOHUJLFEURQFKRV SDVPEORRG
G\VFUDVLDVRUFRQYXOVLRQVWKDWGRQRWUHVXOWLQKRVSLWDOL]DWLRQ RUGHYHORSPHQWRIGUXJ
GHSHQGHQF\RUGUXJDEXVH
 &ODVVLILFDWLRQ RIDQ$GYHUVH(YHQW
 $VVHVVP HQWRI6HYHULW\
7KH,QYHVWLJDWRUZLOOPDNHDQD VVHVVPHQWRIVHYHULW\IRUHDFK$ (DQG6$(UHSRUWHG
GXULQJWKHVWXG\DQGDVVLJQLWWR RIWKHIROORZLQJFDWHJRULHV 
x 0LOG$QHYHQWWKDWLVHDVLO\WR OHUDWHGE\WKHSDWLHQWFDXVLQ JPLQLPDOGLVFRPIRUW
DQGQRWLQWHUIHULQJZLWKHYHU\GD\DFWLYLWLHV
x 0RGHUDWH$QHYHQWWKDWFDXVHVV XIILFLHQWGLVFRPIRUWDQGLQWHU IHUHVZLWKQRUPDO
HYHU\GD\DFWLYLWLHV
x 6HYHUH$QHYHQWWKDWSUHYHQWV QRUPDOHYHU\GD\DFWLYLWLHV$Q $(WKDWLV
DVVHVVHGDVVHYHUHVKRXOGQRWE HFRQIXVHGZLWKD6$(6HYHUHLV DFDWHJRU\
XWLOL]HGIRUUDWLQJWKHLQWHQVLW \RIDQHYHQWDQGERWK$(VDQG 6$(VFDQEH
DVVHVVHGDVVHYHUH
$QHYHQWLVGHILQHGDVÂµVHULRXV Â¶ZKHQLWPHHWVDWOHDVWRIWK HSUHGHILQHGRXWFRPHVDV
GHVFULEHGLQWKHGHILQLWLRQRI DQ6$(127ZKHQLWLVUDWHGDV VHYHUH
 $VVHVVPHQWRI&DXVDOLW\
$OO$(VPXVWKDYHWKHLUUHODWLRQV KLSWRWKHLQYHVWLJDWLRQDOSUR GXFWDQGRUVWXG\
SDUWLFLSDWLRQDVVHVVHGE\WKH,QYH VWLJDWRUZKRH[DPLQHVDQGHYD OXDWHVWKHSDWLHQW
EDVHGRQWHPSRUDOUHODWLRQVKLS DQGKLVRUKHUFOLQLFDOMXGJPHQW $OWHUQDWLYHFDXVHV
VXFKDVXQGHUO\LQJGLVHDVHFRQF RPLWDQWWKHUDS\DQGRWKHUULVN IDFWRUVDVZHOODVWKH
WHPSRUDOUHODWLRQVKLSRIWKHHY HQWWRLQYHVWLJDWLRQDOSURGXFWD GPLQLVWUDWLRQZLOOEH
FRQVLGHUHGDQGLQYHVWLJDWHG7KH ,QYHVWLJDWRUZLOODOVRFRQVXOW WKH,%LQKLVRUKHU
DVVHVVPHQW
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI7KHGHJUHHRIFHUWDLQW\DERXWF DXVDOLW\ZLOOEHJUDGHGXVLQJWK HFDWHJRULHVEHORZ
x5HODWHGÂ±7KH$(LVNQRZQWRRFFXUZLWKW KHLQYHVWLJDWLRQDOSURGXFWW KHUHLVD
UHDVRQDEOHSRVVLELOLW\WKDWWKHLQ YHVWLJDWLRQDOSURGXFWFDXVHG WKH$(RUWKHUHLVD
WHPSRUDOUHODWLRQVKLSEHWZHHQW KHLQYHVWLJDWLRQDOSURGXFWDQGH YHQW5HDVRQDEOH
SRVVLELOLW\PHDQVWKDWWKHUHLVHYLGHQFHWRVXJJHVWDFDXVDOUH ODWLRQVKLSEHWZHHQ
WKHLQYHVWLJDWLRQDOSURGXFWDQGWKH$(
x1RW5HODWHG Â±7KHUHLVQRWDUHDVRQDEOHSR VVLELOLW\WKDWWKHDGPLQLVWUDWLR QRIWKH
LQYHVWLJDWLRQDOSURGXFWFDXVHGW KHHYHQWWKHUHLVQRWHPSRUDO UHODWLRQVKLS
EHWZHHQWKHLQYHVWLJDWLRQDOSU RGXFWDQGHYHQWRQVHWRUDQDOWH UQDWHHWLRORJ\KDV
EHHQHVWDEOLVKHG
)RUHDFK$(WKH,QYHVWLJDWRUPXV WGRFXPHQWLQWKHPHGLFDOQRWH VWKDWKHRUVKHKDV
UHYLHZHGWKHHYHQWDQGKDVSURYL GHGDQDVVHVVPHQWRIFDXVDOLW\ 7KH,QYHVWLJDWRUPD\
FKDQJHKLVRUKHURSLQLRQRIFDXVD OLW\LQOLJKWRIIROORZXSLQ IRUPDWLRQDQGXSGDWHG
FDXVDOLW\DVVHVVPHQWUHSRUWHG
 ([SHFWHGQHVV 
7KH,QYHVWLJDWRUZLOOEHUHVSRQV LEOHIRUGHWHUPLQLQJZKHWKHUDQ 6$(LVH[SHFWHGRU
XQH[SHFWHG$Q6$(ZLO OEHFRQVLGHUHGXQH[ SHFWHGLIWKHQDWXUH VHYHULW\RUIUHTXHQF\
RIWKHHYHQWLVQRWFRQVLVWHQW ZLWKWKHULVNLQIRUPDWLRQSUHYLR XVO\GHVFULEHGIRUWKH
LQYHVWLJDWLRQDOSURGXFW
 7LPH3HULRGDQG )UHTXHQF\IRU(YHQW $VVHVVPHQWDQG)ROORZ XS
$OO$(VZLOOEHFROOHFWHGIURP WKHVLJQLQJRIWKH,&)XQWLOWKH (QGRI6WXG\)ROORZXS
YLVLW
:KHQHYHUSRVVLEOHDOO$(VVKRXO GEHIROORZHGXQWLOVDWLVIDFWRU \UHVROXWLRQRUXQWLOWKH
VLWH,QYHVWLJDWRUGHHPVWKHHYHQW WREHFKURQLFRUWKHSDWLHQW LVVWDEOH
$OO6$(VZLOOEHUHFRUGHGDQGU HSRUWHGWRWKHVSRQVRURUGHVLJQ HHZLWKLQKRXUV
ZKHWKHUFRQVLGHUHGLQYHVWLJDWLR QDOSURGXFWUHODWHGRUQRWDQG PXVWLQFOXGHDQ
DVVHVVPHQWRILIWKHUHLVDUHDV RQDEOHSRVVLELOLW\WKDWWKHLQY HVWLJDWLRQDOSURGXFWFDXVHG
WKHHYHQW7KH,QYHVWLJDWRU ZLOODOVRVXEPLW DQ\XSGDWHG6$(GD WDWRWKHVSRQVRUZLWKLQ
à¯—KRXUVRILWEHLQJDYDLODEOH
,QYHVWLJDWRUVDUHQRW REOLJDWHGWRDFWLYHO\VHHN$(VRU6$(VDI WHUFRQFOXVLRQRIWKH
VWXG\SDUWLFLSDWLRQ+RZHYHUL IWKH,QYHVWLJDWRUOHDUQVRIDQ\ 6$(LQFOXGLQJDGHDWKDW
DQ\WLPHDIWHUDSDWLHQWKDV EHHQGLVFKDUJHGIURPWKHVWXG\DQ GKHRUVKHFRQVLGHUV
WKHHYHQWWREHUHDVRQDEO\UHODW HGWRWKHLQYHVWLJDWLRQDOSURGX FWRUVWXG\SDUWLFLSDWLRQ
WKH,QYHVWLJDWRUPXVWSURP SWO\QRWLI\WKHVSRQVRU
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI $GYHUVH(YHQW5HSRUWLQJ
$WHDFKVWXG\YLVLWSDWLHQWVZLO OEHHYDOXDWHGIRUQHZ$(VDQG WKHVWDWXVRIH[LVWLQJ
$(V&DUHZLOOEHWDNHQQRWWRLQW URGXFHELDVZKHQHYDOXDWLQJI RU$(V7KH,QYHVWLJDWRU
VKRXOGXVHRSHQHQGHGTXHVWLRQVZKHQ VROLFLWLQJLQIRUPDWLRQIUR PDSDWLHQWUHJDUGLQJ
$(VIROORZHGE\DSSURSULDWHTXHVW LRQVWKDWFODULI\WKHSDWLHQW Â¶VYHUEDWLPGHVFULSWLRQRI
$(VRUFKDQJHLQFRQFRPLWDQWPHGLFDWLRQV
:KHQDQ$(RFFXUVLWLVWKHUHVS RQVLELOLW\RIWKH,QYHVWLJDWRU WRUHYLHZDOO
GRFXPHQWDWLRQHJKRVSLWDO SURJUHVVQRWHVODERUDWRU\UHSRUW VDQGGLDJQRVWLFV
UHSRUWVUHODWHGWRWKHHYHQW7 KH,QYHVWLJDWRUZLOODWWHPSWWR HVWDEOLVKDGLDJQRVLVRIWKH
HYHQWEDVHGRQVLJQVV\PSWRPV DQGRURWKHUFOLQLFDOLQIRUPDWL RQ:KHQHYHUSRVVLEOH
WKHGLDJQRVLVQRWWKHLQGLYLGXDO VLJQVV\PSWRPVZLOOEHGRFXP HQWHGDVWKH$(
7KH,QYHVWLJDWRUZLOOWKHQUHFRUG DOOUHOHYDQW$(LQIRUPDWLRQL QWKH&5),WLVQRW
DFFHSWDEOHIRUWKH,QYHVWLJDW RUWRVHQGSKRWRFRSLHVRIWKHSDWL HQWÂ¶VPHGLFDOUHFRUGVLQ
OLHXRIFRPSOHWLRQRIWKH&5)S DJH1HZRUXSGDWHGLQIRUPDWLRQ ZLOOEHUHFRUGHGLQWKH
RULJLQDOO\FRPSOHWHG&5)+RZHY HUWKHUHPD\EHLQVWDQFHVZKHQ FRSLHVRIPHGLFDO
UHFRUGVIRUFHUWDLQFDVHVDUHU HTXHVWHG,QWKLVFDVHDOOSDWL HQWLGHQWLILHUVZLWKWKH
H[FHSWLRQRIWKHSDWL HQWQXPEHUZLOOEHU HGDFWHGRQWKHFRSLHV RIWKHPHGLFDOUHFRUGV
EHIRUHVXEPLVVLRQ
,IDSDWLHQWGLHVGXULQJSDUWLFLSDW LRQLQWKHVWXG \RUGXULQJD UHFRJQL]HGIROORZXSSHULRG
WKH,QYHVWLJDWRUZLOOSURYLGHD FRS\RIDQ\SRVWPRUWHPILQGLQJV LQFOXGLQJKLVWRSDWKRORJ\
ZKHQDYDLODEOH
,IDVLWHUHFHLYHVUHSRUWRIDQHZ 6$(IURPDVWXG\SDWLHQWRU UHFHLYHVXSGDWHGGDWDRQ
DSUHYLRXVO\UHSRUWHG6$(DIWHU GDWDEDVHORFNRIWKHHOHFWURQLF GDWDFDSWXUH('&
V\VWHPWKHQWKHVLWHFDQUHSRU WWKLVLQIRUPDWLRQRQDSDSHU6$ (IRUPRUWRWKHVSRQVRU
E\WHOHSKRQH6HHWKH6WXG\0DQXDO IRUDGGLWLRQDOLQIRUPDWLRQR Q6$(UHSRUWLQJ
7KHVWXG\VSRQVRURUGHVLJQHHZLO OEHUHVSRQVLEOHIRUQRWLI\L QJDOODSSOLFDEOHUHJXODWRU\
DXWKRULWLHVRIDQ\UHTXLUHGVDIHW\ HYHQWVLQFRPSOLDQFHZLWKFR XQWU\VSHFLILFUHJXODWRU\
UHTXLUHPHQWV,QDGGLWLRQWKHV SRQVRUPXVWQRWLI\DSSOLFDEOHU HJXODWRU\DXWKRULWLHVDQG
DOOSDUWLFLSDWLQJ,QYHVWLJDWRU VRIVXVSHFWHGXQH[SHFWHGVHULRXV DGYHUVHUHDFWLRQV
686$5VIURPFOLQLFDOWULDOVRUDQ\RWKHUVRXUFH
$Q,QYHVWLJDWRUZKRUHFHLYHVDQ ,QYHVWLJDWRUVDIHW\UHSRUWGHVF ULELQJD6$(RURWKHU
VSHFLILFVDIHW\LQIRUPDWLRQHJ VXPPDU\RUOLVWLQJRI6$(V IURPWKHVSRQVRUZLOO
UHYLHZDQGWKHQILOHLWDORQJZL WKWKH,%DQGZLOOQRWLI\WKH, QVWLWXWLRQDO5HYLHZ%RDUG
,QGHSHQGHQW(WKLFV&RPPLWWHH,5% ,(&LIDSSURSULDWHDFFRUGLQ JWRORFDO
UHTXLUHPHQWV
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI 5HSRUWLQJRI3UHJQDQF\
3UHJQDQF\LWVHOILVQRWUHJDUGHGDV DQ$(XQOHVVWKHUHLVDVXV SLFLRQWKDWWKH
LQYHVWLJDWLRQDOSURGXFWPD\KDYH LQWHUIHUHGZLWKWKHHIIHFWLYHQ HVVRIDFRQWUDFHSWLYH
PHGLFDWLRQ3UHJQDQF\LQDSDWL HQWÂ¶VSDUWQHULVQRWFRQVLGHUHG DQ$($EQRUPDO
SUHJQDQF\RXWFRPHVHJVSRQWDQHRXVDERUWLRQIHWDOGHDWKVW LOOELUWKFRQJHQLWDO
DQRPDOLHVHFWRSLFSUHJQDQF\DUH FRQVLGHUHG6$(V(OHFWLYHDER UWLRQVZLWKRXW
FRPSOLFDWLRQVVKRXOGQRWEHKDQGO HGDV$(VKRZHYHUDQLQGXFHG WKHUDSHXWLFDERUWLRQ
WRWHUPLQDWHDSUHJQDQF\EHFDXVHR IFRPSOLFDWLRQVRUPHGLFDOUH DVRQVPXVWEH
UHSRUWHGDVDQ6$(7KH XQGHUO\LQJPHGLFDOGL DJQRVLVIRUWKLVS URFHGXUHVKRXOGEH
UHSRUWHGDVWKH6$(WHUP$VSRQW DQHRXVDERUWLRQLQDVWXG\SDW LHQWLVDOZD\V
FRQVLGHUHGDQ6$(
$OOSUHJQDQFLHVLQIHPDOHSDW LHQWVDQGLILQGLFDWHGSUHJQDQFL HVLQIHPDOHSDUWQHUVRI
PDOHSDWLHQWVZLOOEH FROOHFWHGDIWHUWKHVWDUWRILQYHVWLJDWL RQDOSURGXFWDQGXQWLO
ZHHNVDIWHUWKHODVWGRVH3U HJQDQF\RXWFRPHVGHILQHGDVWKHI LUVWZHOOEDE\YLVLWIRU
OLYHELUWKVRUVSRQWDQHRXVRULQGX FHGDERUWLRQZLOOEHGRFXPH QWHGHYHQDIWHUWKH
SDWLHQWLVZLWKGUDZQIURPR UFRPSOHWHVWKHVWXG\
,IDSUHJQDQF\LVUHSRUWHGWKH,Q YHVWLJDWRUVKRXOGLQIRUPWKH VSRQVRUZLWKLQKRXUVRI
OHDUQLQJRIWKHSUHJQDQF\DQGVKRXO GIROORZWKHSURFHGXUHVRXWO LQHGLQ$SSHQGL[ 
 7UHDWPHQWRI2YHUGRVH
7KHUHDUHQRGDWDRQRY HUGRVHEHFDXVHWKLVLVWKHILUVWVWXG\R I%26LQSDWLHQWV
DQGLQDSULRUVWXG\LQKHDOWK\ KXPDQYROXQWHHUVQRHYLGHQFH RIRYHUGRVHZDV
UHSRUWHG7KHUHLVQRGHILQLWLR QRIZKDWFRQVWLWXWHVDQRYHUGRV HDQGQRNQRZQDQWLGRWH
$Q\SDWLHQWZKRUHFHLYHVDKL JKHUGRVHWKDQWKDWLQWHQGHGLH PRUHWKDQPJSHU
GRVHPRUHWKDQPJLQDJLY HQGD\VKRXOGEHPRQLWRUHGFORV HO\PDQDJHGZLWK
DSSURSULDWHVXSSRUWLYHFDUHDQG IROORZHGXSDSSURSULDWHO\,I SRVVLEOHDEORRGVDPSOH
IRU3.VKRXOGEHFROOHFWHGDVVRRQ DVLVIHDVLEOHIURPDQ\SDWL HQWZKRWDNHVDKLJKHU
GRVHWKDQWKDWLQWHQGHG
,I$(VRU6$(VDUHUHSRUWHGDQGDU HFRQVLGHUHGUHODWHGWRDSDW LHQWUHFHLYLQJDKLJKHU
GRVHWKDQLQWHQGHGGRVLQJVKRXOG EHLQWHUUXSWHGLIGHHPHGQHFH VVDU\E\WKH
,QYHVWLJDWRUDQGWKHFDVHGLVFX VVHGIXUWKHUZLWKWKH0HGLFDO0R QLWRU
 3KDUPDFRNLQHWLFV
3ODVPDVDPSOHVRIDSSUR[LPDWHO\ P/ZLOOEHFROOHFWHGIRUPHDV XUHPHQWRISODVPD
FRQFHQWUDWLRQVRI%26DWWKHIROORZLQJWLPHVDQGDVVSHFLIL HGLQWKH6FKHGXOHRI
$FWLYLWLHV 6HFWLRQ 
x 2Q'D\DWSUHGRVHDQGDW DQGKRXUVSRVWGRVH
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRIx 2Q'D\DWSUHGRVHDQGDW DQGKRXUVSRVWGRVH, IVDPSOHVFDQQRW
EHREWDLQHGRQ'D\W KHQVDPSOHVVKRXOG EHREWDLQHGRQ'D\ 
x $SUHGRVHVDPSOHZLOOEHREWDLQH GRQDOORWKHU7UHDWPHQW6WXG\ 9LVLWV
$OORZDEOHVDPSOLQJZLQGRZVIRU3. EORRGGUDZVZLO OEHPLQXWH VSULRUWRGRVLQJIRU
WKHSUHGRVHVDPSOHWKHQ Â“PLQXWHVIRUWKHDQG KRXUSRVWGRVHWLPHSRLQWVDQG
Â“PLQXWHVIRUWKHDQG KRXUVSRVWGRVHWLPHSRLQWV
,QVWUXFWLRQVIRUWKHFROOHFWL RQDQGKDQGOLQJRIELRORJLFDOVDPS OHVZLOOEHSU RYLGHGE\WKH
VSRQVRU7KHDFWXDOWLPHRIGRVL QJDQGDFWXDOGDWHDQGWLPH KRXUFORFNWLPHRI
HDFKVDPSOHZLOOEHUHFRUGHG
'UXJFRQFHQWUDWLRQLQIRUPDWLRQ WKDWPD\XQEOLQGWKHVWXG\ZLOO QRWEHUHSRUWHGWR
LQYHVWLJDWLYHVLWHVRUEOLQGHG SHUVRQQHOXQWLOWKHVWXG\KDVEH HQXQEOLQGHG
$Q\FKDQJHVLQWKHWLPLQJRU DGGLWLRQRIWLPHSRLQWVIRUDQ\SOD QQHGVWXG\DVVHVVPHQWV
PXVWEHGRFXPHQWHGDQGDSSURYHGE\ WKHUHOHYDQWVWXG\WHDPPHPE HUDQGWKHQ
DUFKLYHGLQWKHVSRQVRUDQGVLWH VWXG\ILOHVEXWZLOOQRWFRQVW LWXWHDSURWRFRODPHQGPHQW
7KH,5%,(&ZLOOEHLQIRUPHGRID Q\VDIHW\LVVXHVWKDWUHTXLUH DOWHUDWLRQRIWKHVDIHW\
PRQLWRULQJVFKHPHRUDPHQGPHQWRIWKH,&)
7KHIROORZLQJ3.SDUDP HWHUVZLOOEHHVWLPDW HGIURPWKHSODVPDF RQFHQWUDWLRQVRI
%26XVLQJHLWKHUWUDGLWLRQDO QRQFRPSDUWPHQWDOPHWKRGVRUD SRSXODWLRQ3.PRGHO
$8&W $UHDXQGHUWKHSODVPDFRQFHQWUDWLRQYHUVXVWLPHFXUYHIURPWLP H]HURWR
WKHODVWTXDQWLILDEOHVDPSOH
$8& $UHDXQGHUWKHSODVPDFRQFHQWUDWLRQYHUVXVWLPHFXUYHIURPWLP H]HURWR
KRXUVSRVWGRVH
&PD[  0D[LPXPREVHUYHGSODVPDFRQFHQWUDWLRQ
&PLQ  0LQLPXPREVHUYHGSODVPDFRQFHQWUDWLRQ
7PD[  WLPHWRPD[LPXPFRQFHQWUDWLRQ
,QDGGLWLRQWRSDUDPHWHUVDERYHW KH$8&IURPWLPH]HURWRKR XUVSRVWGRVH$8& 
PD\EHFDOFXODWHGXVLQJSUHGRVH FRQFHQWUDWLRQVRWKHUWKDQ'D\ SUHGRVHWRLPSXWHD
KRXUFRQFHQWUDWLRQ'HWDLOV ZLOOEHSURYLGHG LQWKH3.DQDO\ VLVSODQ
 %LRPDUNHUV3K DUPDFRG\QDPLFV
 CCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI





 67$7,67,&$/&216,'(5$7,216
 7LPLQJRI$QDO\VHV
)RUPDOK\SRWKHVLVWHVWLQJZLOORF FXUDWWKHHQGRIWKHVWXG\DQ GSRVWGDWDEDVHORFN
7KHUHDUHQRSODQQHG' DWD6DIHW\RU$GM XGLFDWLRQ&RPPLWWHHVI RUWKLVVWXG\DQGQR
SODQQHGVWDWLVWLFDOLQWHULPDQDO\VHV
 6DPSOH6L]H 'HWHUPLQDWLRQ
7KLVLVDSKDVHDVWXG\LQZKLF KDKLHUDUFKLFDOK\SRWKHVLVWHV WZLOOEHHPSOR\HGIRUWKH
SULPDU\HIILFDF\HQGSRLQW7KH SULPDU\HQGSRLQWLVGHILQHGDVD FKDQJHLQWKHKRXU
:$3VFRUHDW'D\FRPSDUHGWR EDVHOLQHDYHUDJHGRYHUWKHZHH NSULRUWRHDFK
UHVSHFWLYHWLPHSRLQW0HDQFKDQ JHIURPEDVHOLQHZLOOEHPHDVXU HGDVDFRQWLQXRXV
YDULDEOHDQGFRPSDUHGEHWZHHQWUHDW PHQWJURXSVLQDKLHUDUFKLFD OWHVWLQJRUGHUXVLQJD
WWHVWRIHTXDOYDULDQFHVDQGD WZRWDLOHGDOSKDRI
7KHVDPSOHVL]HZDVEDVHGRQWKH ILUVWK\SRWKHVLVWHVWLQWKHK LHUDUFKLFDOSODQZLWK
SRZHUWZRVLGHGDOSKDRI DQGDVWDQGDUGGHYLDWLRQ6 'RISRLQWVRQWKH
156WRGHWHFWDPLQLPXPFKD QJHEHWZHHQWUHDWPHQWJURXSV1  SDWLHQWV7R
DFFRXQWIRUDWWULWLRQDQGDSRWHQW LDOKLJKHU3%2UDWHDWRWDO RISDWLHQWVZLOOEH
UDQGRPL]HGWRRQHRIWUHDWPHQWJ URXSVLQDUDWLRSD WLHQWVSHUWUHDWPHQW
JURXS
 3RSXODWLRQVIRU$QDO\VHV
 7KH,QWHQWLRQWR7UHDW,77 DQDO\VLVGDWDVHWZLOOFRPSULVH DOOUDQGRPL]HG
SDWLHQWV
 7KH3HUSURWRFRO$QDO\VLV'DWD VHWZLOOFRPSULVHSDWLHQWVLQ WKH,77$QDO\VLV
'DWDVHWZKRUHFHLYHGDWOHDVWG RVHRILQYHVWLJDWLRQDOSURGXFW DQGGLGQRWKDYH
DQ\PDMRUSURWRFROGHYLDWLRQV
 7KH6DIHW\$QDO\VLV'DWDVHW ZLOOFRPSULVHDOOSDWLHQWVZKRU HFHLYHGDWOHDVW
GRVHRILQYHVWLJDWLRQDOSURGXFWCCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI 7KH3KDUPDFRNLQHWLF$QDO\VLV 'DWDVHWZLOOFRPSULVHDOOUDQGR PL]HGSDWLHQWVZKR
UHFHLYHGWKHDFWLYHVWXG\GUXJ DQGKDYHDYDLODEOHVHUXPWLPHFR QFHQWUDWLRQGDWD
 6WDWLVWLFDO$QDO\VHV
'HWDLOHGPHWKRGRORJ\IRUGHVFULSWL YHDQGLQIHUHQWLDOVWDWLVWLFD ODQDO\VHVRIWKHGDWD
FROOHFWHGLQWKHVWXG\ ZLOOEHGRFXPHQWHGLQ WKH6WDWLVWLFDO$Q DO\VLV3ODQ6$37KH
6$3ZLOOEHSUHSDUHG E\WKH6WXG\%LRVWDW LVWLFLDQDQGDJUHHGXS RQE\WKH6SRQVRU7KH
6$3ZLOOEHILQDOL]HG DQGDSSURYHGSULRUWRGDWDEDVHORFN7KH 6$3ZLOOWDNH
SUHFHGHQFHRYHUWKHSURWRFROIRU GHWDLOVUHJDUGLQJWKHVWDWLVWL FDODQDO\VHVWREH
FRQGXFWHGIRUWKHVWXG\,QDGGLWLRQWRWKH6$3RWKHUJUDSKLFD OUHSUHVHQWDWLRQVRIWKH
UHVXOWVPD\EHSURGXFHGDIWHUUHYLHZRIWKHGDWD SRVWKRF$Q\PDMRUPRGLILFDWLRQVRI
WKH3ULPDU\(QGSRLQWÂ¶V GHILQLWLRQDQGRUL WVDQDO\VLVZLOOEHU HIOHFWHGLQDSURWRFRO
DPHQGPHQW
,QJHQHUDOGHVFULSWLYHVWDWLVW LFDOPHWKRGVZLOOEHXVHGWRVXP PDUL]HWKHGDWDIURPWKLV
VWXG\8QOHVVVWDWHGRWKHUZLVHW KHWHUPÂ³GHVFULSWLYHVWDWLVWLF VÂ´UHIHUVWRQXPEHURI
SDWLHQWVQPHDQPHGLDQ6'P LQLPXPDQGPD[LPXPIRUFRQWLQ XRXVGDWDDQG
IUHTXHQFLHVDQGSHUFHQWDJHVIR UFDWHJRULFDOGDWD
$OOVWDWLVWLFDODQDO\VHVZLOOEH SHUIRUPHGXVLQJ6WDWLVWLFDO$Q DO\VLV6\VWHP6$6ÂŠ
VRIWZDUH9HUVLRQRUKLJKHU
 (IILFDF\$QDO\VHV
 3ULPDU\(QGSRLQW
7KLVLVDSURRIRISULQFLSOHVWXG\ LQZKLFKDKLHUDUFKLFDOK\SR WKHVLVWHVWZLOOEHHPSOR\HG
IRUWKHSULPDU\HIILFDF\HQGSRL QWGHILQHGDVDFKDQJHLQWKH KRXU:$3VFRUHDW
'D\FRPSDUHGWREDVHOLQHDYH UDJHGRYHUWKHZHHNSULRUWRHD FKUHVSHFWLYH
WLPHSRLQW0HDQFKDQJH IURPEDVHOLQHZLOOEHPHDVXUHGDVDFRQ WLQXRXVYDULDEOHDQG
FRPSDUHGEHWZHHQWUHDWPHQWJURXSV LQWKHIROORZLQJWHVWLQJRUGH UXVLQJDWWHVWRIHTXDO
YDULDQFHVDQGDWZRWDLOHGDOSKDRI
+\SRWKHVLV
$FWLYH7UHDWPHQW*URXS&RKRUW &RKRUWYHUVXV3%2&RKRUW 
,IVWDWLVWLFDOO\VLJQLILFDQWDW 3WKHQSURFHHGWR+\SRWKHVLV
+\SRWKHVLV 
&RKRUW+LJK'RVHYHUVXV&RKRUW3%2,IVWDWLVWLFDOO\VLJQLILFDQWDW 3WKHQSURFHHGWR+\SRWKHVLV
+\SRWKHVLV 
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI&RKRUW/RZ'RVHYHUVXV&RKRUW3%2
,IVWDWLVWLFDOO\VLJQLILFDQWDW 3WKHQSURFHHGWR+\SRWKHVLV
+\SRWKHVLV 
&RKRUW+LJK'RVHYHUV XV&RKRUW/RZ'RVH
 6HFRQGDU\(QGSRLQW
0HDQGDLO\%6)6VFRUHVWRROW\ SHDQGPHDQGDLO\IUHTXHQF\RI ERZHOPRYHPHQWVZLOO
EHWDEXODWHGDQGVXPPDUL]HGE\VW XG\GD\IRUHDFKWUHDWPHQWIRU WKH,77DQG
3HUSURWRFRO$QDO\VLV'DWDVHW SRSXODWLRQV0HDQGDLO\%6)6VFRU HVWRROW\SHZLOOEH
DQDO\]HGVHSDUDWHO\EDVHGRQWKH PRVWUHSUHVHQWDWLYHVWRROFRQV LVWHQF\LQWKHSDVW
KRXUVDQGWKHZRUVWVWRROFRQVLV WHQF\GHILQHGDVORRVHVWVW RROZLWKWKHKLJKHVW
%6)6VFRUHLQWKHSDVWKRXUV HDFKPHDVXUHDYHUDJHGRYHUWK HZHHNSULRUWRHDFK
UHVSHFWLYHWLPHSRLQW7LPHSU RILOHVDQGER[SORWVZLOODOVREH SUHVHQWHGE\VWXG\GD\
DQGE\WUHDWPHQWJURXS3RROHGDFWL YHGDWDPD\EHFRPSDUHGWR3 %2IRUWKHDQDO\VHV
DQGDOVRE\FRKRUW
 2WKHU(IILFDF\(QGSRLQWV
6FRUHVIURP,%6*6DQG,%666 TXHVWLRQQDLUHVZLOOEHVXPPDUL]HG IRUWKH,77DQG
3HUSURWRFRO$QDO\VLV'DWDVHW SRSXODWLRQV3RROHGDFWLYHGDWDP D\EHFRPSDUHGWR
3%2IRUWKHDQDO\VHVDQGDOVRE\FRKRUW
 0LVVLQJ'DWD
6WXG\LPSOHPHQWDWLRQSURFHGXUHV DQGWUDLQLQJZLO ODVVLVWLQOLP LWLQJWKHDPRXQWRI
PLVVLQJGDWDLQWKHWULDO+RZHY HUVHQVLWLYLW\DQDO\VHVPD\EH SHUIRUPHGZKHQ
LQGLFDWHGIRUWKHVWXG\HQGSRLQ WDQGWKHDPRXQWRIPLVVLQJGDWD WREHKDQGOHG'HWDLOV
RIWKHVWDWLVWLFDOPHWKRGVIRU KDQGOLQJPLVVLQJGDWDZLOOEHGH VFULEHGLQWKH6$3
 6DIHW\$QDO\VHV 
 $GYHUVH(YHQWV
$GYHUVHHYHQWVZLOOEHUHFRUGHG IURPWKHWLPHRIFRQVHQWXQWLO WKH'D\(QGRI6WXG\
)ROORZXSYLVLW7KHQXPEHUDQG SHUFHQWDJHRISDWLHQWVZLWK$(V ZLOOEHGLVSOD\HGE\
V\VWHPRUJDQFODVVDQGSUHIHUUHG WHUPXVLQJ0HGLFDO'LFWLRQDU\ IRU5HJXODWRU\$FWLYLWLHV
0HG'5$9HUVLRQRUKLJKHUE \VWXG\WUHDWPHQW6XPPDULHV LQWHUPVRIVHYHULW\
DQGUHODWLRQVKLSWRLQYHVWLJDWL RQDOSURGXFWZLOODOVREHSURYLG HG$OO6$(VZLOOEH
VXPPDUL]HGLQDVLPLODUPDQQHU3D WLHQWOLVWLQJVRIDOO$(VFDX VLQJGLVFRQWLQXDWLRQRI
LQYHVWLJDWLRQDOSURGXFWDQG DOO6$(VZLO OEHSURGXFHG
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI$OO$(VZLOOEHOLVWHGIRULQGLYL GXDOSDWLHQWVV KRZLQJERWKYHU EDWLPDQGSUHIHUUHGWHUPV
6HSDUDWHVXPPDULHVRIWUHDWPHQWH PHUJHQW6$(VDQGWUHDWPHQWHPH UJHQW$(V
7($(VUHODWHGWRLQYHVWLJDW LRQDOSURGXFWZLOOEHJHQHUDWHG
$Q\HYHQWUHSRUWHGRQWKH&5)WKD WRFFXUVRQDWWKHWLPHRIRU DIWHUWKHLQLWLDWLRQRI
LQYHVWLJDWLRQDOSURGXFWLVGHIL QHGDVWUHDWPHQWHPHUJHQW$GGLW LRQDOO\DQ$(WKDWLV
UHSRUWHGWRKDYHVWDUWHGRQ'D \ZLWKRXWDQDVVRFLDWHGRQVHWW LPHZLOOEHDVVXPHGWR
KDYHRFFXUUHGDIWHUWKHLQLWLDWL RQRILQYHVWLJDWLRQDOSURGXFW +HQFH$(VRFFXUULQJRQ
'D\ZLWKQRDVVRFLDWHGRQVHWWL PHZLOOEHDVVXPHGWREHWUHDW PHQWHPHUJHQW
6HULRXV$(VDVVRFLDWHGZLWKDSUR WRFROVSHFLILHGSURFHGXUHDQG RFFXUULQJDIWHUWKHWLPH
RIFRQVHQWEXWEHIRUHDGPLQLVWUDW LRQRIILUVWGRVHRILQYHVWLJD WLRQDOSURGXFWZLOOEH
GHILQHGDVQRQWUHDWPHQW HPHUJHQW$(V17($(V
$OOVDIHW\DQDO\VHVZLOOEHSHUIR UPHGLQWKH6DIHW\$QDO\VLV'D WDVHW
 &OLQLFDO/D ERUDWRU\(YDOXDWLRQV
/DERUDWRU\GDWDZLOOEH OLVWHGIRUDOOSDW LHQWV/DERUDWRU\GDW DZLOOEHUHYLHZHGE\WKH
,QYHVWLJDWRUDVWKH\EHFRPHDYDL ODEOH$OODEQRUPDOODERUDWRU\ UHVXOWVZLOOEHHYDOXDWHG
E\WKH,QYHVWLJDWRUDVHLWKHUF OLQLFDOO\VLJQLILFDQWRUQRWFOL QLFDOO\VLJQLILFDQW
'HVFULSWLYHVXPPDULHVRIFOLQLF DOODERUDWRU\UHVXOWVZLOOEHSU HVHQWHGE\GDWHDQGWLPH
RIFROOHFWLRQ7KHQXPEHUDQGSHU FHQWDJHRISDWLHQWVH[SHULHQFL QJWUHDWPHQWHPHUJHQW
JUDGHGWR[LFLWLHVZLOOEHVXPPDUL ]HGE\WUHDWPHQWDUPDQGVHYHU LW\JUDGH/DERUDWRU\
WR[LFLW\VKLIWVIURPEDVHOLQHWR SRVWEDVHOLQHDVVHVVPHQWVZLOO EHVXPPDUL]HGE\
WUHDWPHQWDUP&KDQJHVIURPEDVH OLQHLQODERUDWRU\WHVWVZLOOE HVXPPDUL]HGIRUHDFK
WUHDWPHQWDUP
 7ZHOYHOHDG( OHFWURFDUGLRJUDPV9LWDO6LJQVDQG3K\VLF DO
([DPLQDWLRQV
7ZHOYHOHDG(&*DQGYLWDOVLJQV GDWDZLOOEH OLVWHGDQGVXPPDUL ]HG
3K\VLFDOH[DPLQDWLRQILQGLQJVZ LOOEHFDSWXUHGDQGOLVWHGDVSD UWRIDSDWLHQWÂ¶VPHGLFDO
KLVWRU\RUDV$(VDVDSSOLFDEOH
 2WKHU$QDO\VHV
 3KDUPDFRNLQHWLF$QDO\VLV
$IXOOGHVFULSWLRQRIWKHPHWKRGVI RUHYDOXDWLQJWKH3.RI%26 LQWKLVSDWLHQW
SRSXODWLRQZLOOEHSURYLGHGLQD 3.GDWDDQDO\VLVSODQ7KH3. GDWDIURPWKLVVWXG\PD\
EHFRPELQHGZLWKGDWDIURPRWKHU VWXGLHVWRFRPSOHWHDSRSXODWL RQ3.DQDO\VLV
$IXOOOLVWRI3.SDUDPHWHUVWR EHFDOFXODWHGLV LQFOXGHGLQ 6HFWLRQ 
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI %DVHOLQH'HVFULSWLYH6WDWLVWLFV
'HPRJUDSKLFDQGEDVHOLQHFKDUDF WHULVWLFVZLOOEHVXPPDUL]HGIRU DOOSDWLHQWVRYHUDOO
DQGE\WUHDWPHQWDUP6XPPDU\VWD WLVWLFVHJQXPEHURISDWLH QWVPHDQPHGLDQ6'
DQGUDQJHZLOOEH JHQHUDWHGIRUFRQWLQXRXV YDULDEOHVHJDJ HDQGZHLJKWDQGWKH
QXPEHUDQGSHUFHQWDJHR ISDWLHQWVZLWKLQHDF KFDWHJRU\ZLOOEH SUHVHQWHGIRU
FDWHJRULFDOYDULDEOHVHJJHQGHUHWKQLFLW\UDFH
$GHWDLOHGGHVFULSWLRQRISDWL HQWGLVSRVLWLRQZLOOEHSURYLGHG ,WZLOOLQFOXGH
x $VXPPDU\RIRYHUDOOSDWLHQW HQUROOPHQWVWDWXVFRQVHQWHGVFU HHQHGVFUHHQ
IDLOXUHVUHSODFHPHQWVUDQGRPL]HG
x $VXPPDU\RISDWLHQWVZ KRGLVFRQWLQXHGWKHVWXG\
x $QDFFRXQWRILGHQWLILHGSURWRFROGHYLDWLRQV
$OOSDWLHQWVZKRDU HFRQVHQWHGIRUWKH VWXG\ZLOOEHDFFRXQWHG IRULQWKHVXPPDWLRQ7KH
QXPEHURISDWLHQWVZK RGRQRWTXDOLI\IRUFHUWDLQDQDO\VLVSRSX ODWLRQVZLOOEH
VXPPDUL]HG
 6XEJURXS$QDO\VHV
1RVXEJURXSDQDO\VHVDUHSRZHUHG IRUWKHVWXG\6XEJURXSDQDO\V HVPD\EH
SHUIRUPHGIRUGHVFULSWLYHSXUSRV HVDVGHVFULEHGLQWKH6$3
 3ODQQHG,QWHULP$QDO\VHV
1RIRUPDOHIILFDF\LQWHULPDQDO\V LVLVSODQQHGIRUWKHSXUSRVHV RIVWDWLVWLFDOO\FRPSDULQJ
WKHGDWDSULRUWRWKHFR PSOHWLRQRIWKHVWXG\

&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI 6833257,1*'2&80(17$7,21$1'23(5$7,21$/
&216,'(5$7,216
 5HJXODWRU\(WKLFDODQG6W XG\2YHUVLJKW&RQVLGHUDWLRQV
 5HJXODWRU\DQGHW KLFDOFRQVLGHUDWLRQV
7KLVVWXG\ZLOOEHFR QGXFWHGLQDFFRUGDQFH ZLWKWKHSURWRFRODQ GZLWKWKHIROORZLQJ
x &RQVHQVXVHWKLFDOSULQFLSOHVGHU LYHGIURPLQWHUQDWLRQDOJXLGHO LQHVLQFOXGLQJWKH
'HFODUDWLRQRI+HOVLQNLDQG& RXQFLOIRU,QWHUQDWLRQDO2UJDQL]DW LRQVRI0HGLFDO
6FLHQFHV,QWHUQDWLRQDO(WKLFDO*XLGHOLQHV
x $SSOLFDEOH,QWHUQDWLRQDO&RXQF LOIRU+DUPRQLVDWLRQ,&+*RRG &OLQLFDO3UDFWLFH
*&3*XLGHOLQHV
x $SSOLFDEOHODZVDQGUHJXODWLRQV
7KHSURWRFROSURWRFRODPHQGPHQW V,&),%DQGRWKHUUHOHYDQW GRFXPHQWV
HJDGYHUWLVHPHQWVPXVWEH VXEPLWWHGDQGUHYLHZHGDQGDSSU RYHGDVQHFHVVDU\WR
WKHUHOHYDQW&RPSHWHQW$XWKRULWLH V,5%VDQG,(&VEHIRUHWKHVW XG\LVLQLWLDWHG
$Q\DPHQGPHQWVWRWKHSURWRFR OZLOOUHTXLUHU HJXODWRU\DSSURYDO EHIRUHLPSOHPHQWDWLRQ
RIFKDQJHVPDGHWRWKHVWXG\GHVLJQH[FHSWIRUFKDQJHVQHFHVVD U\WRHOLPLQDWHDQ
LPPHGLDWHKD]DUGWR VWXG\SDWLHQWV
7KH,QYHVWLJDWRUZLOOEHUHV SRQVLEOHIRUWKHIROORZLQJ
x 3URYLGLQJZULWWHQVXPPDULHVR IWKHVWDWXVRIWKHVWXG\WRWKH ,5%,(&DQQXDOO\RU
PRUHIUHTXHQWO\LQDFFRUGDQFHZLWK WKHUHTXLUHPHQWVSROLFLHV DQGSURFHGXUHV
HVWDEOLVKHGE\WKH,5%,(&
x 1RWLI\LQJWKH,5%,(&RI6$(VRU RWKHUVLJQLILFDQWVDIHW\ILQG LQJVDVUHTXLUHGE\
,5%,(&SURFHGXUHV
x 3URYLGLQJRYHUVLJKWRIWKHFRQGXF WRIWKHVWXG\DWWKHVLWHDQ GDGKHUHQFHWR
UHTXLUHPHQWVRI&RGHRI)HGHU DO5HJXODWLRQV&)5,&+JXLGH OLQHVWKH,5%,(&
(XURSHDQUHJXODWLRQIRUF OLQLFDOVWXGLHVLIDSSOLFDEO HDQGDOORWKHU
DSSOLFDEOHORFDOUHJXODWLRQV 
 ,QIRUPHG&RQVHQW$VVHQW3URFHVV
$QLQLWLDOVDPSOH,&)LVSURYL GHGIRUWKH,QYHVWLJDWRUWRSUHSD UHWKHLQIRUPHGFRQVHQW
GRFXPHQWWREHXVHGDWKLVRUKH UVLWH8SGDWHVWRWKHVDPSOH, &)DUHWREH
FRPPXQLFDWHGIRUPDOO\LQZULWLQJ IURPWKH6SRQVRURU6SRQVRUÂ¶V GHVLJQHHWRWKH
,QYHVWLJDWRU7KHZULWWHQ,& )LVWREHSUHSDUHGLQWKHODQJXDJH RIWKHSRWHQWLDOSDWLHQW
SRSXODWLRQ
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI7KH,QYHVWLJDWRURUKLVKHUUHSU HVHQWDWLYHZLOO H[SODLQWKHQDW XUHRIWKHVWXG\WRWKH
SDWLHQWRUKLVKHUOHJDOO\DXWKRU L]HGUHSUHVHQWDWLYHDQGDQVZHU DOOTXHVWLRQVUHJDUGLQJ
WKHVWXG\
3DWLHQWVPXVWEHLQIRUPHGWKDWW KHLUSDUWLFLSDWLRQLVYROXQWDU\ 3DWLHQWVRUWKHLUOHJDOO\
DXWKRUL]HGUHSUHVHQWDWLY HZLOOEHUHTXLUHGWR VLJQDVWDWHPHQW RILQIRUPHGFRQVHQW
DQGRUDVVHQWWKDWPHHWVWKHUHTXL UHPHQWVRI&)5ORFDO UHJXODWLRQV,&+
JXLGHOLQHV+HDOWK,QVXUDQFH3RUW DELOLW\DQG$FFRXQWDELOLW\$FW UHTXLUHPHQWVZKHUH
DSSOLFDEOHDQGWKH,5%,( &RUVWXG\FHQWHU
7KHPHGLFDOUHFRUGPXVWLQFOXGH DVWDWHPHQWWKDWZULWWHQLQIRUP HGFRQVHQWZDV
REWDLQHGEHIRUHWKHSDWLHQWZDV HQUROOHGLQWKHVWXG\DQGWKHG DWHWKHZULWWHQFRQVHQW
ZDVREWDLQHG7KHDXWKRUL]HGSHUV RQREWDLQLQJWKHLQIRUPHGFRQV HQWPXVWDOVRVLJQWKH
,&)
3DWLHQWVPXVWEHUHFRQVHQWHGWRW KHPRVWFXUUHQWYHUVLRQRIWK H,&)VGXULQJWKHLU
SDUWLFLSDWLRQLQWKHVWXG\ LIRQHEHFRPHVDYDLODEOH
$FRS\RIWKH,&)VPXVWEHSU RYLGHGWRWKHSDWLHQWRUWKHSDW LHQWÂ¶VOHJDOO\DXWKRUL]HG
UHSUHVHQWDWLYH
7KH,QYHVWLJDWRULVDOVRUHVSRQV LEOHIRUDVNLQJWKHSDWLHQWLI WKHSDWLHQWKDVDSULPDU\
FDUHSK\VLFLDQDQGLIWKHSDWLHQ WDJUHHVWRKDYHKLVKHUSULPDU \FDUHSK\VLFLDQLQIRUPHG
RIWKHSDWLHQWÂ¶VSDUWLFLSDWLRQLQ WKHFOLQLFDOVWXG\LILWLVD ORFDOUHTXLUHPHQW ,IWKHSDWLHQW
DJUHHVWRVXFKQRWLILFDWLRQWKH,Q YHVWLJDWRULVWRLQIRUPWKH SDWLHQWÂ¶VSULPDU\FDUH
SK\VLFLDQRIWKHSDWLHQW Â¶VSDUWLFLSDWLRQLQWKHFOLQLFDOVWXG\ ,IWKHSDWLHQWGRHVQRWKDYHD
SULPDU\FDUHSK\VLFLDQDQGWKH,Q YHVWLJDWRUZLOOEHDFWLQJLQW KDWFDSDFLW\WKH
,QYHVWLJDWRULVWRGRFXPHQWVXF KLQWKHSDWLHQWÂ¶VPHGLFDOUHFRU G
,IDSDWLHQWLVXQDEOHWRUHDGRUL IDOHJDOO\DFFHSWDEOHUHSUH VHQWDWLYHLVXQDEOHWRUHDG
DQLPSDUWLDOZLWQHVVV KRXOGEHSUHVHQWGXULQ JWKHHQWLUHLQIRUP HGFRQVHQWGLVFXVVLRQ
$IWHUWKHZULWWHQ,&)DQGDQ\RW KHUZULWWHQLQIRUPDWLRQWREHS URYLGHGWRSDWLHQWVLVUHDG
DQGH[SODLQHGWRWKHSDWLHQWRU WKHSDWLHQWÂ¶VOHJDOO\DFFHSWDEO HUHSUHVHQWDWLYHDQGDIWHU
WKHSDWLHQWRUWKHSDWLHQWÂ¶VO HJDOO\DFFHSWDEOHUHSUHVHQWDWLYH KDVRUDOO\FRQVHQWHGWRWKH
SDWLHQWÂ¶VSDUWLFLSDWLRQLQWKH WULDODQGLIFDSDEOHRIGRLQJV RKDVVLJQHGDQGSHUVRQDOO\
GDWHGWKH,&)WKHZLWQHVVVKRXO GVLJQDQGSHUVRQDO O\GDWHWKH FRQVHQWIRUP%\VLJQLQJ
WKHFRQVHQWIRUPWKHZLWQHVVD WWHVWVWKDWWKHLQIRUPDWLRQLQW KHFRQVHQWIRUPDQGDQ\
RWKHUZULWWHQLQIRUPDWLRQZDVD FFXUDWHO\H[SODLQHGWRDQGDSSD UHQWO\XQGHUVWRRGE\
WKHSDWLHQWRUWKHSDWLHQWÂ¶VO HJDOO\DFFHSWDEOHUHSUHVHQWDWLYH DQGWKDWLQIRUPHGFRQVHQW
ZDVIUHHO\JLYHQE\WKHSDWLHQ WRUWKHSDWLHQWÂ¶VOHJDOO\DFFHSW DEOHUHSUHVHQWDWLYH5HIHU
WR,&+*&3JXLGHOLQH6HFWLRQ

&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI &RQILGHQWLDOLW\DQG3ULYDF\
3DWLHQWFRQILGHQWLDOLW\DQGSULYDF \LVVWULFWO\KHOGLQWUXVWE \WKHSDUWLFLSDWLQJ
,QYHVWLJDWRUVWKHLUVWDIIDQGW KHVSRQVRUDQGLWVGHVLJQHHV 7KLVFRQILGHQWLDOLW\LV
H[WHQGHGWRFRYHUWHVWLQJRIELR ORJLFDOVDPSOHVDQGJHQHWLFWHV WVLQDGGLWLRQWRWKH
FOLQLFDOLQIRUPDWLRQUHODWLQJWR SDWLHQWV7KHU HIRUHWKHVWXG\ GRFXPHQWDWLRQGDWDDQG
DOORWKHULQIRUPDWLRQJHQHUDWHGZ LOOEHKHOGLQVWULFWFRQILGHQ FH1RLQIRUPDWLRQ
FRQFHUQLQJWKHVWXG\R UWKHVWXG\GDWDZLOO EHUHOHDVHGWRDQ\ XQDXWKRUL]HGWKLUGSDUW\
ZLWKRXWSULRUZULWWHQDSSURYDORIWKHVSRQVRU
6WXG\SDWLHQWUHVHDU FKGDWDZLOOQRWLQFO XGHWKHSDWLHQWÂ¶VFRQW DFWRULGHQWLI\LQJ
LQIRUPDWLRQ5DWKHULQGLYLGXDO SDWLHQWVDQGWKHLUUHVHDUFKGDW DZLOOEHLGHQWLILHGE\D
XQLTXHVWXG\LGHQWLILFDW LRQQXPEHU$Q\SDWLHQWUHFRUGVRUGDWD VHWVWKDWDUHWUDQVIHUUHG
WRWKHVSRQVRUZLOOFRQWDLQWKHL GHQWLILHURQO\SDWLHQWQDPHV RUDQ\LQIRUPDWLRQZKLFK
ZRXOGPDNHWKHSDWLHQWLGHQWLILDEO HZLOOQRWEHWUDQVIHUUHG5H VHDUFKGDWDZLOOEHXVHGLQ
DFFRUGDQFHZLWKORFDO GDWDSURWHFWLRQODZV
7KHVWXG\PRQLWRURWKHUDXWKRUL] HGUHSUHVHQWDWLYHVRIWKHVSRQ VRUUHSUHVHQWDWLYHVRI
WKH,5%,(&RUUHJXODWRU\DJHQFLH VPD\LQVSHFWDOOGRFXPHQWVDQ GUHFRUGVUHTXLUHGWR
EHPDLQWDLQHGE\WKH,QYHVWLJDWRU LQFOXGLQJEXWQRWOLPLWHGWR PHGLFDOUHFRUGVRIILFH
FOLQLFRUKRVSLWDODQGSKDUPDF\ UHFRUGVIRUWKHSDWLHQWVLQW KLVVWXG\7KHFOLQLFDOVWXG\
VLWHZLOOSHUPLWDFFHVVWRVXFKUHFRUGV
 4XDOLW\$VVXUDQ FHDQG4XDOLW\&RQWURO
4XDOLW\FRQWURO4&SURFHGXU HVZLOOEHLPSOHPHQWHGEHJLQQLQJZ LWKWKHGDWDHQWU\
V\VWHPDQGGDWD4&FKHFNVWKDW ZLOOEHUXQRQW KHGDWDEDVHZLOO EHJHQHUDWHG$Q\
PLVVLQJGDWDRUGDWDD QRPDOLHVZLOOEHFRPP XQLFDWHGWRWKHVLWH VIRU
FODULILFDWLRQUHVROXWLRQ
)ROORZLQJZULWWHQ6WDQGDU G2SHUDWLQJ3URFHGXUHVWKHPRQLWRUVZ LOOYHULI\WKDWWKH
FOLQLFDOWULDOLVFRQGXFWHGGDW DDUHJHQHUDWHGDQGELRORJLFDO VSHFLPHQVDUHFROOHFWHG
GRFXPHQWHGUHFRUGHGDQGUHSRUW HGLQFRPSOLDQF HZLWKWKHSURW RFRO,&+*&3DQG
DSSOLFDEOHUHJXODWRU\ UHTXLUHPHQWVHJ *RRG/DERUDWRU\3UDFW LFHV*RRG
0DQXIDFWXULQJ3UDFWLFHV
7KHLQYHVWLJDWLRQDOVLWHZLOO SURYLGHGLUHFWDFFHVVWRDOOWULD OUHODWHGVLWHVVRXUFH
GDWDGRFXPHQWVDQGUHSRUWVIRU WKHSXUSRVHRIPRQLWRULQJDQGD XGLWLQJE\WKHVSRQVRU
DQGLQVSHFWLRQE\ORFDODQG UHJXODWRU\DXWKRULWLHV
 'DWD+DQGOLQJDQG5HFRUG.HHSLQJ
 'DWD&ROOHFWLRQDQG 0DQDJHPHQW5HVSRQVLELOLWLHV
'DWDFROOHFWLRQLVWKHUHVSRQVLE LOLW\RIWKHFOLQLFDOWULDOVWD IIDWWKHVLWHXQGHUWKH
VXSHUYLVLRQRIWKHVLWH,QYHVWLJDW RU7KH,QYHVWLJDWRULVUHVSR QVLEOHIRUHQVXULQJWKH
DFFXUDF\FRPSOHWHQHVVOHJLELOLW \DQGWLPHOLQHVVRIWKHGDWD UHSRUWHG
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI7KH,QYHVWLJDWRUPXVWPDLQWDLQ DGHTXDWHVRXUFH GRFXPHQWDWLRQ$ OOVRXUFHGRFXPHQWV
VKRXOGEHFRPSOHWHGLQDQHDWO HJLEOHPDQQHUWRHQVXUHDFFXUDW HLQWHUSUHWDWLRQRIGDWD
&OLQLFDOGDWDLQFOXGLQJ$(VF RQFRPLWDQWPHGLFDWLRQVDQGH[SH FWHGDGYHUVHUHDFWLRQV
GDWDZLOOEHHQWHUHGLQWRD &)53DUWFRPSOLDQW('&V\VWH PRUWUDQVPLWWHG
HOHFWURQLFDOO\HJODERUDWRU \GDWD7KHGDWDV\VWHPVLQFO XGHVSDVVZRUGSURWHFWLRQ
DQGLQWHUQDOTXDOLW\FKHFNVVXF KDVDXWRPDWLFUDQJHFKHFNVWR LGHQWLI\GDWDWKDW
DSSHDULQFRQVLVWHQWLQFRPSOHWHR ULQDFFXUDWH&OLQLFDOGDWDZ LOOEHHQWHUHGGLUHFWO\IURP
WKHVRXUFHGRFXPHQWV'DWDUHFR UGHGLQWKH&5)VKRXOGEHFRQVLV WHQWZLWKWKHGDWD
UHFRUGHGRQWKHVRXUFHGRFXPHQWV RUWKHGLVFUHSDQFLHVPXVWEHH [SODLQHG
7KHVSRQVRURUGHVLJQHHLVUHV SRQVLEOHIRUWKH GDWDPDQDJHPHQW RIWKLVVWXG\LQFOXGLQJ
TXDOLW\FKHFNLQJRIWKHGDWD7 KHVSRQVRUDVVXPHVDFFRXQWDELOLW \IRUDFWLRQVGHOHJDWHG
WRRWKHULQGLYLGXDOVHJ&RQW UDFW5HVHDUFK2UJDQL]DWLRQV
6WXG\PRQLWRUVZLOOSHUIRUPRQJRLQJ VRXUFHGDWDYHULILFDWLRQWR FRQILUPWKDWGDWDHQWHUHG
LQWRWKH&5)E\DXWKRUL]HGVLWHS HUVRQQHODUHDFFXUDWHFRPSOHW HDQGYHULILDEOHIURP
VRXUFHGRFXPHQWVWKDWWKHVDIHW\ DQGULJKWVRISDWLHQWVDUHEH LQJSURWHFWHGDQGWKDW
WKHVWXG\LVEHLQJFRQ GXFWHGLQDFFRUGDQFH ZLWKWKHFXUUHQWO\D SSURYHGSURWRFRODQG
DQ\RWKHUVWXG\DJU HHPHQWV,&+*&3DQG DOODSSOLFDEOHUHJXODW RU\UHTXLUHPHQWV
 6WXG\5HFRUGV5HWHQWLRQ
5HFRUGVDQGGRFXPHQWVLQFOXGLQJ VLJQHG,&)VSHUWDLQLQJWRWKH FRQGXFWRIWKLVVWXG\
PXVWEHUHWDLQHGIRUDPLQLPXP RI\HDUVDIWHUWKHODVWDSSURY DORIDPDUNHWLQJ
DSSOLFDWLRQLQDQ,&+UHJLRQDQ GXQWLOWKHUHDU HQRSHQGLQJRU FRQWHPSODWHGPDUNHWLQJ
DSSOLFDWLRQVLQDQ,&+UHJLRQRU XQWLODWOHDVW\HDUVKDYHHO DSVHGVLQFHWKHIRUPDO
GLVFRQWLQXDWLRQRIFOLQLFDOGHYHO RSPHQWRIWKHLQYHVWLJDWLRQDO SURGXFW7KHVHGRFXPHQWV
VKRXOGEHUHWDLQHGIRUDORQJHUS HULRGKRZHYHULIUHTXLUHGE\ ORFDOUHJXODWLRQV
1RUHFRUGVZLOOEHGHV WUR\HGZLWKRXWWKHZULWWHQFRQVHQWRIWKH VSRQVRU1RUHFRUGVPD\
EHWUDQVIHUUHGWRDQRWKHUORFDWL RQRUSDUW\ZLWKRXWZULWWHQQRW LILFDWLRQWRWKHVSRQVRU
,WLVWKHUHVSRQVLELOLW\RIWKHV SRQVRUWRLQIRUPWKH,QYHVWLJD WRUZKHQWKHVHGRFXPHQWV
QRORQJHUQHHGWREHUHWDLQHG
 6WXG\DQG6LWH'L VFRQWLQXDWLRQDQG&ORVXUH
7KHVSRQVRURULWVGHVLJQHHUHVH UYHVWKHULJKWWRVXVSHQGRUSU HPDWXUHO\WHUPLQDWHD
VWXG\VLWHRUVWXG\DWDQ\WLPH IRUDQ\UHDVRQDQGDWWKHVROH GLVFUHWLRQRIWKHVSRQVRU
$Q,QYHVWLJDWRUPD\LQLWLDWHVL WHFORVXUHDWDQ\WLPHSURYLGHG WKHUHLVUHDVRQDEOHFDXVH
DQGVXIILFLHQWQRWLFHLVJLYHQ WRWKHVSRQVRULQDGYDQFHRIWKH LQWHQGHGWHUPLQDWLRQ
:ULWWHQQRWLILFDWLRQGRFXPHQWL QJWKHUHDVRQIRUVLWHRUVWXG\ VXVSHQVLRQRUWHUPLQDWLRQ
ZLOOEHSURYLGHGE\WKHVXVSHQGLQJ RUWHUPLQDWLQJSDUW\WRVWXG \SDUWLFLSDQWV
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI,QYHVWLJDWRUIXQGLQJDJHQF\WKH,Q YHVWLJDWLRQDO1HZ'UXJVSRQ VRUDQGUHJXODWRU\
DXWKRULWLHV
,IWKHVWXG\LVSUHPDWXUHO\WH UPLQDWHGRUVXVSHQGHGWKH,QYHVW LJDWRUZLOOSURPSWO\
LQIRUPVWXG\SDUWLFLSDQWVWKH ,5%,(&DQGVSRQVRUDQGZLOOS URYLGHWKHUHDVRQVIRU
WKHWHUPLQDWLRQRUVXVSHQVLRQ6W XG\SDUWLFLSDQWVZLOOEHFRQWD FWHGDVDSSOLFDEOHDQG
EHLQIRUPHGRIFKDQJHVWRVWXG\YLVLWVFKHGXOH
&LUFXPVWDQFHVWKDWPD\ZDUUDQWW HUPLQDWLRQRUVXVSHQVLRQLQFOXG HEXWDUHQRWOLPLWHG
WR
x 'HWHUPLQDWLRQRIXQH[SHFWHGVL JQLILFDQWRUXQDFFHSWDEOHULVN WRSDUWLFLSDQWV
x 'HPRQVWUDWLRQRIHIILFDF\WKDWZRXOGZDUUDQWVWRSSLQJ
x ,QVXIILFLHQWFRPSOLDQFHWRWKH SURWRFROUHJXODWRU\UHTXLUHPHQ WVRU*&3
JXLGHOLQHV
x 'DWDWKDWDUHQRWVXIILFLHQW O\FRPSOHWHDQGRUHYDOXDEOH
x 'HWHUPLQDWLRQWKDWWKHSU LPDU\HQGSRLQWKDVEHHQPHW
x 'HWHUPLQDWLRQRIIXWLOLW\
x ,QDGHTXDWHUHFUXLWPHQWRISDWLHQWV
 'LVVHPLQDWLRQRI& OLQLFDO6WXG\'DWD
$&OLQLFDO6WXG\5HSRUW&65 ZLOOEHSUHSDUHGLQ DFFRUGDQFHZL WKWKH,&+JXLGHOLQHRQ
VWUXFWXUHDQGFRQWHQWVRI&65V DQGDQ\DSSOLFDEOHUHJXODWRU\DQ GOHJDOUHTXLUHPHQWV
 3XEOLFDWLRQ3ROLF\
7KHUHVXOWVRIWKLVVWXG\PD\ EHSXEOLVKHGRUSUHVHQWHGDWVFLH QWLILFPHHWLQJV,IWKLVLV
IRUHVHHQWKH,QYHVWLJDWRUDJUHHVWRVXEPLWDOOPDQXVFULSWVRU DEVWUDFWVWRWKHVSRQVRU
EHIRUHVXEPLVVLRQ7KLVDOORZVW KHVSRQVRUWRSURWHFWSURSULHWD U\LQIRUPDWLRQDQGWR
SURYLGHFRPPHQWV
7KHVSRQVRUZLOOFRPSO\ZLWKWKH UHTXLUHPHQWVIRUSXEOLFDWLRQR IVWXG\UHVXOWV,Q
DFFRUGDQFHZLWKVWDQGDU GHGLWRULDODQGHWKLFDOSUDFWLFHWKHVS RQVRUZLOOJHQHUDOO\
VXSSRUWSXEOLFDWLRQRIPXOWLFHQWHU VWXGLHVRQO\LQWKHLUHQWLUH W\DQGQRWDVLQGLYLGXDOVLWH
GDWD,QWKLVFDVHDFRRUGLQDWL QJ,QYHVWLJDWRU ZLOOEHGHVLJQD WHGE\PXWXDODJUHHPHQW
$XWKRUVKLSZLOOEHGHWHUPLQHGE\ PXWXDODJUHHPHQWDQGLQOLQHZ LWK,QWHUQDWLRQDO
&RPPLWWHHRI0HGLFDO-RXUQDO(GL WRUVDXWKRUVKLSUHTXLUHPHQWV
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI 5()(5(1&(6

























CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI

























CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI



86'HSDUWPHQWRI+HDOWKDQG+X PDQ6HUYLFHV)RRGDQG'UXJ$GP LQLVWUDWLRQ&HQWHU
IRU'UXJ(YDOXDWLRQDQ G5HVHDUFK0D\ *XLGDQFHIRU,QGXV WU\,UULWDEOH%RZHO
6\QGURPHÂ±&OLQLFDO(YDOXDWLRQR I'UXJVIRU7UHDWPHQW5HWULHYH GIURP
KWWSVZZZIGDJRYGRZQORDGV 'UXJV*XLGDQFHV8&0SGI 




CCI
CCI
CCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI $33(1',&(6

&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI$SSHQGL[&OLQLFDO/DERUDWRU\7HVWV
7KHWHVWVGHWDLOHGLQ 7DEOHZLOOEHSHUIRUPHGE\WKHFHQW UDOODERUDWRU\ZLWKWKH
H[FHSWLRQRIHU\WKURF\WHVHGLP HQWDWLRQUDWHDQGXULQHSUHJQDQF\ WHVWV7KHFHQWUDO
ODERUDWRU\ZLOOSURYLG HNLWVDQGLQVWUXFWLRQVWRSHUIRUPWKHVH DVVHVVPHQWVRQVLWH
/RFDOODERUDWRU\UHVXOWVDUH RQO\UHTXLUHGLQWKHHYHQWWKDWWK HFHQWUDOODERUDWRU\UHVXOWV
DUHQRWDYDLODEOHLQWLPHIRUH LWKHULQYHVWLJDWLRQDOSURGXFWDG PLQLVWUDWLRQDQGRU
UHVSRQVHHYDOXDWLRQ,IDORFDO VDPSOHLVUHTXLUHGLWLVLPSRU WDQWWKDWWKHVDPSOHIRU
FHQWUDODQDO\VLVLVREWDLQHGDWW KHVDPHWLPH$GGLWLRQDOO\LI WKHORFDOODERUDWRU\UHVXOWV
DUHXVHGWRPDNHHLWKHUDQLQYH VWLJDWLRQDOSURGXF WGHFLVLRQRU UHVSRQVHHYDOXDWLRQWKH
UHVXOWVPXVWEHHQWHUHGLQWRWKH&5)
3URWRFROVSHFLILFUHTXLUHPHQWVIR ULQFOXVLRQRUH[FOXVLRQRISD WLHQWVDUHGHWDLOHGLQ
6HFWLRQRIWKHSURWRFRO
$GGLWLRQDOWHVWVPD\EHSHUIRUPH GDWDQ\WLPHGXULQJWKHVWXG\ DVGHWHUPLQHG
QHFHVVDU\E\WKH,QYHVWLJDWRUR UUHTXLUHGE\ORFDOUHJXODWLRQV 
3UHJQDQF\WHVWLQJ5HIHUWR 6HFWLRQIRU6FUHHQLQJSUH JQDQF\FULWHULD
7DEOH 3URWRFROUHTXLUHG6DIHW\/DERUDWRU\$VVHVVPHQWV 
/DERUDWRU\
$VVHVVPHQWV 3DUDPHWHUV
+HPDWRORJ\ 3ODWHOHWFRXQW  5%&,QGLFHV
0HDQFRUSXVFXODU
YROXPH
0HDQFRUSXVFXODU+HPRJORELQ
5HWLFXORF\WHV:KLWHEORRGFHOOFRXQW
ZLWKGLIIHUHQWLDO
1HXWURSKLOV
/\PSKRF\WHV0RQRF\WHV
(RVLQRSKLOV
%DVRSKLOV5HGEORRGFHOO5%&FRXQW
+HPRJORELQ+HPDWRFULW
&OLQLFDO
&KHPLVWU\%ORRG
XUHD
QLWURJHQ3RWDVVLXP $VSDUWDWH
DPLQRWUDQVIHUDVH6HUXP
JOXWDPLFR[DORDFHWLF
WUDQVDPLQDVH7RWDODQGGLUHFW
ELOLUXELQ
 &UHDWLQLQH 6RGLXP $ODQLQH
DPLQRWUDQVIHUDVH6HUXP
JOXWDPLFS\UXYLF
WUDQVDPLQDVH7RWDOSURWHLQ
 *OXFRVH
IDVWHGD&DOFLXP $ONDOLQHSKRVSKDWDVH 
 


 
5RXWLQH
8ULQDO\VLV6SHFLILFJUDYLW\
S+JOXFRVHSURWHLQEORRGNHWRQHVELOLUXELQXURELOLQRJHQ QLWULWHOHXNRF\WHHVWHUDVH
E\GLSVWLFN
0LFURVFRSLFH[DPLQDWLRQLI EORRGRUSURWHLQLVDEQRUPDOCCI CCI CCI CCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI7DEOH 3URWRFROUHTXLUHG6DIHW\/DERUDWRU\$VVHVVPHQWV 
/DERUDWRU\
$VVHVVPHQWV 3DUDPHWHUV
2WKHU
6FUHHQLQJ
7HVWV+HPRJORELQ$F
)ROOLFOHVWLPXODWLQJKRUPRQHDQG HVWUDGLRODVQHHGHGLQZRPHQ RIQRQFKLOGEHDULQJ
SRWHQWLDORQO\
8ULQHKXPDQFKRULRQLFJRQDGRWURSL QK&*SUHJQDQF\WHVWDVQHH GHGIRUZRPHQRI
FKLOGEHDULQJSRWHQWLDO
6HURORJ\+,9DQWLERG\KHSDWLWLV %VXUIDFHDQWLJHQDQGKHSDWL WLV&YLUXVDQWLERG\
VHUXPWLVVXHWUDQVJOXWDPLQDVH,J $DQWLERG\W7*,J$DQG,J$L IDSSOLFDEOH
D3DWLHQWVVKRXOGUHIUDLQIURPI RRGRUGULQNVRWKHUWKDQZDWHU IRUDWOHDVWKRXUVSULRUWRREWDLQLQJD
IDVWLQJJOXFRVHOHYHO

,QYHVWLJDWRUVPXVWGRFXPHQWWKHL UUHYLHZRIHDFKODERUDWRU\VDI HW\UHSRUW
/DERUDWRU\UHVXOWVWKDWFRXOGXQE OLQGWKHVWXG\ZLOOQRWEHUHS RUWHGWRLQYHVWLJDWLYHVLWHV
RURWKHUEOLQGHGSHUVRQQHOXQWLO WKHVWXG\KDVEHHQXQEOLQGHG
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI$SSHQGL[&RQWUDFHSWLYH*XLGDQ FHDQG&ROOHFWLRQRI3UHJQDQF\ ,QIRUPDWLRQ
'HILQLWLRQV 
:RPDQRI&KLOGEHDULQJ3RWHQWLDO:2&%3
$ZRPDQLVFRQVLGHUHGIHUWLOH IROORZLQJPHQDUF KHDQGXQWLOEHFR PLQJSRVWPHQRSDXVDO
XQOHVVSHUPDQHQWO\VWHULOHVHHEHORZ
:RPHQLQWKHIROORZLQJFDWHJRULHV DUHQRWFRQVLGHUHG:2&%3 
 3UHPHQDUFKDO 3UHPHQRSDXVDOIHPDOHZ LWKRIWKHIROORZLQJ
D 'RFXPHQWHGK\VWHUHFWRP\E 'RFXPHQWHGELODWHUDOVDOSLQJHFWRP\F 'RFXPHQWHGELODWHUDORRSKRUHFWRP\
1RWH'RFXPHQWDWLRQFDQFRPHIUR PWKHVLWHSHUVRQQHOÂ¶VUHYLHZR IWKHSDWLHQWÂ¶VPHGLFDO
UHFRUGVPHGLFDOH[DPLQDWLRQR UPHGLFDOKLVWRU\LQWHUYLHZ
 3RVWPHQRSDXVDOIHPDOH
D $SRVWPHQRSDXVDOVWDWHLVGHIL QHGDVQRPHQVHVIRUPRQWKV ZLWKRXWDQ
DOWHUQDWLYHPHGLFDOFDXVH$K LJKIROOLFOHVWLPXODWLQJKRUPRQH )6+OHYHOLQWKH
SRVWPHQRSDXVDOUDQJHPD\EHXVHG WRFRQILUPDSRVWPHQRSDXVDOVW DWHLQ
ZRPHQQRWXVLQJKRUPRQDOFRQWUDF HSWLRQRUKRUPRQDOUHSODFHPHQW WKHUDS\
+57+RZHYHULQWKHDEVHQFHR IPRQWKVRIDPHQRUUKHDDVL QJOH)6+
PHDVXUHPHQWLVLQVXIILFLHQW
E )HPDOHVRQ+57DQGZKRVHPH QRSDXVDOVWDWXVLVLQGRXEWZLOO EHUHTXLUHGWR
XVHRQHRIWKHQRQHVWURJHQKRUPRQDOK LJKO\HIIHFWLYHFRQWUDFHSW LRQPHWKRGVLI
WKH\ZLVKWRFRQWLQXHWKHLU+57 GXULQJWKHVWXG\2WKHUZLVHWK H\PXVW
GLVFRQWLQXH+57WRDOORZFRQIL UPDWLRQRISRVWPHQRSDXVDOVWDWXV EHIRUHVWXG\
HQUROOPHQW
&RQWUDFHSWLRQ*XLGDQFH
0DOHSDWLHQWV
0DOHSDWLHQWVZLWKIHPDOHSDUW QHUVRIFKLOGEHDULQJSRWHQWLDODU HHOLJLEOHWRSD UWLFLSDWHLI
WKH\DJUHHWR21(RIWKHIROORZLQJ GXULQJWKHWUHDWPHQWSHULRG DQGIRUDW
OHDVWZHHNVDIWHUWKHODVW GRVHRILQYHVWLJDWLRQDOSURGXFW 
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRIx $UHDEVWLQHQWIURPSHQLOHYDJL QDOLQWHUFRXUVHDVWKHLUXVXDOD QGSUHIHUUHGOLIHVW\OH
DEVWLQHQWRQDORQJWHUPDQGSHU VLVWHQWEDVLVDQGDJUHHWRUH PDLQDEVWLQHQW
x $JUHHWRXVHDPDOHFRQGRPSOXV SDUWQHUXVHRIDFRQWUDFHSWLYH PHWKRGZLWKD
IDLOXUHUDWHRISHU \HDUDVGHVFULEHGLQ 7DEOHZKHQKDYLQJSHQLOHYDJLQDO
LQWHUFRXUVHZLWKD:2&%3ZKRLV QRWFXUUHQWO\SUHJQDQWXQOHVV FRQILUPHGWREH
D]RRVSHUPLFYDVHFWRPL]HGRUVHFRQGDU\WRPHGLFDOFDXVH
,QDGGLWLRQPDOHSDWLHQWVPXVWU HIUDLQIURPGRQDWLQJVSHUPIRU WKHGXUDWLRQRIWKHVWXG\
DQGIRUZHHNVDIWHUWKHODVWG RVHRILQYHVWLJDWLRQDOSURGXFW 
0DOHSDWLHQWVZLWKDSUHJQDQWR UEUHDVWIHHGLQJSDUWQHUPXVWDJU HHWRUHPDLQDEVWLQHQW
IURPSHQLOHYDJLQDOLQWHUFRXUVH RUXVHDPDOHFRQGRPGXULQJHDF KHSLVRGHRISHQLOH
SHQHWUDWLRQIRUWKHGXUDWLRQRIW KHVWXG\DQGIRUZHHNVDIWH UWKHODVWGRVHRI
LQYHVWLJDWLRQDOSURGXFW
)HPDOHSDWLHQWV)HPDOHSDWLHQWVRIFKLOGEHDULQJ SRWHQWLDODUHHOLJLEOHWRSDUWL FLSDWHLIWKH\DJUHHWRXVHD
KLJKO\HIIHFWLYHPHWKRGRIFRQW UDFHSWLRQDVGHVFULEHGLQ 7DEOHFRQVLVWHQWO\DQG
FRUUHFWO\
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI7DEOH +LJKO\(IIHFW LYH&RQWUDFHSWLYH0HWKRGV 
+LJKO\(IIHFWLYH&RQWUDFHSWLYH0HWKRGV7KDW$UH8VHU'HSHQGHQWD
)DLOXUHUDWHRISHU\HDUZK HQXVHGFRQVLVWHQWO\DQGFRUUHFW O\
&RPELQHGHVWURJHQDQGSURJHVWRJ HQFRQWDLQLQJKRUPRQDOFRQWUDF HSWLRQDVVRFLDWHGZLWKLQKLELWLRQRI
RYXODWLRQE
x2 U D O  
x ,QWUDYDJLQDO
x 7UDQVGHUPDO
3URJHVWRJHQRQO\KRUPRQDOFRQWUDFH SWLRQDVVRFLDWHGZLWKLQKLELW LRQRIRYXODWLRQE
x2 U D O  
x ,QMHFWDEOH
+LJKO\(IIHFWLYH0HWKRGV7KDW$UH8VHU,QGHSHQGHQW 
x ,PSODQWDEOHSURJHVWRJHQRQO\KRU PRQDOFRQWUDFHSWLRQDVVRFLDWHG ZLWKLQKLELWLRQRIRYXODWLRQE
x ,QWUDXWHULQHGHYLFH,8'
x ,QWUDXWHULQHKRUPRQHUHOHDVLQJV\VWHP,86
x %LODWHUDOWXEDORFFOXVLRQ
9DVHFWRPL]HG3DUWQHU 
$YDVHFWRPL]HGSDUWQHULVDKLJKO \HIIHFWLYHFRQWUDFHSWLRQPHWK RGSURYLGHGWKDWWKHSDUWQHULVWKHVROH
PDOHVH[XDOSDUWQHURIWKH:2&%3 DQGWKHDEVHQFHRIVSHUPKDVE HHQFRQILUPHG,IQRWDQDGGLWLRQDO
KLJKO\HIIHFWLYHPHWKRGRIFRQW UDFHSWLRQVKRXOGEHXVHG
6H[XDO$EVWLQHQFH 
6H[XDODEVWLQHQFHLVFRQVLGHUHG DKLJKO\HIIHFWLYHPHWKRGRQO\ LIGHILQHGDVUHIUDLQLQJIURPKHWHURVH[XDO
LQWHUFRXUVHGXULQJWKHHQWLUHSHU LRGRIULVNDVVRFLDWHGZLWKWK HLQYHVWLJDWLRQDOSURGXFW7KHUHOLDELOLW\RI
VH[XDODEVWLQHQFHQHHGVWREHHY DOXDWHGLQUHODWLRQWRWKHGXUD WLRQRIWKHVWXG\ DQGWKHSUHIHUUHGDQG
XVXDOOLIHVW\OHRIWKHSDWLHQW
127(6
D 7\SLFDOXVHIDLOXUHUDWHVPD\GLIIHUIURPWKRVHZKHQXVHGFRQV LVWHQWO\DQGFRUUHFWO\8VHVKRXOGEH
FRQVLVWHQWZLWKORFDOUHJXODWL RQVUHJDUGLQJWKHXVHRIFRQWUDFH SWLYHPHWKRGVIRUS DWLHQWVSDUWLFLSDWLQJ
LQFOLQLFDOVWXGLHV6KRXOGEHLQ LWLDWHGRUPRUHPHQVWUXDOF\ FOHVSULRUWRVFUHHQLQJ
E +RUPRQDOFRQWUDFHSWL RQPD\EHVXVFHSWLEOHWRLQWHUDFWLRQZLWK WKHLQYHVWLJDWLRQDOSURGXFWZKLFKPD\
UHGXFHWKHHIILFDF\RIWKHFRQWUD FHSWLYHPHWKRG,QWKHFDVHRI KRUPRQDOFRQWUDFHSWLRQDVWKH
SULPDU\PHWKRGRIFRQWUDFHSWLRQDVXSSOHPHQWDU\EDUULHUPHWKRG SUHIHUDEO\PDOHFRQGRPVKRXOG
EHXWLOL]HGGXULQJWKHWUHDWPHQW SHULRGDQGIRUDWOHDVWZHHN VDIWHUWKHODVWGRVHRILQYHVWLJDWLRQDO
SURGXFW

3UHJQDQF\7HVWLQJ
x $Q\:2&%3VKRXOGRQO\EHLQFO XGHGDIWHUDQHJDWLYHSUHJQDQF\W HVW
x $GGLWLRQDOXULQHSUHJQDQF\WHVW LQJVKRXOGEHSHUIRUPHGDWWKH 'D\YLVLWDQGWKH
'D\(QGRI6WXG\)ROORZXSYLVLW
x 3UHJQDQF\WHVWLQJZLOOEHSHUIR UPHGZKHQHYHUDPHQVWUXDOF\FOH LVPLVVHGRUZKHQ
SUHJQDQF\LVRWKHUZLVHVXVSHFWHG
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI&ROOHFWLRQRI3UHJQDQF\,QIRUPDWLRQ 
x $OORFFXUUHQFHVRISUHJQDQFLHV PXVWEHUHSRUWHGRQD3UHJQDQF\ 1RWLILFDWLRQDQG
2XWFRPH)RUPZLWKLQKRXUVR IDZDUHQHVVRIDQ\VXFKSUHJQDQF \WKDWRFFXUVIRU
HLWKHUWKHVWXG\SDWLHQWRUIRU WKHIHPDOHSDUWQHURIDPDOHSD WLHQWDOOSUHJQDQFLHV
ZLOOEHIROORZHGWRRXWFRPHZKL FKPHDQVXQWLOHLWKHUWKHILUVW ZHOOEDE\YLVLWIRUOLYH
ELUWKVRUXQWLOGRFXPHQWHG VSRQWDQHRXVRULQGXFHGDERUWLRQ
x :KLOHSUHJQDQF\LWVHOILVQR WFRQVLGHUHGWREHDQ$(RU6$(D Q\SUHJQDQF\
FRPSOLFDWLRQRUHOHFWLYHWHUPLQDW LRQRIDSUHJQDQF\ZLOOEHUHS RUWHGDVDQ$(RU6$(
$VSRQWDQHRXVDERUWLRQLVDOZD \VFRQVLGHUHGWREHDQ6$(DQGZL OOEHUHSRUWHGDV
VXFK
x 3UHJQDQFLHVWKDWRFFXUEH\RQGGD \VDIWHUWKHODVWGRVHRIV WXG\GUXJZLOORQO\
QHHGWREHUHSRUWHGLIWKHUHLV DQDVVRFLDWHG6$(WKDWWKH,QYH VWLJDWRUDVVHVVHGDV
UHODWHGWRVWXG\GUXJ
x 6DIHW\7HDPZLOOIROORZXSZLWKW KH,QYHVWLJDWRUHYHU\PRQWK VUHJDUGLQJSUHJQDQF\
RXWFRPH7KH,QYHVWLJDWRUPXV WIROORZWKHSUHJQDQF\WRFRQFOXVL RQLQRUGHUWR
GHWHUPLQHWKHRXWFRPH,IWKHFDVH LVEH\RQGGD\VIURPWKHH [SHFWHGGXHGDWH
DQGQRLQIRUPDWLRQKDVEHHQUHFHLY HGUHJDUGLQJWKHRXWFRPHWKH 6DIHW\7HDPZLOO
FRQWDFWWKH,QYHVWLJDWRUWRUHTXHVWRXWFRPH
0DOH3DWLHQWV:LWK3DUWQ HUV:KR%HFRPH3UHJQDQW
x 7KH,QYHVWLJDWRUZLOODWWHPSWWR FROOHFWSUHJQDQF\LQIRUPDWLRQ RQDQ\PDOHSDWLHQWÂ¶V
IHPDOHSDUWQHUZKREHFRPHVSUHJQDQ WZKLOHWKHPDOHSDWLHQWLVL QWKLVVWXG\7KLV
DSSOLHVRQO\WRPDOHSDWLHQW VZKRUHFHLYH%26
x $IWHUREWDLQLQJWKHQHFHVVDU\VLJQHGLQIRUPHGFRQVHQWIURPWKH SUHJQDQWIHPDOH
SDUWQHUGLUHFWO\WKH,QYHVWL JDWRUZLOOUHFRUGSUHJQDQF\LQIRUP DWLRQRQWKHDSSURSULDWH
IRUPDQGVXEPLWLWWRWKHVSRQVRUDVRXWOLQHGDERYH
)HPDOH3DWLHQWV:KR%HFRPH3UHJQDQW
x 7KH,QYHVWLJDWRUZLOOFROOHFWSUHJQDQF\LQIRUPDWLRQRQDQ\IHP DOHSDWLHQWZKR
EHFRPHVSUHJQDQWZKLOHSDUWLFLSDW LQJLQWKLVVWXG\,QIRUPDWLRQ ZLOOEHUHFRUGHGRQ
WKHDSSURSULDWHIRUPDVQRWHGDERYH
x $Q\IHPDOHSDWLHQWZKREHFRPHV SUHJQDQWZKLOHSDUWLFLSDWLQJLQ WKHVWXG\ZLOOEH
ZLWKGUDZQIURPWKHVWXG\

&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI$SSHQGL[7KH%ULVWRO6WRRO)RUP6FDOH


  
CCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI$SSHQGL[&RQFRPLWDQW0HGLFDWLRQV
,IWKHVWXG\VLWHLQYHVWLJDWRU KDVDQ\TXHVWLRQV UHJDUGLQJSHUP LWWHGRUH[FOXGHG
PHGLFDWLRQVWKHPHGLFDOPRQLWR UVKRXOGEHFRQWDFWHGIRUIXUWKH UGLVFXVVLRQ
0HGLFDWLRQVSHUPLWWHGGXUL QJWKHFRXUVHRIWKHVWXG\
x $Q\PHGLFDWLRQRUYDFFLQHLQFOX GLQJRYHUWKHFRXQWHURUSUHVF ULSWLRQPHGLFLQHV
YLWDPLQVDQGRUVXSSOHPHQWVWKD WLQWKHRSLQLRQRIWKH,QYHVW LJDWRUVKRXOGQRW
LQWHUIHUHZLWKVWXG\SURFHGXUHVF RPSURPLVHVDIHW\RUWKHVFLH QWLILFLQWHJULW\RI
WKHGDWD
x 6WDEOHGRVHVRIPHGLFDWLRQVIRUD OOHUJLHVPLJUDLQHVZLWKWKH H[FHSWLRQRI
RSLRLGVIRUDFXWHWUHDWPHQW DQ[LHW\HJDVQHHGHGXVHRIE HQ]RGLD]HSLQHV
GHSUHVVLRQRURWKHUFKURQLFFRQGL WLRQVDWWKHGLVFUHWLRQRIWKH ,QYHVWLJDWRU
x 6WDEOHGRVHVRIDQWLGHSUHVVDQW V$VQHHGHGXVHRIEXVSLURQHDQ G
EHQ]RGLD]HSLQHVIRUDQ[LHW\
x /RSHUDPLGHFDQEHXV HGGXULQJVWXG\DVUHVFXHPHGLFDWLRQEDVHG RQ
SURWRFROVSHFLILHG JXLGHOLQHVVHH 6HFWLRQ IRUDOORZDEOHRQVWXG\UHVFXH
PHGLFDWLRQV
x $FHWDPLQRSKHQXSWRJGD\IR UXSWRFRQVHFXWLYHGD\V
x 7KH,QYHVWLJDWRUVKRXOGPRQLWRU FORVHO\IRUSRWHQWLDOVLGHHII HFWVUHODWHGWRDQ\RI
WKHIROORZLQJPHGLFLQHVZKLFKDU HFRQVLGHUHGPRGHUDWHWRKLJKO\ VHQVLWLYH
VXEVWUDWHVRI&<3$

DOSUD]RODPDSUHSLWDQWDWRUYDVWDWLQDYDQDILOEXGHVRQLGHEXVSLURQHFROFKLFLQHGDULIHQDFLQGURQHGDURQH
HEDVWLQHHOHWULSWDQIHORGLSLQHORPLWDSLGHORYDVWDWLQPLGD]RODPQDOR[HJROQLVROGLSLQH
SLPR]LGHULYDUR[DEDQVLOGHQDILOVLPYDVWDWLQWDGDODILOWULD]RODPYDUGHQDILO

&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI0HGLFDWLRQVH[FOXGHGGXUL QJWKHFRXUVHRIWKHVWXG\
x K\GUR[\WULSWDPLQH+7 RU+7 UHFHSWRUDQWDJRQLVWVHJDORVHWURQ
RQGDQVHWURQRUUDPRVHWURQ
x (OX[DGROLQH
x %LOHDFLGVHTXHVWUDQWVVXFKDVF KROHVW\UDPLQHFROHVWLSRORU FROHVHYHODP
x 6WURQJLQKLELWRUVRI3JO\FRSURWHLQ
DPLRGDURQH à¯—
FDUYHGLOROFODULWKURP\FLQGURQHGDURQH
LWUDFRQD]ROHSURSDIHQRQHTXLQLGLQH
UDQROD]LQHYHUDSDPLO

x $VSLULQRUDVSLULQFRQWDLQLQJ PHGLFDWLRQV!PJRIDVSLULQ SHUGD\RU
QRQVWHURLGDODQWLLQIODPPDWRU\G UXJVZKHQWDNHQVSHFLILFDOO\I RUWKHV\PSWRPV
RI,%6
x 1DUFRWLFRURSLRLG FRQWDLQLQJDJHQWV
x &DQQDELVFRQWDLQLQJSURGXFWV
x 'RFXVDWH
x (QHPDV
x *,SUHSDUDWLRQVLQFOXGLQJDQWDFLG VFRQWDLQLQJDOXPLQXPRUPDJ QHVLXP
DQWLGLDUUKHDODJHQWVDQWLVSDV PRGLFDJHQWVELVPXWKSHSSHUPLQW RLO,%JDUG
)'JDUGRUSURNLQHWLFDJHQWV
x 3ODQQHGXVHRIULID[LPLQRURUDO DQWLELRWLFVZLWKWKHH[FHSWL RQRIWRSLFDO
DQWLELRWLFVRUDGD\FRXUVHZLW KDQDQWLELRWLFDSDWLHQWZL OOEHDOORZHGWR
UHPDLQLQWKHVWXG\VKRXOGXQSOD QQHGXVHRIDQWLELRWLFVRWKHUW KDQULID[LPLQRFFXU
DIWHUWKHSDWLHQW KDVEHHQUDQGRPL]HG
x $Q\LQYHVWLJDWLRQDOGUXJ
 
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI$SSHQGL[3URWRFRO$PHQGPHQW+LVWRU\

'2&80(17+,6725<
'RFXPHQW 'DWHRI,VVXH
$PHQGPHQWY $XJXVW
$PHQGPHQWY 0D\
2ULJLQDOY -DQXDU\

&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI$SSHQGL[3URWRFRO6XPPDU\RI&KDQJHV
6HFWLRQ 'HVFULSWLRQRI&KDQJHV  5DWLRQDOH
*OREDO 5HSODFH
3URWRFRO'DWHDQG9HUVLRQ0D\Y
:LWK
3URWRFRO'DWHDQG9HUVLRQ $XJXVW Y$GPLQLVWUDWLYH
*OREDO &KDQJH
&KDQJHG9HUVLRQQXPEHUIURP$PHQGPHQWY
WR$PHQGPHQW YDQG9HUVLRQGDWHIURP
0D\WR $XJXVW $GPLQLVWUDWLYH
*OREDO 0DGHDGPLQLVWUDWLYHDQG HGLWRULDOIRUPDWWLQJ
W\SRJUDSKLFDODQGJUDPPDWLFDOXSGDWHV$GPLQLVWUDWLYH
35272&2/
6800$5<6HFWLRQ
6\QRSVLV
6HFWLRQ 6WXG\
6FKHPD
6HFWLRQ 2YHUDOO
'HVLJQ
6HFWLRQ 6WXG\
3HULRGV
5HSODFH
$3UHWUHDWPHQW3KDVHRIXS WRZHHNVLQZKLFKDOO
SDWLHQWVZLOOEHDVVHVVHGWR GHWHUPLQHHOLJLELOLW\
:LWK
$3UHWUHDWPHQW3KDVHRIXSWR ZHHNVLQZKLFKDOO
SDWLHQWVZLOOEHDVVHVVHGWR GHWHUPLQHHOLJLELOLW\8SGDWHWRSUHWUHDWPHQW
OHQJWKRIWLPH
35272&2/
6800$5< 
6HFWLRQ 
6\QRSVLV
5HSODFH
7KHGXUDWLRQRISDWLHQWSDUWL FLSDWLRQLVDQWLFLSDWHGWR
EHXSWRZHHNV
:LWK
7KHGXUDWLRQRISDWLHQWSDUWL FLSDWLRQLVDQWLFLSDWHGWR
EHXSWRZHHNV8SGDWHWRDFFRXQWIRUWKH
H[WUDZHHNRIVFUHHQLQJ
35272&2/
6800$5<6HFWLRQ6FKHGXOHRI
$VVHVVPHQWV7DEOH5HSODFH

:LWK8SGDWHWRVFUHHQLQJ
ZLQGRZWRDOLJQZLWK
XSGDWHWRSUHWUHDWPHQW
OHQJWKRIWLPH

&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI6HFWLRQ 'HVFULSWLRQRI&KDQJHV  5DWLRQDOH

35272&2/
6800$5<6HFWLRQ6FKHGXOHRI
$VVHVVPHQWV
7DEOH$GG
7KHIXOOZHHN'D\VWRPD\EHXVHGWR
UDQGRPL]HHOLJLEOHSDWLHQWV+RZHYHUHIIRUWVVKRXOGEHPDGHWRUDQGRPL]HHOLJLEOHSDWLHQWV
ZLWKLQWRGD\VDIWHUFRPSOHWLQJUXQLQSHULRG3URWRFROFODULILFDWLRQRQ
OHQJWKRIWLPHIRUUDQGRPL]DWLRQ
35272&2/
6800$5<6HFWLRQ6FKHGXOHRI
$VVHVVPHQWV7DEOH
$SSHQGL[ &OLQLFDO
/DERUDWRU\7HVWV$GG
3DWLHQWVVKRXOGUHIUDLQIURPIRRGRUGULQNVRWKHU
WKDQZDWHUIRUDWOHDVWKRXUVSULRUWRREWDLQLQJDIDVWLQJJOXFRVHOHYHO3URWRFROFODULILFDWLRQ
DGGHGRQSDWLHQWIDVWLQJ
6HFWLRQ 6WXG\
'XUDWLRQIRU3DWLHQWV5HSODFH
8QOHVVVKRUWHQHGE\LQWROHU DEOH$(VRUUDSLGGLVHDVH
SURJUHVVLRQHDFKSDWLHQWÂ¶V SDUWLFLSDWLRQLQWKLVVWXG\LV
DQWLFLSDWHGWRODVWXSWRZHHNV
:LWK
8QOHVVVKRUWHQHGE\LQWROHU DEOH$(VRUUDSLGGLVHDVH
SURJUHVVLRQHDFKSDWLHQWÂ¶V SDUWLFLSDWLRQLQWKLVVWXG\LV
DQWLFLSDWHGWRODVWXSWR ZHHNV3URWRFROFODULILFDWLRQRQ
OHQJWKRIWLPHIRUSDWLHQWSDUWLFLSDWLRQWRDOLJQZLWK
XSGDWHWRSUHWUHDWPHQW
OHQJWKRIWLPH
6HFWLRQ 
,QFOXVLRQ&ULWHULD 5HSODFH
 2YHUWKHZHHNSULRUWRUDQGRPL]DWLRQWKH
SDWLHQWKDVDQDYHUDJHRIZ RUVWDEGRPLQDOSDLQ:$3
VFRUHVLQWKHSULRUKRXUV RIWRRQDWR
QXPHULFDOUDWLQJVFDOHZKH UHLQGLFDWHVQRSDLQDQG
LQGLFDWHVZRUVWSDLQLPDJLQDEOH
:LWK
 2YHU WKHILQDOGD\VRIWKHUXQLQSHULRG 
WKHSDWLHQWKDVDQDYHUDJHRI :$3VFRUHVLQWKHSULRU
KRXUVRI WRRQDWRQXPHULFDOUDWLQJ
VFDOHZKHUHLQGLFDWHVQRSDLQDQGLQGLFDWHV
ZRUVWSDLQLPDJLQDEOH3URWRFROFODULILFDWLRQ
6HFWLRQ 
,QFOXVLRQ&ULWHULD 5HSODFH
 2YHUWKHZHHNSULRUWRUDQGRPL]DWLRQWKH3URWRFROFODULILFDWLRQ

&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI6HFWLRQ 'HVFULSWLRQRI&KDQJHV  5DWLRQDOH
SDWLHQWKDVDQDYHUDJHGDLO\ %6)6VFRUHÂ•RQD
WRVFDOHZKHUH KDU GOXPS\VWRROVDQG 
ZDWHU\OLTXLGVWRROVDQGD WOHDVWGD\VZLWKD%6)6
VFRUHÂ•
:LWK
 2YHU WKHILQDOGD\VRIWKHUXQLQSHULRG 
WKHSDWLHQWKDVDQDYHUDJHGDL O\%6)6VFRUHÂ•RQ
DWRVFDOHZKHUH KD UGOXPS\VWRROVDQG 
ZDWHU\OLTXLGVWRROV DQGWKHUHPXVWEHDWOHDVW 
GD\VZLWK VWRROFRQVLVWHQF\RI7\SHÂ• 
6HFWLRQ 
,QFOXVLRQ&ULWHULD 'HOHWH
 2YHUWKHZHHNSULRUWRUDQGRPL]DWLRQWKH
SDWLHQWKDVDQDYHUDJHGDLO\ ,%6*6VFRUHRIÂ•RQ
DWRVFDOHZKHUH Q RQH PLOG PRGHUDWH
 VHYHUH YHU\VHYHUH
3URWRFROFODULILFDWLRQ
6HFWLRQ 
,QFOXVLRQ&ULWHULD $GG
D ,IDWOHDVWRQHRIWKHIR OORZLQJDODUPIHDWXUHV
DUHSUHVHQWWKHQWKH SDWLHQWPXVWKDYHKDGD
FRORQRVFRS\ WKDWVKRXOGLQFOXGHELRSV\ VLQFHWKH
RQVHWRIV\PSWRPVRUZL WKLQWKHSDVW\HDUV
ZKLFKHYHULVOHVV3URWRFROFODULILFDWLRQ
6HFWLRQ 
,QFOXVLRQ&ULWHULD $GG
E ,IQRDODUPIHDWXUHV DUHSUHVHQWWKHQWKH
SDWLHQWPXVWKDYHKDGDFRORQRVFRS\RURWKHUDSSURSULDWHH[DPEDVHGRQF ULWHULDDVRXWOLQHGEHORZ
&RORUHFWDOFDQFHUVFUHHQLQJWHVWVRWKHUWKDQ
FRORQRVFRS\DUHFRQVLGHUHGVHFRQGWLHUDQGFDQ
EHGLVFXVVHGZLWKWKHVSRQVRU> @ 3URWRFROFODULILFDWLRQ
6HFWLRQ
([FOXVLRQ&ULWHULD 5HSODFH
)HFDOFDOSURWHFWLQÂ•ÈJJ

:LWK
)HFDOFDOSURWHFWLQ !ÈJJ 
,QFDUHIXOOLWHUDWXUH
UHYLHZ 
DQ
H[FOXVLRQFXWRIIRI!Â—JJDORQJZLWK
FRORQRVFRS\ZKHQ
DSSURSULDWHKDVDGHTXDWHVHQVLWLYLW\DQG
VSHFLILFLW\WRGLVWLQJXLVK
SDWLHQWVZLWK,%6IURP
RWKHUJDVWURLQWHVWLQDO
GLVRUGHUVHVSHFLDOO\LQWKRVHSDWLHQWVZLWK
DSSURSULDWHZRUNXSCCI
CCICCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI6HFWLRQ 'HVFULSWLRQRI&KDQJHV  5DWLRQDOH
KLVWRU\SK\VLFDO
H[DPLQDWLRQDQG
FRORQRVFRS\DVUHTXLUHGLQWKLVVWXG\
6HFWLRQ 
([FOXVLRQ&ULWHULD $GG
 (YLGHQFHRIKHSDWLWLV&YLUXV+&9LQIHFWLRQ
EDVHGRQDSRVLWLYH+ &9DQWLERG\VFUHHQ 3DWLHQWV
ZLWKDSRVLWLYH+&9DQWLERG\DWVFUHHQLQJPD\EH
HOLJLEOHLIFRQILUPDWRU\WHVWLQJLH5,%$RU+&9
51$YLUDOORDGSURYLGHGE\WKHVWXG\VLWHLV
QHJDWLYH3DWLHQWVZKRKDYH EHHQVXFFHVVIXOO\
WUHDWHGIRU+&9DUHHOLJLEOHLIDQXQGHWHFWDEOH+&9
YLUDOORDGDWOHDVWPRQW KVDIWHUFRPSOHWLRQRI
WUHDWPHQWFDQEHGHPRQVWUDWHG3URWRFROFODULILFDWLRQ
6HFWLRQ 
([FOXVLRQ&ULWHULD $GG
 :LWKLQGD\VRIUDQ GRPL]DWLRQSDWLHQWKDV
XVHGHLWKHURIWKHIROORZLQJ
Â‡ K\GUR[\WULSWDPLQH+7RU+7UHFHSWRU
DQWDJRQLVWVHJDORVHWURQ RQGDQVHWURQRU
UDPRVHWURQ 
Â‡(OX[DGROLQH 3URWRFROFODULILFDWLRQ
6HFWLRQ 
([FOXVLRQ&ULWHULD $GG
Â‡%LOHDFLGVHTXHVWUDQWVVX FKDVFKROHVW\UDPLQH
FROHVWLSRORUFROHVHYHODP

$GGIRRWQRWHDW ERWWRPRISDJH

3DWLHQWVZLWKGLDJQRVLVRIRUVXVSHFWHGWRKDYH
ELOHDFLGPDODEVRUSWLRQDUHQRWVSHFLILFDOO\
H[FOXGHGJLYHQWKHFKDOOHQJHRIGLDJQRVLQJ
WKHVHSDWLHQWVKRZHYHUXVHRIELOHDFLGVHTXHVWUDQWVDUHSURKLELWHG 3URWRFROFODULILFDWLRQ
6HFWLRQ 
5HVFXH0HGLFLQH 5HSODFH
'XULQJWKHGRXEOHEOLQG7U HDWPHQW3KDVHRIWKHVWXG\
SDWLHQWVZLOOEHDOORZHG WRWDNHORSHUDPLGHUHVFXH
PHGLFDWLRQIRUWKHDFXWH WUHDWPHQWRIXQFRQWUROOHG
GLDUUKHD/RSHUDPLGHDWD XQLWGRVHRIPJPD\EH
WDNHQRQFHDSSUR[LPDWHO\ HYHU\KRXUVZLWKWKH
IROORZLQJJXLGHOLQHV
:LWK
'XULQJWKHGRXEOHEOLQG7U HDWPHQW3KDVHRIWKHVWXG\
SDWLHQWVZLOOEHDOORZHG WRWDNHORSHUDPLGHUHVFXH
PHGLFDWLRQIRUWKHDFXWH WUHDWPHQWRIXQFRQWUROOHG
GLDUUKHD,WLVUHFRPPHQGHGWKDWSDWLHQWVUHIULDQ3URWRFROFODULILFDWLRQ
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI6HFWLRQ 'HVFULSWLRQRI&KDQJHV  5DWLRQDOH
IURPORSHUDPLGHXQOHVVDPLQLPXPRIRUPRUH
XQFRQWUROOHGGLDUUKHDHYHQWVWKDWFDXVHVLJQLILFDQW
GLVFRPIRUWDQGSUHYHQWQRUPDOHYHU\GD\DFWLYLWLHV
DUHH[SHULHQFHGLQDJLYHQKRXUSHULRG 
,IORSHUDPLGHPXVWEHXVHGSDWLHQWVPXVWQRW
H[FHHGWKH PJXQLWGRVHZKLFK PD\EHWDNHQ
RQFHDSSUR[LPDWHO\HYHU\KRXUV DQGPXVWQRW
H[FHHGWKHIROORZLQJ GRVLQJUHTXLUHPHQWV 
6HFWLRQ 
'LVFRQWLQXDWLRQ:LWKGUDZDOIURPWKH
6WXG\5HSODFH
x 1RERZHOPRYHPHQWIRUGD\V
:LWK
x 1RERZHOPRYHPHQWIRU GD\V3URWRFROFODULILFDWLRQ
6HFWLRQ 
6FUHHQLQJ
$VVHVVPHQWV 5HSODFH
3DWLHQWVZKRDUH
Â‡ &RPSOLDQWLQFRPSOHWLQJWKHVFUHHQLQJGLDU\RQD
GDLO\EDVLVRQDWOHDVW RIWKHGD\VGXULQJWKH
ZHHNSULRUWRUDQGRPL]DWLRQ$1'RQDWOHDVW
RIWKHGD\VGXULQJW KHZHHNVSULRUWR
UDQGRPL]DWLRQDQG
Â‡ +DYHDQDYHUDJH:$3VFRUHLQWKHSDVW
KRXUVRIEHWZHHQ DQGRQDWRVFDOH
RYHUWKHZHHNSULRUWRUDQGRPL]DWLRQDQG
Â‡ +DYHDQDYHUDJHGDLO\%6)6RIÂ•DQGDW
OHDVWGD\VZLWKD%6)6 VFRUHÂ•RQDWR
VFDOHRYHUWKHZHHNSULR UWRUDQGRPL]DWLRQDQG
Â‡ +DYHDQDYHUDJHGDLO\, %6*6VFRUHRIÂ•RQ
DWRVFDOHRYHUWKHZHHNSULRUWR
UDQGRPL]DWLRQDQG
Â‡ :KRKDYHQRWXVHGDQ\ORSHUDPLGHUHVFXH
PHGLFDWLRQLQWKHZHHNVSULRUWRUDQGRPL]DWLRQ
ZLOOEHHOLJLEOHIRUSDUWLFLSDWLRQDQGLPPHGLDWH
UDQGRPL]DWLRQLQWRWKHGRXEO HEOLQGWUHDWPHQWSKDVH
LHDOOGLDU\FRQGLWLRQVPXVWEHPHWWRTXDOLI\IRU
UDQGRPL]DWLRQ
:LWK
3DWLHQWVZKR PHHWWKHIROORZLQJUHTXLUHPHQWVZLOO
EHHOLJLEOHIRUSDUWLFLSDWLRQDQGLPPHGLDWH
UDQGRPL]DWLRQLQWRWKHGRXEOHEOLQGWUHDWPHQW
SKDVHLHDOOGLDU\FRQGLWLRQVOLVWHGPXVWEHPHWWRTXDOLI\IRUUDQGRPL]DWLRQ
xKDYHFRPSOHWHGWKHGDLO\HOHFWURQLFGLDU\3URWRFROFODULILFDWLRQ
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI6HFWLRQ 'HVFULSWLRQRI&KDQJHV  5DWLRQDOH
RQDWOHDVWRIWKHGD\VGXULQJWKHZHHN
SULRUWRUDQGRPL]DWLRQ$1'DWOHDVWRI
WKHGD\VGXULQJWKHZHHNVSULRUWR
UDQGRPL]DWLRQ
xRYHUWKHILQDOGD\VRIWKHUXQLQSHULRG
WKHSDWLHQWKDVDQDYHUDJHRI:$3VFRUHV
LQWKHSULRUKRXUVRIWRRQDWR
QXPHULFDOUDWLQJVFDOHZKHUH
LQGLFDWHVQRSDLQDQGLQGLFDWHVZRUVWSDLQLPDJLQDEOH
xRYHUWKHILQDOGD\VRIWKHUXQLQSHULRG
WKHSDWLHQWKDVDQDYHUDJHGDLO\%6)6
VFRUHÂ•RQDWRVFDOHZKHUH 
KDUGOXPS\VWRROVDQG ZDWHU\OLTXLG
VWRROVDQGWKHUHPXVWEHDWOHDVWGD\V
ZLWKVWRROFRQVLVWHQF\RI7\SHÂ•DQG
6HFWLRQ 
6FUHHQLQJ$VVHVVPHQWV 5HSODFH
,IDIWHUZHHNVSDWLHQWVGR QRWPHHWDOORIWKHGLDU\
FRQGLWLRQVUHTXLUHGIRU HQWU\WKHUXQLQPD\EH
H[WHQGHGE\XSWRRQHZHHN LQDFFRUGDQFHZLWK
LQYHVWLJDWRUMXGJHPHQWIRUDWRWDOUXQLQSHULRGRIXS
WRZHHNV

:LWK
,ISDWLHQWVGRQRWPHHWDOORIWKH GLDU\FRQGLWLRQV
UHTXLUHGIRUHQWU\ GXULQJWKHZHHNUXQLQSHULRG 
WKHUXQLQPD\EHH[WHQGHG IRUDQDGGLWLRQDO ZHHNLQ
DFFRUGDQFHZLWKLQYHVWLJDWRUMXGJHPHQWIRUDWRWDOUXQLQSHULRGRIXSWRZHHNV (OLJLELOLW\ZLOOWKHQ
EHEDVHGRQWKHPRVWUHFHQWGD\VRIWKHH[WHQGHGUXQLQSHULRG3URWRFROFODULILFDWLRQ
6HFWLRQ
%ULVWRO6WRRO)RUP
6FDOH$GG
3DWLHQWVZLOOEHDVNHGWRUHFRUGGDLO\VWRROFRQVLVWHQF\
DFFRUGLQJWRWKH%6)6PRVWU HSUHVHQWDWLYHRIWKHSDVW
KRXUVDQGZRUVWVWRROFRQVLVWHQF\GHILQHGDV
ORRVHVWVWRROZLWKWKHKLJKHVW%6)6VFRUHLQWKH
SDVWKRXUV 7KHSDWLHQWUHSRUWHG%6)6
FRQVLVWHQF\VFRUHLVEDVHGRQDWRVFDOHZKHUHFRUUHVSRQGVWRDKDUG VWRRODQGFRUUHVSRQGVWR
ZDWHU\GLDUUKHD 3OHDVH
UHIHUWR$SSHQGL[ &ROOHFWLRQRIDGGLWLRQDO
GDWDGXULQJWKHVWXG\
6HFWLRQ 
3K\VLFDO5HSODFH
$FRPSOHWHSK\VLFDOH[DPLQDWLRQ3(ZLOOEH3URWRFROFODULILFDWLRQ CCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI6HFWLRQ 'HVFULSWLRQRI&KDQJHV  5DWLRQDOH
([DPLQDWLRQV  SHUIRUPHGDW6FUHHQLQJ$V\PSWRPGLUHFWHG3(ZLOO
EHSHUIRUPHGDWWKHWLPHSRL QWVVSHFLILHGLQWKH
6FKHGXOHRI$FWLYLWLHV 6HFWLRQ DQGDVFOLQLFDOO\
LQGLFDWHGDQGUHVXOWVUHFRUGHGLQWKHVRXUFH
GRFXPHQW$Q\FOLQLFDOO\VL JQLILFDQW3(ILQGLQJQRWHG
DW6FUHHQLQJZLOOEHUHFRUGHG DVPHGLFDOKLVWRU\$Q\
FOLQLFDOO\VLJQLILFDQW3(ILQGLQJQRWHGDWDIWHU
HQUROOPHQWZLOOEHUHYLHZHG IRUUHSRUWLQJDVDQ$(
VHH6HFWLRQ 
:LWK
$FRPSOHWHSK\VLFDOH[DPLQDWLRQ3(ZLOOEH
SHUIRUPHGDW6FUHHQLQJ$ WDPLQLPXPDWDUJHWHG
3(ZLOOEHSHUIRUPHGDWWKHW LPHSRLQWVVSHFLILHGLQWKH
6FKHGXOHRI$FWLYLW LHV6HFWLRQ ZLWKDGGLWLRQDO
V\PSWRPGLUHFWHGH[DPLQDWLRQSHUIRUPHG DV
FOLQLFDOO\LQGLFDWHG$Q\FOLQLFDOO\VLJQLILFDQW3(ILQGLQJ
QRWHGDW6FUHHQLQJZLOOEHUH FRUGHGDVPHGLFDOKLVWRU\
LQWKHVRXUFHGRFXPHQW $Q\FOLQLFDOO\VLJQLILFDQW3(
ILQGLQJQRWHGDWDIWHUHQUROOPHQWZLOOEHUHYLHZHGIRUUHSRUWLQJDVDQ$(VHH 6HFWLRQ 
6HFWLRQ 
3K\VLFDO
([DPLQDWLRQV 'HOHWH
$WDUJHWHG3(ZLOOLQFOXGHDWDPLQLPXP
DVVHVVPHQWVRIWKHVNLQO XQJVFDUGLRYDVFXODU
V\VWHPDQGDEGRPHQO LYHUDQGVSOHHQ3URWRFROFODULILFDWLRQ
6HFWLRQ 
([SHFWHGQHVV $GG
7KH,QYHVWLJDWRUZLOOEHUHVSRQVLEOHIRUGHWHUPLQLQJ
ZKHWKHUDQ 6$(LVH[SHFWHGRUXQH[SHFWHG$Q 6$(
ZLOOEHFRQVLGHUHGXQH[SHFW HGLIWKHQDWXUHVHYHULW\
RUIUHTXHQF\RIWKHHYHQWLV QRWFRQVLVWHQWZLWKWKHULVN
LQIRUPDWLRQSUHYLRXVO\GHVFU LEHGIRUWKHLQYHVWLJDWLRQDO
SURGXFW3URWRFROFODULILFDWLRQ
6HFWLRQ 
3KDUPDFRNLQHWLFV $GG
7PD[  WLPHWRPD[LPXPFRQFHQWUDWLRQ3URWRFROFODULILFDWLRQ
6HFWLRQ 
6HFRQGDU\(QGSRLQW $GG
0HDQGDLO\%6)6VFRUHVW RROW\SHDQGPHDQGDLO\
IUHTXHQF\RIERZHOPRYHPHQW VZLOOEHWDEXODWHGDQG
VXPPDUL]HGE\VWXG\GD\I RUHDFKWUHDWPHQWIRUWKH
,77DQG3HUSURWRFRO$QDO\V LV'DWDVHWSRSXODWLRQV
0HDQGDLO\%6)6VFRUHVWRROW\SHZLOOEH
DQDO\]HGVHSDUDWHO\EDVHGRQWKHPRVWUHSUHVHQWDWLYHVWRROFRQVLVWHQF\LQWKHSDVWKRXUVDQGWKHZRUVWVWRROFRQVLVWHQF\GHILQHG
DVORRVHVWVWRROZLWKWKHKLJKHVW%6)6VFRUHLQ&ROOHFWLRQRIDGGLWLRQDO
GDWDGXULQJWKHVWXG\
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI6HFWLRQ 'HVFULSWLRQRI&KDQJHV  5DWLRQDOH
WKHSDVWKRXUVHDFKPHDVXUHDYHUDJHGRYHU
WKHZHHNSULRUWRHDFKUHVSHFWLYHWLPHSRLQW 7LPH
SURILOHVDQGER[SORWVZLOOD OVREHSUHVHQWHGE\VWXG\
GD\DQGE\WUHDWPHQWJURXS 3RROHGDFWLYHGDWDPD\
EHFRPSDUHGWR3%2IRUWKHDQDO\VHVDQGDOVRE\FRKRUW
6HFWLRQ 
5()(5(1&(6 $GG



$GG

$GPLQLVWUDWLYHFKDQJH
$SSHQGL[ 
&RQWUDFHSWLYH*XLGDQFHDQG&ROOHFWLRQRI3UHJQDQF\
,QIRUPDWLRQ $GG
Â‡ $JUHHWRXVHDPDOHFRQGRPSOXVSDUWQHUXVH
RIDFRQWUDFHSWLYHPHWKRGZL WKDIDLOXUHUDWHRI
SHU\HDUDVGHVFULEHGLQ 7DEOHZKHQKDYLQJSHQLOH
YDJLQDOLQWHUFRXUVH ZLWKD:2&%3ZKRLVQRWFXUUHQWO\
SUHJQDQWXQOHVVFRQILUPHGWREHD]RRVSHUPLF
YDVHFWRPL]HGRUVHFRQGDU \WRPHGLFDOFDXVH 3URWRFROFODULILFDWLRQ
$SSHQGL[ 
&RQWUDFHSWLYH*XLGDQFHDQG&ROOHFWLRQRI
3UHJQDQF\
,QIRUPDWLRQ $GG
3URJHVWRJHQRQO\KRUPRQDOF RQWUDFHSWLRQDVVRFLDWHG
ZLWKLQKLELWLRQRIRYXODWLRQ
E$GPLQLVWUDWLYHFRUUHFWLRQ
WRLQGLFDWHFRUUHFWIRRWQRWH
$SSHQGL[ 
&RQWUDFHSWLYH*XLGDQFHDQG
&ROOHFWLRQRI
3UHJQDQF\,QIRUPDWLRQ 'HOHWH
+LJKO\(IIHFWLYH0HWKRGV7KDW$UH8VHU,QGHSHQGHQW
D$GPLQLVWUDWLYHFRUUHFWLRQ
WRLQGLFDWHFRUUHFWIRRWQRWH
$SSHQGL[ 
&RQWUDFHSWLYH
*XLGDQFHDQG
&ROOHFWLRQRI3UHJQDQF\,QIRUPDWLRQ $GG
7\SLFDOXVHIDLOXUHUDWHVPD \GLIIHUIURPWKRVHZKHQ
XVHGFRQVLVWHQWO\DQGFRUUHFWO\8VHVKRXOGEH
FRQVLVWHQWZLWKORFDOUHJXODW LRQVUHJDUGLQJWKHXVHRI
FRQWUDFHSWLYHPHWKRGVIRU SDWLHQWVSDUWLFLSDWLQJLQ
FOLQLFDOVWXGLHV 6KRXOGEHLQLWLDWHGRUPRUH
PHQVWUXDOF\FOHVSULRUWRVFUHHQLQJ 3URWRFROFODULILFDWLRQCCI
CCI
&RPSRXQG%26 %RVWRQ3KDUPDFHXWLFDOV,QF
3URWRFRO%26
3URWRFRO'DWHDQG9HUVLRQ$XJXVWY

&RQILGHQWLDO  3DJHRI6HFWLRQ 'HVFULSWLRQRI&KDQJHV  5DWLRQDOH
$SSHQGL[
&RQWUDFHSWLYH
*XLGDQFHDQG
&ROOHFWLRQRI
3UHJQDQF\,QIRUPDWLRQ 5HSODFH
+RUPRQDOFRQWUDFHSWLRQPD\EHVXVFHSWLEOHWR
LQWHUDFWLRQZLWKWKHLQYHVWLJ DWLRQDOSURGXFWZKLFKPD\
UHGXFHWKHHIILFDF\RIWKHFRQW UDFHSWLYHPHWKRG,QWKLV
FDVHKLJKO\HIIHFWLYH PHWKRGVRIFRQWUDFHSWLRQ
VKRXOGEHXWLOL]HGGXULQJW KHWUHDWPHQWSHULRGDQGIRU
DWOHDVWZHHNVDIWHUWKHOD VWGRVHRILQYHVWLJDWLRQDO
SURGXFW
:LWK
+RUPRQDOFRQWUDFHSWLRQPD\EHVXVFHSWLEOHWR
LQWHUDFWLRQZLWKWKHLQYHVWLJ DWLRQDOSURGXFWZKLFKPD\
UHGXFHWKHHIILFDF\RIWKH FRQWUDFHSWLYHPHWKRG,Q WKH
FDVHRIKRUPRQDOFRQWUDFHSWLRQDVWKHSULPDU\
PHWKRGRIFRQWUDFHSWLRQDVXSSOHPHQWDU\EDUULHU
PHWKRGSUHIHUDEO\PDOHFRQGRP VKRXOGEHXWLOL]HG
GXULQJWKHWUHDWPHQWSHULRGDQGIRUDWOHDVWZHHNV
DIWHUWKHODVWGRVHRILQYHVWLJDWLRQDOSURGXFW3URWRFROFODULILFDWLRQ
$SSHQGL[
&RQFRPLWDQW
0HGLFDWLRQ $GG
0HGLFDWLRQVH[FOXGHGGXULQJ WKHFRXUVHRIWKHVWXG\
Â‡K\GUR[\WULSWDPLQH+7RU+7UHFHSWRU
DQWDJRQLVWVHJDORVHWURQ RQGDQVHWURQRU
UDPRVHWURQ 
Â‡(OX[DGROLQH
Â‡%LOHDFLGVHTXHVWUDQWV VXFKDVFKROHVW\UDPLQH
FROHVWLSRORUFROHVHYHODP 3URWRFROFODULILFDWLRQ

 
CLINICAL TRIAL PROTOCOL  
Study Title:  A Phase 2a, Randomized, Double-blind, 
Placebo -controlled, Multicenter Study to Evaluate the 
Efficacy, Safety, and Tolerability of BOS -589 in the 
Treatment of Patients with Diarrhea -predominant Irritable 
Bowel Syndrome (IBS-D) 
Study Number:  BOS-589-201 
Regulatory 
Identification Number(s): 
 IND 142421 
Study Phase:  2a 
Investigational Product:  BOS-589 
Indication:  Diarrhea-predominant Irritable Bowel Syndrome 
Sponsor:  Boston Pharmaceuticals, Inc. 
55 Cambridge Parkway, Suite 400  
Cambridge, Massachusetts 02142  
USA 
 
Version  Date  
Final v.2.0 09 May 2019 
Confidentiality Statement 
The information in this document is confidential and will not be disclosed to others 
without written authorization from the sponsor , except to the extent necessary to 
obtain informed consent from persons receiving the study drug or their legal 
guardians, or for discussions with Regulato ry Authorities, Institutional Review Boards, 
Independent Ethics Committees, or persons pa rticipating in the conduct of the study. 
Do not copy or distribute without written permission from the sponsor.  

Boston Pharmaceuticals, Inc. BOS-589-201
Protocol Version 2.0
Confidential Page 2 of 78SPONSOR SIGNATURE PAGE
Protocol Title: A Phase 2a, Randomized, Do uble-blind, Placebo-controlled, Multicenter 
Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of 
Patients with Diarrhea-predominant  Irritable Bowel Syndrome (IBS-D)
Protocol Number: BOS-589-201Version Number and Date: v.2.0, 09 May 2019I, the undersigned, have approved the fina l version of this Clinical Trial Protocol.
Date
Date
PPD
PPD
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 3 of 78 INVESTIGATOR AGREEMENT 
Protocol Title: A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multicenter 
Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of 
Patients with Diarrhea-predominant  Irritable Bowel Syndrome (IBS-D) 
Protocol Number: BOS-589-201 Version Number and Date: v.2.0, 09 May 2019 I, the undersigned, have read the protocol and agree to conduct the trial in compliance 
with the International Conference on/Council for Harmonization (ICH) guidelines and any other applicable regulatory requirements; as well as Good Clinical Practice (GCP) 
standards (CPMP/ICH/135/95). 
I will provide copies of the protocol and al l pertinent information to all individuals who 
assist in the conduct of this study. I will di scuss this material with them to ensure they 
are fully informed regarding the investigational product and the conduct of the study. 
I will use only the Informed Consent Form ap proved by the sponsor or its representative 
and will fulfill all responsibilities for submitting pertinent information to the Institutional Review Board/Independent Ethics Committee (IRB/IEC) responsible for this study. 
I agree that the sponsor or its represen tatives will have access to any source 
documents from which case report form information may have been generated. 
 
   
Investigator's Signature  Date 
Name of Investigator (typed or printed)  
Institution Name   
 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 4 of 78 TABLE OF CONTENTS 
TABLE OF CONTENTS .................................................................................................. 4  
LIST OF TABLES ............................................................................................................ 7  
LIST OF FIGURES .......................................................................................................... 7  
LIST OF APPENDICES ................................................................................................... 7  
ABBREVIATIONS ........................................................................................................... 8  
1 PROTOCOL SUMMARY ........................................................................................ 11  
1.1 Synopsis ............................................................................................................. 11  
1.2 Study Schema .................................................................................................... 16  
1.3 Schedule of Activities ......................................................................................... 17  
2 INTRODUCTION .................................................................................................... 19  
2.1 Study Rationale .................................................................................................. 19  
2.2 Background ........................................................................................................ 19  
2.2.1  Disease Under Study .................................................................................... 19  
2.2.2  The â€œRETâ€ (â€œREarranged During Transfectionâ€) Gene and the Enteric 
Nervous System ........................................................................................... 20  
2.2.3  Investigational Product .................................................................................. 21  
2.2.3.1  Nonclinical Summary ............................................................................... 21  
2.2.3.1.1  In Vitro  Studies ................................................................................... 21  
2.2.3.1.2  In Vivo  Studies ................................................................................... 22  
2.2.3.1.3  Pharmacokinetics and Product Metabolism in Animals ...................... 22  
2.2.3.1.4  Toxicology and Nonclinical Assessment of Safety ............................. 23  
2.2.3.2  Clinical Experience .................................................................................. 24  
2.3 Risk/Benefit Assessment .................................................................................... 25  
2.3.1  Risk Assessment ........................................................................................... 26  
2.3.2  Benefit Assessment ...................................................................................... 26  
2.3.3  Overall Risk/Benefit Conclusion .................................................................... 26  
3 OBJECTIVES AND ENDPOINTS ........................................................................... 27  
4 STUDY DESIGN ..................................................................................................... 28  
4.1 Overall Design .................................................................................................... 28  
4.1.1  Study Duration for Patients ........................................................................... 29  
4.1.2  Number of Patients ....................................................................................... 29  
4.1.3  Replacement of Patients ............................................................................... 29  
4.1.4  Number of Sites ............................................................................................ 29  
4.2 Rationale for Study Design ................................................................................. 29  
4.3 Justification for Dose .......................................................................................... 30  
4.4 End of Study Definition ....................................................................................... 31  
5 STUDY POPULATION ............................................................................................ 32  
5.1 Inclusion Criteria ................................................................................................. 32  
5.2 Exclusion Criteria ................................................................................................ 34  
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 5 of 78 5.3 Lifestyle Considerations ..................................................................................... 38  
5.4 Screen Failures .................................................................................................. 38  
6 INVESTIGATIONAL PRODUCT ............................................................................. 39  
6.1 Investigational Products ..................................................................................... 39  
6.1.1  Investigational Product Description ............................................................... 39  
6.2 Preparation/Handling/Storage/Accountability ..................................................... 39  
6.2.1  Acquisition and accountability ....................................................................... 39  
6.2.2  Product Storage and Stability ........................................................................ 39  
6.3 Measures to Minimize Bias ................................................................................. 40  
6.4 Dosing and Administration .................................................................................. 40  
6.5 Dose modification ............................................................................................... 41  
6.6 Investigational Product Compliance ................................................................... 41  
6.7 Concomitant Therapy ......................................................................................... 41  
6.7.1  Rescue Medicine ........................................................................................... 42  
6.8 Intervention After the End of the Study ............................................................... 42  
7 DISCONTINUATION / WITHDRAWAL ................................................................... 43  
7.1 Discontinuation of Investigational Product .......................................................... 43  
7.2 Discontinuation/Withdrawal from the Study ........................................................ 43  
7.3 Lost to Follow-up ................................................................................................ 45  
8 STUDY ASSESSMENTS AND PROCEDURES ..................................................... 46  
8.1 Study Periods ..................................................................................................... 46  
8.2 Screening Assessments ..................................................................................... 46  
8.3 Efficacy Assessments ......................................................................................... 47  
8.3.1  Worst Abdominal Pain ................................................................................... 47  
8.3.2  Bristol Stool Form Scale ................................................................................ 47  
8.3.3  IBS-D Global Symptom Score ....................................................................... 47  
8.3.4  IBS Severity Score System ........................................................................... 48  
8.4 Safety and Other Assessments .......................................................................... 48  
8.4.1  Adverse Events and Serious Adverse Events ............................................... 48  
8.4.2  Physical Examinations .................................................................................. 48  
8.4.3  Vital Signs ..................................................................................................... 48  
8.4.4  Electrocardiograms ....................................................................................... 48  
8.4.5  Clinical Safety Laboratory Assessments ....................................................... 49  
8.5 Adverse Events and Serious Adverse Events .................................................... 49  
8.5.1  Definition of Adverse Events ......................................................................... 49  
8.5.2  Events of Special Interest.............................................................................. 50  
8.5.3  Definition of Serious Adverse Events ............................................................ 50  
8.5.4  Classification of an Adverse Event ................................................................ 51  
8.5.4.1  Assessment of Severity ........................................................................... 51  
8.5.4.2  Assessment of Causality .......................................................................... 51  
8.5.4.3  Expectedness .......................................................................................... 52  
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 6 of 78 8.5.5  Time Period and Frequency for Event Assessment and Follow-up ............... 52  
8.5.6  Adverse Event Reporting .............................................................................. 52  
8.5.7  Reporting of Pregnancy ................................................................................ 53  
8.6 Treatment of Overdose ....................................................................................... 54  
8.7 Pharmacokinetics ............................................................................................... 54  
8.8 Biomarkers/Pharmacodynamics ......................................................................... 55  
9 STATISTICAL CONSIDERATIONS ........................................................................ 55  
9.1 Timing of Analyses ............................................................................................. 55  
9.2 Sample Size Determination ................................................................................ 55  
9.3 Populations for Analyses .................................................................................... 56  
9.4 Statistical Analyses ............................................................................................. 56  
9.4.1  Efficacy Analyses .......................................................................................... 56  
9.4.1.1  Primary Endpoint ..................................................................................... 56  
9.4.1.2  Secondary Endpoint ................................................................................ 57  
9.4.1.3  Other Efficacy Endpoints ......................................................................... 57  
9.4.1.4  Missing Data ............................................................................................ 57  
9.4.2  Safety Analyses ............................................................................................ 58  
9.4.2.1  Adverse Events ........................................................................................ 58  
9.4.2.2  Clinical Laboratory Evaluations ................................................................ 58  
9.4.2.3  Twelve-lead Electrocardiograms, Vital Signs, and Physical 
Examinations ........................................................................................... 58  
9.4.3  Other Analyses .............................................................................................. 59  
9.4.3.1  Pharmacokinetic Analysis ........................................................................ 59  
9.4.4  Baseline Descriptive Statistics ...................................................................... 59  
9.4.5  Subgroup Analyses ....................................................................................... 59  
9.5 Planned Interim Analyses ................................................................................... 59  
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS................................................................................................ 60  
10.1  Regulatory, Ethical, and Study Oversight Considerations .................................. 60  
10.1.1  Regulatory and ethical considerations .......................................................... 60  
10.1.2  Informed Consent/Assent Process ................................................................ 60  
10.1.3  Confidentiality and Privacy ............................................................................ 61  
10.1.4  Quality Assurance and Quality Control ......................................................... 62  
10.1.5  Data Handling and Record Keeping .............................................................. 62  
10.1.5.1  Data Collection and Management Responsibilities .................................. 62  
10.1.5.2  Study Records Retention ......................................................................... 63  
10.1.6  Study and Site Discontinuation and Closure ................................................. 63  
10.1.7  Dissemination of Clinical Study Data ............................................................ 64  
10.1.8  Publication Policy .......................................................................................... 64  
11 REFERENCES ....................................................................................................... 65  
12 APPENDICES ......................................................................................................... 68  
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 7 of 78  
LIST OF TABLES 
Table 1.  Schedule of Activities ............................................................................... 17  
Table 2.  Protocol-required Safety Laboratory Assessments .................................. 69  
Table 3.  Highly Effective Contraceptive Methods .................................................. 73  
 
LIST OF FIGURES 
Figure 1.  Study Schematic ...................................................................................... 16  
 
LIST OF APPENDICES 
Appendix 1.  Clinical Laboratory Tests ......................................................................... 69  
Appendix 2.  Contraceptive Guidance and Collection of Pregnancy Information .......... 71  
Appendix 3.  The Bristol Stool Form Scale ................................................................... 75  
Appendix 4.  Concomitant Medications ......................................................................... 76  
 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 8 of 78 ABBREVIATIONS  
AE adverse event 
AKT protein kinase B  
ALT alanine aminotransferase  
AST aspartate aminotransferase  
AUC area under the concentration versus time curve  
AUC 0-4 area under the concentration versus time curve from time zero to 
4 hours postdose  
AUC 0-12 area under the concentration versus time curve from time zero to 
12 hours postdose 
AUC 0-t area under the concentration versus time curve from time zero to 
the last measurable concentration  
bid twice daily 
BSFS Bristol Stool Form Scale  
BMI body mass index  
CFR Code of Federal Regulations  
Cmax maximum plasma concentration  
Cmin minimum plasma concentration  
CNS central nervous system  
CONSORT Consolidated Standards of Reporting Trials 
CRF case report form  
CSR clinical study report  
CYP cytochrome P450  
ECG electrocardiogram  
EDC electronic data capture  
ENS enteric nervous system  
ERK extracellular signal-regulated kinase  
FDA Food and Drug Administration  
FDR first-degree relative 
GCP Good Clinical Practice  
GDNF glial cell line-derived neurotrophic factor  
GFR-Î± glial cell line-derived neurotrophic factor family receptor-alpha  
GI gastrointestinal  
GLP-1 glucagon-like peptide-1  
HBV hepatitis B virus  
HCV hepatitis C virus  
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 9 of 78 HDPE high-density polyethylene 
hERG human ether-Ã -go-go related gene  
HIV human immunodeficiency virus  
HRT hormone replacement therapy 
IB Investigatorâ€™s Brochure  
IBS irritable bowel syndrome  
IBS-C irritable bowel syndrome-constipation  
IBS-GS Irritable Bowel Syndrome Global Scale  
IBS-D irritable bowel syndrome-diarrhea  
IBS-M irritable bowel syndrome-mixed  
IBS-SS Irritable Bowel Syndrome Severity Score  
IBS-U irritable bowel syndrome-unclassified 
IC50 half-maximal inhibitory concentration  
ICF Informed Consent Form  
ICH International Conference on/Council for Harmonisation  
IEC Independent Ethics Committee 
ILC3 group 3 innate lymphoid cells  
IRB Institutional Review Board  
ITT intention-to-treat  
IV intravenous  
IWRS interactive web response system  
JAK Janus kinase  
MedDRA Medical Dictionary for Regulatory Activities  
NOAEL no observed adverse effect level  
NRS numeric rating scale 
NTEAE non-treatment-emergent adverse event  
PBO placebo  
PD pharmacodynamic(s) 
PE physical examination  
P-gp P-glycoprotein  
PI3K phosphoinositide 3-kinase  
PK pharmacokinetic(s)  
PRO patient-reported outcome  
PYY pancreatic peptide YY  
QC quality control  
QTcB QT interval corrected by Bazettâ€™s formula  
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 10 of 78 QTcF QT interval corrected by Fridericiaâ€™s formula  
RAS rat sarcoma  
RBC red blood cell  
RET REarranged during Transfection  
SAE serious adverse event  
SAP Statistical Analysis Plan  
SC subcutaneous  
SD standard deviation  
SK-N-AS a human neuroblastoma cell line  
STAT signal transducer and activator of transcription proteins  
SUSAR suspected unexpected serious adverse reaction  
TEAE treatment-emergent adverse event  
Tmax time to maximum concentration  
TT a human thyroid medullary carcinoma cell line  
ULN upper limit of normal  
WAP worst abdominal pain  
WOCBP woman of childbearing potential  
 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 11 of 78 1 PROTOCOL SUMMARY 
1.1 Synopsis  
Sponsor: Boston Pharmaceuticals Inc.  
Title: A Phase 2a, Randomized, Double-blind, Placebo-controlled, 
Multicenter Study to Evaluate the Efficacy, Safety, and 
Tolerability of BOS -589 in the Treatment of Patients with 
Diarrhea -predominant Irritable Bowel Syndrome (IBS-D) 
Protocol Number: BOS-589-201 
Phase: 2a 
Objectives and 
Endpoints:  OBJECTIVES ENDPOINTS 
Primary 
x To evaluate in patients 
with IBS-D the abdominal 
pain response to BOS -
589 after 4 weeks of 
treatment, relative to 
placebo (PBO). x 24-hour worst abdominal 
pain scores (WAP) at Day 29 compared to 
baseline (averaged over 
the week prior to each 
respective timepoint). 
x To evaluate the overall 
safety and tolerability of 
BOS- 589 in the treatment 
of IBS-D during 4 weeks 
of treatment, relative to 
PBO. x Incidence of adverse 
events (AEs), serious 
adverse events (SAEs), 
discontinuat ions because 
of AEs, and any treatment-related 
severe 
AEs.  
Secondary 
x To evaluate the treatment 
effect of BOS-589 on defecation 
after 4 weeks, 
relative to PBO. x Change in stool 
consistency, measured by 
the daily Bristol Stool 
Form Score (BSFS) at 
Day 29 compared to 
baseline (averaged over the week prior to each 
respective timepoint). 
x Change in stool frequency, 
measured by 
the total number of  
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 12 of 78  spontaneous bowel 
movements in 24 hours at 
Day 29 compared to 
baseline (averaged over 
the week prior to each 
respective timepoint). 
x To evaluate the treatment 
effect of BOS-589 on 
IBS-related signs and symptoms. x Change in the IBS 
Severity Score (IBS- SS) 
at Day 29 compared to 
baseline. 
x Change in the IBS Global 
Scale (IBS-GS) at Day 29 
compared to baseline 
(averaged over the week 
prior to each respective 
timepoint). 
x To evaluate the 
steady-state 
pharmacokinetics (PK) of 
BOS-589.  x Maximum observed 
plasma concentration 
(Cmax); time to C max (Tmax); 
minimum plasma concentration (C
min); area 
under the concentration 
versus time curve (AUC) 
from time zero to 4 hours 
postdose (AUC 0-4); AUC 
from time zero to the last quantifiable concentration (AUC
0-t). 
Study Design:  A phase 2a, randomized, double-blind, PBO-controlled, multicenter trial
 to provide proof-of-principle efficacy of 
BOS -589 in IBS-D patients and to inform dose selection for 
subsequent development.  
The study will comprise 3 phases:  
A Pre-treatment Phase  of up to 4 weeks, in which all 
patients will be assessed to determine eligibility.  This phase 
will consist  of initial screening assessments after which 
eligible patient s will enter a Run-in  Period of up to 3 weeks.   
During the Run-in period the patients will complete an 
electronic diary to collect daily  information related to their 
IBS-D symptoms, bowel function, and rescue medication use, 
to confirm disease activity, and diary compliance.  
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 13 of 78 Upon completion of the Run-in Peri od, patients will return to 
the study site to confirm eligibility for randomization into the 
double -blinded Treatment Phase. 
A Treatment Phase , in which eligible patients will be 
randomized (1:1:1) to receive BOS -589 or PBO twice daily 
(bid) for a total of 4 weeks. BOS-589 will be administered at 
1 of 2 dose levels. Patients will be randomized to the 
following cohorts:   
x Cohort 1 (High Dose): 200 mg BOS-589 bid orally;  
x Cohort 2 (Low Dose): 50 mg BOS-589 bid orally; 
x Cohort 3 (PBO): matching PBO oral tablets bid. 
During the treatment phase, patients will continue to 
complete the electronic diary to collect daily information 
related to their IBS -D symptoms, bowel function, and rescue 
medicine . 
A Post-treatment Phase , in wh ich all patients who complete 
4 weeks of treatment will return to the clinical for a 2-week  
follow -up visit.   
Patients who discontinue treatment early will be asked to 
return to the clinic for safety assessments.        
Study Population:  Male and female patients 18 to 65 years of age, inclusive, 
with a diagnosis of IBS-D. 
Number of Patients 
Planned : Approximately 300 patients will be screened with the intent of 
randomiz ing 132 patients for the study. 
Duration of Patient 
Participation and  
Study:  The duration of patient participation is anticipated to be up to 
10 weeks. 
The duration of the study is anticipated to be approximately 
12 months. 
Study Sites:  Up to 66 sites in the United States. 
Investigational 
Product:  BOS-589 (oral doses bid). 
Reference 
Treatment:  Matching PBO (oral doses bid). 
Concomitant 
Product:  Not applicable. 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 14 of 78 Statistical Methods:  Efficacy: 
This is a phase 2a proof-of-principle study. Descriptive and 
inferential statistical methods will be employed. A standalone Statistical
 Analysis Plan will be developed and approved prior 
to database lock.  
A hierarchical hypothesis test will be employed for the 
primary efficacy endpoint, defined as a change from baseline 
to Day 29 in the patient-reported outcome  for WAP measured 
daily on an 11 -point numeric rating scale. Mean change from 
baseline will be measured as a continuous variable and compared between treatment groups in the following testing 
order using a t
-test of equal variances with a two- tailed alpha 
of 0.05:  
Hypothesis 1: 
Active Treatment Group (Cohort 1 + Cohort 2) versus 
PBO (Cohort 3); 
If statistically significant at P < 0.05, then proceed to 
Hypothesis 2. 
Hypothesis 2: 
Cohort 1 (High Dose) versus Cohort 3 (PBO); 
If statistically significant at P < 0.05, th en proceed to 
Hypothesis 3. 
Hypothesis 3: 
Cohort 2 (Low Dose) versus Cohort 3 (PBO); 
If statistically significant at P < 0.05 then, proceed to 
Hypothesis 4. 
Hypothesis 4: 
Cohort 1 (High Dose) versus Cohort 2 (Low Dose). 
Safety:  
Adverse events will be recorded from the time of consent until 
the Day 43/End-of-Study Follow-up visit. The number and 
percentage of patients with AEs will be displayed by system 
organ class and preferred term using Medical Dictionary for 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 15 of 78 Regulatory Activities Version 20.0 or higher, by study 
treatment. Summaries in terms of  severity and relationship to 
investigational product will also be provided. All serious AEs will be summarized in a similar manner. Patient listings of all AEs causing discontinuation of in vestigational product and all 
SAEs will be produced.
 
All AEs will be listed for individual patients , showing both 
verbatim and preferred terms. Separate summaries of 
treatment -emergent SAEs and treatment-emergent AEs 
related to investigational product will be generat ed. 
Confidential   Page 16 of 78 1.2 Study Schema 
Figure 1. Study Schematic 
 

Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential   Page 17 of 78 1.3 Schedule of Activities 
Table 1. Schedule of Activities 
 
Screening 
Days -29 to -1,  
Study Visit 1 
Run-in Perioda 
Days -15 to -1,  
Study Visit 2 
Baseline 
Day 1, 
Study Visit 3 
Day 8 ( Â± 1 day)  
Study Visit 4 
 
Day 15 ( Â± 1 day) 
Study Visit 5 
 
Day 22 ( Â± 1 day) 
Study Visit 6 
 
Day 29 ( Â± 1 day) 
End of Treatment 
/Early Terminationb 
Study Visit 7  
Day 43 ( Â± 3 days) 
End of Study 
Study Visit 8  
 
Procedures  Pre-treatment Treatment Follow-up 
Informed consent X        
Demographics X        
Medical and surgical history X        
Rome IV assessment X        
Concomitant medication review X X X X X X X X 
Adverse event review and evaluation  X- - - - - - - - - - - - - - - - - - - - - - - - - - - - continuous - - - - - - - - - - - - - - - - - - - - - - - - - - - X 
Physical examinationc  X  X    X  
Height, weight, and body mass index Xd  X  X  X X 
Vital signs X  X X X X X X 
12-lead electrocardiogram X      X  
Clinical safety laboratory testse X  X  X  X X 
HIV, HCV/HBV testing X        
Urine pregnancy test  X  X    X X 
C-reactive protein and erythrocyte 
sedimentation rate tests X  X  X  X X 
Biomarker sample collection   X  X  X X 
Pharmacokinetic sample collectionf   X X X X   
Worst abdominal pain X Xg X- - - - - - - - - - - - - - - - - - - - - - -h- - - - - - - - - - - - - - - - - - - - - X Xh 
Bristol Stool Form Scale X Xg X- - - - - - - - - - - - - - - - - - - - - - -h- - - - - - - - - - - - - - - - - - - - - X Xh 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential   Page 18 of 78  
Screening 
Days -29 to -1,  
Study Visit 1 
Run-in Perioda 
Days -15 to -1,  
Study Visit 2 
Baseline 
Day 1, 
Study Visit 3 
Day 8 ( Â± 1 day)  
Study Visit 4 
 
Day 15 ( Â± 1 day) 
Study Visit 5 
 
Day 22 ( Â± 1 day) 
Study Visit 6 
 
Day 29 ( Â± 1 day) 
End of Treatment 
/Early Terminationb 
Study Visit 7  
Day 43 ( Â± 3 days) 
End of Study 
Study Visit 8  
 
Procedures  Pre-treatment Treatment Follow-up 
Spontaneous bowel movements (total 
number of stools)  Xg X- - - - - - - - - - - - - - - - - - - - - - -h- - - - - - - - - - - - - - - - - - - - - X Xh 
IBS-GS  Xg X- - - - - - - - - - - - - - - - - - - - - - -h- - - - - - - - - - - - - - - - - - - - - X Xh 
Rescue medications  Xg X- - - - - - - - - - - - - - - - - - - - - - -h- - - - - - - - - - - - - - - - - - - - - X Xh 
IBS-SS   X    X X 
Eligibility review X  X      
Randomization   X      
Administration of investigational product   Day 1 - - - - - - - - - - - - - - - - - - - - - - - - - - - Day 28   
HBV = hepatitis B virus; HCV = hepatitis C vi rus; HIV = human immunodeficiency virus; IBS-GS = Irritable Bowel Syndrome Global Scale; 
IBS-SS = Irritable Bowel Syndrome Severity Score .  
a Run-in may be extended by up to one week in accordance with the investigators judgement. 
b Procedures performed at Visit 7/End of Treatment or upon Early Termination. Early Termination procedures are to be performed in  close 
proximity to discontinuation of dosing for patients who are withdrawn from the study. Other procedures may be performed at Inve stigator or 
Sponsor discretion. 
c Full physical exam to be conducted at Screening. Symptom-directed  physical examinations should be conducted at subsequent visit s. 
d Height and body mass index to be collected at Screening Visit only. 
e Hematologic, complete serum chemistry, urinalysis panels  and fecal calprotectin to be completed as noted in Appendix 1 . 
f Pharmacokinetic (PK) serial blood samples are to be collected on  Day 1 and Day 15 at predose and at 0.5, 1, 2, and 4 hours post dose. If PK 
serial blood samples cannot be collected on  Day 15, PK serial blood samples should be collected on Day 22. A predose sample wil l be 
obtained on all other Treatment Study Visits. Allowable sampli ng windows for PK blood draws will be 30 minutes prior t o dosing for the predose 
sample, then Â± 5 minutes for 0.5 and 1 hour postdos e, and Â± 10 minutes for 2 and 4 hours postdose.  
g Data will be collected daily for entire Run-in Period. 
h Data will be collected daily until Early Terminatio n or until End-of-Study Vi sit, whichever is later. 
 
Boston Pharmaceuticals, Inc. BOS-589-201
Protocol Version 2.0
Confidential Page 19 of 782 INTRODUCTION
2.1 Study Rationale
Irritable bowel syndrome (IBS) is a gastrointestinal (GI) illness with a prevalence of 
approximately 5% to 20% globally and charac terized by a constellation of clinical 
symptoms. Establishing a diagnosis and assessing response to treatment remains challenging because there are no biomarkers th at reliably correlate with disease state.
BOS-589 is an oral agent with limited systemic absorption that inhibits RET 
(REarranged during Transfection), a receptor tyrosine kinase that is hypothesized to 
play a key role in the maintenance of a health y enteric nervous system (ENS). Inhibition
of RET may represent a novel therapeutic strategy for the treatment of IBS by 
attenuating visceral hypersensitivity and/or colonic motility.
BOS-589 has been evaluated in healthy human subjects at doses up to 200 mg twice 
daily (bid) for 2 weeks. Consistent with its low oral bioavailability, BOS-589 was safe 
and well tolerated with no significant safety signals identified. The purpose of this study is to evaluate the efficacy, safety, and to lerability of BOS-589 in the treatment of 
patients with diarrhea-predominant IBS (IBS-D).
2.2 Background 
2.2.1 Disease Under Study
Irritable bowel syndrome is a relatively common GI illness characterized by a number of 
clinical symptoms, including abdominal pain and discomfort, abnormal bowel habits, 
and bloating ( ). Subtypes of IBS, based on the 
predominant bowel habit(s) reported by IBS patients, include diarrhea ( IBS-D), 
constipation (IBS -C), mixed (IBS -M), or unclassified (IBS -U). Currently approved 
medications  for IBS address the restoration of patients â€™ bowel habits and are minimally 
effective in addressing abdominal pain and discomfort. Because the etiology of the 
disease has not been clearly established, diagnosis  is difficult and relies primarily on the 
presence of a specific symptom complex occurring in the absence of an alternative 
explanation. The development of criteria by expert panels, with recent iterations as 
recently as 2016, has improved the diagnosis and management of IBS patients 
( ). 
It is generally believed that the sensory inputs/outputs in the ENS and central nervous 
system (CNS) are altered in patients with IBS and this contributes to the signs and 
symptoms they experience. For example, pat ients with IBS have a heightened and 
disproportionate sensory experience (visceral hypersensitivity) for a given stimulus 
( ). Visceral hypersensitivity and abnormal bowel habits may result 
from visceral afferent neurons or increased nerve fiber density and sprouting that have 
been observed in the intestinal mucosal tissues of IBS patients ( ; 
). The sensitizing event causing visceral 
hypersensitivity may be transient or chroni c; however, its impact on the CNS and ENS CCI
CCI
CCI
CCI
CCI
Boston Pharmaceuticals, Inc. BOS-589-201
Protocol Version 2.0
Confidential Page 20 of 78may be long lasting ( ). Supernatants from these intestinal 
tissues can stimulate nerve outgrowth and increase neuronal signaling in vitro , 
suggesting that neurotrophic factors and/or inflammatory cytokines might be mediators 
of neuronal plasticity in IBS ( ; 
). Given the central role the ENS may play in mediating signals 
between the CNS and the intestine, ENS modulati on may provide therapeutic benefit to 
IBS patients by impacting visceral hypersensitivity and intestinal motility.
The only drugs currently approved by the Food and Drug Administration (FDA) for the 
treatment of IBS are alosetron (for women only ), rifaximin, and eluxadoline for refractory 
IBS-D, and plecanatide, linaclotide, and lubiprostone for IBS -C. The majority of these 
drugs, and those used off label to treat IBS,  target patientsâ€™ symptoms by altering GI 
motility and are minimally effective in addr essing abdominal pain a nd discomfort. Of the 
FDA-approved agents, only alosetron is hy pothesized to modulate the CNS and ENS 
( ). Therefore, an agent such as BOS -589, 
which m ay ameliorate visceral hypersensitivity a nd potentially impact intestinal motility, 
would address a significant unmet medical need for IBS -associated pain.
2.2.2 The â€œRETâ€ (â€œREarranged During Tran sfectionâ€) Gene and the Enteric 
Nervous System
The RET gene, localized on human chromosome 10q11.2, encodes a receptor -type 
tyrosine kinase with an extracellular domain, a transmembrane domain, and an 
intracellular tyrosine kinase domain ( ). The ligands for RET have  
been identified as neurotrophic factors of the glial cell line -derived neurotrophic factor 
(GDNF) family, including GDNF, neurturin, arte min, and persephin. Ligand binding to its 
corresponding GDNF family receptor -alpha (GFR Î±) co-receptor triggers RET 
dimerization and subsequent transphosphorylation of intracellular tyrosines 
( ) and leads to the activation of different intracellular signaling 
cascades, including the Janus kinase/signal transducer and ac tivator of transcription 
proteins (JAK/STAT), phosphoinositide 3 -kinase/protein kinase B (PI3K/AKT), and rat 
sarcoma/extracellular signal -regulated kinase (RAS/ERK) pathways.
Mice deficient in the GDNF ligand, its coreceptor GFR Î±1, or the RET protein itsel f, 
exhibit severe defects in kidney and ENS development. This implicates RET signaling 
as critical to the development of normal kidneys and the ENS ( ). The 
role of RET in the development of the ENS is als o apparent in patients with 
Hirschsprung â€™s disease, who frequently suffer from colonic obstruction because of a 
lack of normal colonic innervation. In Hirschprung â€™s disease, different loss -of-function 
mutations that occur in the RET gene account for the hi ghest proportion of both familial 
and sporadic cases of the disease  ( ). 
While  its role during the development of the ENS has been well established, recent 
reports also implicate a significant role for RET in the maintenance and plasticity of the adult ENS. Neurons within the submucosal a nd myenteric plexus of the adult human 
colon have been shown to express RET and its coreceptors, GFR Î±1 and GFR Î±2, while 
the GDNF ligand is expressed in the muscularis mucosa and in circular and longitudinal CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
Boston Pharmaceuticals, Inc. BOS-589-201
Protocol Version 2.0
Confidential Page 21 of 78muscle tissue ( ). Systemic administrat ion of GDNF in adult 
rodents results in significant increases in submucosal neuron density in both the small 
intestine and colon and altered function ( ). Furthermore, a conditional 
knockout of the RET co-receptor, GFR Î±3, results in decreased colonic hypersensitivity 
implicating a role for RET signaling in visceral nociception ( ). 
Therefore, by reducing RET signaling, inhibition of RET may modulate ENS  activity .
2.2.3 Investigational Product
BOS -589, formerly GSK3352589, is a potent and selective inhibitor of RET that has 
been shown to reduce visceral hypersensitivit y in an animal model of IBS and inhibit 
cholinergic -induced increases in colonic motility (details are provided in the BOS -589 
Investigatorâ€™s Brochure [IB]). The results from these preclinical studies suggest that 
inhibition of RET with a potent, selective, and gut -restricted small molecule may 
represent a novel therapeutic strategy for the treatment of abdominal pain and 
defecation abnormalities (i.e., diarrhea) in patients with IBS through the attenuation of visceral hypersensitivity and/or cholinergically mediated ion transport and colonic motility. The patient population likely to derive the greatest benefit would comprise individuals with IBS -D with increased GI motility.
2.2.3.1 Nonclinical Summary
A range of in vitro  and in vivo  studies have been conducted to investigate the primary, 
secondary, and safety pharmacology of BOS -589. Details are provided in the BOS -589 
IB.
2.2.3.1.1 In Vitro Studies
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
CCICCI
CCI
CCI
Boston Pharmaceuticals, Inc. BOS-589-201
Protocol Version 2.0
Confidential Page 22 of 78 
2.2.3.1.2 In Vivo Studies
 
 
 
 
 
 
 
 
 
 
2.2.3.1.3 Pharmacokinetics and Product Metabolism in Animals
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
CCI
CCI
CCI
CCI
Boston Pharmaceuticals, Inc. BOS-589-201
Protocol Version 2.0
Confidential Page 23 of 782.2.3.1.4 Toxicology and Nonclinical Assessment of Safety
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
CCI
CCI
CCI
CCI
CCI
Boston Pharmaceuticals, Inc. BOS-589-201
Protocol Version 2.0
Confidential Page 24 of 78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.3.2 Clinical Experience 
Study  evaluated the sa fety, tolerability, pharmacokinetics (PK), and 
exploratory pharmacodynamics  (PD) of escalating single and multiple oral doses of 
BOS -589 ranging from 2 to 400 mg in the fasted state, and 25 mg in the fed state. All 
doses in the single ascending -dose portion of the study were generally safe and well 
tolerated, with a safety profile similar to that of placebo (PBO). Similarly, repeat -dose 
administration of BOS -589 for 14 days at doses ranging from 5 to 200 mg bid in the fed CCICCI
CCI
CCI
CCI
CCI
Boston Pharmaceuticals, Inc. BOS-589-201
Protocol Version 2.0
Confidential Page 25 of 78state was generally safe and well tolerated. There were no drug -related clinically 
significant changes in safety laboratory tests,  vital signs, ECGs, or stool patterns as 
assessed by the Bristol Stool Form Scale (BS FS) in this study. There were no serious 
adverse events (SAEs) considered related to the administration of BOS -589. A review of 
all GI adverse events (AEs) demonstrated that the occurrence of GI  AEs was similar in 
the PBO - and BOS -589-treatment groups. There was no pattern or trend with dose 
escalation suggestive of a treatment effect. 
The PK profile of BOS -589 demonstrated limited oral bioavailability and systemic 
exposure, with plasma concentrations g enerally less than 2 ng/mL, when measured 
utilizing a sensitive analytical method to detect concentrations as low as 5 pg/mL. Exposures were dose dependent and less than dose proportional, although box plots of dose -normalized parameters suggested dose proportionality between 15 mg and 
100 mg. Dosing was escalated to the highest possible dose because predicted mean 
systemic exposures did not exceed the defined plasma toxicokinetic limits (AUC
0-t and 
Cmax of 40.4 ng*h/mL and 26.7 ng/mL, respectively) and there was no evidence of 
dose -limiting toxicities. There was accumulation of BOS -589 with repeat dosing, but 
systemic exposures remained very low afte r 14 days of dosing, with respective 
geometric mean (CV%) AUC 0-t and C max values of 24.1 (45.9) h*ng/mL and 
1.53 (43.6) ng/mL for the highest dose of 200 mg bid; BOS -589 was likely at steady 
state before that time. Accumulation was lo wer for doses below 100 mg bid (1.3 to 
1.8 fold) and highest for the highest dose of 200 mg bid (2.0 to 2.7 fold).
The study included a pilot food -effect group to evaluate the magnitude of a food 
challenge on the bioavailability of single -dose BOS -589. Following administration of a 
single dose of BOS -589 25 mg in the fed state, there was a small decrease in exposure 
with food, with decreases in mean C max and AUC  values in the range of 20% to 35%. 
The time to C max (Tmax) remained the same with or without food. These food -effect 
results were deemed not clinically important; dosing BOS -589 with or without food is not 
anticipated to affect future eva luation of safety or efficacy.
Because RET is expressed in  enteroendocrine cells lining th e intestinal mucosa, an 
exploratory objective of the study was to explore the effect of BOS -589 on glucagon -like 
peptide -1 (GLP -1) and pancreatic peptide YY (PYY) excursions in plasma; however, no 
clear relationship or impact on BOS -589 administration and peptide secretion was 
identified.  
2.3 Risk/Benefit Assessment  
Summaries of findings from nonclinical and clinical studies conducted with BOS -589 
can be found in the IB (refer to the IB for additional details). The following section outlines the risk assessment and mitigation strategy for this protocol. 
The current study, BOS -589-201, represents the first administration of BOS -589 to 
patients with IBS -
D. Considerations for safety monitoring are derived  primarily from the 
literature regarding RET expression in th e intestine, nonclinical data, and clinical 
experience dosing BOS -589 to normal healthy volunteers (Study ), in CCI
Boston Pharmaceuticals, Inc. BOS-589-201
Protocol Version 2.0
Confidential Page 26 of 78which no clinically relevant risks were identif ied that would preclude dosing a RET 
inhibitor for up to 4 weeks in patients with IBS -D.
2.3.1 Risk Assessment
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
2.3.2 Benefit AssessmentPatients randomized to the active treatment arms may potentially experience 
improvement in their IBS -D during the course of the study. Those randomized to the 
PBO arm are not expected to obtain any benefit beyond that of their background 
treatment. 
2.3.3 Overall Risk/Benefit ConclusionOn the basis of nonclinical and clinical study results to date, limited effective alternative 
treatments, and the strength of the scientific hypothesis under evaluation, BOS -589 is 
considered to have a favorable benefit
-risk profile for patients with IBS -D.CCI
CCI
CCI
CCI
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 27 of 78 3 OBJECTIVES AND ENDPOINTS 
OBJECTIVES ENDPOINTS 
Primary 
x To evaluate in patients with IBS-D 
the abdominal pain response to 
BOS-589 after 4 weeks of treatment, 
relative to placebo (PBO). x 24-hour worst abdominal pain scores 
(WAP) at Day 29 compared to baseline 
(averaged over the week prior to each 
respective timepoint). 
x To evaluate the overall safety and 
tolerability of BOS-589 in the treatment of IBS-D during 4 
weeks 
of treatment, relative to PBO. x Incidence of adverse events (AEs) 
serious adverse events (SAEs), discontinuations because of AEs
, and 
any treatment-related severe AEs. 
Secondary  
x To evaluate the treatment effect of 
BOS-589 on defecation after 4 weeks, relative to PBO. 
 x Change in stool consistency, measured 
by the daily Bristol Stool Form Score 
(BSFS) at Day 29 compared to baseline 
(averaged over the week prior to each 
respective timepoint). 
x Change in stool frequency, measured 
by the total number of spontaneous bowel movements in 24 hours at 
Day 29 
compared to baseline (averaged over 
the week prior to each respective 
timepoint).  
x To evaluate the treatment effect of 
BOS-589 on IBS- related signs and 
symptoms. 
 x Change in the IBS Severity Score 
(IBS-SS) at Day 29 compared to baseline. 
x
 Change in the IBS Global Scale 
(IBS-GS) at Day 29 compared to 
baseline (averaged over the week prior to each respective timepoint). 
x To evaluate the steady-state 
pharmacokinetics of BOS-589.  x Maximum observed plasma 
concentration (C max); time to C max (Tmax); 
minimum plasma concentration (C min); 
area under the concentration versus 
time curve (AUC) from time zero to 4 hours postdose (AUC
0-4); AUC from 
time zero to the last quantifiable 
concentration (AUC 0-t). 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 28 of 78 4 STUDY DESIGN  
4.1 Overall Design 
This study is a phase 2a, randomized, double -blind, PBO -controlled, multicenter trial 
designed to provide the first proof -of-principle efficacy of BOS -589 in IBS -D patients, 
and to inform dose selection for subsequent development. The study will consist of a pre-treatment phase, a 4 -week double -blind treatment phase, and a 2 -week 
post-treatment follow -up period.  
Pre-Treatment Phase: During the pre -treatment phase, patients will be evaluated for 
up to 4 weeks to assess eligibility. The pre -treatment phase will consist of initial 
screening assessments and a Run -in period.  
After the initial screening assessments have been performed, eligible patients will enter 
a Run -in period of up to 3 -weeks. During the Run -in period, the patients will complete 
an electronic diary to collect daily information related to their IBS -D symptoms, bowel 
function, and rescue medicine use, to confirm disease activity and diary compliance. Patients will also be requested to discont inue any prohibited medications during this 
phase of the study.  
Upon completion of the Run -in period, patients will return to the study site to confirm 
eligibility for randomization into a 4 -week double -blinded Treatment Phase.  
Treatment Phase : Eligible patients will be randomized (1 :1:1) into the following cohorts:   
x Cohort 1 (High Dose): 200 mg BOS -589 bid orally  
x Cohort 2 (Low Dose): 50 mg BOS -589 bid orally  
x Cohort 3 (PBO): matching PBO oral tablets bid orally  
During the 4 weeks of double -blind treatment, patients will continue to record their daily 
IBS-D symptoms, bowel function, and rescue medi cine use in the electronic diary, as 
described in Section 8.3 . 
Post -treatment Phase
: A 2-week post -treatment follow -up visit will occur for patients 
who complete the Treatment Phase. During the 2 weeks of follow -up, patients should 
continue to record their daily IBS -D symptoms, bowel function, and rescue medicine use 
in the electronic diary.    
Patients who prematurely discontinue treatm ent should return to the study center to 
complete the early termination assessments as soon as possible after stopping the 
treatment.  
Data analyses will occur after all patients in the trial have completed  the last visit or 
procedure shown in the Schedule of Activities, Section 1.3 . 
Boston Pharmaceuticals, Inc. BOS-589-201
Protocol Version 2.0
Confidential Page 29 of 78Post -study Access to Therapy : No post -treatment access to therapy will be provided 
to patients randomized in the study.
4.1.1 Study Duration for PatientsUnless shortened by intolerable AEs or rapid disease progression, each patientâ€™s 
participation in this study is anticipated to last up to 10 weeks. 
The total duration of this study is anticipa ted to be approximately 12 months, including 
patient enrollment, treatment, and follow -up.
4.1.2 Number of Patients
Approximately 300 patients will be screened to randomize approximately 132 patients 
with IBS -D (44 patients per cohort).
4.1.3 Replacement of PatientsPatients who sign the ICF and are randomiz ed but do not receive the investigational 
product may be replaced. Once randomized, patients who have received at least 1 dose of investigational product and are withdrawn from therapy before completing 28 days of dosing or are discontinued from the study for any reason will not be replaced. 
4.1.4 Number of SitesUp to 66 sites in the United States may participate in this study.
4.2 Rationale for Study Design
Key aspects of the study (e.g., eligibility, co hort size, stopping criteria, safety data 
collection, efficacy assessments, use of PBO as control, and use of patient -reported 
outcome [PRO] tools) are based upon generally accepted clinical trial methodologies for 
phase 2a efficacy studies and prior studies conducted in patients with IBS. 
The Rome IV ( ) diagnostic criteria for IBS is the best accepted tool for 
standardized IBS diagnosis.
A Run -in Phase is designed to account for fluctuat ions in symptoms and the potential for 
wide variations in bowel habi ts; patient diaries that record frequency and severity of 
daily symptoms will be used to ensure that symptom severity fluctuations are identified 
and taken into account for subject eligibility . Patients will also be assessed on their 
ability to record their disease -related information in the required manner.
The use of PBO as a control comparator in IBS clinical trials is acceptable given the 
lack of consistently effective treatments. Placebo is an important component of IBS clinical trials given the high PBO effect in this population.  CCI
Boston Pharmaceuticals, Inc. BOS-589-201
Protocol Version 2.0
Confidential Page 30 of 78The key primary and secondary endpoints in this study are based on PRO 
assessments. These assessments evaluate  pain, defecation, and IBS signs and 
symptoms. Abdominal pain intensity is measured using an 11 -point (i.e., 0 to 10) 
numeric rating scale (NRS) that a sks patients daily to rate their worst abdominal pain 
over the past 24 -hours  as recommended by the FDA guidance on IBS ( FDA, 
May 2012 ).The use of theNRS for pain has been validated in IBS clinical studies 
( ). The IBS Severity Score (IBS -SS) ( ) and IBS 
Global Scale (IBS -GS) ( ) are validated and standard methods of 
assessing IBS symptoms in clinical trials. 
Although treatment durations longer than 4 weeks will be required for true assessment 
of efficacy in IBS patients, in this initial phase 2a study, 4 weeks should be sufficient to 
identify any efficacy signal that warrants further clinical invention.  
The use of multiple enrolling sites is aimed at maximizing external validity and to 
minimizing the potential influence of regional variations in diet, exercise habits, and 
ethnicity.
4.3 Justification for Dose
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
CCI
CCICCI CCI
CCI
Boston Pharmaceuticals, Inc. BOS-589-201
Protocol Version 2.0
Confidential Page 31 of 78 
4.4 End of Study Definition
The end of the study is defined as completion of the last visit or procedure shown in the 
Schedule of Activities in the trial globally. A patient will be considered to have completed 
the study if he or she has completed all phases of the study, including the last visit or the last scheduled procedure shown in the Schedule of Activities, Section 1.3 .CCI
Boston Pharmaceuticals, Inc. BOS-589-201
Protocol Version 2.0
Confidential Page 32 of 785 STUDY POPULATION
Before any study-specific activities/pro cedures, the appropriate written informed 
consent must be obtained. Prospective approv al of protocol deviations to recruitment 
and enrollment criteria, also known as protocol  waivers or exemptions, is not permitted. 
5.1 Inclusion Criteria
In order to be eligible to participate in this  study, an individual must meet all of the 
following criteria:
Age
1. Male and female patients must be 18 to 65 years of age, inclusive, at the time of 
signing informed consent.
Run-in eDiary Compliance2. Patient has completed the daily electronic d iary on at least 6 of the 7 days during the 
week prior to randomization AND at least 11 of the 14 days during the 2 weeks prior to randomization. Patients have up to 3 weeks to meet these criteria.
Type of Patient and Disease Characteristics
3.Patient meets the diagnosis of IBS based on the Rome IV diagnostic criteria 
( ):*
xRecurrent abdominal pain occurring, on av erage, at least 1 day per week and 
associated with 2 or more of the following:
oRelated to defecation; 
oAssociated with a change in frequency of bowel movements;
oAssociated with a change in form (appearance) of stool;
* These criteria must be fulfilled for the last 3 months prior to randomization and 
onset must have occurred at least 6 months prior to randomization. 
4.Patient meet s the diagnosis of IBS-Dsubtype based on Rome IV diagnostic criteria
( ).On days when the patient experiences IBS symptoms:
xAt least 25% of stools are loose or watery; AND 
xFewer than 25% of stools are hard.CCI
CCI
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 33 of 78 5. Over the week prior to randomization, the patient has an average of worst abdominal 
pain (WAP) scores in the prior 24 hours of 4.0 to 8.0 (on a 0 to 10 numerical rating 
scale, where 0 indicates no pain and 10 indicates worst pain imaginable).    
6. Over the week prior to randomization, the patient has an average daily BSFS score 
â‰¥ 5.0 (on a 1 to 7 scale, where 1 = hard, lump y stools, and 7 = watery, liquid stools) 
and at least 5 days with a BSFS score â‰¥ 5.0. 
7. Over the week prior to randomization, the patient has an average daily IBS-GS 
score of â‰¥ 2.0 (on a 0 to 4 scale, where 0  = none, 1 = mild, 2 = moderate, 3 = severe, 
4 = very severe). 
8. Patient is not planning to change his or her  usual diet and lifestyle during the course 
of the study.  
Diagnostic Assessments 9. Patient must undergo or previously have undergone (a) an appropriate evaluation for 
their IBS symptoms, including an evaluation for organic/structural etiologies (if in the 
presence of alarm symptoms); and (b) age-appropriate screening for colorectal 
cancer, if applicable. 
a) If at least one of the following alarm features are present, then the patient must 
have had a colonoscopy since the onset of symptoms or within the past 5 years 
(whichever is less):  
x Documented and unexplained weight loss of â‰¥ 10% within the past 
6 months; 
x Nocturnal diarrhea; 
x Blood mixed with stool (except hemorrhoidal bleeding, defined as 
occasional blood found on the toilet paper only or limited dripping of blood into the toilet bowl after defecation; 
x Unexplained iron-deficiency anemia. 
b) If no alarm features are present, then  the patient must have had a colonoscopy 
or other appropriate exam, based on criteria as outlined below: 
x Age â‰¥ 50 (â‰¥ 45 if African -American): Colonoscopy within the past 10 years; 
x First-degree relative (FDR) diagnosed with colorectal cancer under age 60 
OR 2 FDRs diagnosed with colorectal cancer at any age: Colonoscopy 
within past 5 years, beginning  10 years before age of youngest FDR (at 
time of diagnosis); 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 34 of 78 x Age â‰¥ 40 AND FDR diagnosed with colorectal cancer (at any age): 
Colonoscopy within past 10 years; 
10. Patient is negative for serum tissue transglutaminase IgA antibody (tTG-IgA) plus 
has evidence of detectable serum IgA within the normal reference range.   
Weight  11. Body mass index (BMI) within the range 16 to 39 kg/m
2 (inclusive).  
Gender  12.  Male and female patients are eligible if:  
a. Male patients: 
A male patient must agree to us e contraception as detailed in Appendix 2  of 
this protocol during the treatment peri od and for at least 14 weeks after the 
last dose of investigational product. Patients must also agree to refrain from donating sperm during this period.  
b. Female patients:   
A female patient is eligible to parti cipate if she is not pregnant (see Appendix  
2), not breastfeeding, and at least 1 of the following conditions applies:  
i. Not a woman of childbearing potential (WOCBP) as defined in Appendix  
2; OR 
ii. A WOCBP who agrees to follow the contraceptive guidance in Appendix  
2 during the treatment period and for at least 5 weeks after the last dose 
of investigational product. 
Informed Consent  13. Capable of giving signed informed consent, which includes compliance with the 
requirements and restrictions listed in the Informed Consent Form (ICF) and in this 
protocol.  
14. Patient is willing to be compliant with  study procedures, including completing the 
daily electronic diary during the Run-in Period and throughout the study. 
5.2 Exclusion Criteria 
An individual for whom any of the foll owing criteria apply will be excluded from 
participation in this study: 
Gastrointestinal-related Medical Conditions  
Boston Pharmaceuticals, Inc. BOS-589-201
Protocol Version 2.0
Confidential Page 35 of 781.At the time of screening, p atient has a diagnosis of an IBS subtype other t han IBS-D,
based on Rome IV criteria ( ). Based on stool patterns on days that 
the patient experiences symptoms, other IBS subtypes are defined as follows:   
a. IBS-C : hard or lumpy stools â‰¥ 25% of bowel movem ents and loose or watery 
stools â‰¤ 25% of bowel movements;
b. IBS-M : hard or lumpy stools â‰¥ 25% of bowel movements and loose or watery 
stools â‰¥ 25% of bowel movements;
c. IBS-U : hard or lumpy stools â‰¤ 25% of bowel movements and loose or watery 
stools â‰¤ 25% of bow el movements.
2. Patient has a history of inflammatory or immune-mediated GI disorders including 
(but not limited to) inflammatory bowel di sease (i.e., Crohn's disease, ulcerative 
colitis, microscopic coliti s, and celiac disease).
3. Patient has had an episode of diverticulitis within 3 months prior to Screening.4. Patient has a history of intestinal obstru ction, stricture, toxic megacolon, GI 
perforation, fecal impaction, gastric banding , bariatric surgery, adhesions, ischemic 
colitis, or impaired intestinal circulat ion (e.g., aortoiliac occlusive disease).
5. Patient has any of the following surgical history:
a. Cholecystectomy with ANY history of post-cholecystectomy biliary tract pain. 
A successful cholecystectomy with no po stoperative biliary tract pain is not 
exclusionary;
b. Any abdominal surgery within th e 3 months prior to Screening; 
c. Major gastric, esophageal, hepatic, pancreatic, or intestinal surgery 
(appendectomy, hemorrhoidectomy, or polypectomy greater than 3 months post-surgery are allowed).
6. Patient has a history or current evidence of laxative abuse.
 
Other Medical Conditions
7. Patient has a history of a cardiovascu lar event, including stroke, myocardial 
infarction, congestive heart failure, or tr ansient ischemic attack within 6 months prior 
to Screening.
8. Patient has a history of malignancy within 5 years prior to Screening (except 
squamous and basal cell carcinomas of the skin and cervical carcinoma in situ ).
9. Patient has a history of alcohol abuse or binge drinking.CCI
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 36 of 78 10. Patient has uncontrolled hypertension, defined as systolic blood pressure 
> 180 mmHg or a diastolic blood pressure > 100 mmHg at the time of Screening. 
11. Patient has a history of significant hypersens itivity, intolerance, or allergy to any drug 
compound, food, or other substance, unless approved by the Investigator. 
Laboratory Assessments  
12. Fecal calprotectin â‰¥ 50Î¼g/g. 
13. H emoglobin A1c level â‰¥ 8.0% or a confirmed fasting plasma glucose level 
â‰¥ 180 mg/dL. 
14. Confirmed alanine aminotransferase (ALT) > 2x upper limit of normal (ULN). 
15. Confirmed total bilirubin > ULN, unless the patient has a documented history of 
Gilbertâ€™s syndrome.  
16. Confirmed QT interval corrected by Fri dericiaâ€™s formula (QTcF) or QT interval 
corrected by Baz ettâ€™s formula (QTcB) > 500 msec.  
17. Evidence of active hepatitis B virus (HBV)  infection, based on a positive hepatitis B 
surface antigen (HBsAg) screen. 
18. Evidence of hepatitis C virus (HCV) infection based on a positive HCV antibody 
screen (patients who have been success fully treated for HCV are eligible if 
an undetectable HCV viral load at least 6 months after completion of treatment can 
be demonstrated). 
19.  Human immunodeficiency virus (HIV)-1 or HIV-2 antibody positive. Prior/Concomitant Therapy  20. Within 14 days of randomization, patient has used either of the following: 
x 5-hydroxytriptamine (5-HT)
3 or 5-HT 4 receptor antagonists (e.g., alosetron); 
x Any of the strong inhibitors of P-glycoprotein listed in Appendix 4. 
21. Within 14 days of randomization, patient has used any of the following:  
x Loperamide; (Note: loperamide can be used during the study as rescue 
medication based on protocol specified guidelines [see Section 6.7.1] );  
x Aspirin or aspirin-conta ining medications (> 325 mg of aspirin per day) or 
nonsteroidal anti-inflammatory drugs, when taken specifically for the symptoms of IBS; 
x Narcotic- or opioid-containing agents; 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 37 of 78 x Cannabis-containing products; 
x Docusate; 
x Enemas; 
x GI preparations (includ ing antacids containing aluminum or magnesium, 
antidiarrheal agents, antispasmodic ag ents, bismuth, peppermint oil, 
IBgard, FDgard, or prokinetic agents). 
22. Within 14 days of randomization, receipt of any prescribed or over-the-counter, 
systemic, herbal (including St. Jo hnâ€™s wort), or topical medication , or any expectation 
of requiring use of such medication whil e participating in the study that, in the 
opinion of the Investigator, would interfere with study procedures, compromise 
safety, or the scientific integrity of the data.  
23. Patient has used, or is expected to use, the following antibiotics: 
x Rifaximin within 90 days prior to randomization;  
x Other oral antibiotics within 28 days of randomization (with the exception 
of topical antibiotics or a 1-day course with an antibiotic). 
However, a patient will be allowed to remain in the study should unplanned use of 
antibiotics other than rifaximin occur after t he patient has been randomly assigned to 
study drug. 
24. Within 3 months prior to randomization, pa tient has had significant changes to his or 
her antidepressant regimen (i.e., addition  of a new agent, discontinuation of a prior 
agent, significant modifications to the dos e of a current medication). Patients on 
chronic stable doses of antidepressants will be allowed to participate in the study. As-needed use of buspirone and benzodiazepines for anxiety is permitted during the study; 
25. Within 30 days prior to randomization (or 5 half-lives, if known), the patient has 
received an investigational drug, or is curr ently enrolled in an investigational study. 
Other Exclusions 
 
26. Patient is unable to swallow solid oral dosage forms whole with the aid of liquid 
(patients may not chew, divide, dissolve, or crush the study drug). 
27. Patient has an elective surgery planned or  expects to need elective surgery at any 
time during the study. 
28. Patient is pregnant or breastfeeding. 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 38 of 78 29. Patient has any medical or psychological di sorder or condition that, in the opinion of 
the Investigator, would compromise the wellbeing of the patient or the study or 
prevent the patient from meeting or performing study requirements. 
30. Patient has poor peripheral venous access. 31. Patient is an employee of the Investigator  or study center with direct involvement in 
the proposed study or other studies under the direction of that Investigator or study 
center, as well as family members of the employees or the Investigator. 
5.3 Lifestyle Considerations 
During this study, patients will be asked to abstain from strenuous exercise for 48 hours 
before each blood collection fo r clinical laboratory tests.  
Only on days when postdose PK blood samples are to be taken (see footnote f in the 
Schedule of Activities; Section 1.3 ), patients will be asked to refrain from consumption 
of food and water for 1 hour prior to and for 2 hours after administration of 
investigational product. Food and water may be consumed ad libitum  at all other times 
during the study. Investigational product should be taken with approximately 240 mL 
water.  
5.4 Screen Failures 
Screen failures are defined as patients who consent to participate in the clinical trial but are not subsequently randomized. A minimal se t of screen failure information is required 
to ensure transparent reporting of screen fa ilure patients, to meet the Consolidated 
Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities. Mini mal information includes demography, screen 
failure details, eligibility  criteria, and any SAE. 
Individuals who do not meet the criteria for pa rticipation in this trial (screen failure) may 
be rescreened with Medical Monitor approval.  
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 39 of 78 6 INVESTIGATIONAL PRODUCT 
6.1 Investigational Products  
6.1.1 Investigational Product Description 
Investigational 
Product Name:   BOS-589 Placebo 
Dosage Formulation:   Tablet  Tablet 
Unit Dose 
Strengths/Dosage Levels:   50 mg (2 x 25- mg tablets) and 
200 mg (2 x 100-mg tablets) Visually matching placebo tablets 
across both BOS -589 dose levels 
Route 
of Administration:  Oral Oral 
Dosing Instructions:  Swallow whole with a glass of 
water, do not chew, divide, 
dissolve, or crush Swallow whole with a glass of 
water, do not chew, divide, 
dissolve, or crush 
Packaging 
and Labeling:   Investigational product will be 
provided in white, opaque,  
high-density polyethylene (HDPE) 
bottles with a child- resistant 
closure. Each bottle will be labeled 
as per country requirement Investigational product will be 
provided in white, opaque, HDPE 
bottles with a child- resistant 
closure. Each bottle will be labeled 
as per country requirement 
Manufacturer :  WuXi STA, Shanghai, China WuXi STA, Shanghai, China 
6.2 Preparation/Handling/Storage/Accountability 
6.2.1 Acquisition and accountability 
The Investigator or designee must confir m appropriate temperature conditions have 
been maintained during transit for all investigational product received and any 
discrepancies are reported and resolved before  use of the investigational product.  
The Investigator, institution, or the head of the medical institution (where applicable) is 
responsible for investigational product accountability, reconciliation, and record 
maintenance (i.e., receipt, reconciliation , and final disposition records).  
6.2.2 Product Storage and Stability All investigational product must be stored in a secure, environmentally controlled, and 
monitored (manual or automated) area in accordance with the labeled storage conditions with access limited to the Investigator and authorized site staff. 
Further guidance and information for the final disposition of unused investigational 
products are provided in the Pharmacy Manual. 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 40 of 78 6.3 Measures to Minimize Bias 
This is a randomized, double -blinded, PBO -controlled study. Patients should be 
randomized as close as possible to the time of the planned first dose of study treatment.  
Randomization will be conducted via an interactive web response system (IWRS) in a 
1:1:1 ratio for patients to receive BOS -589 200  mg, BOS -589 50  mg, or PBO. Patients 
will be assigned to the treatment arms using a permuted block randomization stratified by site (44 patients per group). The randomization schedule will be generated by the Study Biostatistician and will be transferred to the IWRS team for loading into the 
system. The randomization file will be held by  the Study Biostatistician until the end of 
the trial and when the database has been locked.  
The sponsor, site staff, and patients will be blinded to the treatment assignment. 
BOS -589 and PBO will be similar in appearance, and provided in white, opaque, 
high-density polyethylene (HDPE) bottles, each with a child -resistant closure. Each 
bottle will be labeled as per country requirement.  
Only in a medical emergency will a patientâ€™ s treatment assignment be unblinded, and 
this process will be performed and document ed in the IWRS. Every effort should be 
made to contact the Medical Monitor to discuss unblinding prior to breaking the blind.  
6.4 Dosing and Administration 
Only patients enrolled in the study may receive investigational product and only 
authorized site staff may supply or administer investigational product.  
Eligible patients will be randomized (1:1:1) to receive for a total of 4 weeks BOS -589 at 
1 of 2 dose levels or PBO bid. Patients will be randomized to the following cohorts:   
x Cohort 1 (High Dose): 2 x 100 mg tablets for the 200 mg BOS -589 bid orally  
x Cohort 2 (Low Dose): 2 x 25 mg tablets for the 50 mg BOS -589 bid orally  
x Cohort 3 (PBO): 2 x visually matched PBO tablets bid orally  
For each dose level and at each dosing timepoint, the 2 tablets are to be swallowed with 
approximately 240 mL room temperature water and are to be swallowed whole (i.e., not 
divided, crushed, dissolved, or chewed). On  days when postdose PK blood samples are 
to be taken (see footnote f in the Schedule of Activities, Section 1.3 , patients will be 
asked to refrain from consumption of food an d water for 1 hour prior to and for 2 hours 
after administration of investigational product. Food and water may be consumed ad 
libitum  at all other times during the study. 
Patients will be instructed to take the investigational product approximately every 
12 hours at approximately the same time each day. If a patient misses a dose at a given 
timepoint, and the time is within 4 hours of the regularly scheduled dosing time, the 
patient should be instructed to take the investig ational product. If it has been longer than 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 41 of 78 4 hours, the patient should skip the missed dose at that timepoint and resume the 
regularly scheduled dosing schedule at the next scheduled timepoint.  
In the event of vomiting following administration, BOS -589 should not be taken until the 
next scheduled dose.  
6.5 Dose modification 
Study treatment should be interrupted if the patient reports any treatment -related severe 
AE. Therapy should only be restarted after approval by the Medical Monitor.  
If therapy is restarted, the same dose should be administered as that prior to 
occurrence of the AE. If the patient is still having tolerability issues and an AE reoccurs, 
the dose may be reduced from 2 tablets of study treatment bid to 1 tablet of study 
treatment bid, without breaking the study blind.   
If another AE occurs after the study treatmen t dose reduction, study treatment will be 
permanently discontinued and the subject followed until the end of the study.  
6.6 Investigational Product Compliance 
All patients in this study will commenc e therapy on site on Study Day 1; oral 
investigational product will be administered un der clinic staff supervision. After patients 
are discharged to continue therapy at home, compliance will be assessed on subsequent visits by returned tablet count.  Administration of investigational product and 
any deviation(s) from the prescribed dosage regimen should be recorded in the case 
report form (CRF) and Drug Accountability Record.  
6.7 Concomitant Therapy 
Refer to Appendix 4.   for more details on which concomitant medications are 
permitted and which are excluded while patients are on study.  
Any prior or concomitant therapy (including ov er the counter or prescription medicines, 
vitamins and/or supplements) taken 28 days pr ior to the first dose of investigational 
product through the End -of-Study Visit must be recorded, along with:   
x Reason for use;  
x Dates of administration including start and end dates;  
x Dosage information including dose and frequency.  
The Medical Monitor should be contacted if there are any questions regarding 
concomitant or prior therapy.   
For this protocol, a prescription medication is defined as a medication that can be 
prescribed only by a properly authorized/licen sed clinician. Medications to be reported 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 42 of 78 in the CRF are concomitant pr escription medications, over -the-counter medications, 
vaccines, vitamins, and supplements.  
6.7.1 Rescue Medicine During the double -blind Treatment Phase of the study, patients will be allowed to take 
loperamide rescue medication for the acute treatment of uncontrolled diarrhea. Loperamide at a unit dose of 2 mg may be taken once approximately every 6 hours with the following guidelines:  
x No more than 4 unit doses over a continuous 24 -hour time period (8 mg/day);  
x No more than 7 unit doses over a continuous 48 -hour time period (14 mg over 
2 days);  
x No more than 11 unit doses over a continuous 7 -day time period.  
The use of loperamide rescue medication should be recorded electronically.  
6.8 Intervention After the End of the Study  
BOS-589 will not be provided to study patients after the end of the study. 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 43 of 78 7 DISCONTINUATION / WITHDRAWAL 
7.1 Discontinuation of Investigational Product 
A patient may discontinue from study treatment at any time at his or her own request or 
may be withdrawn at any time at the discretio n of the Investigator for safety, behavioral, 
or administrative reasons. Discontinuation from the investigational product does not mean discontinuation from the study, and remaining study procedures should be completed as indicated by the study protocol. If  a clinically significant finding is identified 
(including, but not limited to, changes from baseline) after enrollment, the Investigator or qualified designee will determine if any change in patient management is needed. Any new clinically relevant finding will be reported as an AE. 
Upon investigational product discontinuation, patients should complete all procedures 
collected in the Day 29/End-of-Treatment visit as applicable per the Schedule of Activities ( Section 1.3 ). 
7.2 Discontinuation/Withdrawal from the Study 
A patient may withdraw from the study at any time at his or her own request or may be 
withdrawn at any time at the discretion of the Investigator for the following reasons: 
x If any clinical AE, laboratory abnormality, or other medical condition or situation 
occurs such that continued participation in the study would not be in the best interest of the patient;  
x Disease progression that requires discont inuation of the investigational product;  
x Pregnancy;  
x If the patient meets an exclusion cri terion (either newly developed or not 
previously recognized) that precludes furt her study participation after consultation 
with the Medical Monitor;  
x Significant investigational product noncompliance;  
x Termination of the study by the sponsor.  
If the patient withdraws consent for disclosur e of future information, the sponsor may 
retain and continue to use any data collected before such a withdrawal of consent.  
If a patient withdraws from the study, he or  she may request destruction of any samples 
taken and not tested, and the Investigator must  document this in the site study records.  
See Schedule of Activities, Section 1.3 , for data to be collected at the time of study 
discontinuation and follow-up and for any further evaluations that need to be completed.  
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 44 of 78 The reason for patient discontinuation or withdrawal from the study will be recorded on 
the CRF.  
Patients who sign the ICF and are randomiz ed but do not receive the investigational 
product may be replaced. Once randomized, patients who are withdrawn from therapy before completing 28  days of dosing or are discontinued from the study for any reason 
will not be replaced.  
Clinical and/or laboratory criteria that may warrant study drug discontinuation.   
If a patient experiences any of the following clinical or laboratory events, study 
treatment should be immediately suspended:  
x Any SAE considered study drug -related;  
x No bowel movement for 7 days;  
x Any clinical evidence suggestive severe constipation, obstipation or intestinal 
obstruction; gastrointestinal hemorrhage, significant gastrointestinal infection;  
x Abnormal liver functions concerning for drug -induced as follows1:  
o Confirmed ALT > 5x ULN  
o Confirmed ALT > 3x ULN and any of the following signs or symptoms 
(fatigue, nausea, vomiting, right upper quadrant pain, fever, rash or 
eosinophilia)2 
o Confirmed ALT > 3x ULN and total bilirubin > 2x ULN or INR > 1.5 ( should 
be repeated in 48 -72 hours ) 
1Should any of these events occur, a full eva luation of other causes of liver enzyme 
elevation should be undertaken and patients would be followed at regular intervals until labs return to normal/stabilize, or an alternate diagnosis is confirmed.   
2If patients develop asymptomatic elevations of the ALT of > 3x ULN and, if there are 
persistent elevations upon repeat testing, close observation should be implemented, and discontinuation of the drug should be considered.  
Depending on the nature, severity, and outco me, the Sponsor will decide to (and 
document with supporting rationale) either : 1) discontinue study drug; 2) request 
additional safety data; or 3) continue dosing at current dose or reduced dose (see Section 6.5).  
If 2 or more patients experience any of the above criteria (note: study drug -related SAEs 
must be in the same system organ class) the study enrollment will be halted.  The 
Sponsor, an independent GI physician not involved with the study, and the lead 
investigator will review available data to dete rmine whether individual patient unblinding 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 45 of 78 is warranted, amendments are required for the protocol, and whether patients currently 
on treatment should also discontinue study drug.  A decision to continue (with or without 
modifications) or discontinue the study will be made.  All supporting rationale will be documented.  
7.3 Lost to Follow-up 
A patient will be considered lost to follow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site staff.  
The following actions must be taken if a patient fails to return to the clinic for a required 
study visit: 
x The site will attempt to contact the pati ent and reschedule the missed visit as soon 
as possible; counsel the patient on the importance of maintaining the assigned visit schedule; and ascertain if the patient wishes to and/or should continue in the study. 
x Before a patient is deemed lost to follow -up, the Investigator or designee will make 
every effort to regain contact with the patie nt (where possible, 3 telephone calls and, 
if necessary, a cert ified letter to the patientâ€™s last known mailing address or local 
equivalent methods. These contact attempts  should be documented in the patientâ€™s 
medical record or study file.  
x Should the patient continue to be unreachable, he or she will be considered to have 
withdrawn from the study with a primary reason of lost to follow-up.  
 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 46 of 78 8 STUDY ASSESSMENTS AND PROCEDURES 
Planned timepoints for all assessments are provided in the Schedule of Activities 
(Section 1.3 ). 
8.1 Study Periods 
The study will comprise 3 phases:  
1. Pre-Treatment Phase  (up to 4 weeks), in which all pa tients will be assessed for 
eligibility. The pre -treatment phase will consist of initial screening assessments 
(Visit  1) and a Run -in period (Visit 2 through Visit 3).  
2. A Treatment Phase  (4 weeks), in which all patients will return to the clinical for 
randomization and start of treatment (Visit 3 â€“ Day 1) followed by weekly visits 
(Visit  4 â€“ Day 8 [ Â± 1 day], Visit 5 â€“ Day 15 [ Â± 1 day], Visit 6 â€“ Day 22 [ Â± 1 day]) until 
Visit 7 â€“ Day 29 ( Â± 1 day), and  
3. A Follow -up Phase  (2 weeks), in which patients who complete Visit 7, will be asked 
to return for an End -of-Study Follow -up visit (Visit 8 â€“ Day 43  [Â± 3 days]) for 
assessment of treatment outcome (e.g ., safety, durability of effect).  
8.2 Screening Assessments 
After signing the ICF(s), the patient will  undergo the initial screening assessments and 
procedures as described in the Schedule of Activities ( Section 1.3 ) to determine 
eligibility.  
Eligible patients will enter the Run-in perio d. At the beginning of the Run-in period, 
patients will receive instructions for comple ting an electronic diary to collect daily 
information related to their IBS-D symptoms, their bowel function, and rescue medication use.  
Patients who are: 
x Compliant in completing the screening diary on a daily basis on at least 6 of the 
7 days during the week prior to randomization AND on at least 11 of the 14 days during the 2 weeks prior to randomization, and 
x Have an average WAP score in the past 24 hours of between 4.0 and 8.0 on a 
0 to 10 scale over the week prior to randomization, and  
x Have an average daily BSFS of â‰¥ 5.0 and at least 5 days with a BSFS score 
â‰¥ 5.0 on a 1 to 7 scale over the week prior to randomization, and  
x Have an average daily IBS-GS score of â‰¥ 2.0 on a 0 to 4 scale over the week 
prior to randomization, and  
Boston Pharmaceuticals, Inc. BOS-589-201
Protocol Version 2.0
Confidential Page 47 of 78xWho have not used any loperamide rescue medication in the 2 weeks prior to 
randomization 
will be eligible for participation and imme diate randomization into the double-blind 
treatment phase (i.e., all 5 diary condition s must be met to qualify for randomization). 
Eligible patients will be instructed to return  to the study site fo r the Baseline visit on 
Day 1. 
If after 2 weeks, patients do not meet all of the 5 diary conditions required for entry, the 
run-in may be extended by up to one week in accordance with investigator judgement(for a total run-in period of up to 3 weeks). 
8.3 Efficacy Assessments 
The efficacy objectives of the study are to evaluate the effect of BOS -589, relative to 
PBO after 4 weeks of therapy, on pain, defecation, and key IBS -D related signs and 
symptoms.
During the 4 weeks of the double -blind treatment phase, patients will be required to 
access their electronic diary every day, prefer ably at the same time each day, to record 
IBS-D symptom data and information related to their bowel function and rescue 
medication use.
8.3.1 Worst Abdominal Pain
Throughout the 4 weeks of the double -blind treatment phase, patients will be asked to 
rate their WAP in the past 24 hours. The patient -reported WAP in the past 24 hours will 
be recorded on a 0 to 10 scale, where 0 corresponds to no pain and 10 corresponds to worst imaginable pain. 
8.3.2 Bristol Stool Form ScalePatients will be asked to record daily stool  consistency according to the BSFS most 
representative of the past 24 hours. The patient -
reported BSFS consistency score is 
based on a 1 to 7 scale where 1 corresponds to a hard stool and 7 corresponds to 
watery diarrhea  ( ). Please refer to Appendix 3.
8.3.3 IBS-D Global Symptom Score
Patients will be asked to record daily thei r overall IBS-D global symptoms in the prior
24 hours. The patient-reported daily IBS-GS is based on a 0 to 4 scale where: 
x0 corresponds to no symptoms; 
x1 corresponds to mild symptoms; 
x2 corresponds to moderate symptoms; CCI
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 48 of 78 x 3 corresponds to severe symptoms; and  
x 4 corresponds to very severe symptoms.  
8.3.4 IBS Severity Score System 
Patients  will be asked to complete 5 questions rega rding the severity of their IBS. Each 
of the 5 questions generate a maximum score of 100, leading to a total possible score of 500.    
8.4 Safety and Other Assessments 
8.4.1 Adverse Events and Serious Adverse Events 
See Section 8.5 . 
8.4.2 Physical Examinations  A complete physical examination (PE) will  be performed at Screening. A symptom -
directed PE will be performed at the timepoint s specified in the Schedule of Activities 
(Section 1.3 ) and as clinically indicated, and results recorded in the source document. 
Any clinically significant PE finding noted at  Screening will be recorded as medical 
history. Any clinically significant PE finding no ted at after enrollment will be reviewed for 
reporting as an AE (see Section 8.5 ). 
A complete PE will include, at a minim um, assessment of the cardiovascular, 
respiratory, GI, and neurological systems. A targeted PE will include, at a minimum, 
assessments of the skin, lungs, cardiovascula r system, and abdomen (liver and spleen).  
Height and weight will also be measured and BMI will be calculated and the data 
recorded at the timepoints specified  in the Schedule of Activities ( Section 1.3 ). 
Investigators should pay special attention to clinical signs related to previous serious 
illnesses.  
8.4.3 Vital Signs  At the timepoints specified in the Schedule of Activities ( Section 1.3 ) and before any 
blood sample collection, vital signs will be meas ured in a supine position after 5 minutes 
rest and will include oral temperature, systolic and diastolic blood pressure, pulse, and respiratory rate. Any clinically significant abnorm al vital sign value will be recorded as an 
AE (see Section 8.5 ). 
8.4.4 Electrocardiograms  Single 12 -lead ECGs will be performed at the timepoints specified in the Schedule of 
Activities ( Section 1.3 ) and before any blood sample collection. Electrocardiogram 
interval measurements and interpretation (normal, abnormal not clinically significant, 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 49 of 78 abnormal clinically significant) will be recorded in the source document. Any clinically 
significant change in ECG interpretati on will be recorded as an AE (see Section 8.5 ). 
8.4.5 Clinical Safety Laboratory Assessments  See Appendix 1  for the list of clinical laboratory tests to be performed and to the 
Schedule of Activities  (Section 1.3 ) for the timing and frequency.    
The Investigator must review the laboratory report, document this review, and record in 
the AE section of the CRF any clinically r elevant changes occurring during the study. 
The laboratory reports must be filed with th e source documents. Clinically significant 
abnormal laboratory findings are those that are not associated with the underlying disease, unless judged by the Investigator to be more severe than expected for the 
patientâ€™s condition.   
All laboratory tests with values considered clinically significantly abnormal during 
participation in the study should be repea ted until the values return to normal or 
baseline or are no longer considered clinically  significant by the Investigator or Medical 
Monitor. If such values do not return to normal/baseline within a period of time judged 
reasonable by the Investigator, the etiology should be identified and the sponsor notified.  
All protocol-required laboratory assessments, as defined in Appendix 1 , must be 
conducted in accordance with the laboratory manual and the Schedule of Activities.   
If laboratory values from non-protocol-specified laboratory assessments performed at 
the institutionâ€™s local laboratory  require a change in patient management or 
are considered clinically significant by the Investigator (e.g., SAE, or AE, or dose 
modification), then the results must be recorded in the CRF. 
8.5 Adverse Events and Serious Adverse Events 
Adverse events will be reported by the patient (or, when appropriate, by a caregiver, surrogate, or the patient's legally authorized representative).  
The Investigator and any qualified designees are responsible for detecting and 
documenting events that meet the definition of an AE or SAE and are responsible for following all AEs.  
8.5.1 Definition of Adverse Events 
An AE is any untoward medical occurrence in a patient or clinical study participant, 
temporally associated with the use of invest igational product, whether or not considered 
related to the investigational product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of investigational product.   
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 50 of 78 8.5.2 Events of Special Interest  
Not applicable. 
8.5.3 Definition of Serious Adverse Events If an event is not an AE per definition above,  then it cannot be an SAE even if serious 
conditions are met (e.g., hospitalization for si gns/symptoms of the disease under study, 
death because of progression of disease).  
A SAE is defined as any untoward medical occurrence that, at any dose:  
x Results in death;  
x Is life threatening;  
The term 'life threatening' in the definition of 'serious' refers to an event in which 
the patient was at risk of death at the time  of the event. It does not refer to an 
event, which hypothetically might have caus ed death, if it were more severe.  
x Requires inpatient hospitalization or prol ongation of existing hospitalization;   
In general, hospitalization signifies that the subject or patient has been detained 
(usually involving at least an overnight stay) at the hospital or emergency ward 
for observation and/or treatment that would not have been appropriate in the physicianâ€™s office or outpatient sett ing. Complications that occur during 
hospitalization are AEs. If a complication prolongs hospitalization or fulfills any 
other serious criteria, the event is serious. When in doubt as to whether â€œhospitalizationâ€ occurred or was necessary, the AE should be considered serious.   
Hospitalization for elective treatment of a pre -existing condition that did not 
worsen from baseline is not considered an AE;  
x Results in persistent disability/incapacity;  
The term disability means a substantial disruption of a personâ€™s ability to conduct 
normal life functions. This definition is not intended to include experiences of 
relatively minor medical significance such as uncomplicated headache, nausea, 
vomiting, diarrhea, influenza, and accidental trauma (e.g., sprained ankle) that may interfere with or prevent everyday life functions but do not constitute a substantial disruption.  
x Is a congenital anomaly/birth defect.  
Medical or scientific judgment should be ex ercised when deciding if SAE reporting is 
appropriate in other situations such as important medical events that may not be 
immediately life threatening or result in death or hospitalization, but may jeopardize the 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 51 of 78 patient or may require medical or surgical intervention to prevent any of the other 
outcomes listed in the above definition. T hese events should usually be considered 
serious. Examples of such events include invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in  hospitalization, or development of drug 
dependency or drug abuse.  
8.5.4 Classification of an Adverse Event 8.5.4.1 Assessment of Severity The Investigator will make an assessment of severity for each AE and SAE reported 
during the study and assign it to 1 of the following categories:    
x Mild: An event that is easily tolerated by the  patient, causing minimal discomfort 
and not interfering with everyday activities;   
x Moderate: An event that causes sufficient  discomfort and interferes with normal 
everyday activities;   
x Severe: An event that prevents normal everyday activities. An AE that is 
assessed as severe should not be confused with a SAE. Severe is a category utilized for rating the intensity of an event; and both AEs and SAEs can be assessed as severe.   
An event is defined as â€˜seriousâ€™ when it m eets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.   
8.5.4.2 Assessment of Causality All AEs must have their relationship to the investigational product and/or study 
participation assessed by the Investigator who examines and evaluates the patient based on temporal relationship and his or her clinical judgment. Alternative causes, 
such as underlying disease, concomitant therap y, and other risk factors, as well as the 
temporal relationship of the event to inve stigational product administration will be 
considered and investigated. The Investigator will also consult th e IB in his or her 
assessment.  
The degree of certainty about causality will be graded using the categories below:  
x Related  â€“ The AE is known to occur with the investigational product, there is a 
reasonable possibility that the investigational  product caused the AE, or there is a 
temporal relationship between the investigational product and event. Reasonable possibility means that there is evidence to  suggest a causal relationship between 
the investigational product and the AE.  
x Not Related  â€“ There is not a reasonable possibility that the administration of the 
investigational product caused the event , there is no temporal relationship 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 52 of 78 between the investigational product and ev ent onset, or an alternate etiology has 
been established.  
For each AE, the Investigator must document in the medical notes that he or she has 
reviewed the event and has provided an assessm ent of causality. The Investigator may 
change his or her opinion of causality in light of follow-up information and updated causality assessment reported. 
8.5.4.3 Expectedness  
The Investigator will be responsible for determining whether an AE is expected or unexpected. An AE will be considered unexpected if the nature, severity, or frequency of the event is not consistent with the ri sk information previously described for the 
investigational product.  
8.5.5 Time Period and Frequency for Event Assessment and Follow-up All AEs will be collected from the signing of the ICF until the End -of-Study Follow -up 
visit.  
Whenever possible, all AEs should be followed until satisfactory resolution or until the 
site Investigator deems the event to be  chronic or the patient is stable.   
All SAEs will be recorded and reported to the sponsor or designee within 24 hours, 
whether considered investigational product related or not, and must include an assessment of if there is a reasonable possibi lity that the investigational product caused 
the event. The Investigator will also submit any updated SAE data to the sponsor within 
24â€‰hours of it being available.  
Investigators are not obligated to actively seek AEs or SAEs after conclusion of the 
study participation. However, if the Investigat or learns of any SAE, including a death, at 
any time after a patient has been discharged from the study, and he or she considers the event to be reasonably related to the inve stigational product or study participation, 
the Investigator must promptly notify the sponsor.  
8.5.6 Adverse Event Reporting  At each study visit, patients will be evaluated for new AEs and the status of existing 
AEs. Care will be taken not to introduce bias when evaluating for AEs. The Investigator 
should use open -ended questions when soliciting information from a patient regarding 
AEs, followed by appropriate questions that cl arify the patientâ€™s verbatim description of 
AEs or change in concomitant medications.  
When an AE occurs, it is the responsibility of the Investigator to review all 
documentation (e.g., hospital progress notes, laboratory reports, and diagnostics reports) related to the event. The Investigator will attempt to establish a diagnosis of the 
event based on signs, symptoms, and/or othe r clinical information. Whenever possible, 
the diagnosis (not the individual signs/symptoms) will be documented as the AE.  
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 53 of 78 The Investigator will then record all relevant AE information in the CRF. It is not 
acceptable for the Investigator to send photocopies of the patientâ€™s medical records in 
lieu of completion of the CRF page. New or updated information will be recorded in the originally completed CRF. However, there may be instances when copies of medical records for certain cases are requested. In th is case, all patient identifiers, with the 
exception of the patient number, will be re dacted on the copies of the medical records 
before submission.  
If a patient dies during participation in  the study or during a recognized follow -up period, 
the Investigator will provide a copy of any postmortem findings, including histopathology when available.  
If a site receives report of a new SAE from a study patient or receives updated data on 
a previously reported SAE after database lock of the electronic data capture (EDC) 
system, then the site can report this information on a paper SAE form or to the sponsor by telephone. See the Study Manual for additional information on SAE reporting.  
The study sponsor, or designee, will be respon sible for notifying all applicable regulatory 
authorities of any required safety events in compliance with country -specific regulatory 
requirements. In addition, the sponsor must notify applicable regulatory authorities and all participating Investigators of suspec ted unexpected serious adverse reactions 
(SUSARs), from clinical trials or any other source.  
An Investigator who receives an Investigator safety report describing a SAE or other 
specific safety information (e.g., summary or listing of SAEs) from the sponsor will 
review and then file it along with the IB an d will notify the Institutional Review Board/ 
Independent Ethics Committee (IRB/IEC), if appropriate according to local requirements.  
8.5.7 Reporting of Pregnancy  Pregnancy itself is not regarded as an AE  unless there is a suspicion that the 
investigational product may have interfered with the effectiveness of a contraceptive 
medication. Pregnancy in a patientâ€™s partner is not considered an AE. Abnormal pregnancy outcomes (e.g., spontaneous abor tion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are conside red SAEs. Elective abortions without 
complications should not be handled as AE s; however, an induced therapeutic abortion 
to terminate a pregnancy because of complications or medical reasons must be 
reported as an SAE. The underlying medical diagnosis for this procedure should be 
reported as the SAE term. A spontaneous abortion in a study patient is always 
considered an SAE.  
All pregnancies in female patients and, if indi cated, pregnancies in female partners of 
male patients, will be collected after the start of investigational product and until 5 weeks after the last dose. Pregnancy outcomes, defined as the first well baby visit for live births, or spontaneous or induced abortion, will be documented even after the 
patient is withdrawn from or completes the study.  
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 54 of 78 If a pregnancy is reported, the Investigator should inform the sponso r within 24 hours of 
learning of the pregnancy and should follow the procedures outlined in Appendix 2 . 
8.6 Treatment of Overdose 
There are no data on overdose because this is the first study of BOS -589 in patients 
and, in a prior study in healthy human volunteers, no evidence of overdose was reported. There is no definition of what c onstitutes an overdose and no known antidote. 
Any patient who receives a higher dose than that intended (i.e., more than 200 mg per dose; more than 400 mg in a given day) should be monitored closely, managed with 
appropriate supportive care, and followed up appropriately. If possible, a blood sample 
for PK should be collected as soon as is feasible from any patient who takes a higher dose than that intended.  
If AEs or SAEs are reported and are considered related to a patient receiving a higher 
dose than intended, dosing should be interrupted if deemed necessary by the Investigator and the case discussed further with the Medical Monitor.  
8.7 Pharmacokinetics 
Plasma samples of approximately 4 mL will be collected for measurement of plasma 
concentrations of BOS -589 at the following times and as specified in the Schedule of 
Activities ( Section 1.3 ).  
x On Day 1 at predose and at 0.5, 1, 2, and 4 hours postdose.  
x On Day 15 at predose and at 0.5, 1, 2, and 4 hours postdose. If samples cannot 
be obtained on Day 15, then samples should be obtained on Day  22.  
x A predose sample will be obtained on all other Treatment Study Visits.  
Allowable sampling windows for PK blood draws will be 30  minutes prior to dosing for 
the predose sample, then Â± 5 minutes for the 0.5 and 1 hour postdose timepoints, and 
Â± 10 minutes for the 2 and 4 hours postdose timepoints.  
Instructions for the collection and handling of biological samples will be provided by the 
sponsor. The actual time of dosing and actual date and time (24 -hour clock time) of 
each sample will be recorded.  
Drug concentration information that may unblind the study will not be reported to 
investigative sites or blinded personnel until the study has been unblinded.  
Any changes in the timing or addition of timepoints for any planned study assessments 
must be documented and approved by the relevant study team member and then archived in the sponsor and site study files bu t will not constitute a protocol amendment. 
The IRB/IEC will be informed of any safety i ssues that require alteration of the safety 
monitoring scheme or amendment of the ICF.  
Boston Pharmaceuticals, Inc. BOS-589-201
Protocol Version 2.0
Confidential Page 55 of 78The following PK parameters will be estimated from the plasma concentrations of 
BOS -589 using either traditional noncompartmental methods or a population -PK model:
AUC 0-t Area under the plasma concentration ve rsus time curve from time zero to 
the last quantifiable sample;
AUC 0-4 Area under the plasma concentration ve rsus time curve from time zero to 
4 hours postdose;
Cmax Maximum observed plasma concentration;
Cmin Minimum observed plasma concentration.
In addition to parameters above, the AUC from time zero to 4 hours postdose (AUC 0-12) 
may be calculated using predose concentrations other than Day 1 predose to impute a 12-hour concentration. Details will be provided in the PK analysis plan.
8.8 Biomarkers/Pharmacodynamics
9 STATISTICAL CONSIDERATIONS
9.1 Timing of Analyses
Formal hypothesis testing will occur at the end of the study and post database lock. 
There are no planned Data, Safety, or Adjudi cation Committees fo r this study and no 
planned statistical interim analyses.
9.2 Sample Size Determination
This is a phase 2a study in which a hierarch ical hypothesis test will be employed for the 
primary efficacy endpoint. The primary endpoint is defined as a change in the 24 -hour 
WAP score at Day 29 compared to baselin e (averaged over the week prior to each 
respective timepoint). Mean change from bas eline will be measured as a continuous 
variable and compared between treatment groups in a hierarchical testing order using a 
t-test of equal variances and a two -tailed alpha of 0.05. CCI
CCI
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 56 of 78 The sample size was based on the first hypot hesis test in the hierarchical plan, with 
80% power, two -sided alpha of 0.05, and a standard deviation (SD) of 3 points on the 
NRS to detect a 1.6 minimum change between  treatment groups (N = 120 patients). To 
account for attrition and a potential higher PBO rate, a total of 132 patients will be randomized to one of 3 treatment groups in  a 1:1:1 ratio (44 patients per treatment 
group).  
9.3 Populations for Analyses 
1. The Intention-to-Treat (ITT) analysis dataset will comprise all randomized 
patients;  
2. The Per-protocol Analysis Dataset will  comprise patients in the ITT Analysis 
Dataset who received at least 1 dose of investigational product and did not have 
any major protocol deviations;  
3. The Safety Analysis Dataset will comprise all patients who received at least 
1 dose of investigational product; 
4. The Pharmacokinetic Analysis Dataset wi ll comprise all randomized patients who 
received the active study drug and have av ailable serum time concentration data. 
9.4 Statistical Analyses 
Detailed methodology for descriptive and infere ntial statistical analyses of the data 
collected in the study will be documented in the Statistical Analysis Plan (SAP). The 
SAP will be prepared by the Study Biostatistician and agreed upon by the Sponsor. The 
SAP will be finalized and approved prior to database lock. The SAP will take precedence over the protocol for details regarding the statistical analyses to be 
conducted for the study. In addition to the SAP, other graphical representations of the 
results may be produced after review of the data ( post hoc ). Any major modifications of 
the Primary Endpointâ€™s definition and/or its analysis will be reflected in a protocol 
amendment.  
In general, descriptive statistical methods will be used to summarize the data from this 
study. Unless stated otherwise, the term â€œdes criptive statisticsâ€ refers to number of 
patients (n), mean, median, SD, minimum, and maximum for continuous data, and frequencies and percentages for categorical data.  
All statistical analyses will be performe d using Statistical Analysis System (SAS
Â®) 
software Version 9.4 or higher.   
9.4.1 Efficacy Analyses 9.4.1.1 Primary Endpoint 
This is a proof -of-principle study in which a hierarchical hypothesis test will be employed 
for the primary efficacy endpoint, defined as a change in the 24 -hour WAP score at 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 57 of 78 Day 29 compared to baseline (averaged over the week prior to each respective 
timepoint). Mean change from baseline will  be measured as a continuous variable and 
compared between treatment groups in the following testing order using a t -test of equal 
variances and a two -tailed alpha of 0.05:  
Hypothesis 1:  
Active Treatment Group (Cohort 1 + Cohort 2) versus PBO (Cohort 3);  
If statistically significant at P < 0.05, then proceed to Hypothesis 2.  
Hypothesis 2:   
Cohort 1 (High Dose) versus Cohort 3 (PBO);  
If statistically significant at P < 0.05, then proceed to Hypothesis 3.  
Hypothesis 3:   
Cohort 2 (Low Dose) versus Cohort 3 (PBO);  
If statistically significant at P < 0.05 then, proceed to Hypothesis 4.  
Hypothesis 4:   
Cohort 1 (High Dose) versus Cohort 2 (Low Dose).  
9.4.1.2 Secondary Endpoint 
Mean daily BSFS score (stool type) and mean daily frequency of bowel movements will 
be tabulated and summarized by study day for each treatment for the ITT and Per-protocol Analysis Dataset populations. Ti me profiles and box plots will also be 
presented by study day and by treatment grou p. Pooled active data may be compared 
to PBO for the analyses, and also by cohort.  
9.4.1.3 Other Efficacy Endpoints Scores from IBS -GS and IBS -SS questionnaires will be summarized for the ITT and 
Per-protocol Analysis Dataset populations. Pooled active data may be compared to 
PBO for the analyses, and also by cohort.  
9.4.1.4 Missing Data Study implementation procedures and training will assist in limiting the amount of 
missing data in the trial. However, sensitivity analyses may be performed when indicated for the study endpoint and the amou nt of missing data to be handled. Details 
of the statistical methods for handling missing data will be described in the SAP.  
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 58 of 78 9.4.2 Safety Analyses  
9.4.2.1 Adverse Events 
Adverse events will be recorded from the time of consent until the Day 43/End -of-Study 
Follow -up visit. The number and percentage of patients with AEs will be displayed by 
system organ class and preferred term using Medical Dictionary for Regulatory Activities (MedDRA) Version 20.0 or higher, by study treatment. Summaries in terms of severity and relationship to investigational product wi ll also be provided. All SAEs will be 
summarized in a similar manner. Patient listings of all AEs causing discontinuation of investigational product and all SAEs will be produced.  
All AEs will be listed for individual patients showing both verbatim and preferred terms. 
Separate summaries of treatment -emergent SAEs and treatment -emergent AEs 
(TEAEs) related to investigational product will be generated.  
Any event reported on the CRF that occurs on at  the time of or after the initiation of 
investigational product is defined as treatment -emergent. Additionally, an AE that is 
reported to have started on Day 1 without an associated onset time will be assumed to have occurred after the initiation of investigational product. Hence, AEs occurring on Day 1 with no associated onset time wi ll be assumed to be treatment emergent.  
Serious AEs associated with a protocol -specified procedure and occurring after the time 
of consent but before administration of first dose of investigational product will be defined as non -treatment -emergent AEs (NTEAEs).  
All safety analyses will be performed in the Safety Analysis Dataset.  
9.4.2.2 Clinical Laboratory Evaluations Laboratory data will be listed for all patient s. Laboratory data will be reviewed by the 
Investigator as they become available. All abnormal laboratory results will be evaluated by the Investigator as either clinically significant or not clinically significant.  
Descriptive summaries of clinical laboratory results will be presented by date and time 
of collection. The number and percent age of patients experiencing treatment -emergent 
graded toxicities will be summarized by treatment arm and severity grade. Laboratory toxicity shifts from baseline to post -baseline assessments will be summarized by 
treatment arm. Changes from baseline in laboratory tests will be summarized for each 
treatment arm.  
9.4.2.3 Twelve-lead Electrocardiograms, Vital Signs, and Physical 
Examinations 
Twelve -lead ECG and vital signs data will be listed and summarized.  
Physical examination findings will be captured and listed as part of a patientâ€™s medical 
history or as AEs as applicable.  
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 59 of 78 9.4.3 Other Analyses 
9.4.3.1 Pharmacokinetic Analysis 
A full description of the methods for evaluating the PK of BOS -589 in this patient 
population will be provided in a PK data analysis plan. The PK data from this study may be combined with data from other studies to complete a population -PK analysis.  
A full list of PK parameters to be calculated is included in Section 8.7 . 
9.4.4 Baseline Descriptive Statistics Demographic and baseline characteristics will be summarized for all patients overall 
and by treatment arm. Summary statistics (e.g ., number of patients, mean, median, SD, 
and range) will be generated for continuous variables (e.g., age and weight) and the number and percentage of patients within each category will be presented for categorical variables (e.g.,  gender, ethnicity, race).  
A detailed description of patient disposit ion will be provided. It will include:  
x A summary of overall patient enrollme nt status (consented, screened, screen 
failures, replacements, randomized);  
x A summary of patients who discontinued the study;  
x An account of identified protocol deviations.  
All patients who are consented for the study wi ll be accounted for in the summation. The 
number of patients who do not qualify fo r certain analysis populations will be 
summarized.  
9.4.5 Subgroup Analyses No subgroup analyses are powered for the study. Subgroup analyses may be 
performed for descriptive purposes as described in the SAP.  
9.5 Planned Interim Analyses  
No formal efficacy interim analysis is planned for the purposes of statistically comparing 
the data prior to the completion of the study.  
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 60 of 78 10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS 
10.1 Regulatory, Ethical, and Study Oversight Considerations 
10.1.1 Regulatory and et hical considerations 
This study will be conducted in accordance with the protocol and with the following: 
x Consensus ethical principles derived from  international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines; 
x Applicable International Conference on/Council for Harmonisation (ICH) Good 
Clinical Practice (GCP) Guidelines; 
x Applicable laws and regulations. 
The protocol, protocol amendments, ICF, IB, and other relevant documents 
(e.g., advertisements) must be submitted, and reviewed and approved as necessary, to the relevant Competent Authorities, IRBs and IECs before the study is initiated.  
Any amendments to the protocol will require regulatory approval before implementation 
of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study patients.  
The Investigator will be responsible for the following: 
x Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures established by the IRB/IEC; 
x Notifying the IRB/IEC of SAEs or other si gnificant safety findings as required by 
IRB/IEC procedures; 
x Providing oversight of the conduct of th e study at the site and adherence to 
requirements of 21 Code of Federal Regulati ons (CFR), ICH guidelines, the IRB/IEC, 
European regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations.  
10.1.2 Informed Consent/Assent Process 
An initial sample ICF is provided for the Inve stigator to prepare the informed consent 
document to be used at his or her site. Updates to the sample ICF are to be communicated formally in writing from the Sponsor or Sponsorâ€™s designee to the Investigator. The written ICF is to be prepar ed in the language of the potential patient 
population. 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 61 of 78 The Investigator or his/her representative wi ll explain the nature of the study to the 
patient or his/her legally authorized repres entative and answer all questions regarding 
the study.  
Patients must be informed that their participa tion is voluntary. Patients or their legally 
authorized representative will be required to sign a statement of informed consent, and/or assent, that meets the requirement s of 21 CFR 50, local regulations, ICH 
guidelines, Health Insurance Portability an d Accountability Act requirements, where 
applicable, and the IRB/IEC or study center.  
The medical record must include a stat ement that written informed consent was 
obtained before the patient was enrolled in the study and the date the written consent was obtained. The authorized person obtaining the informed consent must also sign the 
ICF. 
Patients must be re-consented to the most current version of the ICF(s) during their 
participation in the study if one becomes available.  
A copy of the ICF(s) must be provided to  the patient or the patientâ€™s legally a uthorized 
representative.  
The Investigator is also responsible for aski ng the patient if the patient has a primary 
care physician and if the patient agrees to have his/her primary care physician informed 
of the patientâ€™s participation in the clinical stud y if it is a local requirement. If the patient 
agrees to such notification, the Investigator  is to inform the patientâ€™s primary care 
physician of the patientâ€™s participation in the c linical study. If the patient does not have a 
primary care physician and the Investigator will be acting in that capacity, the Investigator is to document such in the patientâ€™s medical record.  
If a patient is unable to read or if a legall y acceptable representative is unable to read, 
an impartial witness should be present during the entire informed consent discussion. After the written ICF and any other written information to be provided to patients, is read and explained to the patient or the patientâ€™s legally acceptable representative, and after the patient or the patientâ€™s leg ally acceptable representative has orally consented to the 
patientâ€™s participation in the trial and, if capable of doing so, has signed and personally 
dated the ICF, the witness should sign and pe rsonally date the consent form. By signing 
the consent form, the witness attests that th e information in the consent form and any 
other written information was accurately explained to, and apparently understood by, 
the patient or the patientâ€™s legally acceptable  representative, and that informed consent 
was freely given by the patient or the patientâ€™s le gally acceptable representative (Refer 
to ICH GCP guideline, Section 4.8.9). 
 10.1.3 Confidentiality and Privacy  
Patient confidentiality and privacy is st rictly held in trust by the participating 
Investigators, their staff, and the sponsor and its designees. This confidentiality is 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 62 of 78 extended to cover testing of biological samp les and genetic tests in addition to the 
clinical information relating to patients. T herefore, the study documentation, data, and 
all other information generated will be held in strict confidence. No information concerning the study or the study data will be released to any unauthorized third party without prior written approval of the sponsor.  
Study patient research data will not incl ude the patientâ€™s contact or identifying 
information. Rather, individual patients and their research data will be identified by a unique study identification number. Any patient records or datasets that are transferred 
to the sponsor will contain the identifier only; patient names or any information which would make the patient identifiable will not be transferred. Research data will be used in 
accordance with local data protection laws.  
The study monitor, other authorized representatives of the sponsor, representatives of 
the IRB/IEC or regulatory agencies may insp ect all documents and records required to 
be maintained by the Investigator, including bu t not limited to, medical records (office, 
clinic, or hospital) and pharmacy records for the patients in this study. The clinical study site will permit access to such records.  
10.1.4 Quality Assurance and Quality Control Quality control (QC) procedures will be im plemented beginning with the data entry 
system and data QC checks that will be ru n on the database will be generated. Any 
missing data or data anomalies will be communicated to the site(s) for clarification/resolution.  
Following written Standard Operating Procedures, the monitors will verify that the 
clinical trial is conducted, data are generated, and biological specimens are collected, documented (recorded), and reported in compliance with the protocol, ICH GCP, and applicable regulatory requirements (e.g., Good Laboratory Practices, Good Manufacturing Practices).  
The investigational site will provide direct  access to all trial related sites, source 
data/documents, and reports for the purpose of monitoring and auditing by the sponsor, and inspection by local and regulatory authorities.  
10.1.5 Data Handling and Record Keeping  
10.1.5.1 Data Collection and Management Responsibilities  
Data collection is the responsibility of the clinical trial staff at the site, under the 
supervision of the site Investigator. The Investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported.  
The Investigator must maintain adequate source documentation. All source documents 
should be completed in a neat, legible manner to  ensure accurate interpretation of data.   
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 63 of 78 Clinical data (including AEs, concomitant m edications, and expected adverse reactions 
data) will be entered into a 21 CFR Part 11 -compliant EDC system or transmitted 
electronically (e.g., laboratory data). The data system(s) includes password protection and internal quality checks, such as automat ic range checks, to identify data that 
appear inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from 
the source documents. Data recorded in t he CRF should be consistent with the data 
recorded on the source documents or the discrepancies must be explained.  
The sponsor or designee is responsible for the data management of this study, including 
quality checking of the data. The sponsor assumes accountability for actions delegated to other individuals (e.g., Contract Research Organizations).  
Study monitors will perform ongoing source data  verification to confirm that data entered 
into the CRF by authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safety and rights  of patients are being protected; and that 
the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, an d all applicable regulatory requirements.  
10.1.5.2 Study Records Retention  Records and documents, including signed ICFs, pertaining to the conduct of this study 
must be retained for a minimum of 2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or until at le ast 2 years have elapsed since the formal 
discontinuation of clinical development of th e investigational product. These documents 
should be retained for a longer period, however, if required by local regulations.  
No records will be destroyed without the writ ten consent of the sponsor. No records may 
be transferred to another location or party without written notification to the sponsor.   
It is the responsibility of the sponsor to inform the Investigator when these documents 
no longer need to be retained.  
10.1.6 Study and Site Discontinuation and Closure The sponsor or its designee reserves the ri ght to suspend or prematurely terminate a 
study site or study at any time for any reas on and at the sole discretion of the sponsor.  
An Investigator may initiate site closure at any time, provided there is reasonable cause 
and sufficient notice is given to the sponsor in advance of the intended termination.   
Written notification, documenting the reason for site or study suspension or termination, 
will be provided by the suspending or terminating party to study participants, Investigator, funding agency, the Investig ational New Drug sponsor, and regulatory 
authorities.   
If the study is prematurely terminated or suspended, the Investigator will promptly 
inform study participants, the IRB/IEC, and sponsor, and will provide the reason(s) for 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 64 of 78 the termination or suspension. Study participa nts will be contacted, as applicable, and 
be informed of changes to study visit schedule.  
Circumstances that may warrant termination or  suspension include, but are not limited 
to: 
x Determination of unexpected, significan t, or unacceptable risk to participants;  
x Demonstration of efficacy that would warrant stopping;  
x Insufficient compliance to the protocol, regulatory requirements, or GCP 
guidelines;  
x Data that are not sufficiently complete and/or evaluable;  
x Determination that the primary endpoint has been met;  
x Determination of futility;  
x Inadequate recruitment of patients.  
10.1.7 Dissemination of Clinical Study Data  A Clinical Study Report (CSR) will be prepared in accordance with the ICH guideline on 
structure and contents of CSRs and any a pplicable regulatory and legal requirements.  
10.1.8 Publication Policy 
The results of this study may be published or presented at scientific meetings. If this is 
foreseen, the Investigator agrees to submit  all manuscripts or abstracts to the sponsor 
before submission. This allows the sponsor to protect proprietary information and to 
provide comments.  
The sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the sponsor will generally support publication of multicenter studies only in  their entirety and not as individual site 
data. In this case, a coordinating Investigator will be designated by mutual agreement.  
Authorship will be determined by mutual agreement and in line with International 
Committee of Medical Journal Ed itors authorship requirements.  
Boston Pharmaceuticals, Inc. BOS-589-201
Protocol Version 2.0
Confidential Page 65 of 7811 REFERENCES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
Boston Pharmaceuticals, Inc. BOS-589-201
Protocol Version 2.0
Confidential Page 66 of 78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
Boston Pharmaceuticals, Inc. BOS-589-201
Protocol Version 2.0
Confidential Page 67 of 78U.S. Department of Health and Human Servic es, Food and Drug Administration, Center 
for Drug Evaluation and Research (May 2012 ). Guidance for Industry, Irritable Bowel 
Syndrome â€“ Clinical Evaluation of Drug s for Treatment. Retrieved from 
https://www.fda.gov/downloads/Drugs/Guidances/UCM205269.pdf.
 
 CCI
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 68 of 78 12 APPENDICES
Boston Pharmaceuticals, Inc. BOS-589-201
Protocol Version 2.0
Confidential Page 69 of 78Appendix 1. Clinical Laboratory Tests
The tests detailed in Table 2 will be performed by the central laboratory with the 
exception of erythrocyte sedimentation rate and urine pregnancy tests.  The central 
laboratory will provide kits and instructions to perform these assessments on site.
Local laboratory results are only required in the event that the central laboratory results 
are not available in time for either inve stigational product administration and/or 
response evaluation. If a local sample is re quired, it is important that the sample for 
central analysis is obtained at the same time . Additionally, if the local laboratory results 
are used to make either an investigational product decision or response evaluation, the 
results must be entered into the CRF.
Protocol-specific requirements for inclusion or exclusion of patients are detailed in 
Section 5 of the protocol.
Additional tests may be performed at any time during the study as determined 
necessary by the Investigator or required by local regulations.
Pregnancy testing: Refer to Section 5.1for Screening pregnancy criteria.
Table 2. Protocol-required Safety Laboratory Assessments
Laboratory 
Assessments Parameters
Hematology Platelet count RBC Indices:
Mean corpuscular 
volume
Mean corpuscular Hemoglobin
% ReticulocytesWhite blood cell count 
with differential:
Neutrophils
LymphocytesMonocytes
Eosinophils
BasophilsRed blood cell (RBC) count
Hemoglobin
Hematocrit
Clinical 
ChemistryBlood 
ureanitrogenPotassium Aspartate 
aminotransferase/ Serum 
glutamic o xaloacetic 
transaminaseTotal and direct 
bilirubin
Creatinine Sodium Alanine 
aminotransferase/ Serum 
glutamic pyruvic 
transaminaseTotal protein
Glucose 
(fasted)Calcium Alkaline phosphatase
Routine 
UrinalysisSpecific gravity
pH, glucose, protein, blood, ketones, bilirub in, urobilinogen, nitrite, leukocyte esterase 
by dipstick
Microscopic examination (if blood or protein is abnormal)CCI CCI CCI CCI
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 70 of 78 Table 2. Protocol-required Safety Laboratory Assessments  
Laboratory 
Assessments Parameters 
Other 
Screening Tests
 Hemoglobin A1c 
Follicle -stimulating hormone and estradiol (as needed in women of nonchildbearing 
potential only)  
Urine human chorionic gonadotropin (hCG) pregnancy test (as needed for women of 
childbearing potential)  
Serology (HIV antibody, hepatitis  B surface antigen, and hepatitis C virus antibody)  
serum tissue transglutaminase IgA antibody  (tTG-IgA) and IgA (if applicable)   
 
Investigators must document their review  of each laboratory safety report. 
Laboratory results that could unblind the study wi ll not be reported to investigative sites 
or other blinded personnel until the study has been unblinded. 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 71 of 78 Appendix 2. Contraceptive Guidance a nd Collection of Pregnancy Information 
Definitions:  
Woman of Childbearing Potential (WOCBP) A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile (see below).  
Women in the following categories are not considered WOCBP  
1. Premenarchal 2. Premenopausal female with 1 of the following: 
a. Documented hysterectomy 
b. Documented bilateral salpingectomy c. Documented bilateral oophorectomy 
Note: Documentation can come from the s ite personnelâ€™s  review of the patientâ€™s medical 
records, medical examination, or  medical history interview. 
3. Postmenopausal female 
a. A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. A high follic le-stimulating hormone (FSH) level in the 
postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.  
b. Females on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highly effective contraception methods if they wish to continue their HRT dur ing the study. Otherwise, they must 
discontinue HRT to allow confirmation of postmenopausal status before study enrollment. 
Contraception Guidance: 
Male patients. Male patients with female partners of childbeari ng potential are eligible to participate if 
they agree to ONE of the following during the treatment period and for at least  14 weeks  after the last dose of  investigational product:  
x Are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle 
(abstinent on a long term and persisten t basis) and agree to remain abstinent 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 72 of 78 x Agree to use a male condom plus partner use of a contraceptive method with a 
failure rate of < 1% per year, as described in Table 3 , when having penile-vaginal 
intercourse with a WOCBP who is not currently pregnant 
In addition, male patients must refrain from donating sperm for the duration of the study 
and for 14 weeks after the last dose of investigational product. 
Male patients with a pregnant or breastfeeding  partner must agree to remain abstinent 
from penile-vaginal intercourse or use a male condom during each episode of penile penetration for the duration of the study and for 14 weeks after the last dose of investigational product. 
Female patients. 
Female patients of childbearing potential are el igible to participate if they agree to use a 
highly effective method of contraception, as described in Table  3, consistently and 
correctly.
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 73 of 78 Table 3. Highly Effective Contraceptive Methods  
Highly Effective Contraceptive Methods That Are User Dependenta  
Failure rate of <1% per year when used consistently and correctly.   
Combined (estrogen and progestogen co ntaining) hormonal contraception associated with inhibition of 
ovulationb  
x Oral  
x Intravaginal  
x Transdermal  
Progestogen only hormonal contraception a ssociated with inhibition of ovulation 
x Oral  
x Injectable  
Highly Effective Methods That Are User Independenta  
Implantable progestogen only hormonal contracept ion associated with inhibition of ovulationb 
x Intrauterine device (IUD) 
x Intrauterine hormone-releasing system (IUS) 
x Bilateral tubal occlusion 
Vasectomized Partner  
A vasectomized partner is a highly effective contraception method , provided that the partner is the sole 
male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional 
highly effective method of contraception should be used.  
Sexual Abstinence  
Sexual abstinence is considered a highly effective meth od only if defined as refraining from heterosexual 
intercourse during the entire peri od of risk associated with the investigational product. The reliability of 
sexual abstinence needs to be evaluated in  relation to the duration of the study  and the preferred and 
usual lifestyle of the patient.  
NOTES:  
a Typical use failure rates may differ from those when used consistently and correctly. Use should be 
consistent with local regulations regarding the use of contraceptive methods for p atients participating 
in clinical studies.  
b Hormonal contraception may be susceptible to interaction with the investigational product , which may 
reduce the efficacy of the contraceptive method . In this case, 2 highly effective methods of 
contraception should be utilized during the treatment period and for at least 5 weeks after the last 
dose of investigational product. 
 
Pregnancy Testing: 
x Any WOCBP should only be included after a negative pregnancy test. 
x Additional urine pregnancy testing should be performed at the Day 29 visit, and the 
Day 43 End-of-Study Follow-up visit. 
x Pregnancy testing will be performed whenever a menstrual cycle is missed or when 
pregnancy is otherwise suspected  
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 74 of 78 Collection of Pregnancy Information:  
x All occurrences of pregnancies must be reported on a Pregnancy Notification and 
Outcome Form (within 24 hours of awarenes s of any such pregnancy that occurs for 
either the study patient or for the female par tner of a male patient); all pregnancies 
will be followed to outcome, which means until either the first well-baby visit for live 
births or until documented spontaneous or induced abortion. 
x While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy will be reported as an AE or SAE. 
A spontaneous abortion is always considered to be an SAE and will be reported as such.  
x Pregnancies that occur beyond 90 days after the last dose of study drug will only 
need to be reported if there is an associated SAE that the Investigator assessed as related to study drug. 
x Safety Team will follow-up with the Investigator every 3 months regarding pregnancy 
outcome. The Investigator must follow the pregnancy to conclusion in order to determine the outcome. If the case is beyond 30 days from the expected due date and no information has been received regarding the outcome, the Safety Team will contact the Investigator to request outcome. 
Male Patients With Partn ers Who Become Pregnant  
x The Investigator will attempt to collect pregnancy information on any male patientâ€™s 
female partner who becomes pregnant while the male patient is in this study. This applies only to male patients who receive BOS-589. 
x After obtaining the necessary signed informed consent from the pregnant female 
partner directly, the Investigator will reco rd pregnancy information on the appropriate 
form and submit it to the sponsor as outlined above.  
Female Patients Who Become Pregnant  
x The Investigator will collect pregnancy information on any female patient who 
becomes pregnant while participating in this study. Information will be recorded on the appropriate form as noted above.  
x Any female patient who becomes pregnant while participating in the study will be 
withdrawn from the study. 
  
Boston Pharmaceuticals, Inc. BOS-589-201
Protocol Version 2.0
Confidential Page 75 of 78Appendix 3. The Bristol Stool Form Scale
( )
 CCI
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 76 of 78 Appendix 4. Concomitant Medications 
If the study site/investigator has any questions regarding permitted or excluded 
medications, the medical monitor should be contacted for further discussion. 
Medications permitted during the course of the study: 
x Any medication or vaccine (including over -the-counter or prescription medicines, 
vitamins, and/or supplements) that in the opinion of the Investigator, should not interfere with study procedures, compromise safety, or the scientific integrity of the data; 
x Stable doses of medications for alle rgies, migraines (with the exception of 
opioids for acute treatment), anxiety (e.g., as-needed use of benzodiazepines), 
depression or other chronic conditions at  the discretion of the Investigator;  
x Stable doses of antidepressants. As-needed use of buspirone and 
benzodiazepines for anxiety; 
x Loperamide can be used during study as rescue medication based on 
protocol-specified guidelines (see Section 6.7.1 ) for allowable on-study rescue 
medications);  
x Acetaminophen, up to 2 g/day for up to 3 consecutive days; 
x The Investigator should monitor closely for potential side effects related to any of 
the following medicines which are consid ered moderate to highly sensitive 
substrates of CYP3A4. 
 
alprazolam  
aprepita nt  
atorvastatin   
avanafil   
budesonide   
buspirone   
colchicine   
darifenacin   dronedarone  
ebastine   
eletriptan   
felodipine   
lomitapide   
lovastatin   
midazolam   
naloxegol   nisoldipine  
pimozide   
rivaroxaban   
sildenafil   
simvastatin   
tadalafil   
triazolam   
vardenafil   
 
Medications excluded during the course of the study: 
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 77 of 78 x 5-hydroxytriptamine (5-HT) 3 or 5-HT 4 receptor antagonists (e.g., alosetron); 
x Strong inhibitors of P-glycoprotein: 
amiodarone â€‰  
carvedilol  
clarithromycin  dronedarone  
itraconazole  propafenone  quinidine  
ranolazine  
verapamil  
 
x Aspirin or aspirin-containing medications  (> 325 mg of aspirin per day) or 
nonsteroidal anti-inflammatory drugs, when taken specifically for the symptoms 
of IBS; 
x Narcotic- or opioid-containing agents; 
x Cannabis-containing products; 
x Docusate; 
x Enemas; 
x GI preparations (includ ing antacids containing aluminum or magnesium, 
antidiarrheal agents, antispasmodic agents,  bismuth, peppermint oil, IBgard, 
FDgard, or prokinetic agents); 
x Planned use of rifaximin or oral antibi otics, with the exception of topical 
antibiotics or a 1-day course with an antibiotic); a patient will be allowed to remain in the study should unplanned use of antibiotics other than rifaximin occur 
after the patient has been randomized; 
x Any investigational drug. 
  
Boston Pharmaceuticals, Inc. BOS-589-201 
Protocol Version 2.0 
 
Confidential  Page 78 of 78 Appendix 5. Protocol Amendment History 
The Protocol Amendment Summary of Changes Table for the current amendment is 
provided as a separate document. 
DOCUMENT HISTORY 
Document Date of Issue 
Amendment 1, v.2.0 09 May 2019 
Original, v.1.0 25 January 2019 
 
&/,1,&$/75,$/35272&2/ 
6WXG\7LWOH  $3KDVHD5DQGRPL]HG'RXEOHEOLQG
3ODFHERFRQWUROOHG0XOWLFHQWHU6WXG\WR(YDOXDWHWKH(IILFDF\6DIHW\DQG7ROHUDELOLW\RI%26LQWKH7UHDWPHQWRI3DWLHQWVZLWK'LDUUKHDSUHGRPLQDQW,UULWDEOH%RZHO6\QGURPH,%6'
6WXG\1XPEHU  %26
5HJXODWRU\
,GHQWLILFDWLRQ1XPEHUV ,1'
6WXG\3KDVH  D
,QYHVWLJDWLRQDO3URGXFW %26
,QGLFDWLRQ  'LDUUKHDSUHGRPLQDQW,UULWDEOH%RZHO6\QGURPH
6SRQVRU  %RVWRQ3KDUPDFHXWLFDOV,QF
&DPEULGJH3DUNZD\6XLWH&DPEULGJH0DVVDFKXVHWWV86$
9HUVLRQ 'DWH
)LQDOY -DQXDU\
&RQILGHQWLDOLW\6WDWHPHQW
7KHLQIRUPDWLRQLQWKLVGRFXPHQWLVFRQILGHQWLDODQGZLOOQRWE HGLVFORVHGWRRWKHUV
ZLWKRXWZULWWHQDXWKRUL]DWLRQIURPWKHVSRQVRU H[FHSWWRWKHH[WHQWQHFHVVDU\WR
REWDLQLQIRUPHGFRQVHQWIURPSHUVRQVUHFHLYLQJWKHVWXG\GUXJR UWKHLUOHJDO
JXDUGLDQVRUIRUGLVFXVVLRQVZLWK5HJXODWRU\$XWKRULWLHV,QVW LWXWLRQDO5HYLHZ%RDUGV
,QGHSHQGHQW(WKLFV&RPPLWWHHVRUSHUVRQVSDUWLFLSDWLQJLQWKH FRQGXFWRIWKHVWXG\
'RQRWFRS\RUGLVWULEXWHZLWKRXWZULWWHQSHUPLVVLRQIURPWKHV SRQVRU

%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI63216256,*1$785(3$*(
3URWRFRO7LWOH$3KDVHD5DQGRPL]HG'RXEOHEOLQG3ODFHERF RQWUROOHG0XOWLFHQWHU
6WXG\WR(YDOXDWHWKH(IILFDF\6DIHW\DQG7ROHUDELOLW\RI%26 LQWKH7UHDWPHQWRI
3DWLHQWVZLWK'LDUUKHDSUHGRPLQDQW,UULWDEOH%RZHO6\QGURPH,% 6'
3URWRFRO1XPEHU%269HUVLRQ1XPEHUDQG'DWHY-DQXDU\
,WKHXQGHUVLJQHGKDYHDSSURYHGWKHILQDOYHUVLRQR IWKLV&OLQLFDO7ULDO3URWRFRO

 'DWH

 'DWH

PPD
PPD
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI,19(67,*$725$*5((0(17
3URWRFRO7LWOH$3KDVHD5DQGRPL]HG'RXEOHEOLQG3ODFHERF RQWUROOHG0XOWLFHQWHU
6WXG\WR(YDOXDWHWKH(IILFDF\6DIHW\DQG7ROHUDELOLW\RI%26 LQWKH7UHDWPHQWRI
3DWLHQWVZLWK'LDUUKHDSUHGRPLQDQW,UULWDEOH%RZHO6\QGURPH,% 6'
3URWRFRO1XPEHU%269HUVLRQ1XPEHUDQG'DWHY-DQXDU\,WKHXQGHUVLJQHGKDYHUHDGWKHSURWRFRODQGDJUHHWRFRQGXFW WKHWULDOLQFRPSOLDQFH
ZLWKWKH,QWHUQDWLRQDO&RQIHUHQFHRQ&RXQFLOIRU+DUPRQL]DWLRQ ,&+JXLGHOLQHVDQG
DQ\RWKHUDSSOLFDEOHUHJXODWRU\UHTXLUHPHQWVDVZHOODV*RRG& OLQLFDO3UDFWLFH*&3
VWDQGDUGV&303,&+
,ZLOOSURYLGHFRSLHVRIWKHSU RWRFRODQGDOOSHUWLQHQWLQIRUPD WLRQWRDOOLQGLYLGXDOVZKR
DVVLVWLQWKHFRQGXFWRIWKLV VWXG\,ZLOOGLVFXVVWKLVPDWHUL DOZLWKWKHPWRHQVXUHWKH\
DUHIXOO\LQIRUPHGUHJDUGLQJWKHLQYHVWLJDWLRQDOSURGXFWDQGWK HFRQGXFWRIWKHVWXG\
,ZLOOXVHRQO\WKH,QIRUPHG&RQV HQW)RUPDSSURYHGE\WKHVSRQV RURULWVUHSUHVHQWDWLYH
DQGZLOOIXOILOODOOUHVSRQVLELOLWLH VIRUVXEPLWWLQJSHUWLQHQW LQIRUPDWLRQWRWKH,QVWLWXWLRQDO
5HYLHZ%RDUG,QGHSHQGHQW(WKLFV&RPPLWWHH,5%,(&UHVSRQVLEOH IRUWKLVVWXG\
,DJUHHWKDWWKHVSRQVRURULWVUHSUHVHQWDWLYHVZLOOKDYHDFFHV VWRDQ\VRXUFH
GRFXPHQWVIURPZKLFKFDVHUHSRUWIRUPLQIRUPDWLRQPD\KDYHEHHQ JHQHUDWHG

 
,QYHVWLJDWRU
V6LJQDWXUH  'DWH
1DPHRI,QYHVWLJDWRU W\SHGRUSULQWHG 
,QVWLWXWLRQ1DPH 

%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI7$%/(2)&217(176
7$%/(2)&217(176  
/,672)7$%/(6  
/,672)),*85(6  
/,672)$33(1',&(6   
$%%5(9,$7,216  
35272&2/6800$5<  
6\QRSVLV  
6WXG\6FKHPD  
6FKHGXOHRI$FWLYLWLHV  
,1752'8&7 ,21  
6WXG\5DWLRQDOH  
%DFNJURXQG  
'LVHDVH8QGHU6WXG\  
7KHÂ³5(7Â´Â³5(DUUDQJHG'XULQJ7UDQVIHFWLRQÂ´*HQHDQGWKH(QWHU LF
1HUYRXV6\VWHP  
,QYHVWLJDWLRQDO3URGXFW  
1RQFOLQLFDO6XPPDU\  
,Q9LWUR6WXGLHV  
,Q9LYR6WXGLHV  
3KDUPDFRNLQHWLFVDQG3URGXFW0HWDEROLVPLQ$QLPDOV  
7R[LFRORJ\DQG1RQFOLQLFDO$VVHVVPHQWRI6DIHW\  
&OLQLFDO([SHULHQFH  
5LVN%HQHILW$VVHVVPHQW  
5LVN$VVHVVPHQW  
%HQHILW$VVHVVPHQW  
2YHUDOO5LVN%HQHILW&RQFOXVLRQ  
2%-(&7,9(6$1'(1'32,176  
678'<'(6,*1  
2YHUDOO'HVLJQ  
6WXG\'XUDWLRQIRU3DWLHQWV  
1XPEHURI3DWLHQWV  
5HSODFHPHQWRI3DWLHQWV  
1XPEHURI6LWHV  
5DWLRQDOHIRU6WXG\'HVLJQ  
-XVWLILFDWLRQIRU'RVH  
(QGRI6WXG\'HILQLWLRQ  
678'<3238/$7,21   
,QFOXVLRQ&ULWHULD  
([FOXVLRQ&ULWHULD   
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI/LIHVW\OH&RQVLGHUDWLRQV  
6FUHHQ)DLOXUHV  
,19(67,*$7,21$/352'8&7  
,QYHVWLJDWLRQDO3URGXFWV  
,QYHVWLJDWLRQDO3URGXFW'HVFULSWLRQ  
3UHSDUDWLRQ+DQGOLQJ6WRUDJH$FFRXQWDELOLW\  
$FTXLVLWLRQDQGDFFRXQWDELOLW\  
3URGXFW6WRUDJHDQG6WDELOLW\  
0HDVXUHVWR0LQLPL]H%LDV  
'RVLQJDQG$GPLQLVWUDWLRQ  
'RVHPRGLILFDWLRQ  
,QYHVWLJDWLRQDO3URGXFW&RPSOLDQFH  
&RQFRPLWDQW7KHUDS\  
5HVFXH0HGLFLQH  
,QWHUYHQWLRQ$IWHUWKH(QGRIWKH6WXG\  
',6&217,18$7,21 :,7+'5$:$/  
'LVFRQWLQXDWLRQRI,QYHVWLJDWLRQDO3URGXFW  
'LVFRQWLQXDWLRQ:LWKGUDZ DOIURPWKH6WXG\  
/RVWWR)ROORZXS  
678'<$66(660(176$ 1'352&( '85(6  
6WXG\3HULRGV  
6FUHHQLQJ$VVHVVPHQWV  
(IILFDF\$VVHVVPHQWV  
:RUVW$EGRPLQDO3DLQ  
%ULVWRO6WRRO)RUP6FDOH  
,%6'*OREDO6\PSWRP6FRUH  
,%66HYHULW\6FRUH6\VWHP  
6DIHW\DQG2WKHU$VVHVVPHQWV  
$GYHUVH(YHQWVDQG6HULRXV$GYHUVH(YHQWV  
3K\VLFDO([DPLQDWLRQV  
9LWDO6LJQV  
(OHFWURFDUGLRJUDPV  
&OLQLFDO6DIHW\/DERUDWRU\$VVHVVPHQWV  
$GYHUVH(YHQWVDQG6HULRXV$GYHUVH(YHQWV  
'HILQLWLRQRI$GYHUVH(YHQWV  
(YHQWVRI6SHFLDO,QWHUHVW  
'HILQLWLRQRI6HULRXV$GYHUVH(YHQWV  
&ODVVLILFDWLRQRIDQ$GYHUVH(YHQW  
$VVHVVPHQWRI6HYHULW\  
$VVHVVPHQWRI&DXVDOLW\   
([SHFWHGQHVV  
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI7LPH3HULRGDQG)UHTXHQF\IRU(YHQW$VVHVVPHQWDQG)ROORZXS  
$GYHUVH(YHQW5HSRUWLQJ  
5HSRUWLQJRI3UHJQDQF\  
7UHDWPHQWRI2YHUGRVH  
3KDUPDFRNLQHWLFV  
%LRPDUNHUV3KDUPDFRG\QDPLFV  
67$7,67,&$/&216,'(5$7,216  
7LPLQJRI$QDO\VHV  
6DPSOH6L]H'HWHUPLQDWLRQ  
3RSXODWLRQVIRU$QDO\VHV  
6WDWLVWLFDO$QDO\VHV   
(IILFDF\$QDO\VHV  
3ULPDU\(QGSRLQW  
6HFRQGDU\(QGSRLQW  
2WKHU(IILFDF\(QGSRLQWV  
0LVVLQJ'DWD  
6DIHW\$QDO\VHV  
$GYHUVH(YHQWV  
&OLQLFDO/DERUDWRU\ (YDOXDWLRQV  
7ZHOYHOHDG(OHFWURFDUGLRJUDPV9LWDO6LJQVDQG3K\VLFDO
([DPLQDWLRQV  
2WKHU$QDO\VHV   
3KDUPDFRNLQHWLF$QDO\VLV  
%DVHOLQH'HVFULSWLYH6WDWLVWLFV  
6XEJURXS$QDO\VHV  
3ODQQHG,QWHULP$QDO\VHV  
6833257,1*'2&80(17$7 ,21$1'23(5$7,21$/
&216,'(5$7,216  
5HJXODWRU\(WKLFDODQG6WXG\ 2YHUVLJKW&RQVLGHUDWLRQV  
5HJXODWRU\DQGHWKLFDOFRQVLGHUDWLRQV  
,QIRUPHG&RQVHQW$VVHQW3URFHVV  
&RQILGHQWLDOLW\DQG3ULYDF\  
4XDOLW\$VVXUDQFHDQG4XDOLW\&RQWURO  
'DWD+DQGOLQJDQG5HFRUG.HHSLQJ  
'DWD&ROOHFWLRQDQG0DQDJHPHQW5HVSRQVLELOLWLHV  
6WXG\5HFRUGV5HWHQWLRQ  
6WXG\DQG6LWH'LVFRQWLQXDWLRQDQG&ORVXUH  
'LVVHPLQDWLRQRI&OLQLFDO6WXG\'DWD  
3XEOLFDWLRQ3ROLF\  
5()(5(1&(6  
$33(1',&(6  
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI
/,672)7$%/(6
7DEOH  6FKHGXOHRI$FWLYLWLHV   
7DEOH  3URWRFROUHTXLUHG6DIHW\/DERUDWRU\$VVHVVPHQWV   
7DEOH  +LJKO\(IIHFWLYH&RQWUDFHSWLYH0HWKRGV   

/,672)),*85(6
)LJXUH  6WXG\6FKHPDWLF   

/,672)$33(1',&(6
$SSHQGL[  &OLQLFDO/DERUDWRU\7HVWV   
$SSHQGL[  &RQWUDFHSWLYH*XLGDQFHDQG&ROOHFWLRQRI3UHJQDQF\,QIRUPDWLRQ   
$SSHQGL[  7KH%ULVWRO6WRRO)RUP6FDOH   
$SSHQGL[  &RQFRPLWDQW0HGLFDWLRQV    

%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI$%%5(9,$7,216 
$( DGYHUVHHYHQW
$.7 SURWHLQNLQDVH% 
$/7 DODQLQHDPLQRWUDQVIHUDVH 
$67 DVSDUWDWHDPLQRWUDQVIHUDVH 
$8& DUHDXQGHUWKHFRQFHQWUDWLRQYHUVXVWLPHFXUYH 
$8& DUHDXQGHUWKHFRQFHQWUDWLRQYHUVXVWLPHFXUYHIURPWLPH]HUR WR
KRXUVSRVWGRVH 
$8& DUHDXQGHUWKHFRQFHQWUDWLRQYHUVXVWLPHFXUYHIURPWLPH]HUR WR
KRXUVSRVWGRVH
$8&W DUHDXQGHUWKHFRQFHQWUDWLRQYHUVXVWLPHFXUYHIURPWLPH]HUR WR
WKHODVWPHDVXUDEOHFRQFHQWUDWLRQ 
ELG WZLFHGDLO\
%6)6 %ULVWRO6WRRO)RUP6FDOH 
%0, ERG\PDVVLQGH[ 
&)5 &RGHRI)HGHUDO5HJXODWLRQV 
&PD[ PD[LPXPSODVPDFRQFHQWUDWLRQ 
&PLQ PLQLPXPSODVPDFRQFHQWUDWLRQ 
&16 FHQWUDOQHUYRXVV\VWHP 
&216257 &RQVROLGDWHG6WDQGDUGVRI5HSRUWLQJ7ULDOV&5) FDVHUHSRUWIRUP 
&65 FOLQLFDOVWXG\UHSRUW 
&<3 F\WRFKURPH3 
(&* HOHFWURFDUGLRJUDP 
('& HOHFWURQLFGDWDFDSWXUH 
(16 HQWHULFQHUYRXVV\VWHP 
(5. H[WUDFHOOXODUVLJQDOUHJXODWHGNLQDVH 
)'$ )RRGDQG'UXJ$GPLQLVWUDWLRQ 
)'5 ILUVWGHJUHHUHODWLYH*&3 *RRG&OLQLFDO3UDFWLFH 
*'1) JOLDOFHOOOLQHGHULYHGQHXURWURSKLFIDFWRU 
*)5Ä® JOLDOFHOOOLQHGHULYHGQHXURWURSKLFIDFWRUIDPLO\UHFHSW RUDOSKD
*, JDVWURLQWHVWLQDO 
*/3 JOXFDJRQOLNHSHSWLGH 
+%9 KHSDWLWLV%YLUXV 
+&9 KHSDWLWLV&YLUXV 
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI+'3( KLJKGHQVLW\SRO\HWK\OHQH
K(5* KXPDQHWKHUjJRJRUHODWHGJHQH 
+,9 KXPDQLPPXQRGHILFLHQF\YLUXV 
+57 KRUPRQHUHSODFHPHQWWKHUDS\,% ,QYHVWLJDWRUÂ¶V%URFKXUH 
,%6 LUULWDEOHERZHOV\QGURPH 
,%6& LUULWDEOHERZHOV\QGURPHFRQVWLSDWLRQ 
,%6*6 ,UULWDEOH%RZHO6\QGURPH*OREDO6FDOH 
,%6' LUULWDEOHERZHOV\QGURPHGLDUUKHD 
,%60 LUULWDEOHERZHOV\QGURPHPL[HG 
,%666 ,UULWDEOH%RZHO6\QGURPH6HYHULW\6FRUH 
,%68 LUULWDEOHERZHOV\QGURPHXQFODVVLILHG
,&
 KDOIPD[LPDOLQKLELWRU\FRQFHQWUDWLRQ 
,&) ,QIRUPHG&RQVHQW)RUP 
,&+ ,QWHUQDWLRQDO&RQIHUHQFHRQ&RXQFLOIRU+DUPRQLVDWLRQ 
,(& ,QGHSHQGHQW(WKLFV&RPPLWWHH,/& JURXSLQQDWHO\PSKRLGFHOOV 
,5% ,QVWLWXWLRQDO5HYLHZ%RDUG 
,77 LQWHQWLRQWRWUHDW 
,9 LQWUDYHQRXV 
,:56 LQWHUDFWLYHZHEUHVSRQVHV\VWHP 
-$. -DQXVNLQDVH 
0HG'5$ 0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV 
12$(/ QRREVHUYHGDGYHUVHHIIHFWOHYHO 
156 QXPHULFUDWLQJVFDOH
17($( QRQWUHDWPHQWHPHUJHQWDGYHUVHHYHQW 
3%2 SODFHER 
3' SKDUPDFRG\QDPLFV
3( SK\VLFDOH[DPLQDWLRQ 
3JS 3JO\FRSURWHLQ 
3,. SKRVSKRLQRVLWLGHNLQDVH 
3. SKDUPDFRNLQHWLFV 
352 SDWLHQWUHSRUWHGRXWFRPH 
3<< SDQFUHDWLFSHSWLGH<< 
4& TXDOLW\FRQWURO 
47F% 47LQWHUYDOFRUUHFWHGE\%D]HWWÂ¶VIRUPXOD
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI47F) 47LQWHUYDOFRUUHFWHGE\)ULGHULFLDÂ¶VIRUPXOD 
5$6 UDWVDUFRPD 
5%& UHGEORRGFHOO 
5(7 5(DUUDQJHGGXULQJ7UDQVIHFWLRQ 
6$( VHULRXVDGYHUVHHYHQW 
6$3 6WDWLVWLFDO$QDO\VLV3ODQ 
6& VXEFXWDQHRXV 
6' VWDQGDUGGHYLDWLRQ 
6.1$6 DKXPDQQHXUREODVWRPDFHOOOLQH 
67$7 VLJQDOWUDQVGXFHUDQGDFWLYDWRURIWUDQVFULSWLRQSURWHLQV 
686$5 VXVSHFWHGXQH[SHFWHGVHULRXVDGYHUVHUHDFWLRQ 
7($( WUHDWPHQWHPHUJHQWDGYHUVHHYHQW 
7PD[ WLPHWRPD[LPXPFRQFHQWUDWLRQ 
77 DKXPDQWK\URLGPHGXOODU\FDUFLQRPDFHOOOLQH 
8/1 XSSHUOLPLWRIQRUPDO 
:$3 ZRUVWDEGRPLQDOSDLQ 
:2&%3 ZRPDQRIFKLOGEHDULQJSRWHQWLDO 

%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI 35272&2/6800$5<
 6\QRSVLV
6SRQVRU %RVWRQ3KDUPDFHXWLFDOV,QF
7LWOH $3KDVHD5DQGRPL]HG'RXEOHEOLQG3ODFHERFRQWUROOHG
0XOWLFHQWHU6WXG\WR(YDOXDWHWKH(IILFDF\6DIHW\DQG7ROHUDELOLW\RI%26LQWKH7UHDWPHQWRI3DWLHQWVZLWK'LDUUKHDSUHGRPLQDQW,UULWDEOH%RZHO6\QGURPH,%6'
3URWRFRO1XPEHU %26
3KDVH D
2EMHFWLYHVDQG
(QGSRLQWV2%-(&7,9(6 (1'32,176
3ULPDU\
x 7RHYDOXDWHLQSDWLHQWV
ZLWK,%6'WKHDEGRPLQDOSDLQUHVSRQVHWR%26DIWHUZHHNVRIWUHDWPHQWUHODWLYHWR
SODFHER3%2x KRXUZRUVWDEGRPLQDO
SDLQVFRUHV:$3DW'D\FRPSDUHGWREDVHOLQHDYHUDJHGRYHUWKHZHHNSULRUWRHDFK
UHVSHFWLYHWLPHSRLQW
x 7RHYDOXDWHWKHRYHUDOO
VDIHW\DQGWROHUDELOLW\RI
%26LQWKHWUHDWPHQWRI,%6'GXULQJZHHNVRIWUHDWPHQWUHODWLYHWR3%2x ,QFLGHQFHRIDGYHUVH
HYHQWV$(VVHULRXV
DGYHUVHHYHQWV6$(VGLVFRQWLQXDWLRQVEHFDXVHRI$(VDQGDQ\WUHDWPHQWUHODWHGVHYHUH$(V
6HFRQGDU\
x 7RHYDOXDWHWKHWUHDWPHQW
HIIHFWRI%26RQ
GHIHFDWLRQDIWHUZHHNVUHODWLYHWR3%2x &KDQJHLQVWRRO
FRQVLVWHQF\PHDVXUHGE\
WKHGDLO\%ULVWRO6WRRO)RUP6FRUH%6)6DW'D\FRPSDUHGWREDVHOLQHDYHUDJHGRYHUWKHZHHNSULRUWRHDFKUHVSHFWLYHWLPHSRLQW
x&KDQJHLQVWRRO
IUHTXHQF\PHDVXUHGE\WKHWRWDOQXPEHURI

%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI VSRQWDQHRXVERZHO
PRYHPHQWVLQKRXUVDW'D\FRPSDUHGWREDVHOLQHDYHUDJHGRYHUWKHZHHNSULRUWRHDFKUHVSHFWLYHWLPHSRLQW
x 7RHYDOXDWHWKHWUHDWPHQW
HIIHFWRI%26RQ,%6UHODWHGVLJQVDQGV\PSWRPVx &KDQJHLQWKH,%6
6HYHULW\6FRUH,%666DW'D\FRPSDUHGWREDVHOLQH
x &KDQJHLQWKH,%6*OREDO
6FDOH,%6*6DW'D\FRPSDUHGWREDVHOLQHDYHUDJHGRYHUWKHZHHNSULRUWRHDFKUHVSHFWLYHWLPHSRLQW
x 7RHYDOXDWHWKH
VWHDG\VWDWH
SKDUPDFRNLQHWLFV3.RI%26 x 0D[LPXPREVHUYHG
SODVPDFRQFHQWUDWLRQ
&
PD[WLPHWR& PD[7PD[
PLQLPXPSODVPDFRQFHQWUDWLRQ&
PLQDUHD
XQGHUWKHFRQFHQWUDWLRQYHUVXVWLPHFXUYH$8&IURPWLPH]HURWRKRXUVSRVWGRVH$8&
$8&
IURPWLPH]HURWRWKHODVWTXDQWLILDEOHFRQFHQWUDWLRQ$8&
W
6WXG\'HVLJQ  $SKDVHDUDQGRPL]HGGRXEOHEOLQG3%2FRQWUROOHG
PXOWLFHQWHUWULDOWRSURYLGHSURRIRISULQFLSOHHIILFDF\RI%26LQ,%6'SDWLHQWVDQGWRLQIRUPGRVHVHOHFWLRQIRUVXEVHTXHQWGHYHORSPHQW
7KHVWXG\ZLOOFRPSULVHSKDVHV
$3UHWUHDWPHQW3KDVH RIXSWRZHHNVLQZKLFKDOO
SDWLHQWVZLOOEHDVVHVVHGWRGHWHUPLQHHOLJLELOLW\7KLVSKDVHZLOOFRQVLVWRILQLWLDOVFUHHQLQJDVVHVVPHQWVDIWHUZKLFKHOLJLEOHSDWLHQWVZLOOHQWHUD5XQLQ 3HULRGRIXSWRZHHNV
'XULQJWKH5XQLQSHULRGWKHSDWLHQWVZLOOFRPSOHWHDQ
HOHFWURQLFGLDU\WRFROOHFWGDLO\LQIRUPDWLRQUHODWHGWRWKHLU,%6'V\PSWRPVERZHOIXQFWLRQ DQGUHVFXHPHGLFDWLRQXVH
WRFRQILUPGLVHDVHDFWLYLW\DQGGLDU\FRPSOLDQFH
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI8SRQFRPSOHWLRQRIWKH5XQLQ3HULRGSDWLHQWVZLOOUHWXUQWR
WKHVWXG\VLWHWRFRQILUPHOLJLE LOLW\IRUUDQGRPL]DWLRQLQWRWK H
GRXEOHEOLQGHG7UHDWPHQW3KDVH
$7UHDWPHQW3KDVH LQZKLFKHOLJLEOHSDWLHQWVZLOOEH
UDQGRPL]HGWRUHFHLYH%26RU3%2WZLFHGDLO\ELGIRUDWRWDORIZHHNV%26ZLOOEHDGPLQLVWHUHGDWRIGRVHOHYHOV3DWLHQWVZLOOEHUDQGRPL]HGWRWKHIROORZLQJFRKRUWV
x &RKRUW+LJK'RVHPJ%26ELGRUDOO\
x &RKRUW/RZ'RVHPJ%26ELGRUDOO\
x &RKRUW3%2PDWFKLQJ3%2RUDOWDEOHWVELG
'XULQJWKHWUHDWPHQWSKDVHS DWLHQWVZLOOFRQWLQXHWR
FRPSOHWHWKHHOHFWURQLFGLDU\WRFROOHFWGDLO\LQIRUPDWLRQUHODWHGWRWKHLU,%6'V\PSWRPVERZHOIXQFWLRQDQGUHVFXHPHGLFLQH
$3RVWWUHDWPHQW3KDVH LQZKLFKDOOSDWLHQWVZKRFRPSOHWH
ZHHNVRIWUHDWPHQWZLOOUHWXUQWRWKHFOLQLFDOIRUDZHHNIROORZXSYLVLW
3DWLHQWVZKRGLVFRQWLQXHWUHDWPHQWHDUO\ZLOOEHDVNHGWR
UHWXUQWRWKHFOLQLFIRUVDIHW\DVVHVVPHQWV
6WXG\3RSXODWLRQ  0DOHDQGIHPDOHSDWLHQWVWR\HDUVRIDJHLQFOXVLYH
ZLWKDGLDJQRVLVRI,%6'
1XPEHURI3DWLHQWV
3ODQQHG$SSUR[LPDWHO\SDWLHQWVZLOOEHVFUHHQHGZLWKWKHLQWHQWRI
UDQGRPL]LQJSDWLHQWVIRUWKHVWXG\
'XUDWLRQRI3DWLHQW
3DUWLFLSDWLRQDQG6WXG\7KHGXUDWLRQRISDWLHQWSDUWLFLSDWLRQLVDQWLFLSDWHGWREHXSW R
ZHHNV
7KHGXUDWLRQRIWKHVWXG\LVDQWLFLSDWHGWREHDSSUR[LPDWHO\
PRQWKV
6WXG\6LWHV  8SWRVLWHVLQWKH8QLWHG6WDWHV
,QYHVWLJDWLRQDO
3URGXFW%26RUDOGRVHVELG
5HIHUHQFH
7UHDWPHQW 0DWFKLQJ3%2RUDOGRVHVELG
&RQFRPLWDQW
3URGXFW1RWDSSOLFDEOH
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI6WDWLVWLFDO0HWKRGV (IILFDF\
7KLVLVDSKDVHDSURRIRISULQFLSOHVWXG\'HVFULSWLYHDQG
LQIHUHQWLDOVWDWLVWLFDOPHWKRGVZLOOEHHPSOR\HG$VWDQGDORQH6WDWLVWLFDO$QDO\VLV3ODQZLOO EHGHYHORSHGDQGDSSURYHGSULRU
WRGDWDEDVHORFN
$KLHUDUFKLFDOK\SRWKHVLVWHVWZLOOEHHPSOR\HGIRUWKH
SULPDU\HIILFDF\HQGSRLQWGHILQHGDVDFKDQJHIURPEDVHOLQHWR'D\LQWKHSDWLHQWUHSRUWHGRXWFRPHIRU:$3PHDVXUHGGDLO\RQDQSRLQWQXPHULFUDWLQJVFDOH0HDQFKDQJHIURPEDVHOLQHZLOOEHPHDVXUHGDVDFRQWLQXRXVYDULDEOHDQGFRPSDUHGEHWZHHQWUHDWPHQWJURXSVLQWKHIROORZLQJWHVWLQJRUGHUXVLQJDWWHVWRIHTXDOYDULDQFHVZLWKDWZRWDLOHGDOSKD 
RI
+\SRWKHVLV
$FWLYH7UHDWPHQW*URXS&RKRUW&RKRUWYHUVXV
3%2&RKRUW
,IVWDWLVWLFDOO\VLJQLILFDQWDW 3WKHQSURFHHGWR
+\SRWKHVLV
+\SRWKHVLV
&RKRUW+LJK'RVHYHUVXV&RKRUW3%2
,IVWDWLVWLFDOO\VLJQLILFDQWDW 3WKHQSURFHHGWR
+\SRWKHVLV
+\SRWKHVLV
&RKRUW/RZ'RVHYHUVXV&RKRUW3%2
,IVWDWLVWLFDOO\VLJQLILFDQWDW 3WKHQSURFHHGWR
+\SRWKHVLV
+\SRWKHVLV
&RKRUW+LJK'RVHYHUVXV&RKRUW/RZ'RVH
6DIHW\$GYHUVHHYHQWVZLOOEHUHFRUGHGIURPWKHWLPHRIFRQVHQWXQWLO
WKH'D\(QGRI6WXG\)ROORZXSYLVLW7KHQXPEHUDQGSHUFHQWDJHRISDWLHQWVZLWK$(VZLOOEHGLVSOD\HGE\V\VWHPRUJDQFODVVDQGSUHIHUUHGWHUPXVLQJ0HGLFDO'LFWLRQDU\IRU
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI5HJXODWRU\$FWLYLWLHV9HUVLRQRUKLJKHUE\VWXG\
WUHDWPHQW6XPPDULHVLQWHUPVRIVHYHULW\DQGUHODWLRQVKLSWRLQYHVWLJDWLRQDOSURGXFWZLOODOVREHSURYLGHG$OOVHULRXV$(VZLOOEHVXPPDUL]HGLQDVLPLODUPDQQHU3DWLHQWOLVWLQJVRIDOO 
$(VFDXVLQJGLVFRQWLQXDWLRQRILQYHVWLJDWLRQDOSURGXFWDQGDOO6$(VZLOOEHSURGXFHG
$OO$(VZLOOEHOLVWHGIRULQGLYLGXDOSDWLHQWVVKRZLQJERWK
YHUEDWLPDQGSUHIHUUHGWHUPV6HSDUDWHVXPPDULHVRIWUHDWPHQWHPHUJHQW6$(VDQGWUHDWPHQWHPHUJHQW$(VUHODWHGWRLQYHVWLJDWLRQDOSURGXFWZLOOEHJHQHUDWHG
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO   3DJHRI
 6WXG\6FKHPD
)LJXUH 6WXG\6FKHPDWLF


%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO   3DJHRI 6FKHGXOHRI$FWLYLWLHV
7DEOH 6FKHGXOHRI$FWLYLWLHV

6FUHHQLQJ
'D\VWR
6WXG\9LVLW
5XQLQ3HULRGD
'D\VWR
6WXG\9LVLW
%DVHOLQH
'D\
6WXG\9LVLW
'D\Â“GD\
6WXG\9LVLW

'D\ Â“GD\
6WXG\9LVLW

'D\ Â“GD\
6WXG\9LVLW

'D\ Â“GD\
(QGRI7UHDWPHQW
(DUO\7HUPLQDWLRQE
6WXG\9LVLW
'D\ Â“GD\V
(QGRI6WXG\
6WXG\9LVLW 

3URFHGXUHV 3UHWUHDWPHQW 7UHDWPHQW )ROORZXS
, Q I R U P H G  F R Q V H Q W  ;  
' H P R J U D S K L F V  ;  
0 H G L F D O  D Q G  V X U J L F D O  K L V W R U \  ;  
5 R P H  , 9  D V V H V V P H Q W  ;  
&RQFRPLWDQWPHGLFDWLRQUHYLHZ ; ; ; ; ; ; ; ;
$GYHUVHHYHQWUHYLHZDQGHYDOXDWLR Q  ;  F RQWLQXRXV  ;
3K\VLFDOH[DPLQDWLRQF  ; ;   ; 
+HLJKWZHLJKWDQGERG\PDVVLQGH[ ;G ; ; ;  ; 
9 L W D O  V L J Q V  ;   ; ; ; ; ; ; 
OHDGHOHFWURFDUGLRJUDP ;      ; 
&OLQLFDOVDIHW\ODERUDWRU\WHVWVH ; ; ; ;  ; 
+ , 9   + & 9  + % 9  W H V W L Q J  ;  
8ULQHSUHJQDQF\WHVW ; ;   ;  ; 
&UHDFWLYHSURWHLQDQGHU\WKURF\WH
VHGLPHQWDWLRQUDWHWHVWV;  ;  ;  ; ;
%LRPDUNHUVDPSOHFROOHFWLRQ   ;  ;  ; ;
3KDUPDFRNLQHWLFVDPSOHFROOHFWLRQI   ; ; ; ; ; 
:RUVWDEGRPLQDOSDLQ ; ;J;  K  ; ;K
%ULVWRO6WRRO)RUP6FDOH ; ;J ;  K  ; ;K
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO   3DJHRI
6FUHHQLQJ
'D\VWR
6WXG\9LVLW
5XQLQ3HULRGD
'D\VWR
6WXG\9LVLW
%DVHOLQH
'D\
6WXG\9LVLW
'D\Â“GD\
6WXG\9LVLW

'D\ Â“GD\
6WXG\9LVLW

'D\ Â“GD\
6WXG\9LVLW

'D\ Â“GD\
(QGRI7UHDWPHQW
(DUO\7HUPLQDWLRQE
6WXG\9LVLW
'D\ Â“GD\V
(QGRI6WXG\
6WXG\9LVLW 

3URFHGXUHV 3UHWUHDWPHQW 7UHDWPHQW )ROORZXS
6SRQWDQHRXVERZHOPRYHPHQWVWRWDO
QXPEHURIVWRROV;J ;  K  ; ;K
,%6*6  ;J ;  K  ; ;K
5HVFXHPHGLFDWLRQV  ;J ;  K  ; ;K
,%666   ;    ; ;
( O L J L E L O L W \  U H Y L H Z  ;   ;  
5 D Q G R P L ] D W L R Q   ;  
$GPLQLVWUDWLRQRILQYHVWLJDWLRQDO SURGXFW   'D\   'D\  
+%9 KHSDWLWLV%YLUXV+&9 KHSDWLWLV&YLUXV+,9 KXPDQL PPXQRGHILFLHQF\YLUXV,%6*6 ,UULWDEOH%RZHO6\QGURPH*OREDO 6FDOH
,%666 ,UULWDEOH%RZHO6\QGURPH6HYHULW\6FRUH
D5XQLQPD\EHH[WHQGHGE\XSWRRQHZHHNZLWK6SRQVRUDSSURYDO DQGWKXVPD\EHJLQRQ'D\
E3URFHGXUHVSHUIRUPHGDW9LVLW(QGRI7UHDWPHQWRUXSRQ(DUO\ 7HUPLQDWLRQ(DUO\7HUPLQDWLRQSURFHGXUHVDUHWREHSHUIRUPHGL QFORVH
SUR[LPLW\WRGLVFRQWLQXDWLRQRIGRVLQJIRUSDWLHQWVZKRDUHZLW KGUDZQIURPWKHVWXG\2WKHUSURFHGXUHVPD\EHSHUIRUPHGDW,QY HVWLJDWRURU
6SRQVRUGLVFUHWLRQ
F)XOOSK\VLFDOH[DPWREHFRQGXFWHGDW6FUHHQLQJ6\PSWRPGLUHFW HGSK\VLFDOH[DPLQDWLRQVVKRXOGEHFRQGXFWHGDWVXEVHTXHQWYLVL WV
G+HLJKWDQGERG\PDVVLQGH[WREHFROOHFWHGDW6FUHHQLQJ9LVLWR QO\
H+HPDWRORJLFFRPSOHWHVHUXPFKHPLVWU\XULQDO\VLVSDQHOVDQGIH FDOFDOSURWHFWLQWREHFRPSOHWHGDVQRWHGLQ $SSHQGL[ 
I3KDUPDFRNLQHWLF3.VHULDOEORRGVDPSOHVDUHWREHFROOHFWHGR Q'D\DQG'D\DWSUHGRVHDQGDWDQGKRXUVSRV WGRVH,I3.
VHULDOEORRGVDPSOHVFDQQRWEHFROOHFWHGRQ'D\3.VHULDOE ORRGVDPSOHVVKRXOGEHFROOHFWHGRQ'D\$SUHGRVHVDPSOHZL OOEH
REWDLQHGRQDOORWKHU7UHDWPHQW6WXG\9LVLWV$OORZDEOHVDPSOLQ JZLQGRZVIRU3.EORRGGUDZVZLOOEHPLQXWHVSULRUWRGRVLQJ IRUWKHSUHGRVH
VDPSOHWKHQÂ“PLQXWHVIRUDQGKRXUSRVWGRVHDQGÂ“ PLQXWHVIRUDQGKRXUVSRVWGRVH
J'DWDZLOOEHFROOHFWHGGDLO\IRUHQWLUH5XQLQ3HULRG
K'DWDZLOOEHFROOHFWHGGDLO\XQWLO(DUO\7HUPLQDWLRQRUXQWLO( QGRI6WXG\9LVLWZKLFKHYHULVODWHU

%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI
 ,1752'8&7,21
 6WXG\5DWLRQDOH
,UULWDEOHERZHOV\QGURPH,%6 LVDJDVWURLQWHVWLQDO*,LOOQH VVZLWKDSUHYDOHQFHRI
DSSUR[LPDWHO\WRJOREDOO\DQGFKDUDFWHUL]HGE\DFRQVWHO ODWLRQRIFOLQLFDO
V\PSWRPV(VWDEOLVKLQJDGLDJQRVLVDQGDVVHVVLQJUHVSRQVHWRWU HDWPHQWUHPDLQV
FKDOOHQJLQJEHFDXVHWKHUHDUHQRELRPDUNHUVWKDWUHOLDEO\FRUUH ODWHZLWKGLVHDVHVWDWH
%26LVDQRUDODJHQWZLWKOLPLWHGV\VWHPLFDEVRUSWLRQWKDW LQKLELWV5(7
5(DUUDQJHGGXULQJ7UDQVIHFWLRQDUHFHSWRUW\URVLQHNLQDVHWK DWLVK\SRWKHVL]HGWR
SOD\DNH\UROHLQWKHPDLQWHQDQFHRIDKHDOWK\HQWHULFQHUYRXV V\VWHP(16,QKLELWLRQ
RI5(7PD\UHSUHVHQWDQRYHOWKHUDSHXWLFVWUDWHJ\IRUWKHWUHDW PHQWRI,%6E\
DWWHQXDWLQJYLVFHUDOK\SHUVHQVLW LYLW\DQGRUFRORQLFPRWLOLW\
%26KDVEHHQHYDOXDWHGLQKHDOWK\KXPDQVXEMHFWVDWGRVHVX SWRPJWZLFH
GDLO\ELGIRUZHHNV&RQVLVWHQWZLWKLWVORZRUDOELRDYDLOD ELOLW\%26ZDVVDIH
DQGZHOOWROHUDWHGZLWKQRVLJQLILFDQWVDIHW\VLJQDOVLGHQWLILH G7KHSXUSRVHRIWKLVVWXG\
LVWRHYDOXDWHWKHHIILFDF\VDIHW\DQGWROHUDELOLW\RI%26 LQWKHWUHDWPHQWRI
SDWLHQWVZLWKGLDUUKHDSUHGRPLQDQW,%6,%6'
 %DFNJURXQG
 'LVHDVH8QGHU6WXG\
,UULWDEOHERZHOV\QGURPHLVDU HODWLYHO\FRPPRQ*,LOOQHVVFKDU DFWHUL]HGE\DQXPEHURI
FOLQLFDOV\PSWRPVLQFOXGLQJDEGRPLQDOSDLQDQGGLVFRPIRUWDEQ RUPDOERZHOKDELWV
DQGEORDWLQJ 6XEW\SHVRI,%6EDVHGRQWKHSUHGRPLQDQWERZHOKDELWVUHSRUWHGE\,%6SDWLHQWVLQFOXGHGL DUUKHD,%6'
FRQVWLSDWLRQ,%6&PL[HG,%60RUXQFODVVLILHG,%68& XUUHQWO\DSSURYHG
PHGLFDWLRQVIRU,%6DGGUHVVWKHUHVWRUDWLRQRISDWLHQWVÂ¶ERZHO KDELWVDQGDUHPLQLPDOO\
HIIHFWLYHLQDGGUHVVLQJDEGRPLQDOSDLQDQGGLVFRPIRUW%HFDXVH WKHHWLRORJ\RIWKH
GLVHDVHKDVQRWEHHQFOHDUO\HVWDEOLVKHGGLDJQRVLVLVGLIILFXO WDQGUHOLHVSULPDULO\RQWKH
SUHVHQFHRIDVSHFLILFV\PSWRPFRPSOH[RFFXUULQJLQWKHDEVHQFH RIDQDOWHUQDWLYH
H[SODQDWLRQ7KHGHYHORSPHQWRIFULWHULDE\H[SHUWSDQHOVZLWK UHFHQWLWHUDWLRQVDV
UHFHQWO\DVKDVLPSURYHGWKHGLDJQRVLVDQGPDQDJHPHQWRI ,%6SDWLHQWV
 
,WLVJHQHUDOO\EHOLHYHGWKDWWKHVHQVRU\LQSXWVRXWSXWVLQWKH (16DQGFHQWUDOQHUYRXV
V\VWHP&16DUHDOWHUHGLQSDWLHQWVZLWK,%6DQGWKLVFRQWULEX WHVWRWKHVLJQVDQG
V\PSWRPVWKH\H[SHULHQFH)RUH[DPSOHSDWLHQWVZLWK,%6KDYHD KHLJKWHQHGDQG
GLVSURSRUWLRQDWHVHQVRU\H[SHULHQFHYLVFHUDOK\SHUVHQVLWLYLW\ IRUDJLYHQVWLPXOXV
 9LVFHUDOK\SHUVHQVLWLYLW\DQGDEQRUPDOERZHOKDELWVPD\UHV XOW
IURPYLVFHUDODIIHUHQWQHXURQVRULQFUHDVHGQHUYHILEHUGHQVLW\ DQGVSURXWLQJWKDWKDYH
EHHQREVHUYHGLQWKHLQWHVWLQDOPXFRVDOWLVVXHVRI,%6SDWLHQWV  
7KHVHQVLWL]LQJHYHQWFDXVLQJYLVFHUDO
K\SHUVHQVLWLYLW\PD\EHWUDQVLHQWRUFKURQLFKRZHYHULWVLPSD FWRQWKH&16DQG(16CCI
CCI
CCI
CCI
CCI
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI
PD\EHORQJODVWLQJ 6XSHUQDWDQWVIURPWKHVHLQWHVWLQDO
WLVVXHVFDQVWLPXODWHQHUYHRXWJURZWKDQGLQFUHDVHQHXURQDOVLJ QDOLQJLQYLWUR
VXJJHVWLQJWKDWQHXURWURSKLFIDFWRUVDQGRULQIODPPDWRU\F\WRNL QHVPLJKWEHPHGLDWRUV
RIQHXURQDOSODVWLFLW\LQ,%6 
*LYHQWKHFHQWUDOUROHWKH(16PD\SOD\LQPHGLDWLQJVLJQDOV 
EHWZHHQWKH&16DQGWKHLQWHVWLQH(16PRGXODWLRQPD\SURYLGHW KHUDSHXWLFEHQHILWWR
,%6SDWLHQWVE\LPSDFWLQJYLVFHUDOK\SHUVHQVLWLYLW\DQGLQWHVWL QDOPRWLOLW\ 
7KHRQO\GUXJVFXUUHQWO\DSSURYHGE\WKH)RRGDQG'UXJ$GPLQLVW UDWLRQ)'$IRUWKH
WUHDWPHQWRI,%6DUHDORVHWURQIRUZRPHQRQO\ULID[LPLQDQG HOX[DGROLQHIRUUHIUDFWRU\
,%6'DQGSOHFDQDWLGHOLQDFORWLGHDQGOXELSURVWRQHIRU,%6& 7KHPDMRULW\RIWKHVH
GUXJVDQGWKRVHXVHGRIIODEHOWRWUHDW,%6WDUJHWSDWLHQWVÂ¶ V\PSWRPVE\DOWHULQJ*,
PRWLOLW\DQGDUHPLQLPDOO\HIIHFWL YHLQDGGUHVVLQJDEGRPLQDOSD LQDQGGLVFRPIRUW2IWKH
)'$DSSURYHGDJHQWVRQO\DORVHWURQLVK\SRWKHVL]HGWRPRGXODWH WKH&16DQG(16
 7KHUHIRUHDQDJHQWVXFKDV%26ZKLFKPD\DPHOLRUDWHYLVFHUDOK\SHUVHQVLWLYLW\DQGSRWHQWLDOO\ LPSDFWLQWHVWLQDOPRWLOLW\
ZRXOGDGGUHVVDVLJQLILFDQWXQPHWPHGLFDOQHHGIRU,%6DVVRFLDW HGSDLQ
 7KHÂ³5(7Â´Â³5(DUUDQJHG'XU LQJ7UDQVIHFWLRQÂ´*HQHDQGWKH (QWHULF
1HUYRXV6\VWHP
7KH5(7JHQHORFDOL]HGRQKXPDQFKURPRVRPHTHQFRGHVD UHFHSWRUW\SH
W\URVLQHNLQDVHZLWKDQH[WUDFHOOXODUGRPDLQDWUDQVPHPEUDQHG RPDLQDQGDQ
LQWUDFHOOXODUW\URVLQHNLQDVHGRPDLQ 7KHOLJDQGVIRU5(7KD YH
EHHQLGHQWLILHGDVQHXURWURSKLFIDFWRUVRIWKHJOLDOFHOOOLQH GHULYHGQHXURWURSKLFIDFWRU
*'1)IDPLO\LQFOXGLQJ*'1)QHXUWXULQDUWHPLQDQGSHUVHSKL Q/LJDQGELQGLQJWRLWV
FRUUHVSRQGLQJ*'1)IDPLO\UHFHSWRU
DOSKD*)5Ä®FR UHFHSWRUWULJJHUV5(7
GLPHUL]DWLRQDQGVXEVHTXHQWWUDQVSKRVSKRU\ODWLRQRILQWUDFHOOXO DUW\URVLQHV
 DQGOHDGVWRWKHDFWLYDWLRQRIGLIIHUHQWLQWUDFHOOXODUVLJQD OLQJ
FDVFDGHVLQFOXGLQJWKH-DQXVNLQDVHVLJQDOWUDQVGXFHUDQGDFWL YDWRURIWUDQVFULSWLRQ
SURWHLQV-$.67$7SKRVSKRLQRVLWLGH NLQDVHSURWHLQNLQDVH%3,.$.7DQGUDW
VDUFRPDH[WUDFHOOXODUVLJQDO UHJXODWHGNLQDVH5$6(5.SDWKZD\V
0LFHGHILFLHQWLQWKH*'1)OLJDQG LWVFRUHFHSWRU*)5Ä®RUWKH 5(7SURWHLQLWVHOI
H[KLELWVHYHUHGHIHFWVLQNLGQH\DQG(16GHYHORSPHQW7KLVLPSO LFDWHV5(7VLJQDOLQJ
DVFULWLFDOWRWKHGHYHORSPHQWRIQRUPDONLGQH\VDQGWKH(16  7KH
UROHRI5(7LQWKHGHYHORSPHQWRIWKH(16LVDOVRDSSDUHQWLQS DWLHQWVZLWK
+LUVFKVSUXQJÂ¶VGLVHDVHZKRIUHTXHQWO\VXIIHUIURPFRORQLFREVW UXFWLRQEHFDXVHRID
ODFNRIQRUPDOFRORQLFLQQHUYDWLRQ,Q+LUVFKSUXQJÂ¶VGLVHDVHG LIIHUHQWORVVRIIXQFWLRQ
PXWDWLRQVWKDWRFFXULQWKH 5(7JHQHDFFRXQWIRUWKHKLJKHVW SURSRUWLRQRIERWKIDPLOLDO
DQGVSRUDGLFFDVHVRIWKHGLVHDVH 
:KLOHLWVUROHGXULQJWKHGHYHORSPHQWRIWKH(16KDVEHHQZHOOHVWDEO LVKHGUHFHQW
UHSRUWVDOVRLPSOLFDWHDVLJQLILFDQWUROHIRU5(7LQWKHPDLQWH QDQFHDQGSODVWLFLW\RIWKH
DGXOW(161HXURQVZLWKLQWKHVXEPXFRVDODQGP\HQWHULFSOH[XVR IWKHDGXOWKXPDQ
FRORQKDYHEHHQVKRZQWRH[SUHVV5(7DQGLWVFRUHFHSWRUV*)5Ä® DQG*)5Ä®ZKLOH
WKH*'1)OLJDQGLVH[SUHVVHGLQWKHPXVFXODULVPXFRVDDQGLQFL UFXODUDQGORQJLWXGLQDOCCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI
PXVFOHWLVVXH 6\VWHPLFDGPLQLVWUDWLRQRI*'1)LQDGXOW
URGHQWVUHVXOWVLQVLJQLILFDQWLQFUHDVHVLQVXEPXFRVDOQHXURQG HQVLW\LQERWKWKHVPDOO
LQWHVWLQHDQGFRORQDQGDOWHUHGIXQFWLRQ  )XUWKHUPRUHDFRQGLWLRQDO
NQRFNRXWRIWKH5(7FRUHFHSWRU*)5Ä®UHVXOWVLQGHFUHDVHGFR ORQLFK\SHUVHQVLWLYLW\
LPSOLFDWLQJDUROHIRU5(7VLJQDOLQJLQYLVFHUDOQRFLFHSWLRQ  
7KHUHIRUHE\UHGXFLQJ5(7VLJQDOLQJLQKLELWLRQRI5(7PD\PRG XODWH(16DFWLYLW\
 ,QYHVWLJDWLRQDO3URGXFW%26IRUPHUO\*6.LVDSRWHQWDQGVHOHFWLYHLQKLELW RURI5(7WKDWKDV
EHHQVKRZQWRUHGXFHYLVFHUDOK\SHUVHQVLWLYLW\LQDQDQLPDOPRG HORI,%6DQGLQKLELW
FKROLQHUJLFLQGXF HGLQFUHDVHVLQ FRORQLFPRWLOLW\GHWDLOVDUH SURYLGHGLQWKH%26
,QYHVWLJDWRUÂ¶V%URFKXUH>,%@7KHUHVXOWVIURPWKHVHSUHFOLQLF DOVWXGLHVVXJJHVWWKDW
LQKLELWLRQRI5(7ZLWKDSRWHQWVHOHFWLYHDQGJXWUHVWULFWHG VPDOOPROHFXOHPD\
UHSUHVHQWDQRYHOWKHUDSHXWLFVWUDWHJ\IRUWKHWUHDWPHQWRIDEG RPLQDOSDLQDQG
GHIHFDWLRQDEQRUPDOLWLHVLHGLDUUKHDLQSDWLHQWVZLWK,%6 WKURXJKWKHDWWHQXDWLRQRI
YLVFHUDOK\SHUVHQVLWLYLW\DQGRUFKROLQHUJLFDOO\PHGLDWHGLRQW UDQVSRUWDQGFRORQLF
PRWLOLW\7KHSDWLHQWSRSXODWLRQOLNHO\WRGHULYHWKHJUHDWHVW EHQHILWZRXOGFRPSULVH
LQGLYLGXDOVZLWK,%6'ZLWK LQFUHDVHG*,PRWLOLW\
 1RQFOLQLFDO6XPPDU\
$UDQJHRI LQYLWURDQGLQYLYRVWXGLHVKDYHEHHQFRQGXFWHGWRLQYHVWLJDWHWKHSULPDU\
VHFRQGDU\DQGVDIHW\SKDUPDFRORJ\RI%26'HWDLOVDUHSURY LGHGLQWKH%26
,%
 ,Q9LWUR6WXGLHV












CCI
CCI
CCICCI
CCI
CCI
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI

 ,Q9LYR6WXGLHV









 3KDUPDFRNLQHWLFVDQG 3URGXFW0HWDEROLVPLQ$QLPDOV



















CCI
CCI
CCI
CCI
CCI
CCI
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI
 7R[LFRORJ\DQG1RQFOLQLFDO$VVHVVPHQWRI6DIHW\




























CCI
CCI
CCI
CCI
CCI
CCI
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI
























 &OLQLFDO([SHULHQFH
6WXG\ HYDOXDWHGWKHVDIHW\WROHUDELOLW\SKDUPDFRNLQHWLFV3. DQG
H[SORUDWRU\SKDUPDFRG\QDPLFV3'RIHVFDODWLQJVLQJOHDQGPXOW LSOHRUDOGRVHVRI
%26UDQJLQJIURPWRPJLQWKHIDVWHGVWDWHDQGPJ LQWKHIHGVWDWH$OO
GRVHVLQWKHVLQJOHDVFHQGLQJGRVHSRUWLRQRIWKHVWXG\ZHUHJH QHUDOO\VDIHDQGZHOO
WROHUDWHGZLWKDVDIHW\SURILOHVLPLODUWRWKDWRISODFHER3% 26LPLODUO\UHSHDWGRVH
DGPLQLVWUDWLRQRI%26IRUGD\VDWGRVHVUDQJLQJIURPW RPJELGLQWKHIHG
VWDWHZDVJHQHUDOO\VDIHDQGZHOOWROHUDWHG7KHUHZHUHQRGUXJ UHODWHGFOLQLFDOO\
VLJQLILFDQWFKDQJHVLQVDIHW\ODERUDWRU\WHVWVYLWDOVLJQV(& *VRUVWRROSDWWHUQVDV
DVVHVVHGE\WKH%ULVWRO6WRRO)RUP6FDOH%6)6LQWKLVVWXG\ 7KHUHZHUHQRVHULRXVCCICCI
CCI
CCI
CCI
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI
DGYHUVHHYHQWV6$(VFRQVLGHUHGUHODWHGWRWKHDGPLQLVWUDWLRQ RI%26$UHYLHZRI
DOO*,DGYHUVHHYHQWV$(VGHPRQVWUDWHGWKDWWKHRFFXUUHQFHRI *,$(VZDVVLPLODULQ
WKH3%2DQG%26WUHDWPHQWJURXSV7KHUHZDVQRSDWWHUQRU WUHQGZLWKGRVH
HVFDODWLRQVXJJHVWLYHRIDWUHDWPHQWHIIHFW
7KH3.SURILOHRI%26GHPRQVWUDWHGOLPLWHGRUDOELRDYDLODEL OLW\DQGV\VWHPLF
H[SRVXUHZLWKSODVPDFRQFHQWUDWLRQVJHQHUDOO\OHVVWKDQQJP /ZKHQPHDVXUHG
XWLOL]LQJDVHQVLWLYHDQDO\WLFDOPHWKRGWRGHWHFWFRQFHQWUDWLRQ VDVORZDVSJP/
([SRVXUHVZHUHGRVHGHSHQGHQWDQGOHVVWKDQGRVHSURSRUWLRQDO DOWKRXJKER[SORWVRI
GRVHQRUPDOL]HGSDUDPHWHUVVXJJHVWHGGRVHSURSRUWLRQDOLW\EHWZH HQPJDQG
PJ'RVLQJZDVHVFDODWHGWRWKHKLJKHVWSRVVLEOHGRVHEHFDX VHSUHGLFWHGPHDQ
V\VWHPLFH[SRVXUHVGLGQRWH[FHHGWKHGHILQHGSODVPDWR[LFRNLQH WLFOLPLWV$8& WDQG
&PD[RIQJ
KP/DQGQJP/UHVSHFWLYHO\DQGWKHUHZDVQR HYLGHQFHRI
GRVHOLPLWLQJWR[LFLWLHV7KHUHZDVDFFXPXODWLRQRI%26ZLW KUHSHDWGRVLQJEXW
V\VWHPLFH[SRVXUHVUHPDLQHGYHU\ORZDIWHUGD\VRIGRVLQJZ LWKUHVSHFWLYH
JHRPHWULFPHDQ&9$8& WDQG& PD[YDOXHVRIK
QJP/DQG
QJP/IRUWKHKLJKHVWGRVHRIPJELG%26Z DVOLNHO\DWVWHDG\
VWDWHEHIRUHWKDWWLPH$FFXPXODWLRQZDVORZHUIRUGRVHVEHORZ PJELGWR
IROGDQGKLJKHVWIRUWKHKLJKHVWGRVHRIPJELGW RIROG
7KHVWXG\LQFOXGHGDSLORWIRRGHIIHFWJURXSWRHYDOXDWHWKHPD JQLWXGHRIDIRRG
FKDOOHQJHRQWKHELRDYDLODELOLW\ RIVLQJOHGRVH%26)ROORZ LQJDGPLQLVWUDWLRQRID
VLQJOHGRVHRI%26PJLQWKHIHGVWDWHWKHUHZDVDVPDO OGHFUHDVHLQH[SRVXUH
ZLWKIRRGZLWKGHFUHDVHVLQPHDQ& PD[DQG$8& YDOXHVLQWKHUDQJHRIWR
7KHWLPHWR& PD[7PD[UHPDLQHGWKHVDPHZLWKRUZLWKRXWIRRG7KHVHIRRGHIIHFW
UHVXOWVZHUHGHHPHGQRWFOLQLFDOO\LPSRUWDQWGRVLQJ%26ZL WKRUZLWKRXWIRRGLVQRW
DQWLFLSDWHGWRDIIHFWIXWXUHHYDOXDWLRQRIVDIHW\RUHIILFDF\
%HFDXVH5(7LVH[SUHVVHGLQHQWHURHQGRFULQHFHOOVOLQLQJWKHLQ WHVWLQDOPXFRVDDQ
H[SORUDWRU\REMHFWLYHRIWKHVWXG\ZDVWRH[SORUHWKHHIIHFWRI %26RQJOXFDJRQOLNH
SHSWLGH*/3DQGSDQFUHDWLFSHSWLGH<<3<<H[FXUVLRQVLQ SODVPDKRZHYHUQR
FOHDUUHODWLRQVKLSRULPSDFWRQ%26DGPLQLVWUDWLRQDQGSHSW LGHVHFUHWLRQZDV
LGHQWLILHG
 5LVN%HQHILW$VVHVVPHQW
6XPPDULHVRIILQGLQJVIURPQRQFOLQLFDODQGFOLQLFDOVWXGLHVFRQ GXFWHGZLWK%26
FDQEHIRXQGLQWKH,%UHIHUWRWKH,%IRUDGGLWLRQDOGHWDLOV 7KHIROORZLQJVHFWLRQ
RXWOLQHVWKHULVNDVVHVVPHQWDQGPLWLJDWLRQVWUDWHJ\IRUWKLVS URWRFRO
7KHFXUUHQWVWXG\%26UHSUHVHQWVWKHILUVWDGPLQLVWUD WLRQRI%26WR
SDWLHQWVZLWK,%6'&RQVLGHUDWLRQVIRUVDIHW\PRQLWRULQJDUHG HULYHGSULPDULO\IURPWKH
OLWHUDWXUHUHJDUGLQJ5(7H[SUHVVLRQLQWKHLQWHVWLQHQRQFOLQLF DOGDWDDQGFOLQLFDO
H[SHULHQFHGRVLQJ%26WRQRUPDOKHDOWK\YROXQWHHUV6WXG\  LQ
ZKLFKQRFOLQLFDOO\UHOHYDQWULVNVZHUHLGHQWLILHGWKDWZRXOGS UHFOXGHGRVLQJD5(7
LQKLELWRUIRUXSWRZHHNVLQSDWLHQWVZLWK,%6'CCI
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI
 5LVN$VVHVVPHQW














 %HQHILW$VVHVVPHQW
3DWLHQWVUDQGRPL]HGWRWKHDFWLYHWUHDWPHQWDUPVPD\SRWHQWLDOO \H[SHULHQFH
LPSURYHPHQWLQWKHLU,%6'GXULQJWKHFRXUVHRIWKHVWXG\7KRV HUDQGRPL]HGWRWKH
3%2DUPDUHQRWH[SHFWHGWRREWDLQDQ\EHQHILWEH\RQGWKDWRIW KHLUEDFNJURXQG
WUHDWPHQW
 2YHUDOO5LVN%HQHILW&RQFOXVLRQ2QWKHEDVLVRIQRQFOLQLFDODQGF OLQLFDOVWXG\UHVXOWVWRGDWH OLPLWHGHIIHFWLYHDOWHUQDWLYH
WUHDWPHQWVDQGWKHVWUHQJWKRIWKHVFLHQWLILFK\SRWKHVLVXQGHU HYDOXDWLRQ%26LV
FRQVLGHUHGWRKDYHDIDYRUDEOHEHQHILW
ULVNSURILOHIRUSDWLHQWVZLWK,%6'CCI
CCI
CCI
CCI
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI 2%-(&7,9(6$1'(1'32,176
2%-(&7,9(6 (1'32,176
3ULPDU\
x 7RHYDOXDWHLQSDWLHQWVZLWK,%6'
WKHDEGRPLQDOSDLQUHVSRQVHWR%26DIWHUZHHNVRIWUHDWPHQWUHODWLYHWRSODFHER3%2x KRXUZRUVWDEGRPLQDOSDLQVFRUHV
:$3DW'D\FRPSDUHGWREDVHOLQHDYHUDJHGRYHUWKHZHHNSULRUWRHDFKUHVSHFWLYHWLPHSRLQW
x 7RHYDOXDWHWKHRYHUDOOVDIHW\DQG
WROHUDELOLW\RI%26LQWKHWUHDWPHQWRI,%6'GXULQJZHHNVRIWUHDWPHQWUHODWLYHWR3%2x ,QFLGHQFHRIDGYHUVHHYHQWV$(V
VHULRXVDGYHUVHHYHQWV6$(VGLVFRQWLQXDWLRQVEHFDXVHRI$(VDQGDQ\WUHDWPHQWUHODWHGVHYHUH$(V
6HFRQGDU\ 
x 7RHYDOXDWHWKHWUHDWPHQWHIIHFWRI
%26RQGHIHFDWLRQDIWHUZHHNVUHODWLYHWR3%2
x &KDQJHLQVWRROFRQVLVWHQF\PHDVXUHG
E\WKHGDLO\%ULVWRO6WRRO)RUP6FRUH%6)6DW'D\FRPSDUHGWREDVHOLQHDYHUDJHGRYHUWKHZHHNSULRUWRHDFKUHVSHFWLYHWLPHSRLQW
x&KDQJHLQVWRROIUHTXHQF\PHDVXUHG
E\WKHWRWDOQXPEHURIVSRQWDQHRXVERZHOPRYHPHQWVLQKRXUVDW'D\FRPSDUHGWREDVHOLQHDYHUDJHGRYHUWKHZHHNSULRUWRHDFKUHVSHFWLYHWLPHSRLQW

x 7RHYDOXDWHWKHWUHDWPHQWHIIHFWRI
%26RQ,%6UHODWHGVLJQVDQGV\PSWRPV
x &KDQJHLQWKH,%66HYHULW\6FRUH
,%666DW'D\FRPSDUHGWREDVHOLQH
x &KDQJHLQWKH,%6*OREDO6FDOH
,%6*6DW'D\FRPSDUHGWR
EDVHOLQHDYHUDJHGRYHUWKHZHHNSULRUWRHDFKUHVSHFWLYHWLPHSRLQW
x7RHYDOXDWHWKHVWHDG\VWDWH
SKDUPDFRNLQHWLFVRI%26 x0D[LPXPREVHUYHGSODVPD
FRQFHQWUDWLRQ& PD[WLPHWR& PD[7PD[
PLQLPXPSODVPDFRQFHQWUDWLRQ& PLQ
DUHDXQGHUWKHFRQFHQWUDWLRQYHUVXVWLPHFXUYH$8&IURPWLPH]HURWRKRXUVSRVWGRVH$8&
$8&IURP
WLPH]HURWRWKHODVWTXDQWLILDEOHFRQFHQWUDWLRQ$8&
W
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI 678'<'(6,*1
 2YHUDOO'HVLJQ
7KLVVWXG\LVDSKDVHDUDQGRPL]HGGRXEOHEOLQG3%2FRQWURO OHGPXOWLFHQWHUWULDO
GHVLJQHGWRSURYLGHWKHILUVWSURRIRISULQFLSOHHIILFDF\RI%2 6LQ,%6'SDWLHQWV
DQGWRLQIRUPGRVHVHOHFWLRQIRUVXEVHTXHQWGHYHORSPHQW7KHVW XG\ZLOOFRQVLVWRID
SUHWUHDWPHQWSKDVHDZHHNGRXEOHEOLQGWUHDWPHQWSKDVHDQG DZHHN
SRVWWUHDWPHQWIROORZXSSHULRG
3UH7UHDWPHQW3KDVH 'XULQJWKHSUHWUHDWPHQWSKDVHSDWLHQWVZLOOEHHYDOXDWHGIRU
XSWRZHHNVWRDVVHVVHOLJLELOLW\7KHSUHWUHDWPHQWSKDVHZL OOFRQVLVWRILQLWLDO
VFUHHQLQJDVVHVVPHQWVDQGD5XQLQSHULRG
$IWHUWKHLQLWLDOVFUHHQLQJDVVHVVPHQWVKDYHEHHQSHUIRUPHGHO LJLEOHSDWLHQWVZLOOHQWHU
D5XQLQSHULRGRIXSWRZHHNV'XULQJWKH5XQLQSHULRGWKH SDWLHQWVZLOOFRPSOHWH
DQHOHFWURQLFGLDU\WRFROOHFWGDLO\LQIRUPDWLRQUHODWHGWRWKH LU,%6'V\PSWRPVERZHO
IXQFWLRQDQGUHVFXHPHGLFLQHXVHWRFRQILUPGLVHDVHDFWLYLW\ DQGGLDU\FRPSOLDQFH
3DWLHQWVZLOODOVREHUHTXHVWHGWR GLVFRQWLQXHDQ\SURKLELWHGP HGLFDWLRQVGXULQJWKLV
SKDVHRIWKHVWXG\
8SRQFRPSOHWLRQRIWKH5XQLQSHU LRGSDWLHQWVZLOOUHWXUQWRW KHVWXG\VLWHWRFRQILUP
HOLJLELOLW\IRUUDQGRPL]DWLRQLQWRDZHHNGRXEOHEOLQGHG7UHD WPHQW3KDVH
7UHDWPHQW3KDVH (OLJLEOHSDWLHQWVZLOOEHUDQGRPL]HGLQWRWKHIROORZL QJFRKRUWV
x &RKRUW+LJK'RVHPJ%26ELGRUDOO\
x &RKRUW/RZ'RVHPJ%26ELGRUDOO\
x &RKRUW3%2PDWFKLQJ3%2RUDOWDEOHWVELGRUDOO\
'XULQJWKHZHHNVRIGRXEOHEOLQGWUHDWPHQWSDWLHQWVZLOOFRQ WLQXHWRUHFRUGWKHLUGDLO\
,%6'V\PSWRPVERZHOIXQFWLRQDQGUHVFXHPHGLFLQHXVHLQWKH HOHFWURQLFGLDU\DV
GHVFULEHGLQ 6HFWLRQ 
3RVWWUHDWPHQW3KDVH $ZHHNSRVWWUHDWPHQWIROORZXSYLVLWZLOORFFXUIRUSDWLHQ WV
ZKRFRPSOHWHWKH7UHDWPHQW3KDVH'XULQJWKHZHHNVRIIROORZ XSSDWLHQWVVKRXOG
FRQWLQXHWRUHFRUGWKHLUGDLO\,%6'V\PSWRPVERZHOIXQFWLRQ DQGUHVFXHPHGLFLQHXVH
LQWKHHOHFWURQLFGLDU\
3DWLHQWVZKRSUHPDWXUHO\GLVFRQWLQXHWUHDWPHQWVKRXOGUHWXUQWR WKHVWXG\FHQWHUWR
FRPSOHWHWKHHDUO\WHUPLQDWLRQDVVHVVPHQWVDVVRRQDVSRVVLEOH DIWHUVWRSSLQJWKH
WUHDWPHQW
'DWDDQDO\VHVZLOORFFXUDIWHUDOOSDWLHQWVLQWKHWULDOKDYHF RPSOHWHG WKHODVWYLVLWRU
SURFHGXUHVKRZQLQWKH6FKHGXOHRI$FWLYLWLHV 6HFWLRQ 
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI3RVWVWXG\$FFHVVWR7KHUDS\ 1RSRVWWUHDWPHQWDFFHVVWRWKHUDS\ZLOOEHSURYLGHG
WRSDWLHQWVUDQGRPL]HGLQWKHVWXG\
 6WXG\'XUDWLRQIRU3DWLHQWV8QOHVVVKRUWHQHGE\LQWROHUDEOH$(VRUUDSLGGLVHDVHSURJUHVVLR QHDFKSDWLHQWÂ¶V
SDUWLFLSDWLRQLQWKLVVWXG\LVDQWLFLSDWHGWRODVWXSWRZHH NV
7KHWRWDOGXUDWLRQRIWKLVVWXG\LVDQWLFLSDWHGWREHDSSUR[LPD WHO\PRQWKVLQFOXGLQJ
SDWLHQWHQUROOPHQWWUHDWPHQWDQGIROORZXS
 1XPEHURI3DWLHQWV$SSUR[LPDWHO\SDWLHQWVZ LOOEHVFUHHQHGWRUDQGRPL]HDSSUR[ LPDWHO\SDWLHQWV
ZLWK,%6'SDWLHQWVSHUFRKRUW
 5HSODFHPHQWRI3DWLHQWV3DWLHQWVZKRVLJQWKH,&)DQGDUHUDQGRPL]HGEXWGRQRWUHFHLYH WKHLQYHVWLJDWLRQDO
SURGXFWPD\EHUHSODFHG2QFHUDQGRPL]HGSDWLHQWVZKRKDYHUHF HLYHGDWOHDVWGRVH
RILQYHVWLJDWLRQDOSURGXFWDQGDUHZLWKGUDZQIURPWKHUDS\EHIRU HFRPSOHWLQJGD\VRI
GRVLQJRUDUHGLVFRQWLQXHGIURP WKHVWXG\IRUDQ\UHDVRQZLOOQ RWEHUHSODFHG
 1XPEHURI6LWHV8SWRVLWHVLQWKH8QLWHG6WDWHVPD\SDUWLFLSDWHLQWKLVVWX G\
 5DWLRQDOHIRU6WXG\'HVLJQ
.H\DVSHFWVRIWKHVWXG\HJHOLJLELOLW\FRKRUWVL]HVWRSS LQJFULWHULDVDIHW\GDWD
FROOHFWLRQHIILFDF\DVVHVVPHQWVXVHRI3%2DVFRQWURODQGXV HRISDWLHQWUHSRUWHG
RXWFRPH>352@WRROVDUHEDVHGXSRQJHQHUDOO\DFFHSWHGFOLQLFDO WULDOPHWKRGRORJLHVIRU
SKDVHDHIILFDF\VWXGLHVDQGSULRUVWXGLHVFRQGXFWHGLQSDWLHQ WVZLWK,%6
7KH5RPH,9 GLDJQRVWLFFULWHULDIRU,%6LVWKHEHVWDFFHSWHG WRROIRU
VWDQGDUGL]HG,%6GLDJQRVLV
$5XQLQ3KDVHLVGHVLJQHGWRDFFRXQWIRUIOXFWXDWLRQVLQV\PSW RPVDQGWKHSRWHQWLDOIRU
ZLGHYDULDWLRQVLQERZHOKDELWVSDWLHQWGLDULHVWKDWUHFRUGIU HTXHQF\DQGVHYHULW\RI
GDLO\V\PSWRPVZLOOEHXVHGWRHQVXUHWKDWV\PSWRPVHYHULW\IOX FWXDWLRQVDUHLGHQWLILHG
DQGWDNHQLQWRDFFRXQWIRUVXEMHFWHOLJLELOLW\3DWLHQWVZLOOD OVREHDVVHVVHGRQWKHLU
DELOLW\WRUHFRUGWKHLUGLVHDVHUHODWHGLQIRUPDWLRQLQWKHUHTX LUHGPDQQHU
7KHXVHRI3%2DVDFRQWUROFRPSDUDWRULQ,%6FOLQLFDOWULDOVL VDFFHSWDEOHJLYHQWKH
ODFNRIFRQVLVWHQWO\HIIHFWLYHWUHDWPHQWV3ODFHERLVDQLPSRUW DQWFRPSRQHQWRI,%6
FOLQLFDOWULDOVJLYHQWKHKLJK3%2HIIHFWLQWKLVSRSXODWLRQ CCI
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI7KHNH\SULPDU\DQGVHFRQGDU\HQGSRLQWVLQWKLVVWXG\DUHEDVHG RQ352
DVVHVVPHQWV7KHVHDVVHVVPHQWVHYDOXDWHSDLQGHIHFDWLRQDQG, %6VLJQVDQG
V\PSWRPV$EGRPLQDOSDLQLQWHQVLW\LVPHDVXUHGXVLQJDQSRLQ WLHWR
QXPHULFUDWLQJVFDOH156WKDW DVNVSDWLHQWVGDLO\WRUDWHWKH LUZRUVWDEGRPLQDOSDLQ
RYHUWKHSDVWKRXUV DVUHFRPPHQGHGE\WKH)'$JXLGDQFHRQ,%6 )'$
0D\ 7KHXVHRIWKH156IRUSDLQKDVEHHQYDOLGDWHGLQ,%6FOLQLF DOVWXGLHV
 7KH,%66HYHULW\6FRUH,%666 DQG,%6*OREDO6FDOH,%6*6 DUHYDOLGDWHGDQGVWDQGDUGPHWKRGVRIDVVHVVLQJ,%6V\PSWRPVLQFOLQLFDOWULDOV
$OWKRXJKWUHDWPHQWGXUDWLRQVO RQJHUWKDQZHHNVZLOOEHUHTXLU HGIRUWUXHDVVHVVPHQW
RIHIILFDF\LQ,%6SDWLHQWVLQWKLVLQLWLDOSKDVHDVWXG\ ZHHNVVKRXOGEHVXIILFLHQWWR
LGHQWLI\DQ\HIILFDF\VLJQDOWKDWZDUUDQWVIXUWKHUFOLQLFDOLQY HQWLRQ
7KHXVHRIPXOWLSOHHQUROOLQJVLWHVLVDLPHGDWPD[LPL]LQJH[WH UQDOYDOLGLW\DQGWR
PLQLPL]LQJWKHSRWHQWLDOLQIOXHQFHRIUHJLRQDOYDULDWLRQVLQGL HWH[HUFLVHKDELWVDQG
HWKQLFLW\
 -XVWLILFDWLRQIRU'RVH





















CCI
CCI
CCI
CCICCI CCI
CCI
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI
 (QGRI6WXG\'HILQLWLRQ
7KHHQGRIWKHVWXG\LVGHILQHGDVFRPSOHWLRQRIWKHODVWYLVLW RUSURFHGXUHVKRZQLQWKH
6FKHGXOHRI$FWLYLWLHVLQWKHWULDOJOREDOO\$SDWLHQWZLOOEH FRQVLGHUHGWRKDYHFRPSOHWHG
WKHVWXG\LIKHRUVKHKDVFRPSOHWHGDOOSKDVHVRIWKHVWXG\L QFOXGLQJWKHODVWYLVLWRU
WKHODVWVFKHGXOHGSURFHGXUHVKRZQLQWKH6FKHGXOHRI$FWLYLWLH V6HFWLRQ CCI
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI 678'<3238/$7,21
%HIRUHDQ\VWXG\VSHFLILFDFWLYLWLHVSURFHGXUHVWKHDSSURSULDW HZULWWHQLQIRUPHG
FRQVHQWPXVWEHREWDLQHG3URVSHFWLYHDSSURYDORISURWRFROGHYL DWLRQVWRUHFUXLWPHQW
DQGHQUROOPHQWFULWHULDDOVRNQRZQDVSURWRFROZDLYHUVRUH[HP SWLRQVLVQRWSHUPLWWHG
 ,QFOXVLRQ&ULWHULD
,QRUGHUWREHHOLJLEOHWRSDUWLFLSDWHLQWKLVVWXG\DQLQGLYL GXDOPXVWPHHWDOORIWKH
IROORZLQJFULWHULD
$JH 0DOHDQGIHPDOHSDWLHQWVPXVWEHWR\HDUVRIDJHLQFO XVLYHDWWKHWLPHRI
VLJQLQJLQIRUPHGFRQVHQW
5XQLQH'LDU\&RPSOLDQFH 3DWLHQWKDVFRPSOHWHGWKHGDLO\HOHFWURQLFGLDU\RQDWOHDVW RIWKHGD\VGXULQJWKH
ZHHNSULRUWRUDQGRPL]DWLRQ$1'DWOHDVWRIWKHGD\VGXUL QJWKHZHHNVSULRU
WRUDQGRPL]DWLRQ3DWLHQWVKDYHXSWRZHHNVWRPHHWWKHVHFUL WHULD
7\SHRI3DWLHQWDQG'LVHDVH&KDUDFWHULVWLFV 3DWLHQWPHHWVWKHGLDJQRVLVRI,%6EDVHGRQWKH5RPH,9GLDJ QRVWLFFULWHULD
  
 
x 5HFXUUHQWDEGRPLQDOSDLQRFFXUULQJRQDYHUDJHDWOHDVWGD\ SHUZHHNDQG
DVVRFLDWHGZLWKRUPRUHRIWKHIROORZLQJ
R 5HODWHGWRGHIHFDWLRQ
R $VVRFLDWHGZLWKDFKDQJHLQIUHTXHQF\RIERZHOPRYHPHQWV
R $VVRFLDWHGZLWKDFKDQJHLQIRUPDSSHDUDQFHRIVWRRO

7KHVHFULWHULDPXVWEHIXOILOOHGIRUWKHODVWPRQWKVSULRU WRUDQGRPL]DWLRQDQG
RQVHWPXVWKDYHRFFXUUHGDWOHDVWPRQWKVSULRUWRUDQGRPL]DWL RQ
 3DWLHQWPHHWVWKHGLDJQRVLVRI,%6'VXEW\SHEDVHGRQ5RPH, 9GLDJQRVWLFFULWHULD
 2QGD\VZKHQWKHSDWLHQWH[SHULHQFHV,%6V\PSWRPV
x $WOHDVWRIVWRROVDUHORRVHRUZDWHU\$1'
x )HZHUWKDQRIVWRROVDUHKDUGCCI
CCI
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI 2YHUWKHZHHNSULRUWRUDQGRPL]DWLRQWKHSDWLHQWKDVDQDYH UDJHRIZRUVWDEGRPLQDO
SDLQ:$3VFRUHVLQWKHSULRUKRXUVRIWRRQDW RQXPHULFDOUDWLQJ
VFDOHZKHUHLQGLFDWHVQRSDLQDQGLQGLFDWHVZRUVWSDLQLP DJLQDEOH
 2YHUWKHZHHNSULRUWRUDQGRPL]DWLRQWKHSDWLHQWKDVDQDYH UDJHGDLO\%6)6VFRUH
Â•RQDWRVFDOHZKHUH KDUGOXPS\VWRROVDQG ZDWHU\OLTXLGVWRROV
DQGDWOHDVWGD\VZLWKD%6)6VFRUHÂ•
 2YHUWKHZHHNSULRUWRUDQGRPL]DWLRQWKHSDWLHQWKDVDQDYH UDJHGDLO\,%6*6
VFRUHRIÂ•RQDWRVFDOHZKHUH QRQH PLOG  PRGHUDWH VHYHUH
 YHU\VHYHUH
 3DWLHQWLVQRWSODQQLQJWRFKDQJHKLVRUKHUXVXDOGLHWDQG OLIHVW\OHGXULQJWKHFRXUVH
RIWKHVWXG\
'LDJQRVWLF$VVHVVPHQWV 3DWLHQWPXVWXQGHUJRRUSUHYLRXVO\KDYHXQGHUJRQHDDQDSS URSULDWHHYDOXDWLRQIRU
WKHLU,%6V\PSWRPVLQFOXGLQJDQHYDOXDWLRQIRURUJDQLFVWUXFWX UDOHWLRORJLHVLILQWKH
SUHVHQFHRIDODUPV\PSWRPVDQGEDJHDSSURSULDWHVFUHHQLQJ IRUFRORUHFWDO
FDQFHULIDSSOLFDEOH
D ,IDWOHDVWRQHRIWKHIROORZLQJDODUPIHDWXUHVDUHSUHVHQW WKHQWKHSDWLHQWPXVW
KDYHKDGDFRORQRVFRS\VLQFHWKHRQVHWRIV\PSWRPVRUZLWKLQWK HSDVW\HDUV
ZKLFKHYHULVOHVV
x 'RFXPHQWHGDQGXQH[SODLQHGZHLJKWORVVRIÂ•ZLWKLQWKHSDV W
PRQWKV
x 1RFWXUQDOGLDUUKHD
x %ORRGPL[HGZLWKVWRROH[FHSWKHPRUUKRLGDOEOHHGLQJGHILQHG DV
RFFDVLRQDOEORRGIRXQGRQWKHWRLOHWSDSHURQO\RUOLPLWHGGULS SLQJRIEORRG
LQWRWKHWRLOHWERZODIWHUGHIHFDWLRQ
x 8QH[SODLQHGLURQGHILFLHQF\DQHPLD
E ,IQRDODUPIHDWXUHVDUHSUHVHQWWKHQWKHSDWLHQWPXVWKDYH KDGDFRORQRVFRS\
RURWKHUDSSURSULDWHH[DPEDVHGRQFULWHULDDVRXWOLQHGEHORZ 
x $JHÂ•Â•LI$IULFDQ$PHULFDQ&RORQRVFRS\VLQFHRQVHWR I
V\PSWRPVRUZLWKLQSDVW\HDUVZKLFKHYHULVOHVV
x )LUVWGHJUHHUHODWLYH)'5GLDJQRVHGZLWKFRORUHFWDOFDQFHUX QGHUDJH
25)'5VGLDJQRVHGZLWKFRORUHFWDOFDQFHUDWDQ\DJH&RORQRVF RS\
ZLWKLQSDVW\HDUV EHJLQQLQJ\HDUVEHIRUHDJHRI\RXQJHVW)'5DW
WLPHRIGLDJQRVLV
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRIx $JHÂ•$1')'5GLDJQRVHGZLWKFRORUHFWDOFDQFHUDWDQ\DJH 
&RORQRVFRS\ZLWKLQSDVW\HDUV
3DWLHQWLVQHJDWLYHIRUVHUXPWLVVXHWUDQVJOXWDPLQDVH,J$D QWLERG\W7*,J$SOXV
KDVHYLGHQFHRIGHWHFWDEOHVHUXP,J$ZLWKLQWKHQRUPDOUHIHUHQF HUDQJH
:HLJKW%RG\PDVVLQGH[%0,ZLWKLQWKHUDQJHWRNJP
LQFOXVLYH
*HQGHU0DOHDQGIHPDOHSDWLHQWVDUHHOLJLEOHLI
D 0DOHSDWLHQWV
$PDOHSDWLHQWPXVWDJUHHWRXVHFRQWUDFHSWLRQDVGHWDLOHGLQ $SSHQGL[ RI
WKLVSURWRFROGXULQJWKHWUHDWPHQWSHULRGDQGIRUDWOHDVWZ HHNVDIWHUWKH
ODVWGRVHRILQYHVWLJDWLRQDOSURGXFW3DWLHQWVPXVWDOVRDJUHH WRUHIUDLQIURP
GRQDWLQJVSHUPGXULQJWKLVSHULRG
E )HPDOHSDWLHQWV
$IHPDOHSDWLHQWLVHOLJLEOHWRSDUWLFLSDWHLIVKHLVQRWSUHJQ DQWVHH
$SSHQGL[QRWEUHDVWIHHGLQJDQGDWOHDVWRIWKHIROORZLQJ FRQGLWLRQV
DSSOLHV
L 1RWDZRPDQRIFKLOGEHDULQJSRWHQWLDO:2&%3DVGHILQHGLQ
$SSHQGL[25
LL $:2&%3ZKRDJUHHVWRIROORZWKHFRQWUDFHSWLYHJXLGDQFHLQ
$SSHQGL[GXULQJWKHWUHDWPHQWSHULRGDQGIRUDWOHDVWZHHNV DIWHUWKH
ODVWGRVHRILQYHVWLJDWLRQDOSURGXFW
,QIRUPHG&RQVHQW
&DSDEOHRIJLYLQJVLJQHGLQIRUPHGFRQVHQWZKLFKLQFOXGHVFRPSO LDQFHZLWKWKH
UHTXLUHPHQWVDQGUHVWULFWLRQVOLVWHGLQWKH,QIRUPHG&RQVHQW)R UP,&)DQGLQWKLV
SURWRFRO
3DWLHQWLVZLOOLQJWREHFRPSOLDQWZLWKVWXG\SURFHGXUHVL QFOXGLQJFRPSOHWLQJWKH
GDLO\HOHFWURQLFGLDU\GXULQJWKH5XQLQ3HULRGDQGWKURXJKRXW WKHVWXG\
 ([FOXVLRQ&ULWHULD
$QLQGLYLGXDOIRU ZKRPDQ\RIWKHIROORZLQJFULWHULDDSSO\ZLOO EHH[FOXGHGIURP
SDUWLFLSDWLRQLQWKLVVWXG\
*DVWURLQWHVWLQDOUHODW HG0HGLFDO&RQGLWLRQV
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI $WWKHWLPHRIVFUHHQLQJSDWLHQWKDVDGLDJQRVLVRIDQ,%6 VXEW\SHRWKHUWKDQ,%6'
EDVHGRQ5RPH,9FULWHULD %DVHGRQVWRROSDWWHUQVRQGD\VW KDW
WKHSDWLHQWH[SHULHQFHVV\PSWRPVRWKHU,%6VXEW\SHVDUHGHILQH GDVIROORZV
D ,%6&KDUGRUOXPS\VWRROVÂ•RIERZHOPRYHPHQWVDQGORR VHRUZDWHU\
VWRROVÂ”RIERZHOPRYHPHQWV
E ,%60KDUGRUOXPS\VWRROVÂ•RIERZHOPRYHPHQWVDQGORR VHRUZDWHU\
VWRROVÂ•RIERZHOPRYHPHQWV
F ,%68KDUGRUOXPS\VWRROVÂ”RIERZHOPRYHPHQWVDQGORR VHRUZDWHU\
VWRROVÂ”RIERZHOPRYHPHQWV
 3DWLHQWKDVDKLVWRU\RILQIODPPDWRU\RULPPXQHPHGLDWHG*, GLVRUGHUVLQFOXGLQJ
EXWQRWOLPLWHGWRLQIODPPDWRU\ERZHOGLVHDVHLH&URKQ
V GLVHDVHXOFHUDWLYH
FROLWLVPLFURVFRSLFFROLWL VDQGFHOLDFGLVHDVH
 3DWLHQWKDVKDGDQHSLVRGHRIGLYHUWLFXOLWLVZLWKLQPRQWKV SULRUWR6FUHHQLQJ
 3DWLHQWKDVDKLVWRU\RILQWHVWLQDOREVWUXFWLRQVWULFWXUH WR[LFPHJDFRORQ*,
SHUIRUDWLRQIHFDOLPSDFWLRQJDVWULFEDQGLQJEDULDWULFVXUJHU \DGKHVLRQVLVFKHPLF
FROLWLVRULPSDLUHGLQWHVWLQDOF LUFXODWLRQHJDRUWRLOLDFR FFOXVLYHGLVHDVH
 3DWLHQWKDVDQ\RIWKHIROORZLQJVXUJLFDOKLVWRU\
D &KROHF\VWHFWRP\ZLWK$1<KLVWRU\RISRVWFKROHF\VWHFWRP\ELO LDU\WUDFWSDLQ
$VXFFHVVIXOFKROHF\VWHFWRP\ZLWKQRSRVWRSHUDWLYHELOLDU\WUDF WSDLQLVQRW
H[FOXVLRQDU\
E $Q\DEGRPLQDOVXUJHU\ZLWKLQWKHPRQWKVSULRUWR6FUHHQLQJ 
F 0DMRUJDVWULFHVRSKDJHDOKHSDWLFSDQFUHDWLFRULQWHVWLQD OVXUJHU\
DSSHQGHFWRP\KHPRUUKRLGHFWRP\RUSRO\SHFWRP\ZLWKLQWKHP RQWKVSULRUWR
6FUHHQLQJ
 3DWLHQWKDVDKLVWRU\RUFXUUHQWHYLGHQFHRIOD[DWLYHDEXVH  
2WKHU0HGLFDO&RQGLWLRQV 3DWLHQWKDVDKLVWRU\RIDFDUGLRYDVFXODUHYHQWLQFOXGLQJV WURNHP\RFDUGLDO
LQIDUFWLRQFRQJHVWLYHKHDUWIDLOXUHRUWUDQVLHQWLVFKHPLFDWW DFNZLWKLQPRQWKVSULRU
WR6FUHHQLQJ
 3DWLHQWKDVDKLVWRU\RIPDOLJQDQF\ZLWKLQ\HDUVSULRUWR 6FUHHQLQJH[FHSW
VTXDPRXVDQGEDVDOFHOOFDUFLQRPDVDQGFHUYLFDOFDUFLQRPD LQVLWX
 3DWLHQWKDVDKLVWRU\RIDOFRKRODEXVHRUELQJHGULQNLQJCCI
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI3DWLHQWKDVXQFRQWUROOHGK\SHUWHQVLRQGHILQHGDVV\VWROLF EORRGSUHVVXUH
!PP+JRUDGLDVWROLFEORRGSUHVVXUH!PP+JDWWKHWLPH RI6FUHHQLQJ
3DWLHQWDKLVWRU\RIVLJQLILFDQWK\SHUVHQVLWLYLW\LQWROHUD QFHRUDOOHUJ\WRDQ\GUXJ
FRPSRXQGIRRGRURWKHUVXEVWDQFHXQOHVVDSSURYHGE\WKH,QYH VWLJDWRU
/DERUDWRU\$VVHVVPHQWV  
)HFDOFDOSURWHFWLQÂ•ÈJJ+HPRJORELQ$FOHYHOÂ•RUDFRQILUPHGIDVWLQJSODVPDJ OXFRVHOHYHO
Â•PJG/
&RQILUPHGDODQLQHDPLQRWUDQVIHUDVH$/7Â•XSSHUOLPLWRI QRUPDO8/1
&RQILUPHGWRWDOELOLUXELQÂ•PJG/ Â•P0/XQOHVVWKHSDWLHQWKDVD
GRFXPHQWHGKLVWRU\RI*LOEHUWÂ¶VV\QGURPH
&RQILUPHG47LQWHUYDOFRUUHFWHGE\)ULGHULFLDÂ¶VIRUPXOD47 F)RU47LQWHUYDO
FRUUHFWHGE\%D]HWWÂ¶VIRUPXOD47F%!PVHF
(YLGHQFHRIDFWLYHKHSDWLWLV%YLUXV+%9LQIHFWLRQEDVHG RQDSRVLWLYHKHSDWLWLV%
VXUIDFHDQWLJHQ+%V$JVFUHHQ
(YLGHQFHRIKHSDWLWLV&YLUXV+&9LQIHFWLRQEDVHGRQDSR VLWLYH+&9DQWLERG\
VFUHHQSDWLHQWVZKRKDYHEHHQVXFFHVVIXOO\WUHDWHGIRU+&9DUH HOLJLEOHLI
DQXQGHWHFWDEOH+&9YLUDOORDGDWOHDVWPRQWKVDIWHUFRPSOHWL RQRIWUHDWPHQWFDQ
EHGHPRQVWUDWHG
+XPDQLPPXQRGHILFLHQF\YLUXV+,9RU+,9DQWLERG\SRV LWLYH
3ULRU&RQFRPLWDQW7KHUDS\:LWKLQGD\VRIUDQGRPL]DWLRQSDWLHQWKDVXVHGK\GUR[\ WULSWDPLQH+7
RU
+7UHFHSWRUDQWDJRQLVWVHJDORVHWURQ
:LWKLQGD\VRIUDQGRPL]DWLRQSDWLHQWKDVXVHGDQ\RIWK HIROORZLQJ
x /RSHUDPLGH1RWHORSHUDPLGHFDQEHXVHGGXULQJWKHVWXG\DV UHVFXH
PHGLFDWLRQEDVHGRQSURWRFROVSHFLILHGJXLGHOLQHV>VHH 6HFWLRQ @
x $VSLULQRUDVSLULQFRQWDLQLQJPHGLFDWLRQV!PJRIDVSLULQ SHUGD\RU
QRQVWHURLGDODQWLLQIODPPDWRU\GUXJVZKHQWDNHQVSHFLILFDOO\I RUWKH
V\PSWRPVRI,%6
x 1DUFRWLFRURSLRLGFRQWDLQLQJDJHQWV
x &DQQDELVFRQWDLQLQJSURGXFWV
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRIx 'RFXVDWH
x (QHPDV
x *,SUHSDUDWLRQVLQFOXGLQJDQWDF LGVFRQWDLQLQJDOXPLQXPRUPDJ QHVLXP
DQWLGLDUUKHDODJHQWVDQWLVSDVPRGLFDJHQWVELVPXWKSHSSHUPLQW RLO
,%JDUG)'JDUGRUSURNLQHWLFDJHQWV
:LWKLQGD\VRIUDQGRPL]DWLRQUHFHLSWRIDQ\SUHVFULEHG RURYHUWKHFRXQWHU
V\VWHPLFKHUEDOLQFOXGLQJ6W- RKQÂ¶VZRUWRUWRSLFDOPHGLFD WLRQRUDQ\H[SHFWDWLRQ
RIUHTXLULQJXVHRIVXFKPHGLFDWLRQZKLOHSDUWLFLSDWLQJLQWKH VWXG\WKDWLQWKH
RSLQLRQRIWKH,QYHVWLJDWRUZRXOGLQWHUIHUHZLWKVWXG\SURFHGX UHVFRPSURPLVH
VDIHW\RUWKHVFLHQWLILFLQWHJULW\RIWKHGDWD
3DWLHQWKDVXVHGRULVH[SHFWHGWRXVHWKHIROORZLQJDQWL ELRWLFV
x 5LID[LPLQZLWKLQGD\VSULRUWRUDQGRPL]DWLRQ
x 2WKHURUDODQWLELRWLFVZLWKLQGD\VRIUDQGRPL]DWLRQZLWKW KHH[FHSWLRQ
RIWRSLFDODQWLELRWLFVRUDGD\FRXUVHZLWKDQDQWLELRWLF
+RZHYHUDSDWLHQWZLOOEHDOORZHGWRUHPDLQLQWKHVWXG\VKRXO GXQSODQQHGXVHRI
DQWLELRWLFVRWKHUWKDQULID[LPLQRFFXUDIWHUWKHSDWLHQWKDVEH HQUDQGRPO\DVVLJQHGWR
VWXG\GUXJ
:LWKLQPRQWKVSULRUWRUDQGRPL]DWLRQSDWLHQWKDVKDGVLJ QLILFDQWFKDQJHVWRKLVRU
KHUDQWLGHSUHVVDQWUHJLPHQLHDGGLWLRQRIDQHZDJHQWGLVF RQWLQXDWLRQRIDSULRU
DJHQWVLJQLILFDQWPRGLILFDWLRQVW RWKHGRVHRIDFXUUHQWPHGLF DWLRQ3DWLHQWVRQ
FKURQLFVWDEOHGRVHVRIDQWLGHSUHVVDQWVZLOOEHDOORZHGWRSDUW LFLSDWHLQWKHVWXG\
$VQHHGHGXVHRIEXVSLURQHDQGEHQ]RGLD]HSLQHVIRUDQ[LHW\LVS HUPLWWHGGXULQJWKH
VWXG\
:LWKLQGD\VSULRUWRUDQGRPL]DWLRQRUKDOIOLYHVLI NQRZQWKHSDWLHQWKDV
UHFHLYHGDQLQYHVWLJDWLRQDOGUXJRULVFXUUHQWO\HQUROOHGLQD QLQYHVWLJDWLRQDOVWXG\
2WKHU([FOXVLRQV  
3DWLHQWLVXQDEOHWRVZDOORZVROLGRUDOGRVDJHIRUPVZKROH ZLWKWKHDLGRIOLTXLG
SDWLHQWVPD\QRWFKHZGLYLGHGLVVROYHRUFUXVKWKHVWXG\GU XJ
3DWLHQWKDVDQHOHFWLYHVXUJHU\SODQQHGRUH[SHFWVWRQHHG HOHFWLYHVXUJHU\DWDQ\
WLPHGXULQJWKHVWXG\
3DWLHQWLVSUHJQDQWRUEUHDVWIHHGLQJ3DWLHQWKDVDQ\PHGLFDORUSV\FKRORJLFDOGLVRUGHURUFRQGLW LRQWKDWLQWKHRSLQLRQRI
WKH,QYHVWLJDWRUZRXOGFRPSURPLVHWKHZHOOEHLQJRIWKHSDWLHQW RUWKHVWXG\RU
SUHYHQWWKHSDWLHQWIURPPHHWLQJRUSHUIRUPLQJVWXG\UHTXLUHPHQ WV
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI3DWLHQWKDVSRRUSHULSKHUDOYHQRXVDFFHVV
3DWLHQWLVDQHPSOR\HHRIWKH,QYHVWLJDWRURUVWXG\FHQWHU ZLWKGLUHFWLQYROYHPHQWLQ
WKHSURSRVHGVWXG\RURWKHUVWXGLHVXQGHUWKHGLUHFWLRQRIWKDW ,QYHVWLJDWRURUVWXG\
FHQWHUDVZHOODVIDPLO\PHPEHUVRIWKHHPSOR\HHVRUWKH,QYHV WLJDWRU
 /LIHVW\OH&RQVLGHUDWLRQV
'XULQJWKLVVWXG\SDWLHQWVZLOOEHDVNHGWRDEVWDLQIURPVWUHQ XRXVH[HUFLVHIRUKRXUV
EHIRUHHDFKEORRGFROOHFWLRQIRUFOLQLFDOODERUDWRU\WHVWV
2QO\RQGD\VZKHQSRVWGRVH3.EORRGVDPSOHVDUHWREHWDNHQVH HIRRWQRWHILQWKH
6FKHGXOHRI$FWLYLWLHV 6HFWLRQ SDWLHQWVZLOOEHDVNHGWRUHIUDLQIURPFRQVXPSWLRQ
RIIRRGDQGZDWHUIRUKRXUSULRUWRDQGIRUKRXUVDIWHUDGP LQLVWUDWLRQRI
LQYHVWLJDWLRQDOSURGXFW)RRGDQGZDWHUPD\EHFRQVXPHG DGOLELWXPDWDOORWKHUWLPHV
GXULQJWKHVWXG\,QYHVWLJDWLRQDOSURGXFWVKRXOGEHWDNHQZLWK DSSUR[LPDWHO\P/
ZDWHU
 6FUHHQ)DLOXUHV
6FUHHQIDLOXUHVDUHGHILQHGDVSDWLHQWVZKRFRQVHQWWRSDUWLFLS DWHLQWKHFOLQLFDOWULDOEXW
DUHQRWVXEVHTXHQWO\UDQGRPL]HG$PLQLPDOVHWRIVFUHHQIDLOXU HLQIRUPDWLRQLVUHTXLUHG
WRHQVXUHWUDQVSDUHQWUHSRUWLQJRIVFUHHQIDLOXUHSDWLHQWVWR PHHWWKH&RQVROLGDWHG
6WDQGDUGVRI5HSRUWLQJ7ULDOV&216257SXEOLVKLQJUHTXLUHPHQWV DQGWRUHVSRQGWR
TXHULHVIURPUHJXODWRU\DXWKRULWLHV0LQLPDOLQIRUPDWLRQLQFOXG HVGHPRJUDSK\VFUHHQ
IDLOXUHGHWDLOV HOLJLELOLW\FULWHULDDQGDQ\6$(
,QGLYLGXDOVZKRGRQRWPHHWWKHFULWHULDIRUSDUWLFLSDWLRQLQW KLVWULDOVFUHHQIDLOXUHPD\
EHUHVFUHHQHGZLWK0HGLFDO0RQLWRUDSSURYDO
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI ,19(67,*$7,21$/352'8&7
 ,QYHVWLJDWLRQDO3URGXFWV
 ,QYHVWLJDWLRQD O3URGXFW'HVFULSWLRQ
,QYHVWLJDWLRQDO
3URGXFW1DPH %26 3ODFHER
'RVDJH)RUPXODWLRQ  7DEOHW 7DEOHW
8QLW'RVH
6WUHQJWKV'RVDJH/HYHOVPJ[PJWDEOHWVDQG
PJ[PJWDEOHWV9LVXDOO\PDWFKLQJSODFHERWDEOHWV
DFURVVERWK%26GRVHOHYHOV
5RXWH
RI$GPLQLVWUDWLRQ 2UDO 2UDO
'RVLQJ,QVWUXFWLRQV
6ZDOORZZKROHZLWKDJODVVRI
ZDWHUGRQRWFKHZGLYLGH
GLVVROYHRUFUXVK6ZDOORZZKROHZLWKDJODVVRI
ZDWHUGRQRWFKHZGLYLGH
GLVVROYHRUFUXVK
3DFNDJLQJ
DQG/DEHOLQJ ,QYHVWLJDWLRQDOSURGXFWZLOOEH
SURYLGHGLQZKLWHRSDTXH
KLJKGHQVLW\SRO\HWK\OHQH+'3(
ERWWOHVZLWKDFKLOGUHVLVWDQW
FORVXUH(DFKERWWOHZLOOEHODEHOHG
DVSHUFRXQWU\UHTXLUHPHQW,QYHVWLJDWLRQDOSURGXFWZLOOEH
SURYLGHGLQZKLWHRSDTXH+'3(
ERWWOHVZLWKDFKLOGUHVLVWDQW
FORVXUH(DFKERWWOHZLOOEHODEHOHG
DVSHUFRXQWU\UHTXLUHPHQW
0DQXIDFWXUHU  :X;L67$6KDQJKDL&KLQD :X;L67$6KDQJKDL&KLQD
 3UHSDUDWLRQ+DQGOLQJ6WRUDJH$FFRXQWDELOLW\
 $FTXLVLWLRQDQGDFFRXQWDELOLW\
7KH,QYHVWLJDWRURUGHVLJQHHPXVWFRQILUPDSSURSULDWHWHPSHUDWX UHFRQGLWLRQVKDYH
EHHQPDLQWDLQHGGXULQJWUDQVLWIRUDOOLQYHVWLJDWLRQDOSURGXFW UHFHLYHGDQGDQ\
GLVFUHSDQFLHVDUHUHSRUWHGDQGUHVROYHGEHIRUHXVHRIWKHLQYHV WLJDWLRQDOSURGXFW
7KH,QYHVWLJDWRULQVWLWXWLRQRUWKHKHDGRIWKHPHGLFDOLQVWL WXWLRQZKHUHDSSOLFDEOHLV
UHVSRQVLEOHIRULQYHVWLJDWLRQDOSURGXFWDFFRXQWDELOLW\UHFRQFL OLDWLRQDQGUHFRUG
PDLQWHQDQFHLHUHFHLSWUHFRQ FLOLDWLRQDQGILQDOGLVSRVLWL RQUHFRUGV
 3URGXFW6WRUDJHDQG6WDELOLW\$OOLQYHVWLJDWLRQDOSURGXFWPXVWEHVWRUHGLQDVHFXUHHQYLURQ PHQWDOO\FRQWUROOHGDQG
PRQLWRUHGPDQXDORUDXWRPDWHGDUHDLQDFFRUGDQFHZLWKWKHODE HOHGVWRUDJH
FRQGLWLRQVZLWKDFFHVVOLPLWHGWRWKH,QYHVWLJDWRUDQGDXWKRUL] HGVLWHVWDII
)XUWKHUJXLGDQFHDQGLQIRUPDWLRQIRUWKHILQDOGLVSRVLWLRQRIX QXVHGLQYHVWLJDWLRQDO
SURGXFWVDUHSURYLGHGLQWKH3KDUPDF\0DQXDO
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI 0HDVXUHVWR0LQLPL]H%LDV
7KLVLVDUDQGRPL]HGGRXEOHEOLQGHG3%2FRQWUROOHGVWXG\3DW LHQWVVKRXOGEH
UDQGRPL]HGDVFORVHDVSRVVLEOHWRWKHWLPHRIWKHSODQQHGILUV WGRVHRIVWXG\WUHDWPHQW
5DQGRPL]DWLRQZLOOEHFRQGXFWHGYLDDQLQWHUDFWLYHZHEUHVSRQVH V\VWHP,:56LQD
UDWLRIRUSDWLHQWVWRUHFHLYH%26PJ%26 PJRU3%23DWLHQWV
ZLOOEHDVVLJQHGWRWKHWUHDWPHQWDUPVXVLQJDSHUPXWHGEORFNU DQGRPL]DWLRQVWUDWLILHG
E\VLWHSDWLHQWVSHUJURXS7KHUDQGRPL]DWLRQVFKHGXOHZLO OEHJHQHUDWHGE\WKH
6WXG\%LRVWDWLVWLFLDQDQGZLOOEHWUDQVIHUUHGWRWKH,:56WHDP IRUORDGLQJLQWRWKH
V\VWHP7KHUDQGRPL]DWLRQILOHZLOOEHKHOGE\WKH6WXG\%LRVWD WLVWLFLDQXQWLOWKHHQGRI
WKHWULDODQGZKHQWKHGDWDEDVHKDVEHHQORFNHG
7KHVSRQVRUVLWHVWDIIDQGSDW LHQWVZLOOEHEOLQGHGWRWKHWU HDWPHQWDVVLJQPHQW
%26DQG3%2ZLOOEHVLPLODULQDSSHDUDQFHDQGSURYLGHGLQ ZKLWHRSDTXH
KLJKGHQVLW\SRO\HWK\OHQH+'3(ERWWOHVHDFKZLWKDFKLOGUHV LVWDQWFORVXUH(DFK
ERWWOHZLOOEHODEHOHGDVSHU FRXQWU\UHTXLUHPHQW
2QO\LQDPHGLFDOHPHUJHQF\ZLOODSDWLHQWÂ¶VWUHDWPHQWDVVLJQPH QWEHXQEOLQGHGDQG
WKLVSURFHVVZLOOEHSHUIRUPHGDQGGRFXPHQWHGLQWKH,:56(YHU \HIIRUWVKRXOGEH
PDGHWRFRQWDFWWKH0HGLFDO0RQLWRUWRGLVFXVVXQEOLQGLQJSULRU WREUHDNLQJWKHEOLQG
 'RVLQJDQG$GPLQLVWUDWLRQ
2QO\SDWLHQWVHQUROOHGLQWKHVWXG\PD\UHFHLYHLQYHVWLJDWLRQDO SURGXFWDQGRQO\
DXWKRUL]HGVLWHVWDIIPD\VXSSO\RUDGPLQLVWHULQYHVWLJDWLRQDO SURGXFW
(OLJLEOHSDWLHQWVZLOOEHUDQGRPL]HGWRUHFHLYHIRUDW RWDORIZHHNV%26DW
RIGRVHOHYHOVRU3%2ELG3DWLHQWVZLOOEHUDQGRPL]HGWRW KHIROORZLQJFRKRUWV
x &RKRUW+LJK'RVH[PJWDEOHWVIRUWKHPJ%26 ELGRUDOO\
x &RKRUW/RZ'RVH[PJWDEOHWVIRUWKHPJ%26E LGRUDOO\
x &RKRUW3%2[YLVXDOO\PDWFKHG3%2WDEOHWVELGRUDOO\
)RUHDFKGRVHOHYHODQGDWHDFKGRVLQJWLPHSRLQWWKHWDEOHWV DUHWREHVZDOORZHGZLWK
DSSUR[LPDWHO\P/URRPWHPSHUDWXUHZDWHUDQGDUHWREHVZDOO RZHGZKROHLHQRW
GLYLGHGFUXVKHGGLVVROYHGRUFKHZHG2QGD\VZKHQSRVWGRVH 3.EORRGVDPSOHVDUH
WREHWDNHQVHHIRRWQRWHILQWKH6FKHGXOHRI$FWLYLWLHV 6HFWLRQ SDWLHQWVZLOOEH
DVNHGWRUHIUDLQIURPFRQVXPSWLRQRIIRRGDQGZDWHUIRUKRXU SULRUWRDQGIRUKRXUV
DIWHUDGPLQLVWUDWLRQRILQYHVWLJDWLRQDOSURGXFW)RRGDQGZDWHU PD\EHFRQVXPHG DG
OLELWXPDWDOORWKHUWLPHVGXULQJWKHVWXG\
3DWLHQWVZLOOEHLQVWUXFWHGWRWDNHWKHLQYHVWLJDWLRQDOSURGXFW DSSUR[LPDWHO\HYHU\
KRXUVDWDSSUR[LPDWHO\WKHVDPHWLPHHDFKGD\,IDSDWLHQW PLVVHVDGRVHDWDJLYHQ
WLPHSRLQWDQGWKHWLPHLVZLWKLQKRXUVRIWKHUHJXODUO\VFKH GXOHGGRVLQJWLPHWKH
SDWLHQWVKRXOGEHLQVWUXFWHGWRWDNHWKHLQYHVWLJDWLRQDOSURGXF W,ILWKDVEHHQORQJHUWKDQ
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRIKRXUVWKHSDWLHQWVKRXOGVNLSWKHPLVVHGGRVHDWWKDWWLPHSR LQWDQGUHVXPHWKH
UHJXODUO\VFKHGXOHGGRVLQJVFKHGXOHDWWKHQH[WVFKHGXOHGWLPHS RLQW
,QWKHHYHQWRIYRPLWLQJIROORZLQJDGPLQLVWUDWLRQ%26VKRX OGQRWEHWDNHQXQWLOWKH
QH[WVFKHGXOHGGRVH
 'RVHPRGLILFDWLRQ
6WXG\WUHDWPHQWVKRXOGEHLQWHUUXSWHGLIWKHSDWLHQWUHSRUWVDQ \WUHDWPHQWUHODWHGVHYHUH
$(7KHUDS\VKRXOGRQO\EHUHVWDUWHGDIWHUDSSURYDOE\WKH0HGL FDO0RQLWRU
,IWKHUDS\LVUHVWDUWHGWKHVDPHGRVHVKRXOGEHDGPLQLVWHUHGD VWKDWSULRUWR
RFFXUUHQFHRIWKH$(,IWKHSDWLHQWLVVWLOOKDYLQJWROHUDELOL W\LVVXHVDQGDQ$(UHRFFXUV
WKHGRVHPD\EHUHGXFHGIURPWDEOHWVRIVWXG\WUHDWPHQWELGW RWDEOHWRIVWXG\
WUHDWPHQWELGZLWKRXWEUHDNLQJWKHVWXG\EOLQG
,IDQRWKHU$(RFFXUVDIWHUWKHVWXG\WUHDWPHQWGRVHUHGXFWLRQ VWXG\WUHDWPHQWZLOOEH
SHUPDQHQWO\GLVFRQWLQXHGDQGWKHVXEMHFWIROORZHGXQWLOWKHHQG RIWKHVWXG\
 ,QYHVWLJDWLRQDO3URGXFW&RPSOLDQFH
$OOSDWLHQWVLQWKLVVWXG\ZLOOFRPPHQFHWKHUDS\RQVLWHRQ6WX G\'D\RUDO
LQYHVWLJDWLRQDOSURGXFWZLOOEHDGPLQLVWHUHGXQGHUFOLQLFVWDII VXSHUYLVLRQ$IWHUSDWLHQWV
DUHGLVFKDUJHGWRFRQWLQXHWKHUDS \DWKRPHFRPSOLDQFHZLOOEH DVVHVVHGRQ
VXEVHTXHQWYLVLWVE\UHWXUQHGWDEOHWFRXQW$GPLQLVWUDWLRQRIL QYHVWLJDWLRQDOSURGXFWDQG
DQ\GHYLDWLRQVIURPWKHSUHVFULEHGGRVDJHUHJLPHQVKRXOGEHU HFRUGHGLQWKHFDVH
UHSRUWIRUP&5)DQG'UX J$FFRXQWDELOLW\5HFRUG
 &RQFRPLWDQW7KHUDS\
5HIHUWR$SSHQGL[ IRUPRUHGHWDLOVRQZKLFKFRQFRPLWDQWPHGLFDWLRQVDUHSHUPLWWHG 
DQGZKLFKDUHH[FOXGHGZKLOHSDWLHQWVDUHRQVWXG\
$Q\SULRURUFRQFRPLWDQWWKHUDS\LQFOXGLQJRYHUWKHFRXQWHURU SUHVFULSWLRQPHGLFLQHV
YLWDPLQVDQGRUVXSSOHPHQWVWDNHQGD\VSULRUWRWKHILUVWG RVHRILQYHVWLJDWLRQDO
SURGXFWWKURXJKWKH(QGRI6WXG\9LVLWPXVWEHUHFRUGHGDORQJ ZLWK
x 5HDVRQIRUXVH
x 'DWHVRIDGPLQLVWUDWLRQLQFOXGLQJVWDUWDQGHQGGDWHV
x 'RVDJHLQIRUPDWLRQLQFOXGLQJGRVHDQGIUHTXHQF\ 
7KH0HGLFDO0RQLWRUVKRXOGEHFRQWDFWHGLIWKHUHDUHDQ\TXHVWL RQVUHJDUGLQJ
FRQFRPLWDQWRUSULRUWKHUDS\
)RUWKLVSURWRFRODSUHVFULSWLRQPHGLFDWLRQLVGHILQHGDVDPH GLFDWLRQWKDWFDQEH
SUHVFULEHGRQO\E\DSURSHUO\DXWKRUL]HGOLFHQVHGFOLQLFLDQ0H GLFDWLRQVWREHUHSRUWHG
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRILQWKH&5)DUHFRQFRPLWDQWSUHVFULSWLRQPHGLFDWLRQVRYHUWKHF RXQWHUPHGLFDWLRQV
YDFFLQHVYLWDPLQVDQGVXSSOHPHQWV
 5HVFXH0HGLFLQH'XULQJWKHGRXEOHEOLQG7UHDWPHQW3KDVHRIWKHVWXG\SDWLHQWV ZLOOEHDOORZHGWRWDNH
ORSHUDPLGHUHVFXHPHGLFDWLRQIRUWKHDFXWHWUHDWPHQWRIXQFRQWU ROOHGGLDUUKHD
/RSHUDPLGHDWDXQLWGRVHRIPJPD\EHWDNHQRQFHDSSUR[LPDWH O\HYHU\KRXUVZLWK
WKHIROORZLQJJXLGHOLQHV
x 1RPRUHWKDQXQLWGRVHVRYHUDFRQWLQXRXVKRXUWLPHSHULR GPJGD\
x 1RPRUHWKDQXQLWGRVHVRYHUDFRQWLQXRXVKRXUWLPHSHULR GPJRYHU
GD\V
x 1RPRUHWKDQXQLWGRVHVRYHUDFRQWLQXRXVGD\WLPHSHULRG 
7KHXVHRIORSHUDPLGHUHVFXHPHGLFDWLRQVKRXOGEHUHFRUGHGHOHF WURQLFDOO\
 ,QWHUYHQWLRQ$IWHUWKH(QGRIWKH6WXG\
%26ZLOOQRWEHSURYLGHGWRVWXG\SDWLHQWVDIWHUWKHHQGRI WKHVWXG\
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI ',6&217,18$7,21:,7+'5$:$/
 'LVFRQWLQXDWLRQRI,QYHVWLJDWLRQDO3URGXFW
$SDWLHQWPD\GLVFRQWLQXHIURPVWXG\WUHDWPHQWDWDQ\WLPHDWK LVRUKHURZQUHTXHVWRU
PD\EHZLWKGUDZQDWDQ\WLPHDWWKHGLVFUHWLRQRIWKH,QYHVWLJD WRUIRUVDIHW\EHKDYLRUDO
RUDGPLQLVWUDWLYHUHDVRQV'LVFRQWLQXDWLRQIURPWKHLQYHVWLJDWL RQDOSURGXFWGRHVQRW
PHDQGLVFRQWLQXDWLRQIURPWKHVWXG\DQGUHPDLQLQJVWXG\SURFHG XUHVVKRXOGEH
FRPSOHWHGDVLQGLFDWHGE\WKHVWXG\SURWRFRO,IDFOLQLFDOO\V LJQLILFDQWILQGLQJLVLGHQWLILHG
LQFOXGLQJEXWQRWOLPLWHGWRFKDQJHVIURPEDVHOLQHDIWHUHQ UROOPHQWWKH,QYHVWLJDWRURU
TXDOLILHGGHVLJQHHZLOOGHWHUPLQHLIDQ\FKDQJHLQSDWLHQWPDQD JHPHQWLVQHHGHG$Q\
QHZFOLQLFDOO\UHOHYDQWILQGLQJZLOOEHUHSRUWHGDVDQ$(
8SRQLQYHVWLJDWLRQDOSURGXFWGLVFRQWLQXDWLRQSDWLHQWVVKRXOGF RPSOHWHDOOSURFHGXUHV
FROOHFWHGLQWKH'D\(QGRI6WXG\)ROORZXSYLVLWDVDSSOLFD EOHSHUWKH6FKHGXOHRI
$FWLYLWLHV 6HFWLRQ 
 'LVFRQWLQXDWLRQ:LWKGUDZDOIURPWKH6WXG\
$SDWLHQWPD\ZLWKGUDZIURPWKHVWXG\DWDQ\WLPHDWKLVRUKHU RZQUHTXHVWRUPD\EH
ZLWKGUDZQDWDQ\WLPHDWWKHGLVFUHWLRQRIWKH,QYHVWLJDWRUIRU WKHIROORZLQJUHDVRQV
x ,IDQ\FOLQLFDO$(ODERUDWRU\DEQRUPDOLW\RURWKHUPHGLFDOF RQGLWLRQRUVLWXDWLRQ
RFFXUVVXFKWKDWFRQWLQXHGSDUWLFLSDWLRQLQWKHVWXG\ZRXOGQRW EHLQWKHEHVW
LQWHUHVWRIWKHSDWLHQW
x 'LVHDVHSURJUHVVLRQWKDWUHTXLUHVGLVFRQWLQXDWLRQRIWKHLQYHV WLJDWLRQDOSURGXFW
x 3UHJQDQF\
x ,IWKHSDWLHQWPHHWVDQH[FOXVLRQFULWHULRQHLWKHUQHZO\GHYH ORSHGRUQRW
SUHYLRXVO\UHFRJQL]HGWKDWSUHFOXGHVIXUWKHUVWXG\SDUWLFLSDWL RQDIWHUFRQVXOWDWLRQ
ZLWKWKH0HGLFDO0RQLWRU
x 6LJQLILFDQWLQYHVWLJDWLRQDOSURGXFWQRQFRPSOLDQFH
x 7HUPLQDWLRQRIWKHVWXG\E\WKHVSRQVRU
,IWKHSDWLHQWZLWKGUDZVFRQVHQWIRUGLVFORVXUHRIIXWXUHLQIRU PDWLRQWKHVSRQVRUPD\
UHWDLQDQGFRQWLQXHWRXVHDQ\GDWDFROOHFWHGEHIRUHVXFKDZLW KGUDZDORIFRQVHQW
,IDSDWLHQWZLWKGUDZVIURPWKHVWXG\KHRUVKHPD\UHTXHVWGH VWUXFWLRQRIDQ\VDPSOHV
WDNHQDQGQRWWHVWHGDQGWKH,QYHVWLJDWRUPXVWGRFXPHQWWKLVL QWKHVLWHVWXG\UHFRUGV
6HH6FKHGXOHRI$ FWLYLWLHV6HFWLRQ IRUGDWDWREHFROOHFWHGDWWKHWLPHRIVWXG\
GLVFRQWLQXDWLRQDQGIROORZXSDQGIRUDQ\IXUWKHUHYDOXDWLRQVW KDWQHHGWREHFRPSOHWHG
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI7KHUHDVRQIRUSDWLHQWGLVFRQWLQXDWLRQRUZLWKGUDZDOIURPWKHV WXG\ZLOOEHUHFRUGHGRQ
WKH&5)
3DWLHQWVZKRVLJQWKH,&)DQGDUHUDQGRPL]HGEXWGRQRWUHFHLYH WKHLQYHVWLJDWLRQDO
SURGXFWPD\EHUHSODFHG2QFHUDQGRPL]HGSDWLHQWVZKRDUHZLWK GUDZQIURPWKHUDS\
EHIRUHFRPSOHWLQJGD\VRIGRVLQJRUDUHGLVFRQWLQXHGIURPWK HVWXG\IRUDQ\UHDVRQ
ZLOOQRWEHUHSODFHG
 /RVWWR)ROORZXS
$SDWLHQWZLOOEHFRQVLGHUHGORVWWRIROORZXSLIKHRUVKHUHS HDWHGO\IDLOVWRUHWXUQIRU
VFKHGXOHGYLVLWVDQGLVXQDEOHWREHFRQWDFWHGE\WKHVWXG\VLW HVWDII
7KHIROORZLQJDFWLRQVPXVWEHWDNHQLIDSDWLHQWIDLOVWRUHWXU QWRWKHFOLQLFIRUDUHTXLUHG
VWXG\YLVLW
x 7KHVLWHZLOODWWHPSWWRFRQWDFWWKHSDWLHQWDQGUHVFKHGXOHWK HPLVVHGYLVLWDVVRRQ
DVSRVVLEOHFRXQVHOWKHSDWLHQWRQWKHLPSRUWDQFHRIPDLQWDLQL QJWKHDVVLJQHGYLVLW
VFKHGXOHDQGDVFHUWDLQLIWKHSDWLHQWZLVKHVWRDQGRUVKRXOG FRQWLQXHLQWKHVWXG\
x %HIRUHDSDWLHQWLVGHHPHGORVWWRIROORZXSWKH,QYHVWLJDWRU RUGHVLJQHHZLOOPDNH
HYHU\HIIRUWWRUHJDLQFRQWDFWZLWKWKHSDWLHQWZKHUHSRVVLEOH WHOHSKRQHFDOOVDQG
LIQHFHVVDU\DFHUWLILHGOHWWHU WRWKHSDWLHQWÂ¶VODVWNQRZQPD LOLQJDGGUHVVRUORFDO
HTXLYDOHQWPHWKRGV7KHVHFRQWDFWDWWHPSWVVKRXOGEHGRFXPHQWHG LQWKHSDWLHQWÂ¶V
PHGLFDOUHFRUGRUVWXG\ILOH
x 6KRXOGWKHSDWLHQWFRQWLQXHWRE HXQUHDFKDEOHKHRUVKHZLOO EHFRQVLGHUHGWRKDYH
ZLWKGUDZQIURPWKHVWXG\ZLWKDSULPDU\UHDVRQRIORVWWRIROOR ZXS

%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI 678'<$66(660(176$1'352&('85(6
3ODQQHGWLPHSRLQWVIRUDOODVVHVVPHQWVDUHSURYLGHGLQWKH6FKH GXOHRI$FWLYLWLHV
6HFWLRQ 
 6WXG\3HULRGV
7KHVWXG\ZLOOFRPSULVHSKDVHV
3UH7UHDWPHQW3KDVH XSWRZHHNVLQZKLFKDOOSDWLHQWVZLOOEHDVVHVVHGIRU
HOLJLELOLW\7KHSUHWUHDWPHQWS KDVHZLOOFRQVLVWRILQLWLDOVF UHHQLQJDVVHVVPHQWV
9LVLWDQGD5XQLQSHULRG9LVLWWKURXJK9LVLW
 $7UHDWPHQW3KDVH ZHHNVLQZKLFKDOOSDWLHQWVZLOOUHWXUQWRWKHFOLQLFDOI RU
UDQGRPL]DWLRQDQGVWDUWRIWUHDWPHQW9LVLWÂ±'D\IROORZHG E\ZHHNO\YLVLWV
9LVLWÂ±'D\> Â“GD\@9LVLWÂ±'D\> Â“GD\@9LVLWÂ±'D\> Â“GD\@XQWLO
9LVLWÂ±'D\ Â“GD\DQG
 $)ROORZXS3KDVH ZHHNVLQZKLFKSDWLHQWVZKRFRPSOHWH9LVLWZLOOEHDVN HG
WRUHWXUQIRUDQ(QGRI6WXG\)ROORZXSYLVLW9LVLWÂ±'D\ >Â“GD\V@IRU
DVVHVVPHQWRIWUHDWPHQWRXWFRPHHJVDIHW\GXUDELOLW\RIHI IHFW
 6FUHHQLQJ$VVHVVPHQWV
$IWHUVLJQLQJWKH,&)VWKH SDWLHQWZLOOXQGHUJRWKHLQLWLDO VFUHHQLQJDVVHVVPHQWVDQG
SURFHGXUHVDVGHVFULEHGLQWKH6FKHGXOHRI $FWLYLWLHV6HFWLRQ WRGHWHUPLQH
HOLJLELOLW\
(OLJLEOHSDWLHQWVZLOOHQWHUWKH 5XQLQSHULRG$WWKHEHJLQQLQ JRIWKH5XQLQSHULRG
SDWLHQWVZLOOUHFHLYHLQVWUXFWL RQVIRUFRPSOHWLQJDQHOHFWURQLF GLDU\WRFROOHFWGDLO\
LQIRUPDWLRQUHODWHGWRWKHLU,%6'V\PSWRPVWKHLUERZHOIXQFWL RQDQGUHVFXH
PHGLFDWLRQXVH
3DWLHQWVZKRDUH
x &RPSOLDQWLQFRPSOHWLQJWKHVFUHHQLQJGLDU\RQDGDLO\EDVLVR QDWOHDVWRIWKH
GD\VGXULQJWKHZHHNSULRUWRUDQGRPL]DWLRQ$1'RQDWOHDVW RIWKHGD\V
GXULQJWKHZHHNVSULRUWRUDQGRPL]DWLRQDQG
x +DYHDQDYHUDJH:$3VFRUHLQWKHSDVWKRXUVRIEHWZHHQ DQGRQD
WRVFDOHRYHUWKHZHHNSULRUWRUDQGRPL]DWLRQDQG
x +DYHDQDYHUDJHGDLO\%6)6RIÂ•DQGDWOHDVWGD\VZLWKD %6)6VFRUH
Â•RQDWRVFDOHRYHUWKHZHHNSULRUWRUDQGRPL]DWLRQD QG
x +DYHDQDYHUDJHGDLO\,%6*6VFRUHRIÂ•RQDWRVFDOH RYHUWKHZHHN
SULRUWRUDQGRPL]DWLRQDQG
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRIx :KRKDYHQRWXVHGDQ\ORSHUDPLGHUHVFXHPHGLFDWLRQLQWKHZH HNVSULRUWR
UDQGRPL]DWLRQ
ZLOOEHHOLJLEOHIRUSDUWLFLSDWLRQDQGLPPHGLDWHUDQGRPL]DWLRQ LQWRWKHGRXEOHEOLQG
WUHDWPHQWSKDVHLHDOOGLDU\FRQGLWLRQVPXVWEHPHWWRTX DOLI\IRUUDQGRPL]DWLRQ
(OLJLEOHSDWLHQWVZLOOEHLQVWUX FWHGWRUHWXUQWRWKHVWXG\VLW HIRUWKH%DVHOLQHYLVLWRQ
'D\
3DWLHQWVZKRGRQRWPHHWDOORIWKHGLDU\FRQGLWLRQVUHTXLUHG IRUHQWU\LQWKHSUHFHGLQJ
ZHHNVPD\EHJUDQWHGDQH[WUDZHHNRIVFUHHQLQJWLPHLQZKLFK WRVDWLVI\DOORIWKH
FULWHULDIRUDWRWDOVFUHHQLQJSHULRGRIZHHNV
 (IILFDF\$VVHVVPHQWV
7KHHIILFDF\REMHFWLYHVRIWKHVWXG\DUHWRHYDOXDWHWKHHIIHFW RI%26UHODWLYHWR
3%2DIWHUZHHNVRIWKHUDS\RQSDLQGHIHFDWLRQDQGNH\,%6 'UHODWHGVLJQVDQG
V\PSWRPV
'XULQJWKHZHHNVRIWKHGRXEOHEOLQGWUHDWPHQWSKDVHSDWLHQW VZLOOEHUHTXLUHGWR
DFFHVVWKHLUHOHFWURQLFGLDU\HYHU\GD\SUHIHUDEO\DWWKHVDPH WLPHHDFKGD\WRUHFRUG
,%6'V\PSWRPGDWDDQGLQIRUPDWLRQUHODWHGWRWKHLUERZHOIXQFW LRQDQGUHVFXH
PHGLFDWLRQXVH
 :RUVW$EGRPLQDO3DLQ7KURXJKRXWWKHZHHNVRIWKHGRXEOHEOLQGWUHDWPHQWSKDVHSDW LHQWVZLOOEHDVNHGWR
UDWHWKHLU:$3LQWKHSDVWKRXUV7KHSDWLHQWUHSRUWHG:$3L QWKHSDVWKRXUVZLOO
EHUHFRUGHGRQDWRVFDOHZKHUHFRUUHVSRQGVWRQRSDLQ DQGFRUUHVSRQGVWR
ZRUVWLPDJLQDEOHSDLQ
 %ULVWRO6WRRO)RUP6FDOH3DWLHQWVZLOOEHDVNHGWRUHFRUGGDLO\VWRROFRQVLVWHQF\DFFRUG LQJWRWKH%6)6PRVW
UHSUHVHQWDWLYHRIWKHSDVWKRXUV7KHSDWLHQWUHSRUWHG%6)6 FRQVLVWHQF\VFRUHLV
EDVHGRQDWRVFDOHZKHUHFRUUHVSRQGVWRDKDUGVWRRODQG FRUUHVSRQGVWR
ZDWHU\GLDUUKHD 3OHDVHUHIHUWR $SSHQGL[ 
 ,%6'*OREDO6\PSWRP6FRUH3DWLHQWVZLOOEHDVNHGWRUHFRUGGDLO\WKHLURYHUDOO,%6'JORE DOV\PSWRPVLQWKHSULRU
KRXUV7KHSDWLHQWUHSRUWHGGDLO\,%6*6LVEDVHGRQDWR VFDOHZKHUH
x FRUUHVSRQGVWRQRV\PSWRPV
x FRUUHVSRQGVWRPLOGV\PSWRPV
x FRUUHVSRQGVWRPRGHUDWHV\PSWRPVCCI
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRIx FRUUHVSRQGVWRVHYHUHV\PSWRPVDQG
x FRUUHVSRQGVWRYHU\VHYHUHV\PSWRPV
 ,%66HYHULW\6FRUH6\VWHP
3DWLHQWVZLOOEHDVNHGWRFRPSOHWHTXHVWLRQVUHJDUGLQJWKHVH YHULW\RIWKHLU,%6(DFK
RIWKHTXHVWLRQVJHQHUDWHDPD[LPXPVFRUHRIOHDGLQJWR DWRWDOSRVVLEOHVFRUH
RI
 6DIHW\DQG2WKHU$VVHVVPHQWV
 $GYHUVH(YHQWVDQG6HULRXV$GYHUVH(YHQWV
6HH6HFWLRQ 
 3K\VLFDO([DPLQDWLRQV$FRPSOHWHSK\VLFDOH[DPLQDWLRQ3(ZLOOEHSHUIRUPHGDW6FUHH QLQJ$V\PSWRP
GLUHFWHG3(ZLOOEHSHUIRUPHGDWWKHWLPHSRLQWVVSHFLILHGLQWK H6FKHGXOHRI$FWLYLWLHV
6HFWLRQ DQGDVFOLQLFDOO\LQGLFDWHGDQGUHVXOWVUHFRUGHGLQWKHVRXUF HGRFXPHQW
$Q\FOLQLFDOO\VLJQLILFDQW3( ILQGLQJQRWHGDW6FUHHQLQJZLOOE HUHFRUGHGDVPHGLFDO
KLVWRU\$Q\FOLQLFDOO\VLJQLILFDQW3(ILQGLQJQRWHGDWDIWHUH QUROOPHQWZLOOEHUHYLHZHGIRU
UHSRUWLQJDVDQ$(VHH6HFWLRQ
$FRPSOHWH3(ZLOOLQFOXGHDWDPLQLPXPDVVHVVPHQWRIWKHFDUG LRYDVFXODU
UHVSLUDWRU\*,DQGQHXURORJLFDOV\VWHPV$WDUJHWHG3(ZLOOLQF OXGHDWDPLQLPXP 
DVVHVVPHQWVRIWKHVNLQOXQJVFDUGLRYDVFXODUV\VWHPDQGDEGRP HQOLYHUDQGVSO HHQ
+HLJKWDQGZHLJKWZLOODOVREHP HDVXUHGDQG%0,ZLOOEHFDOFXODW HGDQGWKHGDWD
UHFRUGHGDWWKHWLPHSRLQWVVSHFLILHGLQWKH6FKHGXOHRI$FWLYLWLH V6HFWLRQ
,QYHVWLJDWRUVVKRXOGSD\VSHFLDODWWHQWLRQWRFOLQLFDOVLJQVUHOD WHGWRSUHYLRXVVHULRX V
LOOQHVVHV
 9LWDO6LJQV
$WWKHWLPHSRLQWVVSHFLILHGLQWKH6FKHGXOHRI$FWLYLWLHV6HFWL RQDQGEHIRUHDQ \
EORRGVDPSOHFROOHFWLRQYLWDOVLJQVZLOOEHPHDVXUHGLQDVXSLQH SRVLWLRQDIWHUPLQ XWHV
UHVWDQGZLOOLQFOXGHRUDOWHPSHUDWXUHV\VWROLFDQGGLDVWROLFEO RRGSUHVVXUHSXOVHD QG
UHVSLUDWRU\UDWH$Q\FOLQLFDOO\VLJQLILFDQWDEQRUPDOYLWDOVLJQ YDOXHZLOOEHUHFRUGHG DV
DQ$(VHH6HFWLRQ
 (OHFWURFDUGLRJUDPV
6LQJOHOHDG(&*VZLOOEHSHUIRUPHGDWWKHWLPHSRLQWVVSHFLILH GLQWKH6FKHGXOH RI
$FWLYLWLHV6HFWLRQDQGEHIRUHDQ\EORRGVDPSOHFROOHFWLRQ (OHFWURFDUGLRJUDP
LQWHUYDOPHDVXUHPHQWVDQGLQWHUSUHWDWLRQQRUPDODEQRUPDOQRW FOLQLFDOO\VLJQLILFDQW
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRIDEQRUPDOFOLQLFDOO\VLJQLILFDQWZLOOEHUHFRUGHGLQWKHVRXUFH GRFXPHQW$Q\FOLQLFDOO\
VLJQLILFDQWFKDQJHLQ(&*LQWHUSUHWDWLRQZLOOEHUHFRUGHGDVDQ $(VHH6HFWLRQ 
 &OLQLFDO6DIHW\/DERUDWRU\$VVHVVPHQWV6HH$SSHQGL[ IRUWKHOLVWRIFOLQLFDOODERUDWRU\WHVWVWREHSHUIRUPHGDQGW RWKH
6FKHGXOHRI$FWLYLWLHV 6HFWLRQ IRUWKHWLPLQJDQGIUHTXHQF\
7KH,QYHVWLJDWRUPXVWUHYLHZWKHODERUDWRU\UHSRUWGRFXPHQWWK LVUHYLHZDQGUHFRUGLQ
WKH$(VHFWLRQRIWKH&5)DQ\FOLQLFDOO\UHOHYDQWFKDQJHVRFFXU ULQJGXULQJWKHVWXG\
7KHODERUDWRU\UHSRUWVPXVWEHILOHGZLWKWKHVRXUFHGRFXPHQWV &OLQLFDOO\VLJQLILFDQW
DEQRUPDOODERUDWRU\ILQGLQJVDUHWKRVHWKDWDUHQRWDVVRFLDWHG ZLWKWKHXQGHUO\LQJ
GLVHDVHXQOHVVMXGJHGE\WKH,QYHVWLJDWRUWREHPRUHVHYHUHWK DQH[SHFWHGIRUWKH
SDWLHQWÂ¶VFRQGLWLRQ
$OOODERUDWRU\WHVWVZLWKYDOXHVFRQVLGHUHGFOLQLFDOO\VLJQLILF DQWO\DEQRUPDOGXULQJ
SDUWLFLSDWLRQLQWKHVWXG\VKRXOGEHUHSHDWHGXQWLOWKHYDOXHV UHWXUQWRQRUPDORU
EDVHOLQHRUDUHQRORQJHUFRQVLGHUHGFOLQLFDOO\VLJQLILFDQWE\ WKH,QYHVWLJDWRURU0HGLFDO
0RQLWRU,IVXFKYDOXHVGRQRWUHWXUQWRQRUPDOEDVHOLQHZLWKLQ DSHULRGRIWLPHMXGJHG
UHDVRQDEOHE\WKH,QYHVWLJDWRUWKHHWLRORJ\VKRXOGEHLGHQWLIL HGDQGWKHVSRQVRU
QRWLILHG
$OOSURWRFROUHTXLUHGODERUDWRU\DVVHVVPHQWVDVGHILQHGLQ $SSHQGL[ PXVWEH
FRQGXFWHGLQDFFRUGDQFHZLWKWKHODERUDWRU\PDQXDODQGWKH6FKH GXOHRI$FWLYLWLHV
,IODERUDWRU\YDOXHVIURPQRQSU RWRFROVSHFLILHGODERUDWRU\DVV HVVPHQWVSHUIRUPHGDW
WKHLQVWLWXWLRQÂ¶VORFDOODERUDWRU\UHTXLUHDFKDQJHLQSDWLHQW PDQDJHPHQWRU
DUHFRQVLGHUHGFOLQLFDOO\VLJQLILFDQWE\WKH,QYHVWLJDWRUHJ 6$(RU$(RUGRVH
PRGLILFDWLRQWKHQWKHUHVXOWVPXVWEHUHFRUGHGLQWKH&5)
 $GYHUVH(YHQWVDQG6HULRXV$GYHUVH(YHQWV
$GYHUVHHYHQWVZLOOEHUHSRUWH GE\WKHSDWLHQWRUZKHQDSSURS ULDWHE\DFDUHJLYHU
VXUURJDWHRUWKHSDWLHQW
VOHJDOO\DXWKRUL]HGUHSUHVHQWDWLYH 
7KH,QYHVWLJDWRUDQGDQ\TXDOLILHGGHVLJQHHVDUHUHVSRQVLEOHIR UGHWHFWLQJDQG
GRFXPHQWLQJHYHQWVWKDWPHHWWKHGHILQLWLRQRIDQ$(RU6$(DQG DUHUHVSRQVLEOHIRU
IROORZLQJDOO$(V
 'HILQLWLRQRI$GYHUVH(YHQWV$Q$(LVDQ\XQWRZDUGPHGLFDORFFXUUHQFHLQDSDWLHQWRUFOLQLF DOVWXG\SDUWLFLSDQW
WHPSRUDOO\DVVRFLDWHGZLWKWKHXVHRILQYHVWLJDWLRQDOSURGXFW ZKHWKHURUQRWFRQVLGHUHG
UHODWHGWRWKHLQYHVWLJDWLRQDOSURGXFW$Q$(FDQWKHUHIRUHEH DQ\XQIDYRUDEOHDQG
XQLQWHQGHGVLJQLQFOXGLQJDQDEQRUPDOODERUDWRU\ILQGLQJV\P SWRPRUGLVHDVHQHZ
RUH[DFHUEDWHGWHPSRUDOO\DVVRFLDWHGZLWKWKHXVHRILQYHVWLJD WLRQDOSURGXFW
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI (YHQWVRI6SHFLDO,QWHUHVW
1RWDSSOLFDEOH 'HILQLWLRQRI6HULRXV$GYHUVH(YHQWV,IDQHYHQWLVQRWDQ$(SHUGHILQLWLRQDERYHWKHQLWFDQQRWE HDQ6$(HYHQLIVHULRXV
FRQGLWLRQVDUHPHWHJKRVSLWDOL]DWLRQIRUVLJQVV\PSWRPVRI WKHGLVHDVHXQGHUVWXG\
GHDWKEHFDXVHRISURJUHVVLRQRIGLVHDVH
$6$(LVGHILQHGDVDQ\XQWRZDUGPHGLFDORFFXUUHQFHWKDWDWDQ \GRVH
x 5HVXOWVLQGHDWK
x ,VOLIHWKUHDWHQLQJ
7KHWHUP
OLIHWKUHDWHQLQJ
LQWKHGHILQLWLRQRI
VHULRXV
UHIH UVWRDQHYHQWLQZKLFK
WKHSDWLHQWZDVDWULVNRIGHDWKDWWKHWLPHRIWKHHYHQW,WG RHVQRWUHIHUWRDQ
HYHQWZKLFKK\SRWKHWLFDOO\PLJKWKDYHFDXVHGGHDWKLILWZHUH PRUHVHYHUH
x 5HTXLUHVLQSDWLHQWKRVSLWDOL]DWLRQRUSURORQJDWLRQRIH[LVWLQJ KRVSLWDOL]DWLRQ
,QJHQHUDOKRVSLWDOL]DWLRQVLJQLILHVWKDWWKHVXEMHFWRUSDWLH QWKDVEHHQGHWDLQHG
XVXDOO\LQYROYLQJDWOHDVWDQ RYHUQLJKWVWD\DWWKHKRVSLWDO RUHPHUJHQF\ZDUG
IRUREVHUYDWLRQDQGRUWUHDWPHQWWKDWZRXOGQRWKDYHEHHQDSSUR SULDWHLQWKH
SK\VLFLDQÂ¶VRIILFHRURXWSDWLHQWVHWWLQJ&RPSOLFDWLRQVWKDWRF FXUGXULQJ
KRVSLWDOL]DWLRQDUH$(V,IDFRPSOLFDWLRQSURORQJVKRVSLWDOL]D WLRQRUIXOILOOVDQ\
RWKHUVHULRXVFULWHULDWKHHYHQWLVVHULRXV:KHQLQGRXEWDV WRZKHWKHU
Â³KRVSLWDOL]DWLRQÂ´RFFXUUHGRUZDVQHFHVVDU\WKH$(VKRXOGEHF RQVLGHUHG
VHULRXV
+RVSLWDOL]DWLRQIRUHOHFWLYHWUHDWPHQWRIDSUHH[LVWLQJFRQGLW LRQWKDWGLGQRW
ZRUVHQIURPEDVHOLQHLVQRWFRQVLGHUHGDQ$(
x 5HVXOWVLQSHUVLVWHQWGLVDELOLW\LQFDSDFLW\
7KHWHUPGLVDELOLW\PHDQVDVXEVWDQWLDOGLVUXSWLRQRIDSHUVRQÂ¶ VDELOLW\WRFRQGXFW
QRUPDOOLIHIXQFWLRQV7KLVGHILQLWLRQLVQRWLQWHQGHGWRLQFOX GHH[SHULHQFHVRI
UHODWLYHO\PLQRUPHGLFDOVLJQLILFDQFHVXFKDVXQFRPSOLFDWHGKHD GDFKHQDXVHD
YRPLWLQJGLDUUKHDLQIOXHQ]DDQGDFFLGHQWDOWUDXPDHJVSU DLQHGDQNOHWKDW
PD\LQWHUIHUHZLWKRUSUHYHQWHYHU\GD\OLIHIXQFWLRQVEXWGRQR WFRQVWLWXWHD
VXEVWDQWLDOGLVUXSWLRQ
x ,VDFRQJHQLWDODQRPDO\ELUWKGHIHFW
0HGLFDORUVFLHQWLILFMXGJPHQWVKRXOGEHH[HUFLVHGZKHQGHFLGLQ JLI6$(UHSRUWLQJLV
DSSURSULDWHLQRWKHUVLWXDWLRQVVXFKDVLPSRUWDQWPHGLFDOHYHQW VWKDWPD\QRWEH
LPPHGLDWHO\OLIHWKUHDWHQLQJRUUHVXOWLQGHDWKRUKRVSLWDOL]DW LRQEXWPD\MHRSDUGL]HWKH
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRISDWLHQWRUPD\UHTXLUHPHGLFDORUVXUJLFDOLQWHUYHQWLRQWRSUHY HQWDQ\RIWKHRWKHU
RXWFRPHVOLVWHGLQWKHDERYHGHILQLWLRQ7KHVHHYHQWVVKRXOGXV XDOO\EHFRQVLGHUHG
VHULRXV([DPSOHVRIVXFKHYHQWVLQFOXGHLQYDVLYHRUPDOLJQDQW FDQFHUVLQWHQVLYH
WUHDWPHQWLQDQHPHUJHQF\URRPRUDWKRPHIRUDOOHUJLFEURQFKRV SDVPEORRG
G\VFUDVLDVRUFRQYXOVLRQVWKDWGRQRWUHVXOWLQKRVSLWDOL]DWLRQ RUGHYHORSPHQWRIGUXJ
GHSHQGHQF\RUGUXJDEXVH
 &ODVVLILFDWLRQRIDQ$GYHUVH(YHQW $VVHVVPHQWRI6HYHULW\7KH,QYHVWLJDWRUZLOOPDNHDQDV VHVVPHQWRIVHYHULW\IRUHDFK$ (DQG6$(UHSRUWHG
GXULQJWKHVWXG\DQGDVVLJQLWWRRIWKHIROORZLQJFDWHJRULHV 
x 0LOG$QHYHQWWKDWLVHDVLO\WROHUDWHGE\WKHSDWLHQWFDXVLQ JPLQLPDOGLVFRPIRUW
DQGQRWLQWHUIHULQJZLWKHYHU\GD\DFWLYLWLHV
x 0RGHUDWH$QHYHQWWKDWFDXVHVVXIILFLHQWGLVFRPIRUWDQGLQWHU IHUHVZLWKQRUPDO
HYHU\GD\DFWLYLWLHV
x 6HYHUH$QHYHQWWKDWSUHYHQWVQRUPDOHYHU\GD\DFWLYLWLHV$Q $(WKDWLV
DVVHVVHGDVVHYHUHVKRXOGQRWEHFRQIXVHGZLWKD6$(6HYHUHLV DFDWHJRU\
XWLOL]HGIRUUDWLQJWKHLQWHQVLW \RIDQHYHQWDQGERWK$(VDQG 6$(VFDQEH
DVVHVVHGDVVHYHUH
$QHYHQWLVGHILQHGDVÂµVHULRXVÂ¶ZKHQLWPHHWVDWOHDVWRIWK HSUHGHILQHGRXWFRPHVDV
GHVFULEHGLQWKHGHILQLWLRQRIDQ6$(127ZKHQLWLVUDWHGDV VHYHUH
 $VVHVVPHQWRI&DXVDOLW\$OO$(VPXVWKDYHWKHLUUHODWLRQVKLSWRWKHLQYHVWLJDWLRQDOSUR GXFWDQGRUVWXG\
SDUWLFLSDWLRQDVVHVVHGE\WKH,QYHVWLJDWRUZKRH[DPLQHVDQGHYD OXDWHVWKHSDWLHQW
EDVHGRQWHPSRUDOUHODWLRQVKLSDQGKLVRUKHUFOLQLFDOMXGJPHQW $OWHUQDWLYHFDXVHV
VXFKDVXQGHUO\LQJGLVHDVHFRQFRPLWDQWWKHUDS\DQGRWKHUULVN IDFWRUVDVZHOODVWKH
WHPSRUDOUHODWLRQVKLSRIWKHHYHQWWRLQYHVWLJDWLRQDOSURGXFWD GPLQLVWUDWLRQZLOOEH
FRQVLGHUHGDQGLQYHVWLJDWHG7KH,QYHVWLJDWRUZLOODOVRFRQVXOW WKH,%LQKLVRUKHU
DVVHVVPHQW
7KHGHJUHHRIFHUWDLQW\DERXWFDXVDOLW\ZLOOEHJUDGHGXVLQJWK HFDWHJRULHVEHORZ
x5HODWHGÂ±7KH$(LVNQRZQWRRFFXUZLWKWKHLQYHVWLJDWLRQDOSURGXFWW KHUHLVD
UHDVRQDEOHSRVVLELOLW\WKDWWKH LQYHVWLJDWLRQDOSURGXFWFDXVHG WKH$(RUWKHUHLVD
WHPSRUDOUHODWLRQVKLSEHWZHHQWKHLQYHVWLJDWLRQDOSURGXFWDQGH YHQW5HDVRQDEOH
SRVVLELOLW\PHDQVWKDWWKHUHLV HYLGHQFHWR VXJJHVWDFDXVDOUH ODWLRQVKLSEHWZHHQ
WKHLQYHVWLJDWLRQDOSURGXFWDQGWKH$(
x1RW5HODWHG Â±7KHUHLVQRWDUHDVRQDEOHSRVVL ELOLW\WKDWWKHDGPLQLVWUDWLR QRIWKH
LQYHVWLJDWLRQDOSURGXFWFDXVHGWKHHYHQWWKHUHLVQRWHPSRUDO UHODWLRQVKLS
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRIEHWZHHQWKHLQYHVWLJDWLRQDOSURGXFWDQGHYHQWRQVHWRUDQDOWH UQDWHHWLRORJ\KDV
EHHQHVWDEOLVKHG
)RUHDFK$(WKH,QYHVWLJDWRUPXVWGRFXPHQWLQWKHPHGLFDOQRWH VWKDWKHRUVKHKDV
UHYLHZHGWKHHYHQWDQGKDVSURYLGHGDQDVVHVVPHQWRIFDXVDOLW\ 7KH,QYHVWLJDWRUPD\
FKDQJHKLVRUKHURSLQLRQRIFDXVDOLW\LQOLJKWRIIROORZXSLQ IRUPDWLRQDQGXSGDWHG
FDXVDOLW\DVVHVVPHQWUHSRUWHG
 ([SHFWHGQHVV 
7KH,QYHVWLJDWRUZLOOEHUHVSRQVLE OHIRUGHWHUPLQLQJZKHWKHUDQ $(LVH[SHFWHGRU
XQH[SHFWHG$Q$(ZLOOEHFRQVLGHUHGXQH[SHFWHGLIWKHQDWXUH VHYHULW\RUIUHTXHQF\RI
WKHHYHQWLVQRWFRQVLVWHQWZLWKWKHULVNLQIRUPDWLRQSUHYLRXVO \GHVFULEHGIRUWKH
LQYHVWLJDWLRQDOSURGXFW
 7LPH3HULRGDQG)UHTXHQF\ IRU(YHQW$VVHVVPHQWDQG)ROORZ XS
$OO$(VZLOOEHFROOHFWHGIURPWKHVLJQLQJRIWKH,&)XQWLOWKH (QGRI6WXG\)ROORZXS
YLVLW
:KHQHYHUSRVVLEOHDOO$(VVKRXOGEHIROORZHGXQWLOVDWLVIDFWRU \UHVROXWLRQRUXQWLOWKH
VLWH,QYHVWLJDWRUGHHPVWKHHYHQWWREHFKURQLFRUWKHSDWLHQW LVVWDEOH
$OO6$(VZLOOEHUHFRUGHGDQGUHSRUWHGWRWKHVSRQVRURUGHVLJQ HHZLWKLQKRXUV
ZKHWKHUFRQVLGHUHGLQYHVWLJDWLRQDOSURGXFWUHODWHGRUQRWDQG PXVWLQFOXGHDQ
DVVHVVPHQWRILIWKHUHLVDUHDVRQDEOHSRVVLELOLW\WKDWWKHLQY HVWLJDWLRQDOSURGXFWFDXVHG
WKHHYHQW7KH,QYHVWLJDWRUZLOODOVRVXEPLWDQ\XSGDWHG6$(GD WDWRWKHVSRQVRUZLWKLQ
à¯—KRXUVRILWEHLQJDYDLODEOH
,QYHVWLJDWRUVDUHQRWREOLJDWHGWRDFWLYHO\VHHN$(VRU6$(VDI WHUFRQFOXVLRQRIWKH
VWXG\SDUWLFLSDWLRQ+RZHYHULIWKH,QYHVWLJDWRUOHDUQVRIDQ\ 6$(LQFOXGLQJDGHDWKDW
DQ\WLPHDIWHUDSDWLHQWKDVEHHQGLVFKDUJHGIURPWKHVWXG\DQ GKHRUVKHFRQVLGHUV
WKHHYHQWWREHUHDVRQDEO\UHODWHGWRWKHLQYHVWLJDWLRQDOSURGX FWRUVWXG\SDUWLFLSDWLRQ
WKH,QYHVWLJDWRUPXVWSURPSWO\QRWLI\WKHVSRQVRU
 $GYHUVH(YHQW5HSRUWLQJ$WHDFKVWXG\YLVLWSDWLHQWVZLOOEHHYDOXDWHGIRUQHZ$(VDQG WKHVWDWXVRIH[LVWLQJ
$(V&DUHZLOOEHWDNHQQRWWRLQWURGXFHELDVZKHQHYDOXDWLQJI RU$(V7KH,QYHVWLJDWRU
VKRXOGXVHRSHQHQGHGTXHVWLRQVZKHQVROLFLWLQJLQIRUPDWLRQIUR PDSDWLHQWUHJDUGLQJ
$(VIROORZHGE\DSSURSULDWHTXHVWLRQVWKDWFODULI\WKHSDWLHQW Â¶VYHUEDWLPGHVFULSWLRQRI
$(VRUFKDQJHLQFRQFRPLWDQWPHGLFDWLRQV
:KHQDQ$(RFFXUVLWLVWKHUHVSRQVLELOLW\RIWKH,QYHVWLJDWRU WRUHYLHZDOO
GRFXPHQWDWLRQHJKRVSLWDOSURJUHVVQRWHVODERUDWRU\UHSRUW VDQGGLDJQRVWLFV
UHSRUWVUHODWHGWRWKHHYHQW7KH,QYHVWLJDWRUZLOODWWHPSWWR HVWDEOLVKDGLDJQRVLVRIWKH
HYHQWEDVHGRQVLJQVV\PSWRPVDQGRURWKHUFOLQLFDOLQIRUPDWL RQ:KHQHYHUSRVVLEOH
WKHGLDJQRVLVQRWWKHLQGLYLGXDO VLJQVV\PSWRPVZLOOEHGRFXP HQWHGDVWKH$(
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI7KH,QYHVWLJDWRUZLOOWKHQUHFRUG DOOUHOHYDQW$(LQIRUPDWLRQL QWKH&5),WLVQRW
DFFHSWDEOHIRUWKH,QYHVWLJDWRUWRVHQGSKRWRFRSLHVRIWKHSDWL HQWÂ¶VPHGLFDOUHFRUGVLQ
OLHXRIFRPSOHWLRQRIWKH&5)SDJH1HZRUXSGDWHGLQIRUPDWLRQ ZLOOEHUHFRUGHGLQWKH
RULJLQDOO\FRPSOHWHG&5)+RZHYHUWKHUHPD\EHLQVWDQFHVZKHQ FRSLHVRIPHGLFDO
UHFRUGVIRUFHUWDLQFDVHVDUHUHTXHVWHG,QWKLVFDVHDOOSDWL HQWLGHQWLILHUVZLWKWKH
H[FHSWLRQRIWKHSDWLHQWQXPEHUZLOOEHUHGDFWHGRQWKHFRSLHV RIWKHPHGLFDOUHFRUGV
EHIRUHVXEPLVVLRQ
,IDSDWLHQWGLHVGXULQJSDUWLFLSDWLRQLQWKHVWXG\RUGXULQJD UHFRJQL]HGIROORZXSSHULRG
WKH,QYHVWLJDWRUZLOOSURYLGHDFRS\RIDQ\SRVWPRUWHPILQGLQJV LQFOXGLQJKLVWRSDWKRORJ\
ZKHQDYDLODEOH
,IDVLWHUHFHLYHVUHSRUWRIDQHZ6$(IURPDVWXG\SDWLHQWRU UHFHLYHVXSGDWHGGDWDRQ
DSUHYLRXVO\UHSRUWHG6$(DIWHUGDWDEDVHORFNRIWKHHOHFWURQLF GDWDFDSWXUH('&
V\VWHPWKHQWKHVLWHFDQUHSRUWWKLVLQIRUPDWLRQRQDSDSHU6$ (IRUPRUWRWKHVSRQVRU
E\WHOHSKRQH6HHWKH6WXG\0DQXDOIRUDGGLWLRQDOLQIRUPDWLRQR Q6$(UHSRUWLQJ
7KHVWXG\VSRQVRURUGHVLJQHHZLOOEHUHVSRQVLEOHIRUQRWLI\L QJDOODSSOLFDEOHUHJXODWRU\
DXWKRULWLHVRIDQ\UHTXLUHGVDIHW\HYHQWVLQFRPSOLDQFHZLWKFR XQWU\VSHFLILFUHJXODWRU\
UHTXLUHPHQWV,QDGGLWLRQWKHVSRQVRUPXVWQRWLI\DSSOLFDEOHU HJXODWRU\DXWKRULWLHVDQG
DOOSDUWLFLSDWLQJ,QYHVWLJDWRUVRIVXVSHFWHGXQH[SHFWHGVHULRXV DGYHUVHUHDFWLRQV
686$5VIURPFOLQLFDOWULDOVRUDQ\RWKHUVRXUFH
$Q,QYHVWLJDWRUZKRUHFHLYHVDQ,QYHVWLJDWRUVDIHW\UHSRUWGHVF ULELQJD6$(RURWKHU
VSHFLILFVDIHW\LQIRUPDWLRQHJVXPPDU\RUOLVWLQJRI6$(V IURPWKHVSRQVRUZLOO
UHYLHZDQGWKHQILOHLWDORQJZLWKWKH,%DQGZLOOQRWLI\WKH, QVWLWXWLRQDO5HYLHZ%RDUG
,QGHSHQGHQW(WKLFV&RPPLWWHH,5%,(&LIDSSURSULDWHDFFRUGLQ JWRORFDO
UHTXLUHPHQWV
 5HSRUWLQJRI3UHJQDQF\3UHJQDQF\LWVHOILVQRWUHJDUGHGDVDQ$(XQOHVVWKHUHLVDVXV SLFLRQWKDWWKH
LQYHVWLJDWLRQDOSURGXFWPD\KDYHLQWHUIHUHGZLWKWKHHIIHFWLYHQ HVVRIDFRQWUDFHSWLYH
PHGLFDWLRQ3UHJQDQF\LQDSDWLHQWÂ¶VSDUWQHULVQRWFRQVLGHUHG DQ$($EQRUPDO
SUHJQDQF\RXWFRPHVHJVSRQWDQHRXVDERUWLRQIHWDOGHDWKVW LOOELUWKFRQJHQLWDO
DQRPDOLHVHFWRSLFSUHJQDQF\DUHFRQVLGHUHG6$(V(OHFWLYHDER UWLRQVZLWKRXW
FRPSOLFDWLRQVVKRXOGQRWEHKDQGOHGDV$(VKRZHYHUDQLQGXFHG WKHUDSHXWLFDERUWLRQ
WRWHUPLQDWHDSUHJQDQF\EHFDXVHRIFRPSOLFDWLRQVRUPHGLFDOUH DVRQVPXVWEH
UHSRUWHGDVDQ6$(7KHXQGHUO\LQJPHGLFDOGLDJQRVLVIRUWKLVS URFHGXUHVKRXOGEH
UHSRUWHGDVWKH6$(WHUP$VSRQWDQHRXVDERUWLRQLQDVWXG\SDW LHQWLVDOZD\V
FRQVLGHUHGDQ6$(
'HWDLOVRIDOOSUHJQDQFLHVLQIHPDOHSDWLHQWVDQGLILQGLFDWHG SUHJQDQFLHVLQIHPDOH
SDUWQHUVRIPDOHSDWLHQWVZLOOEHFROOHFWHGDIWHUWKHVWDUWRI LQYHVWLJDWLRQDOSURGXFWDQG
XQWLOZHHNVDIWHUWKHODVWGRVH
,IDSUHJQDQF\LVUHSRUWHGWKH,QYHVWLJDWRUVKRXOGLQIRUPWKH VSRQVRUZLWKLQKRXUVRI
OHDUQLQJRIWKHSUHJQDQF\DQGVKRXOGIROORZWKHSURFHGXUHVRXWO LQHGLQ$SSHQGL[ 
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI 7UHDWPHQWRI2YHUGRVH
7KHUHDUHQRGDWDRQRYHUGRVHEHFDXVHWKLVLVWKHILUVWVWXG\R I%26LQSDWLHQWV
DQGLQDSULRUVWXG\LQKHDOWK\KXPDQYROXQWHHUVQRHYLGHQFH RIRYHUGRVHZDV
UHSRUWHG7KHUHLVQRGHILQLWLRQRIZKDWFRQVWLWXWHVDQRYHUGRV HDQGQRNQRZQDQWLGRWH
$Q\SDWLHQWZKRUHFHLYHVDKLJKHUGRVHWKDQWKDWLQWHQGHGLH PRUHWKDQPJSHU
GRVHPRUHWKDQPJLQDJLYHQGD\VKRXOGEHPRQLWRUHGFORV HO\PDQDJHGZLWK
DSSURSULDWHVXSSRUWLYHFDUHDQGIROORZHGXSDSSURSULDWHO\,I SRVVLEOHDEORRGVDPSOH
IRU3.VKRXOGEHFROOHFWHGDVVRRQDVLVIHDVLEOHIURPDQ\SDWL HQWZKRWDNHVDKLJKHU
GRVHWKDQWKDWLQWHQGHG
,I$(VRU6$(VDUHUHSRUWHGDQGDUHFRQVLGHUHGUHODWHGWRDSDW LHQWUHFHLYLQJDKLJKHU
GRVHWKDQLQWHQGHGGRVLQJVKRXOGEHLQWHUUXSWHGLIGHHPHGQHFH VVDU\E\WKH
,QYHVWLJDWRUDQGWKHFDVHGLVFXVVHGIXUWKHUZLWKWKH0HGLFDO0R QLWRU
 3KDUPDFRNLQHWLFV
3ODVPDVDPSOHVRIDSSUR[LPDWHO\P/ZLOOEHFROOHFWHGIRUPHDV XUHPHQWRISODVPD
FRQFHQWUDWLRQVRI%26DWWKHIROORZLQJWLPHVDQGDVVSHFLIL HGLQWKH6FKHGXOHRI
$FWLYLWLHV 6HFWLRQ 
x 2Q'D\DWSUHGRVHDQGDWDQGKRXUVSRVWGRVH
x 2Q'D\DWSUHGRVHDQGDWDQGKRXUVSRVWGRVH, IVDPSOHVFDQQRW
EHREWDLQHGRQ'D\WKHQVDPSOHVVKRXOGEHREWDLQHGRQ'D\ 
x $SUHGRVHVDPSOHZLOOEHREWDLQHGRQDOORWKHU7UHDWPHQW6WXG\ 9LVLWV
$OORZDEOHVDPSOLQJZLQGRZVIRU3.EORRGGUDZVZLOOEHPLQXWH VSULRUWRGRVLQJIRU
WKHSUHGRVHVDPSOHWKHQ Â“PLQXWHVIRUWKHDQGKRXUSRVWGRVHWLPHSRLQWVDQG
Â“PLQXWHVIRUWKHDQGKRXUVSRVWGRVHWLPHSRLQWV
,QVWUXFWLRQVIRUWKHFROOHFWLRQDQGKDQGOLQJRIELRORJLFDOVDPS OHVZLOOEHSURYLGHGE\WKH
VSRQVRU7KHDFWXDOWLPHRIGRVLQJDQGDFWXDOGDWHDQGWLPH KRXUFORFNWLPHRI
HDFKVDPSOHZLOOEHUHFRUGHG
'UXJFRQFHQWUDWLRQLQIRUPDWLRQWKDWPD\XQEOLQGWKHVWXG\ZLOO QRWEHUHSRUWHGWR
LQYHVWLJDWLYHVLWHVRUEOLQGHGSHUVRQQHOXQWLOWKHVWXG\KDVEH HQXQEOLQGHG
$Q\FKDQJHVLQWKHWLPLQJRUDGGLWLRQRIWLPHSRLQWVIRUDQ\SOD QQHGVWXG\DVVHVVPHQWV
PXVWEHGRFXPHQWHGDQGDSSURYHGE\WKHUHOHYDQWVWXG\WHDPPHPE HUDQGWKHQ
DUFKLYHGLQWKHVSRQVRUDQGVLWHVWXG\ILOHVEXWZLOOQRWFRQVW LWXWHDSURWRFRODPHQGPHQW
7KH,5%,(&ZLOOEHLQIRUPHGRIDQ\VDIHW\LVVXHVWKDWUHTXLUH DOWHUDWLRQRIWKHVDIHW\
PRQLWRULQJVFKHPHRUDPHQGPHQWRIWKH,&)
7KHIROORZLQJ3.SDUDPHWHUVZLOOEHHVWLPDWHGIURPWKHSODVPDF RQFHQWUDWLRQVRI
%26XVLQJHLWKHUWUDGLWLRQDOQRQFRPSDUWPHQWDOPHWKRGVRUD SRSXODWLRQ3.PRGHO
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI$8&W $UHDXQGHUWKHSODVPDFRQFHQWUDWLRQYHUVXVWLPHFXUYHIURPWLP H]HURWR
WKHODVWTXDQWLILDEOHVDPSOH
$8& $UHDXQGHUWKHSODVPDFRQFHQWUDWLRQYHUVXVWLPHFXUYHIURPWLP H]HURWR
KRXUVSRVWGRVH
&PD[  0D[LPXPREVHUYHGSODVPDFRQFHQWUDWLRQ
&PLQ  0LQLPXPREVHUYHGSODVPDFRQFHQWUDWLRQ
,QDGGLWLRQWRSDUDPHWHUVDERYHWKH$8&IURPWLPH]HURWRKR XUVSRVWGRVH$8& 
PD\EHFDOFXODWHGXVLQJSUHGRVHFRQFHQWUDWLRQVRWKHUWKDQ'D\ SUHGRVHWRLPSXWHD
KRXUFRQFHQWUDWLRQ'HWDLOVZLOOEHSURYLGHGLQWKH3.DQDO\ VLVSODQ
 %LRPDUNHUV3KDUPDFRG\QDPLFV







 67$7,67,&$/&216,'(5$7,216
 7LPLQJRI$QDO\VHV
)RUPDOK\SRWKHVLVWHVWLQJZLOORFFXUDWWKHHQGRIWKHVWXG\DQ GSRVWGDWDEDVHORFN
7KHUHDUHQRSODQQHG'DWD6DIHW\RU$GMXGLFDWLRQ&RPPLWWHHVI RUWKLVVWXG\DQGQR
SODQQHGVWDWLVWLFDOLQWHULPDQDO\VHV
 6DPSOH6L]H'HWHUPLQDWLRQ
7KLVLVDSKDVHDVWXG\LQZKLFKDKLHUDUFKLFDOK\SRWKHVLVWHV WZLOOEHHPSOR\HGIRUWKH
SULPDU\HIILFDF\HQGSRLQW7KHSULPDU\HQGSRLQWLVGHILQHGDVD FKDQJHLQWKHKRXU
:$3VFRUHDW'D\FRPSDUHGWREDVHOLQHDYHUDJHGRYHUWKHZHH NSULRUWRHDFK
UHVSHFWLYHWLPHSRLQW0HDQFKDQJ HIURPEDVHOLQHZLOOEHPHDVXU HGDVDFRQWLQXRXV
YDULDEOHDQGFRPSDUHGEHWZHHQWUHDWPHQWJURXSVLQDKLHUDUFKLFD OWHVWLQJRUGHUXVLQJD
WWHVWRIHTXDOYDULDQFHVDQG DWZRWDLOHGDOSKDRI
7KHVDPSOHVL]HZDVEDVHGRQWKHILUVWK\SRWKHVLVWHVWLQWKHK LHUDUFKLFDOSODQZLWK
SRZHUWZRVLGHGDOSKDRIDQGDVWDQGDUGGHYLDWLRQ6 'RISRLQWVRQWKH
156WRGHWHFWDPLQLPXPFKDQJHEHWZHHQWUHDWPHQWJURXSV1  SDWLHQWV7RCCI
CCI
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRIDFFRXQWIRUDWWULWLRQDQGDSRWHQWLDOKLJKHU3%2UDWHDWRWDO RISDWLHQWVZLOOEH
UDQGRPL]HGWRRQHRIWUHDWPHQWJURXSVLQDUDWLRSD WLHQWVSHUWUHDWPHQW
JURXS
 3RSXODWLRQVIRU$QDO\VHV
 7KH,QWHQWLRQWR7UHDW,77DQDO\VLVGDWDVHWZLOOFRPSULVH DOOUDQGRPL]HG
SDWLHQWV
 7KH3HUSURWRFRO$QDO\VLV'DWDVHWZLOOFRPSULVHSDWLHQWVLQ WKH,77$QDO\VLV
'DWDVHWZKRUHFHLYHGDWOHDVWGRVHRILQYHVWLJDWLRQDOSURGXFW DQGGLGQRWKDYH
DQ\PDMRUSURWRFROGHYLDWLRQV
 7KH6DIHW\$QDO\VLV'DWDVHWZLOOFRPSULVHDOOSDWLHQWVZKRU HFHLYHGDWOHDVW
GRVHRILQYHVWLJDWLRQDOSURGXFW
 7KH3KDUPDFRNLQHWLF$QDO\VLV'DWDVHWZLOOFRPSULVHDOOUDQGR PL]HGSDWLHQWVZKR
UHFHLYHGWKHDFWLYHVWXG\GUXJDQGKDYHDYDLODEOHVHUXPWLPHFR QFHQWUDWLRQGDWD
 6WDWLVWLFDO$QDO\VHV
'HWDLOHGPHWKRGRORJ\IRUGHVFULSWLYHDQGLQIHUHQWLDOVWDWLVWLFD ODQDO\VHVRIWKHGDWD
FROOHFWHGLQWKHVWXG\ZLOOEHGRFXPHQWHGLQWKH6WDWLVWLFDO$Q DO\VLV3ODQ6$37KH
6$3ZLOOEHSUHSDUHGE\WKH6WXG\%LRVWDWLVWLFLDQDQGDJUHHGXS RQE\WKH6SRQVRU7KH
6$3ZLOOEHILQDOL]HGDQGDSSURYHGSULRUWRGDWDEDVHORFN7KH 6$3ZLOOWDNH
SUHFHGHQFHRYHUWKHSURWRFROIRUGHWDLOVUHJDUGLQJWKHVWDWLVWL FDODQDO\VHVWREH
FRQGXFWHGIRUWKHVWXG\,QDGGLWLRQWRWKH6$3RWKHUJUDSKLFD OUHSUHVHQWDWLRQVRIWKH
UHVXOWVPD\EHSURGXFHGDIWHUUHYLHZRIWKHGDWD SRVWKRF$Q\PDMRUPRGLILFDWLRQVRI
WKH3ULPDU\(QGSRLQWÂ¶VGHILQLWLRQDQGRULWVDQDO\VLVZLOOEHU HIOHFWHGLQDSURWRFRO
DPHQGPHQW
,QJHQHUDOGHVFULSWLYHVWDWLVW LFDOPHWKRGVZLOOEHXVHGWRVXP PDUL]HWKHGDWDIURPWKLV
VWXG\8QOHVVVWDWHGRWKHUZLVHWKHWHUPÂ³GHVFULSWLYHVWDWLVWLF VÂ´UHIHUVWRQXPEHURI
SDWLHQWVQPHDQPHGLDQ6'PLQLPXPDQGPD[LPXPIRUFRQWLQ XRXVGDWDDQG
IUHTXHQFLHVDQGSHUFHQWDJHVIRUFDWHJRULFDOGDWD
$OOVWDWLVWLFDODQDO\VHVZLOOEHSHUIRUPHGXVLQJ6WDWLVWLFDO$Q DO\VLV6\VWHP6$6ÂŠ
VRIWZDUH9HUVLRQRUKLJKHU
 (IILFDF\$QDO\VHV 3ULPDU\(QGSRLQW7KLVLVDSURRIRISULQFLSOHVWXG\LQZKLFKDKLHUDUFKLFDOK\SR WKHVLVWHVWZLOOEHHPSOR\HG
IRUWKHSULPDU\HIILFDF\HQGSRLQWGHILQHGDVDFKDQJHLQWKH KRXU:$3VFRUHDW
'D\FRPSDUHGWREDVHOLQHDYHUDJHGRYHUWKHZHHNSULRUWRHD FKUHVSHFWLYH
WLPHSRLQW0HDQFKDQJHIURPEDV HOLQHZLOOEHPHDVXUHGDVDFRQ WLQXRXVYDULDEOHDQG
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRIFRPSDUHGEHWZHHQWUHDWPHQWJURXSVLQWKHIROORZLQJWHVWLQJRUGH UXVLQJDWWHVWRIHTXDO
YDULDQFHVDQGDWZRWDLOHGDOSKDRI
+\SRWKHVLV
$FWLYH7UHDWPHQW*URXS&RKRUW&RKRUWYHUVXV3%2&RKRUW 
,IVWDWLVWLFDOO\VLJQLILFDQWDW 3WKHQSURFHHGWR+\SRWKHVLV
+\SRWKHVLV 
&RKRUW+LJK'RVHYHUVXV&RKRUW3%2
,IVWDWLVWLFDOO\VLJQLILFDQWDW 3WKHQSURFHHGWR+\SRWKHVLV
+\SRWKHVLV 
&RKRUW/RZ'RVHYHUVXV&RKRUW3%2
,IVWDWLVWLFDOO\VLJQLILFDQWDW 3WKHQSURFHHGWR+\SRWKHVLV
+\SRWKHVLV 
&RKRUW+LJK'RVHYHUVXV&RKRUW/RZ'RVH
 6HFRQGDU\(QGSRLQW0HDQGDLO\%6)6VFRUHVWRROW\SHDQGPHDQGDLO\IUHTXHQF\RI ERZHOPRYHPHQWVZLOO
EHWDEXODWHGDQGVXPPDUL]HGE\VWXG\GD\IRUHDFKWUHDWPHQWIRU WKH,77DQG
3HUSURWRFRO$QDO\VLV'DWDVHWSRSXODWLRQV7LPHSURILOHVDQGER [SORWVZLOODOVREH
SUHVHQWHGE\VWXG\GD\DQGE\WUHDWPHQWJURXS3RROHGDFWLYHGD WDPD\EHFRPSDUHG
WR3%2IRUWKHDQDO\VHVDQGDOVRE\FRKRUW
 2WKHU(IILFDF\(QGSRLQWV6FRUHVIURP,%6*6DQG,%666TXHVWLRQQDLUHVZLOOEHVXPPDUL]HG IRUWKH,77DQG
3HUSURWRFRO$QDO\VLV'DWDVHWSRSXODWLRQV3RROHGDFWLYHGDWDP D\EHFRPSDUHGWR
3%2IRUWKHDQDO\VHVDQGDOVRE\FRKRUW
 0LVVLQJ'DWD6WXG\LPSOHPHQWDWLRQSURFHGXUHVDQGWUDLQLQJZLOODVVLVWLQOLP LWLQJWKHDPRXQWRI
PLVVLQJGDWDLQWKHWULDO+RZHYHUVHQVLWLYLW\DQDO\VHVPD\EH SHUIRUPHGZKHQ
LQGLFDWHGIRUWKHVWXG\HQGSRLQWDQGWKHDPRXQWRIPLVVLQJGDWD WREHKDQGOHG'HWDLOV
RIWKHVWDWLVWLFDOPHWKRGVIRUKDQGOLQJPLVVLQJGDWDZLOOEHGH VFULEHGLQWKH6$3
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI 6DIHW\$QDO\VHV 
 $GYHUVH(YHQWV
$GYHUVHHYHQWVZLOOEHUHFRUGHGI URPWKHWLPHRIFRQVHQWXQWLO WKH'D\(QGRI6WXG\
)ROORZXSYLVLW7KHQXPEHUDQGSHUFHQWDJHRISDWLHQWVZLWK$(V ZLOOEHGLVSOD\HGE\
V\VWHPRUJDQFODVVDQGSUHIHUUHGWHUPXVLQJ0HGLFDO'LFWLRQDU\ IRU5HJXODWRU\$FWLYLWLHV
0HG'5$9HUVLRQRUKLJKHUE\VWXG\WUHDWPHQW6XPPDULHV LQWHUPVRIVHYHULW\
DQGUHODWLRQVKLSWRLQYHVWLJDWLRQDOSURGXFWZLOODOVREHSURYLG HG$OO6$(VZLOOEH
VXPPDUL]HGLQDVLPLODUPDQQHU3 DWLHQWOLVWLQJVRIDOO$(VFDX VLQJGLVFRQWLQXDWLRQRI
LQYHVWLJDWLRQDOSURGXFWDQGDOO6$(VZLOOEHSURGXFHG
$OO$(VZLOOEHOLVWHGIRULQGLYLGXDOSDWLHQWVVKRZLQJERWKYHU EDWLPDQGSUHIHUUHGWHUPV
6HSDUDWHVXPPDULHVRIWUHDWPHQWHPHUJHQW6$(VDQGWUHDWPHQWHPH UJHQW$(V
7($(VUHODWHGWRLQYHVWLJDWLRQDOSURGXFWZLOOEHJHQHUDWHG
$Q\HYHQWUHSRUWHGRQWKH&5)WKDWRFFXUVRQDWWKHWLPHRIRU DIWHUWKHLQLWLDWLRQRI
LQYHVWLJDWLRQDOSURGXFWLVGHILQHGDVWUHDWPHQWHPHUJHQW$GGLW LRQDOO\DQ$(WKDWLV
UHSRUWHGWRKDYHVWDUWHGRQ'D\ZLWKRXWDQDVVRFLDWHGRQVHWW LPHZLOOEHDVVXPHGWR
KDYHRFFXUUHGDIWHUWKHLQLWLDWLRQRILQYHVWLJDWLRQDOSURGXFW +HQFH$(VRFFXUULQJRQ
'D\ZLWKQRDVVRFLDWHGRQVHWWLPHZLOOEHDVVXPHGWREHWUHDW PHQWHPHUJHQW
6HULRXV$(VDVVRFLDWHGZLWKDSURWRFROVSHFLILHGSURFHGXUHDQG RFFXUULQJDIWHUWKHWLPH
RIFRQVHQWEXWEHIRUHDGPLQLVWUDWLRQRIILUVWGRVHRILQYHVWLJD WLRQDOSURGXFWZLOOEH
GHILQHGDVQRQWUHDWPHQWHPHUJHQW$(V17($(V
$OOVDIHW\DQDO\VHVZLOOEHSHUIRUPHGLQWKH6DIHW\$QDO\VLV'D WDVHW
 &OLQLFDO/DERUDWRU\(YDOXDWLRQV/DERUDWRU\GDWDZLOOEHOLVWHGIR UDOOSDWLHQWV/DERUDWRU\GDW DZLOOEHUHYLHZHGE\WKH
,QYHVWLJDWRUDVWKH\EHFRPHDYDLODEOH$OODEQRUPDOODERUDWRU\ UHVXOWVZLOOEHHYDOXDWHG
E\WKH,QYHVWLJDWRUDVHLWKHUFOLQLFDOO\VLJQLILFDQWRUQRWFOL QLFDOO\VLJQLILFDQW
'HVFULSWLYHVXPPDULHVRIFOLQLFDOODERUDWRU\UHVXOWVZLOOEHSU HVHQWHGE\GDWHDQGWLPH
RIFROOHFWLRQ7KHQXPEHUDQGSHUFHQWDJHRISDWLHQWVH[SHULHQFL QJWUHDWPHQWHPHUJHQW
JUDGHGWR[LFLWLHVZLOOEHVXPPDUL ]HGE\WUHDWPHQWDUPDQGVHYHU LW\JUDGH/DERUDWRU\
WR[LFLW\VKLIWVIURPEDVHOLQHWRSRVWEDVHOLQHDVVHVVPHQWVZLOO EHVXPPDUL]HGE\
WUHDWPHQWDUP&KDQJHVIURPEDVH OLQHLQODERUDWRU\WHVWVZLOOE HVXPPDUL]HGIRUHDFK
WUHDWPHQWDUP
 7ZHOYHOHDG(OHFWURFDUGLRJUDPV9LWDO6LJQVDQG3K\VLF DO
([DPLQDWLRQV
7ZHOYHOHDG(&*DQGYLWDOVLJQVGDWDZLOOEHOLVWHGDQGVXPPDUL ]HG
3K\VLFDOH[DPLQDWLRQILQGLQJVZLOOEHFDSWXUHGDQGOLVWHGDVSD UWRIDSDWLHQWÂ¶VPHGLFDO
KLVWRU\RUDV$(VDVDSSOLFDEOH
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI 2WKHU$QDO\VHV
 3KDUPDFRNLQHWLF$QDO\VLV$IXOOGHVFULSWLRQRIWKHPHWKRGVIRUHYDOXDWLQJWKH3.RI%26 LQWKLVSDWLHQW
SRSXODWLRQZLOOEHSURYLGHGLQD 3.GDWDDQDO\VLVSODQ7KH3. GDWDIURPWKLVVWXG\PD\
EHFRPELQHGZLWKGDWDIURPRWKHUVWXGLHVWRFRPSOHWHDSRSXODWL RQ3.DQDO\VLV
$IXOOOLVWRI3.SDUDPHWHUVWREHFDOFXODWHGLVLQFOXGHGLQ 6HFWLRQ 
 %DVHOLQH'HVFULSWLYH6WDWLVWLFV'HPRJUDSKLFDQGEDVHOLQHFKDUDFWHULVWLFVZLOOEHVXPPDUL]HGIRU DOOSDWLHQWVRYHUDOO
DQGE\WUHDWPHQWDUP6XPPDU\VWDWLVWLFVHJQXPEHURISDWLH QWVPHDQPHGLDQ6'
DQGUDQJHZLOOEHJHQHUDWHGIRUF RQWLQXRXVYDULDEOHVHJDJ HDQGZHLJKWDQGWKH
QXPEHUDQGSHUFHQWDJHRISDWLHQWVZLWKLQHDFKFDWHJRU\ZLOOEH SUHVHQWHGIRU
FDWHJRULFDOYDULDEOHVHJJHQGHUHWKQLFLW\UDFH
$GHWDLOHGGHVFULSWLRQRISDWL HQWGLVSRVLWLRQZLOOEHSURYLGHG ,WZLOOLQFOXGH
x $VXPPDU\RIRYHUDOOSDWLHQWHQUROOPHQWVWDWXVFRQVHQWHGVFU HHQHGVFUHHQ
IDLOXUHVUHSODFHPHQWVUDQGRPL]HG
x $VXPPDU\RISDWLHQWVZKRGLVFRQWLQXHGWKHVWXG\
x $QDFFRXQWRILGHQWLILHGSURWRFROGHYLDWLRQV
$OOSDWLHQWVZKRDUHFRQVHQWHGIRUWKHVWXG\ZLOOEHDFFRXQWHG IRULQWKHVXPPDWLRQ7KH
QXPEHURISDWLHQWVZKRGRQRWTXDOLI\IRUFHUWDLQDQDO\VLVSRSX ODWLRQVZLOOEH
VXPPDUL]HG
 6XEJURXS$QDO\VHV1RVXEJURXSDQDO\VHVDUHSRZHUHGIRUWKHVWXG\6XEJURXSDQDO\V HVPD\EH
SHUIRUPHGIRUGHVFULSWLYHSXUSRVHVDVGHVFULEHGLQWKH6$3
 3ODQQHG,QWHULP$QDO\VHV
1RIRUPDOHIILFDF\LQWHULPDQDO\VLVLVSODQQHGIRUWKHSXUSRVHV RIVWDWLVWLFDOO\FRPSDULQJ
WKHGDWDSULRUWRWKHFRPSOHWLRQRIWKHVWXG\
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI 6833257,1*'2&80(17$7,21$1'23(5$7,21$/
&216,'(5$7,216
 5HJXODWRU\(WKLFDODQG6WXG\2YHUVLJKW&RQVLGHUDWLRQV
 5HJXODWRU\DQGHWKLFDOFRQVLGHUDWLRQV
7KLVVWXG\ZLOOEHFRQGXFWHGLQDFFRUGDQFHZLWKWKHSURWRFRODQ GZLWKWKHIROORZLQJ
x &RQVHQVXVHWKLFDOSULQFLSOHVGHULYHGIURPLQWHUQDWLRQDOJXLGHO LQHVLQFOXGLQJWKH
'HFODUDWLRQRI+HOVLQNLDQG&RXQFLOIRU,QWHUQDWLRQDO2UJDQL]DW LRQVRI0HGLFDO
6FLHQFHV,QWHUQDWLRQDO(WKLFDO*XLGHOLQHV
x $SSOLFDEOH,QWHUQDWLRQDO&RQIHUHQFHRQ&RXQFLOIRU+DUPRQLVDWL RQ,&+*RRG
&OLQLFDO3UDFWLFH*&3*XLGHOLQHV
x $SSOLFDEOHODZVDQGUHJXODWLRQV
7KHSURWRFROSURWRFRODPHQGPHQWV,&),%DQGRWKHUUHOHYDQW GRFXPHQWV
HJDGYHUWLVHPHQWVPXVWEHVXEPLWWHGDQGUHYLHZHGDQGDSSU RYHGDVQHFHVVDU\WR
WKHUHOHYDQW&RPSHWHQW$XWKRULWLHV,5%VDQG,(&VEHIRUHWKHVW XG\LVLQLWLDWHG
$Q\DPHQGPHQWVWRWKHSURWRFRO ZLOOUHTXLUHUHJXODWRU\DSSURYDO EHIRUHLPSOHPHQWDWLRQ
RIFKDQJHVPDGHWRWKHVWXG\GHVLJQH[FHSWIRUFKDQJHVQHFHVVD U\WRHOLPLQDWHDQ
LPPHGLDWHKD]DUGWRVWXG\SDWLHQWV
7KH,QYHVWLJDWRUZLOOEHUHVSRQVLEOHIRUWKHIROORZLQJ
x 3URYLGLQJZULWWHQVXPPDULHVRIWKHVWDWXVRIWKHVWXG\WRWKH ,5%,(&DQQXDOO\RU
PRUHIUHTXHQWO\LQDFFRUGDQFHZLWKWKHUHTXLUHPHQWVSROLFLHV DQGSURFHGXUHV
HVWDEOLVKHGE\WKH,5%,(&
x 1RWLI\LQJWKH,5%,(&RI6$(VRURWKHUVLJQLILFDQWVDIHW\ILQG LQJVDVUHTXLUHGE\
,5%,(&SURFHGXUHV
x 3URYLGLQJRYHUVLJKWRIWKHFRQGXFWRIWKHVWXG\DWWKHVLWHDQ GDGKHUHQFHWR
UHTXLUHPHQWVRI&RGHRI)HGHUDO5HJXODWLRQV&)5,&+JXLGH OLQHVWKH,5%,(&
(XURSHDQUHJXODWLRQIRUFOLQLFDOVWXGLHVLIDSSOLFDEO HDQGDOORWKHU
DSSOLFDEOHORFDOUHJXODWLRQV 
 ,QIRUPHG&RQVHQW$VVHQW3URFHVV$QLQLWLDOVDPSOH,&)LVSURYLGHGIRUWKH,QYHVWLJDWRUWRSUHSD UHWKHLQIRUPHGFRQVHQW
GRFXPHQWWREHXVHGDWKLVRUKHU VLWH8SGDWHVWRWKHVDPSOH, &)DUHWREH
FRPPXQLFDWHGIRUPDOO\LQZULWLQJIURPWKH6SRQVRURU6SRQVRUÂ¶V GHVLJQHHWRWKH
,QYHVWLJDWRU7KHZULWWHQ,&)LVWREHSUHSDUHGLQWKHODQJXDJH RIWKHSRWHQWLDOSDWLHQW
SRSXODWLRQ
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI7KH,QYHVWLJDWRURUKLVKHUUHSUHVHQWDWLYHZLOOH[SODLQWKHQDW XUHRIWKHVWXG\WRWKH
SDWLHQWRUKLVKHUOHJDOO\DXWKRUL]HGUHSUHVHQWDWLYHDQGDQVZHU DOOTXHVWLRQVUHJDUGLQJ
WKHVWXG\
3DWLHQWVPXVWEHLQIRUPHGWKDWWKHLUSDUWLFLSDWLRQLVYROXQWDU\ 3DWLHQWVRUWKHLUOHJDOO\
DXWKRUL]HGUHSUHVHQWDWLYHZLOOEHUHTXLUHGWRVLJQDVWDWHPHQW RILQIRUPHGFRQVHQW
DQGRUDVVHQWWKDWPHHWVWKHUHTXLUHPHQWVRI&)5ORFDO UHJXODWLRQV,&+
JXLGHOLQHV+HDOWK,QVXUDQFH3RUWDELOLW\DQG$FFRXQWDELOLW\$FW UHTXLUHPHQWVZKHUH
DSSOLFDEOHDQGWKH,5%,(&RUVWXG\FHQWHU
7KHPHGLFDOUHFRUGPXVWLQFOXGHDVWDWHPHQWWKDWZULWWHQLQIRUP HGFRQVHQWZDV
REWDLQHGEHIRUHWKHSDWLHQWZDVHQUROOHGLQWKHVWXG\DQGWKHG DWHWKHZULWWHQFRQVHQW
ZDVREWDLQHG7KHDXWKRUL]HGSHUVRQREWDLQLQJWKHLQIRUPHGFRQV HQWPXVWDOVRVLJQWKH
,&)
3DWLHQWVPXVWEHUHFRQVHQWHGWRWKHPRVWFXUUHQWYHUVLRQRIWK H,&)VGXULQJWKHLU
SDUWLFLSDWLRQLQWKHVWXG\LIRQHEHFRPHVDYDLODEOH
$FRS\RIWKH,&)VPXVWEHSURYLGHGWRWKHSDWLHQWRUWKHSDW LHQWÂ¶VOHJDOO\DXWKRUL]HG
UHSUHVHQWDWLYH
7KH,QYHVWLJDWRULVDOVRUHVSRQVLEOHIRUDVNLQJWKHSDWLHQWLI WKHSDWLHQWKDVDSULPDU\
FDUHSK\VLFLDQDQGLIWKHSDWLHQWDJUHHVWRKDYHKLVKHUSULPDU \FDUHSK\VLFLDQLQIRUPHG
RIWKHSDWLHQWÂ¶VSDUWLFLSDWLRQLQ WKHFOLQLFDOVWXG\LILWLVD ORFDOUHTXLUHPHQW,IWKHSDWLHQW
DJUHHVWRVXFKQRWLILFDWLRQWKH,QYHVWLJDWRULVWRLQIRUPWKH SDWLHQWÂ¶VSULPDU\FDUH
SK\VLFLDQRIWKHSDWLHQWÂ¶VSDUWLFLSDWLRQLQWKHFOLQLFDOVWXG\ ,IWKHSDWLHQWGRHVQRWKDYHD
SULPDU\FDUHSK\VLFLDQDQGWKH,QYHVWLJDWRUZLOOEHDFWLQJLQW KDWFDSDFLW\WKH
,QYHVWLJDWRULVWRGRFXPHQWVXFKLQWKHSDWLHQWÂ¶VPHGLFDOUHFRU G
,IDSDWLHQWLVXQDEOHWRUHDGRULIDOHJDOO\DFFHSWDEOHUHSUH VHQWDWLYHLVXQDEOHWRUHDG
DQLPSDUWLDOZLWQHVVVKRXOGEHSUHVHQWGXULQJWKHHQWLUHLQIRUP HGFRQVHQWGLVFXVVLRQ
$IWHUWKHZULWWHQ,&)DQGDQ\RWKHUZULWWHQLQIRUPDWLRQWREHS URYLGHGWRSDWLHQWVLVUHDG
DQGH[SODLQHGWRWKHSDWLHQWRUWKHSDWLHQWÂ¶VOHJDOO\DFFHSWDEO HUHSUHVHQWDWLYHDQGDIWHU
WKHSDWLHQWRUWKHSDWLHQWÂ¶VOHJDOO\DFFHSWDEOHUHSUHVHQWDWLYH KDVRUDOO\FRQVHQWHGWRWKH
SDWLHQWÂ¶VSDUWLFLSDWLRQLQWKHWULDODQGLIFDSDEOHRIGRLQJV RKDVVLJQHGDQGSHUVRQDOO\
GDWHGWKH,&)WKHZLWQHVVVKRXOGVLJQDQGSHUVRQDOO\GDWHWKH FRQVHQWIRUP%\VLJQLQJ
WKHFRQVHQWIRUPWKHZLWQHVVDWWHVWVWKDWWKHLQIRUPDWLRQLQW KHFRQVHQWIRUPDQGDQ\
RWKHUZULWWHQLQIRUPDWLRQZDVDFFXUDWHO\H[SODLQHGWRDQGDSSD UHQWO\XQGHUVWRRGE\
WKHSDWLHQWRUWKHSDWLHQWÂ¶VOHJDOO\DFFHSWDEOHUHSUHVHQWDWLYH DQGWKDWLQIRUPHGFRQVHQW
ZDVIUHHO\JLYHQE\WKHSDWLHQWRUWKHSDWLHQWÂ¶VOHJDOO\DFFHSW DEOHUHSUHVHQWDWLYH5HIHU
WR,&+*&3JXLGHOLQH6HFWLRQ
7KH,&)ZLOOFRQWDLQDVHSDUDWH VHFWLRQWKDWDGGUHVVHVWKHXVH RIUHPDLQLQJPDQGDWRU\
VDPSOHVIRURSWLRQDOH[SORUDWRU\UHVHDUFK7KH,QYHVWLJDWRURU DXWKRUL]HGGHVLJQHHZLOO
H[SODLQWRHDFKSDWLHQWWKHREMHFWLYHVRIWKHH[SORUDWRU\UHVHD UFK3DWLHQWVZLOOEHWROG
WKDWWKH\DUHIUHHWRUHIXVHWRSDUWLFLSDWHDQGPD\ZLWKGUDZWK HLUFRQVHQWDWDQ\WLPH
DQGIRUDQ\UHDVRQGXULQJWKHVWRUDJHSHULRG$VHSDUDWHVLJQDW XUHZLOOEHUHTXLUHGWR
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRIGRFXPHQWDSDWLHQW
VDJUHHPHQWWR DOORZDQ\UHPDLQLQJVSHFLPHQV WREHXVHGIRU
H[SORUDWRU\UHVHDUFK3DWLHQWVZKRGHFOLQHWRSDUWLFLSDWHLQWK LVRSWLRQDOUHVHDUFKZLOO
QRWSURYLGHWKLVVHSDUDWHVLJQDWXUH
 &RQILGHQWLDOLW\DQG3ULYDF\3DWLHQWFRQILGHQWLDOLW\DQGSULYDF\LVVWULFWO\KHOGLQWUXVWE \WKHSDUWLFLSDWLQJ
,QYHVWLJDWRUVWKHLUVWDIIDQGWKHVSRQVRUDQGLWVGHVLJQHHV 7KLVFRQILGHQWLDOLW\LV
H[WHQGHGWRFRYHUWHVWLQJRIELRORJLFDOVDPSOHVDQGJHQHWLFWHV WVLQDGGLWLRQWRWKH
FOLQLFDOLQIRUPDWLRQUHODWLQJ WRSDWLHQWV7KHUHIRUHWKHVWXG\ GRFXPHQWDWLRQGDWDDQG
DOORWKHULQIRUPDWLRQJHQHUDWHGZLOOEHKHOGLQVWULFWFRQILGHQ FH1RLQIRUPDWLRQ
FRQFHUQLQJWKHVWXG\RUWKHVWXG\GDWDZLOOEHUHOHDVHGWRDQ\ XQDXWKRUL]HGWKLUGSDUW\
ZLWKRXWSULRUZULWWHQDSSURYDORIWKHVSRQVRU
6WXG\SDWLHQWUHVHDUFKGDWDZLOOQRWLQFOXGHWKHSDWLHQWÂ¶VFRQW DFWRULGHQWLI\LQJ
LQIRUPDWLRQ5DWKHULQGLYLGXDOSDWLHQWVDQGWKHLUUHVHDUFKGDW DZLOOEHLGHQWLILHGE\D
XQLTXHVWXG\LGHQWLILFDWLRQQXPEHU$Q\SDWLHQWUHFRUGVRUGDWD VHWVWKDWDUHWUDQVIHUUHG
WRWKHVSRQVRUZLOOFRQWDLQWKHLG HQWLILHURQO\SDWLHQWQDPHV RUDQ\LQIRUPDWLRQZKLFK
ZRXOGPDNHWKHSDWLHQWLGHQWLIL DEOHZLOOQRWEHWUDQVIHUUHG5H VHDUFKGDWDZLOOEHXVHGLQ
DFFRUGDQFHZLWKORFDOGDWDSURWHFWLRQODZV
7KHVWXG\PRQLWRURWKHUDXWKRUL]HGUHSUHVHQWDWLYHVRIWKHVSRQ VRUUHSUHVHQWDWLYHVRI
WKH,5%,(&RUUHJXODWRU\DJHQFLHVPD\LQVSHFWDOOGRFXPHQWVDQ GUHFRUGVUHTXLUHGWR
EHPDLQWDLQHGE\WKH,QYHVWLJDWRULQFOXGLQJEXWQRWOLPLWHGWR PHGLFDOUHFRUGVRIILFH
FOLQLFRUKRVSLWDODQGSKDUPDF\UHFRUGVIRUWKHSDWLHQWVLQW KLVVWXG\7KHFOLQLFDOVWXG\
VLWHZLOOSHUPLWDFFHVVWRVXFKUHFRUGV
 4XDOLW\$VVXUDQFHDQG4XDOLW\&RQWURO4XDOLW\FRQWURO4&SURFHGXUH VZLOOEHLPSOHPHQWHGEHJLQQLQJZ LWKWKHGDWDHQWU\
V\VWHPDQGGDWD4&FKHFNVWKDWZLOOEHUXQRQWKHGDWDEDVHZLOO EHJHQHUDWHG$Q\
PLVVLQJGDWDRUGDWDDQRPDOLHVZLOOEHFRPPXQLFDWHGWRWKHVLWH VIRU
FODULILFDWLRQUHVROXWLRQ
)ROORZLQJZULWWHQ6WDQGDUG2SHUDWLQJ3URFHGXUHVWKHPRQLWRUVZ LOOYHULI\WKDWWKH
FOLQLFDOWULDOLVFRQGXFWHGGDWDDUHJHQHUDWHGDQGELRORJLFDO VSHFLPHQVDUHFROOHFWHG
GRFXPHQWHGUHFRUGHGDQGUHSRUWHGLQFRPSOLDQFHZLWKWKHSURW RFRO,&+*&3DQG
DSSOLFDEOHUHJXODWRU\UHTXLUHPHQWVHJ*RRG/DERUDWRU\3UDFW LFHV*RRG
0DQXIDFWXULQJ3UDFWLFHV
7KHLQYHVWLJDWLRQDOVLWHZLOOSURYLGHGLUHFWDFFHVVWRDOOWULD OUHODWHGVLWHVVRXUFH
GDWDGRFXPHQWVDQGUHSRUWVIRUWKHSXUSRVHRIPRQLWRULQJDQGD XGLWLQJE\WKHVSRQVRU
DQGLQVSHFWLRQE\ORFDODQGUHJXODWRU\DXWKRULWLHV
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI 'DWD+DQGOLQJDQG5HFRUG.HHSLQJ
 'DWD&ROOHFWLRQDQG0DQDJHPHQW5HVSRQVLELOLWLHV'DWDFROOHFWLRQLVWKHUHVSRQVLELOLW\RIWKHFOLQLFDOWULDOVWD IIDWWKHVLWHXQGHUWKH
VXSHUYLVLRQRIWKHVLWH,QYHVWLJDWRU7KH,QYHVWLJDWRULVUHVSR QVLEOHIRUHQVXULQJWKH
DFFXUDF\FRPSOHWHQHVVOHJLELOLW\DQGWLPHOLQHVVRIWKHGDWD UHSRUWHG
7KH,QYHVWLJDWRUPXVWPDLQWDLQDGHTXDWHVRXUFHGRFXPHQWDWLRQ$ OOVRXUFHGRFXPHQWV
VKRXOGEHFRPSOHWHGLQDQHDWOHJLEOHPDQQHUWRHQVXUHDFFXUDW HLQWHUSUHWDWLRQRIGDWD
&OLQLFDOGDWDLQFOXGLQJ$(VFRQFRPLWDQWPHGLFDWLRQVDQGH[SH FWHGDGYHUVHUHDFWLRQV
GDWDZLOOEHHQWHUHGLQWRD&)53DUWFRPSOLDQW('&V\VWH PRUWUDQVPLWWHG
HOHFWURQLFDOO\HJODERUDWRU\GDWD7KHGDWDV\VWHPVLQFO XGHVSDVVZRUGSURWHFWLRQ
DQGLQWHUQDOTXDOLW\FKHFNVVXFKDVDXWRPDWLFUDQJHFKHFNVWR LGHQWLI\GDWDWKDW
DSSHDULQFRQVLVWHQWLQF RPSOHWHRULQDFFXUDWH&OLQLFDOGDWDZ LOOEHHQWHUHGGLUHFWO\IURP
WKHVRXUFHGRFXPHQWV'DWDUHFRUGHGLQWKH&5)VKRXOGEHFRQVLV WHQWZLWKWKHGDWD
UHFRUGHGRQWKHVRXUFHGRFXPHQWVRUWKHGLVFUHSDQFLHVPXVWEHH [SODLQHG
7KHVSRQVRURUGHVLJQHHLVUHVSRQVLEOHIRUWKHGDWDPDQDJHPHQW RIWKLVVWXG\LQFOXGLQJ
TXDOLW\FKHFNLQJRIWKHGDWD7KHVSRQVRUDVVXPHVDFFRXQWDELOLW \IRUDFWLRQVGHOHJDWHG
WRRWKHULQGLYLGXDOVHJ&RQWUDFW5HVHDUFK2UJDQL]DWLRQV
6WXG\PRQLWRUVZLOOSHUIRUPRQJRL QJVRXUFHGDWDYHULILFDWLRQWR FRQILUPWKDWGDWDHQWHUHG
LQWRWKH&5)E\DXWKRUL]HGVLWHSHUVRQQHODUHDFFXUDWHFRPSOHW HDQGYHULILDEOHIURP
VRXUFHGRFXPHQWVWKDWWKHVDIHW\DQGULJKWVRISDWLHQWVDUHEH LQJSURWHFWHGDQGWKDW
WKHVWXG\LVEHLQJFRQGXFWHGLQDFFRUGDQFHZLWKWKHFXUUHQWO\D SSURYHGSURWRFRODQG
DQ\RWKHUVWXG\DJUHHPHQWV,&+*&3DQGDOODSSOLFDEOHUHJXODW RU\UHTXLUHPHQWV
 6WXG\5HFRUGV5HWHQWLRQ5HFRUGVDQGGRFXPHQWVLQFOXGLQJVLJQHG,&)VSHUWDLQLQJWRWKH FRQGXFWRIWKLVVWXG\
PXVWEHUHWDLQHGIRUDPLQLPXPRI\HDUVDIWHUWKHODVWDSSURY DORIDPDUNHWLQJ
DSSOLFDWLRQLQDQ,&+UHJLRQDQGXQWLOWKHUHDUHQRSHQGLQJRU FRQWHPSODWHGPDUNHWLQJ
DSSOLFDWLRQVLQDQ,&+UHJLRQRUXQWLODWOHDVW\HDUVKDYHHO DSVHGVLQFHWKHIRUPDO
GLVFRQWLQXDWLRQRIFOLQLFDOGHYHORSPHQWRIWKHLQYHVWLJDWLRQDO SURGXFW7KHVHGRFXPHQWV
VKRXOGEHUHWDLQHGIRUDORQJHUSHULRGKRZHYHULIUHTXLUHGE\ ORFDOUHJXODWLRQV
1RUHFRUGVZLOOEHGHVWUR\HGZLWKRXWWKHZULWWHQFRQVHQWRIWKH VSRQVRU1RUHFRUGVPD\
EHWUDQVIHUUHGWRDQRWKHUORFDWLRQRUSDUW\ZLWKRXWZULWWHQQRW LILFDWLRQWRWKHVSRQVRU
,WLVWKHUHVSRQVLELOLW\RIWKHVSRQVRUWRLQIRUPWKH,QYHVWLJD WRUZKHQWKHVHGRFXPHQWV
QRORQJHUQHHGWREHUHWDLQHG
 6WXG\DQG6LWH'L VFRQWLQXDWLRQDQG&ORVXUH
7KHVSRQVRURULWVGHVLJQHHUHVHUYHVWKHULJKWWRVXVSHQGRUSU HPDWXUHO\WHUPLQDWHD
VWXG\VLWHRUVWXG\DWDQ\WLPHIRUDQ\UHDVRQDQGDWWKHVROH GLVFUHWLRQRIWKHVSRQVRU
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI$Q,QYHVWLJDWRUPD\LQLWLDWHVLWHFORVXUHDWDQ\WLPHSURYLGHG WKHUHLVUHDVRQDEOHFDXVH
DQGVXIILFLHQWQRWLFHLVJLYHQWRWKHVSRQVRULQDGYDQFHRIWKH LQWHQGHGWHUPLQDWLRQ
:ULWWHQQRWLILFDWLRQGRFXPHQWLQJWKHUHDVRQIRUVLWHRUVWXG\ VXVSHQVLRQRUWHUPLQDWLRQ
ZLOOEHSURYLGHGE\WKHVXVSHQGLQJRUWHUPLQDWLQJSDUW\WRVWXG \SDUWLFLSDQWV
,QYHVWLJDWRUIXQGLQJDJHQF\WKH,QYHVWLJDWLRQDO1HZ'UXJVSRQ VRUDQGUHJXODWRU\
DXWKRULWLHV
,IWKHVWXG\LVSUHPDWXUHO\WHUPLQDWHGRUVXVSHQGHGWKH,QYHVW LJDWRUZLOOSURPSWO\
LQIRUPVWXG\SDUWLFLSDQWVWKH ,5%,(&DQGVSRQVRUDQGZLOOS URYLGHWKHUHDVRQVIRU
WKHWHUPLQDWLRQRUVXVSHQVLRQ6WXG\SDUWLFLSDQWVZLOOEHFRQWD FWHGDVDSSOLFDEOHDQG
EHLQIRUPHGRIFKDQJHVWRVWXG\YLVLWVFKHGXOH
&LUFXPVWDQFHVWKDWPD\ZDUUDQWWHUPLQDWLRQRUVXVSHQVLRQLQFOXG HEXWDUHQRWOLPLWHG
WR
x 'HWHUPLQDWLRQRIXQH[SHFWHGVLJQLILFDQWRUXQDFFHSWDEOHULVN WRSDUWLFLSDQWV
x 'HPRQVWUDWLRQRIHIILFDF\WKDWZRXOGZDUUDQWVWRSSLQJ
x ,QVXIILFLHQWFRPSOLDQFHWRWKHSURWRFROUHJXODWRU\UHTXLUHPHQ WVRU*&3
JXLGHOLQHV
x 'DWDWKDWDUHQRWVXIILFLHQWO\FRPSOHWHDQGRUHYDOXDEOH
x 'HWHUPLQDWLRQWKDWWKHSULPDU\HQGSRLQWKDVEHHQPHW
x 'HWHUPLQDWLRQRIIXWLOLW\
x ,QDGHTXDWHUHFUXLWPHQWRISDWLHQWV
 'LVVHPLQDWLRQRI&OLQLFDO6WXG\'DWD$&OLQLFDO6WXG\5HSRUW&65Z LOOEHSUHSDUHGLQDFFRUGDQFHZL WKWKH,&+JXLGHOLQHRQ
VWUXFWXUHDQGFRQWHQWVRI&65VDQGDQ\DSSOLFDEOHUHJXODWRU\DQ GOHJDOUHTXLUHPHQWV
 3XEOLFDWLRQ3ROLF\7KHUHVXOWVRIWKLVVWXG\PD\EHSXEOLVKHGRUSUHVHQWHGDWVFLH QWLILFPHHWLQJV,IWKLVLV
IRUHVHHQWKH,QYHVWLJDWRUDJUHHVWRVXEPLWDOOPDQXVFULSWVRU DEVWUDFWVWRWKHVSRQVRU
EHIRUHVXEPLVVLRQ7KLVDOORZVWKHVSRQVRUWRSURWHFWSURSULHWD U\LQIRUPDWLRQDQGWR
SURYLGHFRPPHQWV
7KHVSRQVRUZLOOFRPSO\ZLWKWKHUHTXLUHPHQWVIRUSXEOLFDWLRQR IVWXG\UHVXOWV,Q
DFFRUGDQFHZLWKVWDQGDUGHGLWRULDODQGHWKLFDOSUDFWLFHWKHVS RQVRUZLOOJHQHUDOO\
VXSSRUWSXEOLFDWLRQRIPXOWLFHQWHUVWXGLHVRQO\LQWKHLUHQWLUH W\DQGQRWDVLQGLYLGXDOVLWH
GDWD,QWKLVFDVHDFRRUGLQDWLQJ,QYHVWLJDWRUZLOOEHGHVLJQD WHGE\PXWXDODJUHHPHQW
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI$XWKRUVKLSZLOOEHGHWHUPLQHGE\PXWXDODJUHHPHQWDQGLQOLQHZ LWK,QWHUQDWLRQDO
&RPPLWWHHRI0HGLFDO-RXUQDO(GLWRUVDXWKRUVKLSUHTXLUHPHQWV
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI 5()(5(1&(6



























CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI


























CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI86'HSDUWPHQWRI+HDOWKDQG+XPDQ6HUYLFHV)RRGDQG'UXJ$GP LQLVWUDWLRQ&HQWHU
IRU'UXJ(YDOXDWLRQDQG5HVHDUFK0D\*XLGDQFHIRU,QGXV WU\,UULWDEOH%RZHO
6\QGURPHÂ±&OLQLFDO(YDOXDWLRQR I'UXJVIRU7UHDWPHQW5HWULHYH GIURP
KWWSVZZZIGDJRYGRZQORDGV'UXJV*XLGDQFHV8&0SGI


CCI
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI $33(1',&(6
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI$SSHQGL[&OLQLFDO/DERUDWRU\7HVWV
7KHWHVWVGHWDLOHGLQ 7DEOHZLOOEHSHUIRUPHGE\WKHFHQWUDOODERUDWRU\
/RFDOODERUDWRU\UHVXOWVDUHRQO\UHTXLUHGLQWKHHYHQWWKDWWK HFHQWUDOODERUDWRU\UHVXOWV
DUHQRWDYDLODEOHLQWLPHIRUHLWKHULQYHVWLJDWLRQDOSURGXFWDG PLQLVWUDWLRQDQGRU
UHVSRQVHHYDOXDWLRQ,IDORFDOVDPSOHLVUHTXLUHGLWLVLPSRU WDQWWKDWWKHVDPSOHIRU
FHQWUDODQDO\VLVLVREWDLQHGDWWKHVDPHWLPH$GGLWLRQDOO\LI WKHORFDOODERUDWRU\UHVXOWV
DUHXVHGWRPDNHHLWKHUDQLQYHVWLJDWLRQDOSURGXFWGHFLVLRQRU UHVSRQVHHYDOXDWLRQWKH
UHVXOWVPXVWEHHQWHUHGLQWRWKH&5)
3URWRFROVSHFLILFUHTXLUHPHQWVIRULQFOXVLRQRUH[FOXVLRQRISD WLHQWVDUHGHWDLOHGLQ
6HFWLRQRIWKHSURWRFRO
$GGLWLRQDOWHVWVPD\EHSHUIRUPHGDWDQ\WLPHGXULQJWKHVWXG\ DVGHWHUPLQHG
QHFHVVDU\E\WKH,QYHVWLJDWRURUUHTXLUHGE\ORFDOUHJXODWLRQV 
3UHJQDQF\WHVWLQJ5HIHUWR 6HFWLRQ IRU6FUHHQLQJSUHJQDQF\FULWHULD
7DEOH 3URWRFROUHTXLUHG6DIHW\/DERUDWRU\$VVHVVPHQWV 
/DERUDWRU\
$VVHVVPHQWV 3DUDPHWHUV
+HPDWRORJ\ 3ODWHOHWFRXQW  5%&,QGLFHV
0HDQFRUSXVFXODU
YROXPH0HDQFRUSXVFXODU+HPRJORELQ5HWLFXORF\WHV:KLWHEORRGFHOOFRXQW
ZLWKGLIIHUHQWLDO
1HXWURSKLOV
/\PSKRF\WHV
0RQRF\WHV
(RVLQRSKLOV
%DVRSKLOV5HGEORRGFHOO5%&FRXQW
+HPRJORELQ
+HPDWRFULW
&OLQLFDO
&KHPLVWU\%ORRG
XUHD
QLWURJHQ3RWDVVLXP $VSDUWDWH
DPLQRWUDQVIHUDVH6HUXP
JOXWDPLFR[DORDFHWLF
WUDQVDPLQDVH7RWDODQGGLUHFW
ELOLUXELQ
 &UHDWLQLQH 6RGLXP $ODQLQH
DPLQRWUDQVIHUDVH6HUXP
JOXWDPLFS\UXYLF
WUDQVDPLQDVH7RWDOSURWHLQ
* O X F R V H 
IDVWHG&DOFLXP $ONDOLQHSKRVSKDWDVH 




 
5RXWLQH
8ULQDO\VLV6SHFLILFJUDYLW\
S+JOXFRVHSURWHLQEORRGNHWRQHVELOLUXELQXURELOLQRJHQ QLWULWHOHXNRF\WHHVWHUDVH
E\GLSVWLFN
0LFURVFRSLFH[DPLQDWLRQLIEORRGRUSURWHLQLVDEQRUPDOCCI CCI CCI CCI
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI7DEOH 3URWRFROUHTXLUHG6DIHW\/DERUDWRU\$VVHVVPHQWV 
/DERUDWRU\
$VVHVVPHQWV 3DUDPHWHUV
2WKHU
6FUHHQLQJ
7HVWV+HPRJORELQ$F
)ROOLFOHVWLPXODWLQJKRUPRQHDQGHVWUDGLRODVQHHGHGLQZRPHQ RIQRQFKLOGEHDULQJ
SRWHQWLDORQO\
8ULQHKXPDQFKRULRQLFJRQDGRWURSLQK&*SUHJQDQF\WHVWDVQHH GHGIRUZRPHQRI
FKLOGEHDULQJSRWHQWLDO
6HURORJ\+,9DQWLERG\KHSDWLWLV%VXUIDFHDQWLJHQDQGKHSDWL WLV&YLUXVDQWLERG\
VHUXPWLVVXHWUDQVJOXWDPLQDVH,J$DQWLERG\W7*,J$DQG,J$L IDSSOLFDEOH

,QYHVWLJDWRUVPXVWGRFXPHQWWKHLUUHYLHZRIHDFKODERUDWRU\VDI HW\UHSRUW
/DERUDWRU\UHVXOWVWKDWFRXOGXQEOLQGWKHVWXG\ZLOOQRWEHUHS RUWHGWRLQYHVWLJDWLYHVLWHV
RURWKHUEOLQGHGSHUVRQQHOXQWLOWKHVWXG\KDVEHHQXQEOLQGHG
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI$SSHQGL[&RQWUDFHSWLYH*XLGDQ FHDQG&ROOHFWLRQRI3UHJQDQF\ ,QIRUPDWLRQ
'HILQLWLRQV 
:RPDQRI&KLOGEHDULQJ3RWHQWLDO:2&%3$ZRPDQLVFRQVLGHUHGIHUWLOHIROORZLQJPHQDUFKHDQGXQWLOEHFR PLQJSRVWPHQRSDXVDO
XQOHVVSHUPDQHQWO\VWHULOHVHHEHORZ
:RPHQLQWKHIROORZLQJFDWHJRULHV DUHQRWFRQVLGHUHG:2&%3 
 3UHPHQDUFKDO 3UHPHQRSDXVDOIHPDOHZLWKRIWKHIROORZLQJ
D 'RFXPHQWHGK\VWHUHFWRP\E 'RFXPHQWHGELODWHUDOVDOSLQJHFWRP\F 'RFXPHQWHGELODWHUDORRSKRUHFWRP\
1RWH'RFXPHQWDWLRQFDQFRPHIURPWKHVLWHSHUVRQQHOÂ¶VUHYLHZR IWKHSDWLHQWÂ¶VPHGLFDO
UHFRUGVPHGLFDOH[DPLQDWLRQRUPHGLFDOKLVWRU\LQWHUYLHZ
 3RVWPHQRSDXVDOIHPDOH
D $SRVWPHQRSDXVDOVWDWHLVGHILQHGDVQRPHQVHVIRUPRQWKV ZLWKRXWDQ
DOWHUQDWLYHPHGLFDOFDXVH$KLJKIROOLFOHVWLPXODWLQJKRUPRQH )6+OHYHOLQWKH
SRVWPHQRSDXVDOUDQJHPD\EHXVHGWRFRQILUPDSRVWPHQRSDXVDOVW DWHLQ
ZRPHQQRWXVLQJKRUPRQDOFRQWUDFHSWLRQRUKRUPRQDOUHSODFHPHQW WKHUDS\
+57+RZHYHULQWKHDEVHQFHRIPRQWKVRIDPHQRUUKHDDVL QJOH)6+
PHDVXUHPHQWLVLQVXIILFLHQW
E )HPDOHVRQ+57DQGZKRVHPHQRSDXVDOVWDWXVLVLQGRXEWZLOO EHUHTXLUHGWR
XVHRQHRIWKHQRQHVWURJHQKRUPRQDOKLJKO\HIIHFWLYHFRQWUDFHSW LRQPHWKRGVLI
WKH\ZLVKWRFRQWLQXHWKHLU+57GXULQJWKHVWXG\2WKHUZLVHWK H\PXVW
GLVFRQWLQXH+57WRDOORZFRQILUPDWLRQRISRVWPHQRSDXVDOVWDWXV EHIRUHVWXG\
HQUROOPHQW
&RQWUDFHSWLRQ*XLGDQFH0DOHSDWLHQWV0DOHSDWLHQWVZLWKIHPDOHSDUWQHUVRIFKLOGEHDULQJSRWHQWLDODU HHOLJLEOHWRSDUWLFLSDWHLI
WKH\DJUHHWR21(RIWKHIROORZLQJGXULQJWKHWUHDWPHQWSHULRG DQGIRUDW
OHDVWZHHNVDIWHUWKHODVWGRVHRILQYHVWLJDWLRQDOSURGXFW 
x $UHDEVWLQHQWIURPSHQLOHYDJLQDOLQWHUFRXUVHDVWKHLUXVXDOD QGSUHIHUUHGOLIHVW\OH
DEVWLQHQWRQDORQJWHUPDQGSHUVLVWHQWEDVLVDQGDJUHHWRUH PDLQDEVWLQHQW
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRIx $JUHHWRXVHDPDOHFRQGRPSOXVSDUWQHUXVHRIDFRQWUDFHSWLYH PHWKRGZLWKD
IDLOXUHUDWHRISHU\HDUDVGHVFULEHGLQ 7DEOHZKHQKDYLQJSHQLOHYDJLQDO
LQWHUFRXUVHZLWKD:2&%3ZKRLVQRWFXUUHQWO\SUHJQDQW
,QDGGLWLRQPDOHSDWLHQWVPXVWUHIUDLQIURPGRQDWLQJVSHUPIRU WKHGXUDWLRQRIWKHVWXG\
DQGIRUZHHNVDIWHUWKHODVWGRVHRILQYHVWLJDWLRQDOSURGXFW 
0DOHSDWLHQWVZLWKDSUHJQDQWRUEUHDVWIHHGLQJSDUWQHUPXVWDJU HHWRUHPDLQDEVWLQHQW
IURPSHQLOHYDJLQDOLQWHUFRXUVHRUXVHDPDOHFRQGRPGXULQJHDF KHSLVRGHRISHQLOH
SHQHWUDWLRQIRUWKHGXUDWLRQRIWKHVWXG\DQGIRUZHHNVDIWH UWKHODVWGRVHRI
LQYHVWLJDWLRQDOSURGXFW
)HPDOHSDWLHQWV)HPDOHSDWLHQWVRIFKLOGEHDULQJSRWHQWLDODUHHOLJLEOHWRSDUWL FLSDWHLIWKH\DJUHHWRXVHD
KLJKO\HIIHFWLYHPHWKRGRIFRQWUDFHSWLRQDVGHVFULEHGLQ 7DEOHFRQVLVWHQWO\DQG
FRUUHFWO\
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI7DEOH +LJKO\(IIHFWLYH&RQWUDFHSWLYH0HWKRGV 
+LJKO\(IIHFWLYH&RQWUDFHSWLYH0HWKRGV7KDW$UH8VHU'HSHQGHQWD
)DLOXUHUDWHRISHU\HDUZKHQXVHGFRQVLVWHQWO\DQGFRUUHFW O\
&RPELQHGHVWURJHQDQGSURJHVWRJHQFRQWDLQLQJKRUPRQDOFRQWUDF HSWLRQDVVRFLDWHGZLWKLQKLELWLRQRI
RYXODWLRQE
x2 U D O  
x ,QWUDYDJLQDO
x 7UDQVGHUPDO
3URJHVWRJHQRQO\KRUPRQDOFRQWUDFHSWLRQDVVRFLDWHGZLWKLQKLELW LRQRIRYXODWLRQ
x2 U D O  
x ,QMHFWDEOH
+LJKO\(IIHFWLYH0HWKRGV7KDW$UH8VHU,QGHSHQGHQWD
,PSODQWDEOHSURJHVWRJHQRQO\KRUPRQDOFRQWUDFHSWLRQDVVRFLDWHG ZLWKLQKLELWLRQRIRYXODWLRQE
x ,QWUDXWHULQHGHYLFH,8'
x ,QWUDXWHULQHKRUPRQHUHOHDVLQJV\VWHP,86
x %LODWHUDOWXEDORFFOXVLRQ
9DVHFWRPL]HG3DUWQHU 
$YDVHFWRPL]HGSDUWQHULVDKLJKO\HIIHFWLYHFRQWUDFHSWLRQPHWK RGSURYLGHGWKDWWKHSDUWQHULVWKHVROH
PDOHVH[XDOSDUWQHURIWKH:2&%3DQGWKHDEVHQFHRIVSHUPKDVE HHQFRQILUPHG,IQRWDQDGGLWLRQDO
KLJKO\HIIHFWLYHPHWKRGRIFRQWUDFHSWLRQVKRXOGEHXVHG
6H[XDO$EVWLQHQFH 
6H[XDODEVWLQHQFHLVFRQVLGHUHGDKLJKO\HIIHFWLYHPHWKRGRQO\ LIGHILQHGDVUHIUDLQLQJIURPKHWHURVH[XDO
LQWHUFRXUVHGXULQJWKHHQWLUHSHULRGRIULVNDVVRFLDWHGZLWKWK HLQYHVWLJDWLRQDOSURGXFW7KHUHOLDELOLW\RI
VH[XDODEVWLQHQFHQHHGVWREHHYDOXDWHGLQUHODWLRQWRWKHGXUD WLRQRIWKHVWXG\DQGWKHSUHIHUUHGDQG
XVXDOOLIHVW\OHRIWKHSDWLHQW
127(6
D 7\SLFDOXVHIDLOXUHUDWHVPD\GLIIHUIURPWKRVHZKHQXVHGFRQV LVWHQWO\DQGFRUUHFWO\8VHVKRXOGEH
FRQVLVWHQWZLWKORFDOUHJXODWLRQVUHJDUGLQJWKHXVHRIFRQWUDFH SWLYHPHWKRGVIRUSDWLHQWVSDUWLFLSDWLQJ
LQFOLQLFDOVWXGLHV
E +RUPRQDOFRQWUDFHSWLRQPD\EHVXVFHSWLEOHWRLQWHUDFWLRQZLWK WKHLQYHVWLJDWLRQDOSURGXFWZKLFKPD\
UHGXFHWKHHIILFDF\RIWKHFRQWUDFHSWLYHPHWKRG,QWKLVFDVH KLJKO\HIIHFWLYHPHWKRGVRI
FRQWUDFHSWLRQVKRXOGEHXWLOL]HGGXULQJWKHWUHDWPHQWSHULRGDQ GIRUDWOHDVWZHHNVDIWHUWKHODVW
GRVHRILQYHVWLJDWLRQDOSURGXFW

3UHJQDQF\7HVWLQJ
x $Q\:2&%3VKRXOGRQO\EHLQFOXGHGDIWHUDQHJDWLYHSUHJQDQF\W HVW
x $GGLWLRQDOXULQHSUHJQDQF\WHVWLQJVKRXOGEHSHUIRUPHGDWWKH 'D\YLVLWDQGWKH
'D\(QGRI6WXG\)ROORZXSYLVLW
x 3UHJQDQF\WHVWLQJZLOOEHSHUIR UPHGZKHQHYHUDP HQVWUXDOF\FOH LVPLVVHGRUZKHQ
SUHJQDQF\LVRWKHUZLVHVXVSHFWHG
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI&ROOHFWLRQRI3UHJQDQF\,QIRUPDWLRQ 
x $OOSUHJQDQFLHVPXVWEHUHSRUWHGRQD3UHJQDQF\1RWLILFDWLRQD QG2XWFRPH)RUP
ZLWKLQKRXUVRIDZDUHQHVVRIDQ\VXFKSUHJQDQF\WKDWRFFXUV IRUHLWKHUWKHVWXG\
SDWLHQWRUIRUWKHIHPDOHSDUWQHURIDPDOHSDWLHQWDOOSUHJQ DQFLHVZLOOEHIROORZHGWR
RXWFRPH
x :KLOHSUHJQDQF\LWVHOILVQRWFRQVLGHUHGWREHDQ$(RU6$(D Q\SUHJQDQF\
FRPSOLFDWLRQRUHOHFWLYHWHUPLQDWLRQRIDSUHJQDQF\ZLOOEHUHS RUWHGDVDQ$(RU6$(
$VSRQWDQHRXVDERUWLRQLVDOZD\VFRQVLGHUHGWREHDQ6$(DQGZL OOEHUHSRUWHGDV
VXFK
x 3UHJQDQFLHVWKDWRFFXUEH\RQGGD\VDIWHUWKHODVWGRVHRIV WXG\GUXJZLOORQO\
QHHGWREHUHSRUWHGLIWKHUHLVDQDVVRFLDWHG6$(WKDWWKH,QYH VWLJDWRUDVVHVVHGDV
UHODWHGWRVWXG\GUXJ
x 6DIHW\7HDPZLOOIROORZXSZLWKWKH,QYHVWLJDWRUHYHU\PRQWK VUHJDUGLQJSUHJQDQF\
RXWFRPH7KH,QYHVWLJDWRUPXVWIROORZWKHSUHJQDQF\WRFRQFOXVL RQLQRUGHUWR
GHWHUPLQHWKHRXWFRPH,IWKHFDVHLVEH\RQGGD\VIURPWKHH [SHFWHGGXHGDWH
DQGQRLQIRUPDWLRQKDVEHHQUHFHLYHGUHJDUGLQJWKHRXWFRPHWKH 6DIHW\7HDPZLOO
FRQWDFWWKH,QYHVWLJDWRUWRUHTXHVWRXWFRPH
0DOH3DWLHQWV:LWK3DUWQHUV:KR%HFRPH3UHJQDQW
x 7KH,QYHVWLJDWRUZLOODWWHPSWWRFROOHFWSUHJQDQF\LQIRUPDWLRQ RQDQ\PDOHSDWLHQWÂ¶V
IHPDOHSDUWQHUZKREHFRPHVSUHJQDQWZKLOHWKHPDOHSDWLHQWLVL QWKLVVWXG\7KLV
DSSOLHVRQO\WRPDOHSDWLHQWVZKRUHFHLYH%26
x $IWHUREWDLQLQJWKHQHFHVVDU\VLJQHGLQIRUPHGFRQVHQWIURPWKH SUHJQDQWIHPDOH
SDUWQHUGLUHFWO\WKH,QYHVWLJDW RUZLOOUHFRUGS UHJQDQF\LQIRUP DWLRQRQWKHDSSURSULDWH
IRUPDQGVXEPLWLWWRWKHVSRQVRUDVRXWOLQHGDERYH
)HPDOH3DWLHQWV:KR%HFRPH3UHJQDQW
x 7KH,QYHVWLJDWRUZLOOFROOHFWSUHJQDQF\LQIRUPDWLRQRQDQ\IHP DOHSDWLHQWZKR
EHFRPHVSUHJQDQWZKLOHSDUWLFLSD WLQJLQWKLVVWXG\,QIRUPDWLRQ ZLOOEHUHFRUGHGRQ
WKHDSSURSULDWHIRUPDVQRWHGDERYH
x $Q\IHPDOHSDWLHQWZKREHFRPHVSUHJQDQWZKLOHSDUWLFLSDWLQJLQ WKHVWXG\ZLOOEH
ZLWKGUDZQIURPWKHVWXG\

%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI$SSHQGL[7KH%ULVWRO6WRRO)RUP6FDOH


 
 
CCI
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRI$SSHQGL[&RQFRPLWDQW0HGLFDWLRQV

0HGLFDWLRQVSHUPLWWHGGXULQJWKHFRXUVHRIWKHVWXG\
x $Q\PHGLFDWLRQRUYDFFLQHLQFOXGLQJRYHUWKHFRXQWHURUSUHVF ULSWLRQPHGLFLQHV
YLWDPLQVDQGRUVXSSOHPHQWVWKDWLQWKHRSLQLRQRIWKH,QYHVW LJDWRUVKRXOGQRW
LQWHUIHUHZLWKVWXG\SURFHGXUHVFRPSURPLVHVDIHW\RUWKHVFLH QWLILFLQWHJULW\RI
WKHGDWD
x 6WDEOHGRVHVRIPHGLFDWLRQVIRUDOOHUJLHVPLJUDLQHVZLWKWKH H[FHSWLRQRI
RSLRLGVIRUDFXWHWUHDWPHQWDQ[LHW\HJDVQHHGHGXVHRIE HQ]RGLD]HSLQHV
GHSUHVVLRQRURWKHUFKURQLFFRQGLWLRQVDWWKHGLVFUHWLRQRIWKH ,QYHVWLJDWRU
x 6WDEOHGRVHVRIDQWLGHSUHVVDQWV$VQHHGHGXVHRIEXVSLURQHDQ G
EHQ]RGLD]HSLQHVIRUDQ[LHW\
x /RSHUDPLGHFDQEHXVHGGXULQJVWXG\DVUHVFXHPHGLFDWLRQEDVHG RQ
SURWRFROVSHFLILHGJXLGHOLQHVVHH 6HFWLRQ IRUDOORZDEOHRQVWXG\UHVFXH
PHGLFDWLRQV
x $FHWDPLQRSKHQXSWRJGD\IRUXSWRFRQVHFXWLYHGD\V
x $Q\GUXJVRUVXEVWDQFHVNQRZQWR EHVHQVLWLYHVXEVWUDWHVRI&< 3$HQ]\PHV
RUNQRZQWREH3JSLQKLELWRUVVKRXOGEHGLVFXVVHGZLWKWKH0HG LFDO0RQLWRU
0HGLFDWLRQVH[FOXGHGGXULQJWKHFRXUVHRIWKHVWXG\
x K\GUR[\WULSWDPLQH+7 RU+7 UHFHSWRUDQWDJRQLVWVHJDORVHWURQ
x $VSLULQRUDVSLULQFRQWDLQLQJPHGLFDWLRQV!PJRIDVSLULQ SHUGD\RU
QRQVWHURLGDODQWLLQIODPPDWRU\GUXJVZKHQWDNHQVSHFLILFDOO\I RUWKHV\PSWRPV
RI,%6
x 1DUFRWLFRURSLRLGFRQWDLQLQJDJHQWV
x &DQQDELVFRQWDLQLQJSURGXFWV
x 'RFXVDWH
x (QHPDV
x *,SUHSDUDWLRQVLQFOXGLQJDQWDF LGVFRQWDLQLQJDOXPLQXPRUPDJ QHVLXP
DQWLGLDUUKHDODJHQWVDQWLVSDVPRGLFDJHQWVELVPXWKSHSSHUPLQW RLO,%JDUG
)'JDUGRUSURNLQHWLFDJHQWV
%RVWRQ3KDUPDFHXWLFDOV,QF %26
3URWRFRO 9HUVLRQ

&RQILGHQWLDO  3DJHRIx 3ODQQHGXVHRIULID[LPLQRURUDODQWLELRWLFVZLWKWKHH[FHSWL RQRIWRSLFDO
DQWLELRWLFVRUDGD\FRXUVHZLWKDQDQWLELRWLFDSDWLHQWZL OOEHDOORZHGWR
UHPDLQLQWKHVWXG\VKRXOGXQSODQQHGXVHRIDQWLELRWLFVRWKHUW KDQULID[LPLQRFFXU
DIWHUWKHSDWLHQWKDVEHHQUDQGRPL]HG
x $Q\LQYHVWLJDWLRQDOGUXJ